<SEC-DOCUMENT>0001213900-20-033954.txt : 20201029
<SEC-HEADER>0001213900-20-033954.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029160018
ACCESSION NUMBER:		0001213900-20-033954
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lantern Pharma Inc.
		CENTRAL INDEX KEY:			0001763950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463973463
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39318
		FILM NUMBER:		201272568

	BUSINESS ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
		BUSINESS PHONE:		972-277-1136

	MAIL ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lantern Pharma
		DATE OF NAME CHANGE:	20190108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0920_lanternpharma.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9746; QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the quarterly period ended September
30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9744; TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Lantern Pharma Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-39318</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-3973463</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<BR>
of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission<BR>
File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1920 McKinney Avenue, 7th Floor<BR>
Dallas, Texas</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>75201</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(972) 277-1136</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(<B>Registrant&rsquo;s telephone number,
including area code</B>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:
Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 34%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LTRN</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Stock Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">&thorn;</FONT> No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). Yes&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">No&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Wingdings">&thorn;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&#9744; No </FONT><FONT STYLE="font-family: Wingdings">&thorn;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of October 28, 2020, the registrant had 6,217,577 shares
of common stock, $0.0001 par value per share outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 83%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="text-align: center"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART I &ndash; FINANCIAL INFORMATION</B></FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 1.</B></FONT></A></TD>
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Changes in Stockholders&rsquo; Equity for the three and nine months ended September 30, 2020 and 2019 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 9pt; text-indent: -9pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Condensed Consolidated Financial Statements (unaudited)</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 2.</B></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 3.</B></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 4.</B></FONT></A></TD>
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="text-align: center"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II &ndash; OTHER INFORMATION</B></FONT></A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 1.</B></FONT></A></TD>
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 1A.</B></FONT></A></TD>
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 2.</B></FONT></A></TD>
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 3.</B></FONT></A></TD>
    <TD><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults Upon Senior Securities.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 4.</B></FONT></A></TD>
    <TD><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 5.</B></FONT></A></TD>
    <TD><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 6.</B></FONT></A></TD>
    <TD><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits.</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signatures</B></FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Quarterly Report on Form 10-Q contains
forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to
the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of
1934, as amended, and other federal securities laws. All statements, other than statements of historical fact, contained in this
Quarterly Report on Form 10-Q, including statements regarding our strategy, future preclinical studies and clinical trials, future
financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo;
&ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &lsquo;will&rdquo; &ldquo;would,&rdquo; or
the negative of these words or other similar expressions are intended to identify forward-looking&nbsp;statements, although not
all forward-looking&nbsp;statements contain these words. Forward-looking statements reflect our current views with respect to future
events and are based on assumptions and subject to risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The forward-looking
statements in this Quarterly Report on Form 10-Q include, among other things, statements relating to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential advantages of our RADR<SUP>&reg;</SUP> platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our strategic plans to advance the development of any of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our strategic plans to expand the number of data points that our RADR<SUP>&reg;</SUP>&nbsp;platform can access and analyze;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our research and development efforts of our internal drug discovery programs and the utilization of our RADR<SUP>&reg;</SUP>&nbsp;platform to streamline the drug development process;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, timing, progress, and results of our preclinical studies or clinical trials on any of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our intention to leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify patient populations that would likely respond to a drug candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our existing cash and cash equivalents;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to secure sufficient funding and alternative source of funding to support our existing and proposed preclinical studies and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding the potential market opportunity for our drug candidates we or any of our collaborators may in the future develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated growth strategies and our ability to manage the expansion of our business operations effectively;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations related to the use of proceeds from our initial public offering, which closed on June 15, 2020;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to keep up with rapidly changing technologies and evolving industry standards, including our ability to achieve technological advances;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential impact the outbreak of COVID-19 may have on our business plans;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to source our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of government laws and regulations on the development and commercialization of our drug candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We may not actually
achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations
disclosed in the forward-looking&nbsp;statements we make. We have included important factors in the cautionary statements included
in this Quarterly Report on Form 10-Q and in the Risk Factors section of the final prospectus, dated June 10, 2020, for our initial
public offering, on file with the Securities and Exchange Commission, and have identified other factors such as the impact of the
COVID-19 pandemic, the results of our clinical trials, and the impact of competition, that we believe could cause actual results
or events to differ materially from the forward-statements that we make. Furthermore, we operate in a competitive and rapidly changing
environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties
that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">You should read this
Quarterly Report on Form 10-Q and the documents that we file with the Securities and Exchange Commission, or the SEC, with the
understanding that our actual future results may be materially different from what we expect. These forward-looking statements
are based on management&rsquo;s current expectations. These statements are neither promises nor guarantees, but involve known and
unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially
different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors
that may cause actual results to differ materially from current expectations include, among other things, those listed elsewhere
in this Quarterly Report on Form 10-Q and those listed under the Risk Factors section of the final prospectus, dated June 10, 2020,
for our initial public offering, on file with the Securities and Exchange Commission. You may access our June 10, 2020 final prospectus
under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC&rsquo;s website at www.sec.gov. Given
these uncertainties, you should not rely on these forward-looking statements as predictions of future events. The forward-looking
statements contained in this Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report, and we do not assume
any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except
as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In addition, statements
that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read
to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These
statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Unless the context requires
otherwise, references to the &ldquo;Company,&rdquo; &ldquo;Lantern,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo;
this Quarterly Report on Form 10-Q refer to Lantern Pharma Inc., a Delaware corporation, and, where appropriate, its wholly-owned
subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_001"></A>PART I &ndash; FINANCIAL
INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_003"></A>Item 1. Financial Statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_004"></A>Lantern Pharma Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">September&nbsp;30,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">20,802,542</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,232,030</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,672,802</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 10pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,475,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,232,818</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,758</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">Deferred offering costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">191,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,492,952</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,432,576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">814,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">489,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-left: 10pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">489,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 10pt">PPP loan payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">108,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">923,057</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">489,292</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">COMMITMENTS AND CONTINGENCIES (NOTE 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Preferred Stock - Par Value (1,000,000 authorized at September 30, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding at September 30, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -10pt; padding-left: 10pt">Common Stock &ndash; Par Value (25,000,000 authorized at September 30, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,217,577 shares issued and outstanding at September 30, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,333,164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,694,547</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,763,891</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,751,705</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,569,895</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">943,284</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,492,952</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,432,576</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>Lantern Pharma Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of
Operations (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,100,719</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">441,251</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,117,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">977,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">600,769</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">894,896</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">775,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,701,488</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">669,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,012,186</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,753,018</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">NET LOSS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,701,488</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(669,652</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,012,186</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,753,018</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net loss per share of common shares, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.27</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.34</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.82</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.89</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Weighted-average number of common shares outstanding, basic and diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,217,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,978,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,661,942</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,978,269</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_006"></A>Lantern Pharma Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Condensed Consolidated Statements of
Stockholders&rsquo; Equity (Deficit) (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred<BR> Stock<BR> Number of<BR> Shares</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred<BR> Stock<BR> Amount</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common<BR> Stock<BR> Number<BR> of Shares</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common<BR> Stock<BR> Amount</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Additional<BR> Paid-in<BR> Capital</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<BR> Deficit</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<BR> Stockholders&rsquo;<BR> Equity <BR>
(Deficit)</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="26" STYLE="text-align: center">Three and Nine Months Ended September 30, 2019</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; text-indent: -5pt; padding-left: 5pt">Balance, December 31, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">1,292,952</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">129</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">1,978,269</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">198</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">4,121,395</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(4,323,520</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 6%; text-align: right">(201,798</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Preferred stock and warrants issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">804,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,384,919</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,385,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,531</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(453,973</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(453,973</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,097,105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">210</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,978,269</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">198</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,521,845</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,777,493</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,744,760</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,029</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,029</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(629,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(629,393</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Balance, June 30, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,097,105</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">210</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,978,269</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">198</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,527,874</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,406,886</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,121,396</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Preferred stock and warrants issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341,761</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,070,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,070,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,796</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(669,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(669,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Balance, September 30, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">244</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,978,269</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">198</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,631,143</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,076,538</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,555,047</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="27" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Three and Nine Months Ended September 30, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Balance, December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,438,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">244</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,978,269</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">198</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7,694,547</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(6,751,705</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">943,284</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,995</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,460</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(477,276</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(477,276</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Balance, March 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">244</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,028,729</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">203</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,765,002</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,228,981</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">536,468</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Common stock issued, net of issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,419,546</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,419,721</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Preferred stock conversion to common stock and fractional shares adjustments from stock split and conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,438,866</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(244</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,438,848</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(261</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(261</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,363</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,363</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(833,422</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(833,422</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Balance, June 30, 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,217,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">622</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,289,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,062,403</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,227,869</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5pt; padding-left: 5pt">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,701,488</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,701,488</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 5pt">Balance, September 30, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,217,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">622</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">31,333,164</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,763,891</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,569,895</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>Lantern Pharma Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Consolidated Statements of
Cash Flows (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,012,186</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,753,018</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,091</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,337</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,356</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,672,014</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25,950</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">431,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">304,474</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash flows used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,083,564</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,419,047</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Purchase of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,717</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash flows used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,145</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,717</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from issuance of common and preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,920,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,745,279</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from stock option exercise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">52,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Borrowings from notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Payments on notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(169,049</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Borrowings on PPP loan payable</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">108,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash flows provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,665,221</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,920,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">CHANGE IN CASH FOR THE PERIOD</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,570,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,495,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">CASH, BEGINNING OF PERIOD</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,232,030</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">445,163</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">CASH, END OF PERIOD</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,802,542</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,940,906</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-cash financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversion of SAFE agreements to Series A preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">535,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Application of deferred offering costs to initial public offering proceeds</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(456,437</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying Notes to Condensed Consolidated
Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 1. Organization, Principal Activities,
and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Lantern Pharma Inc.,
and Subsidiary (the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence
(&ldquo;A.I.&rdquo;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&rsquo;s portfolio of therapies consists of small molecule
drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds
that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company&rsquo;s A.I. platform,
known as RADR<SUP>&reg;</SUP>, uses big data analytics (combining molecular data, drug efficacy data, data from historical studies,
data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning.
The Company&rsquo;s data-driven, genomically-targeted&nbsp;and biomarker-driven&nbsp;approach allows it to pursue a transformational
drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January&nbsp;15, 2020. The Company&rsquo;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017. All intercompany balances and transactions have been eliminated in
consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24pt">&nbsp;</TD>
    <TD STYLE="width: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100&nbsp;(irofulven), out-licensed&nbsp;to Allarity Therapeutics (formerly known as Oncology Venture), in a phase II trial for the treatment of prostate cancer;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24pt">&nbsp;</TD>
    <TD STYLE="width: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300&nbsp;(Tavocept) in planning stages for phase II trial for the treatment of non-small&nbsp;cell lung cancer; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24pt">&nbsp;</TD>
    <TD STYLE="width: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184&nbsp;in preclinical studies for treatment of solid tumors including prostate, liver and pancreatic cancers and glioblastoma.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
Company&rsquo;s reincorporation in the state of Delaware on January&nbsp;15, 2020, the par value of the Company&rsquo;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying condensed consolidated financial statements. Additional funds have been reclassified
from Common Stock and Series A Preferred Stock to additional paid-in&nbsp;capital to reflect the change in par value associated
with the reincorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company&rsquo;s
fiscal year ends on December 31 of each calendar year. The accompanying interim condensed consolidated financial statements are
unaudited and have been prepared on substantially the same basis as the Company&rsquo;s annual consolidated financial statements
for the fiscal year ended December&nbsp;31, 2019. In the opinion of the Company&rsquo;s management, these interim condensed consolidated
financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair
statement of the Company&rsquo;s financial position, results of operations and cash flows for the periods presented. The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of
expenses during the reporting periods. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The December 31, 2019
year-end condensed consolidated balance sheet data in the accompanying interim condensed consolidated financial statements was
derived from audited consolidated financial statements. These condensed consolidated financial statements and notes do not include
all disclosures required by U.S. generally accepted accounting principles and should be read in conjunction with the Company&rsquo;s
audited consolidated financial statements as of and for the year ended December 31, 2019 and the notes thereto included in the
Company&rsquo;s final prospectus, dated June 10, 2020, for the Company&rsquo;s initial public offering, on file with the Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The results of operations
and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative
of the results to be expected for any future period or the entire fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&ldquo;ASC&rdquo;) and Accounting Standards Update (&ldquo;ASU&rdquo;)
of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;). To date, the Company has operated its business as one segment.
The Company&rsquo;s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary,
Lantern Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Effective June 11, 2020,
in connection with the Company&rsquo;s initial public offering (&ldquo;IPO&rdquo;), the Company completed a forward stock split
of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&rsquo;s preferred stock converted into common
stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying condensed
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying condensed consolidated financial statements
and in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the
forward stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2. Liquidity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company incurred
a net loss of $3,012,186 and $1,753,018 during the nine months ended September 30, 2020 and September 30, 2019, respectively. As
of September 30, 2020, the Company had working capital of $21,660,787, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 5). The Company had working capital of $743,526 as of December 31, 2019. The Company
has received funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in
supporting its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional
source of liquidity. As of December 31, 2019, there was substantial doubt about the Company&rsquo;s ability to continue as a going
concern in the absence of additional funding. We believe that our existing cash and cash equivalents as of September 30, 2020,
and our anticipated expenditures and capital commitments for the remainder of calendar year 2020 and for calendar year 2021, will
enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this quarterly
report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3. Summary of Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Use of Estimates and Assumptions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The significant areas of estimation include determining deferred tax asset
valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could
differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks and Uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the
potential risk of business failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&rsquo;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted.
If the Company&rsquo;s operations are impacted by this outbreak for an extended period, the Company&rsquo;s results of operations
or liquidity may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Deferred Offering Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In conjunction with
the Company&rsquo;s IPO, costs incurred related to the IPO were capitalized as deferred equity issuance costs in other non-current
assets until the time of completion of the IPO. Upon completion of the IPO, these costs have been offset against proceeds received.
Offering costs include direct and incremental costs related to the offering such as legal fees and related costs associated with
the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2020, the Company classified deferred offering costs of $456,437 as a reduction to additional paid-in capital
upon completion of the Company&rsquo;s IPO on June 15, 2020. As of December 31, 2019, the Company recorded deferred offering costs
of $191,000 and as of September 30, 2020, there were no deferred offering costs recorded on the Company&rsquo;s condensed consolidated
balance sheets.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&rsquo;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prepaid Expenses and Other Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Prepaid expenses and
other current assets as of September 30, 2020 totaled approximately $1,673,000 and included approximately $357,000 of upfront payments
for contractor and academic research studies and services, approximately $48,000 of licensing and other fees to AF Chemicals, LLC,
approximately $6,000 associated with receivables and undeposited funds, and approximately $1,262,000 of prepaid annual insurance
fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Loan Pursuant to Paycheck Protection
Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company received
$108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;) from JPMorgan Chase Bank (the &ldquo;Lender&rdquo;) pursuant to
the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan is evidenced
by a loan application and payment agreement (the &ldquo;PPP Loan Agreement&rdquo;) by and between the Company and the Lender. This
amount is recorded as a loan payable on the Company&rsquo;s condensed consolidated balance sheet at September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4: Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>BioNumerik
Pharmaceuticals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2018, the
Company entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with BioNumerik Pharmaceuticals, Inc. (&ldquo;BioNumerik&rdquo;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300&nbsp;(Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced a License Agreement
that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling $25,000 in connection
with entry into the Assignment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In the event the Company
develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related&nbsp;payment recipients
designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million,
with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million
and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">If the Company enters
into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients a specified
percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300&nbsp;that are not otherwise reimbursed from such third
party transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In addition, the Assignment
Agreement provides that the Company will use commercially diligent efforts to develop LP-300&nbsp;and make specified regulatory
filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that the Company
will provide TriviumVet DAC (&ldquo;TriviumVet&rdquo;) with (i) specified data and information generated by the Company with respect
to LP-300, and (ii) an exclusive license to use specified LP-300-related&nbsp;patent rights, trademark rights and related intellectual
property to support LP-300&nbsp;development in non-human&nbsp;(animal) treatment indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company is also
required to pay all patent costs on covered patents related to LP-300. These patent costs are fully recoverable at the time of
any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In addition to the recovery
of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection with entry into the Assignment
Agreement, which payments are recoverable prior to making any royalty or third party transaction sharing payments. The Company
also has the right to recover previously incurred LP-300&nbsp;development and regulatory costs, with up to a mid-single&nbsp;digit
percentage of net revenue amounts to be applied towards repayment of development and regulatory costs until such costs are fully
recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">There is approximately
$11,000 payable to BioNumerik as of September 30, 2020 and December 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>AF Chemicals</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&ldquo;AF Chemicals&rdquo;) for the treatment of cancer in humans for the compounds LP-100&nbsp;(Irofulven) and LP-184. In
February 2016, the Company and AF Chemicals entered into an Addendum providing for additions and amendments to the Technology License
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Pursuant to the Technology
License Agreement and Addendum (collectively, the &ldquo;AFC License Agreement&rdquo;) the Company is obligated to make annual
licensing fee payments to AF Chemicals in the amount of $30,000 per year relating to LP-184. The Company paid $0 and $30,000 to
AF Chemicals relating to the LP-184 annual fee&nbsp;during the three and nine months ended September 30, 2020, $7,500 and $22,500
of which was expensed during the three and nine months ended September 30, 2020, respectively. The Company paid $0 and $30,000
to AF Chemicals relating to the LP-184&nbsp;annual fee during the three and nine months ended September&nbsp;30, 2019, $7,500 and
$22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively. Such amounts are included
in research and development expenses in the accompanying condensed consolidated statements of operations. In addition, the Company
is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application (&ldquo;IND&rdquo;)
filing relating to LP-184&nbsp;and also upon reaching additional specified milestones in connection with the development and potential
marketing approval of LP-184&nbsp;in the United States, specified countries in Europe, and other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In the event of a sublicense
of the LP-184&nbsp;rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income and
fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double digit
percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184&nbsp;and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company
to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development
time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three
and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing
milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September
30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements
of operations. The Company paid AF Chemicals $37,500 during the year ended December&nbsp;31, 2019 in connection with extension
of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts
of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension
payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.
The Company is also obligated to make annual licensing fee payments to AF Chemicals relating to LP-100&nbsp;as described below
under &ldquo;Oncology Venture.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Nothing was accrued
or payable to AF Chemicals as of September 30, 2020 and December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Allarity Therapeutics (formerly known
as Oncology Venture)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In May 2015, the
Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics A/S (&ldquo;Allarity&rdquo;) entered into
an addendum and an amendment providing for additions and amendments to the Drug License and Development Agreement. In
connection with the Drug License and Development Agreement, as amended (collectively, the &ldquo;Allarity License and
Development Agreement&rdquo;), Allarity agreed to directly pay to AF Chemicals on behalf of the Company amounts owed to AF
Chemicals with respect to LP-100&nbsp;under the AFC License Agreement. Amounts paid by Allarity to AF&nbsp;Chemicals on
behalf of the Company are then deducted from amounts owed by Allarity to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The amounts owed to
AF Chemicals with respect to LP-100&nbsp;are in many ways similar to the amounts owed with respect to LP-184&nbsp;as described
above under &ldquo;AF Chemicals&rdquo;. In the event any such amounts relating to LP-100&nbsp;are not paid to AF Chemicals by Allarity,
the Company is obligated to pay such unpaid amounts. In addition to the payments to be made by Allarity, the Company is obligated
to make annual licensing fee payments to AF&nbsp;Chemicals in the amount of $30,000 per year relating to LP-100. The Company paid
$0 and $30,000 to AF Chemicals relating to the LP-100 annual fee&nbsp;during the three and nine months ended September 30, 2020,
respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2020, respectively.
The Company paid $0 and $30,000 to AF Chemicals relating to the LP-100&nbsp;annual fee during the three and nine months ended September
30, 2019, respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively.
Such amounts are included in research and development expenses in the accompanying condensed consolidated statements of operations.
In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in
clinical trials, and file a potential NDA with respect to LP-100. During the three and nine months ended September 30, 2020, the
Company paid AF Chemicals $25,000 relating to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately
$4,000 of which was expensed during the three and nine months ended September 30, 2020 and included under research and development
expenses in the accompanying condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">There is nothing accrued
or payable related to the Allarity License and Development Agreement as of September 30, 2020 and December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>EU
Grant</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In September 2018, Lantern
Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form of state
aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &ldquo;General Block Exemption&rdquo;), Article 25
Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and development
activities for the prostate cancer biomarker analysis of the LP-184&nbsp;drug candidate. Following the Company&rsquo;s research
and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development expenses
not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting and
consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made under
the grant as of September 30, 2020 and December 31, 2019. No revenue has been recognized from this grant through September 30,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patheon API Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, the Company
entered into an agreement with Patheon API Services, Inc. (&ldquo;Patheon&rdquo;) for the manufacture and supply of cGMP material
to support the Company&rsquo;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300
API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer previously
validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used to support
non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing milestones
are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700 pharmaceuticals
for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated global network of
facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company paid approximately
$194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was
expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services
received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying
condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid
expenses on the Company&rsquo;s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Southwest Research Institute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
part of the Company&rsquo;s research and development activities, the Company has engaged Southwest Research Institute (&ldquo;SwRI&rdquo;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&rsquo;s product candidates.
Approximately $4,000 and $21,000 was expensed with respect to SwRI during the three months ended September 30, 2020 and September
30, 2019, respectively, and approximately $5,000 and $221,000 was expensed with respect to SwRI during the nine months ended September
30, 2020 and September 30, 2019, respectively. All of such expensed amounts are included in research and development expenses in
the accompanying condensed consolidated statements of operations. Approximately $99,000 was payable to SwRI as of September 30,
2020, and approximately $21,000 was payable to SwRI as of September 30, 2019. In September 2020, the Company entered into an agreement
with SwRI for the non-GMP synthesis of LP-184 material and related analytical development to assist with preclinical studies. Approximately
$97,000 relating to the SwRI agreement is included under prepaid expenses on the Company&rsquo;s condensed consolidated balance
sheet for the period ended September 30, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company
expects to pay additional amounts to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The Research
Institute of Fox Chase Cancer Center</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&ldquo;FCCC&rdquo;)
as part of the Company&rsquo;s research and development activities, with a focus on <FONT STYLE="background-color: white">advancing
the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.</FONT> Approximately $6,000 was expensed with
respect to the FCCC agreement during the three months ended September 30, 2020, which amount is included in research and development
expenses in the accompanying condensed consolidated statements of operations. As of September 30, 2020, approximately $71,000 was
payable to FCCC. Approximately $65,000 relating to the FCCC agreement is included under other current assets on the Company&rsquo;s
condensed consolidated balance sheet as of September 30, 2020. The Company expects to pay additional amounts to FCCC in future
periods in accordance with the payment schedule specified under the FCCC agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Other Research
and Service Provider Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Operating Lease</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company leased office
space in Dallas, Texas under month-to-month lease arrangements during the nine months ended September 30, 2020 and the year ended
December 31, 2019. In connection with the Company&rsquo;s employees working remotely due to COVID-19, the Company in August 2020
reduced its monthly lease commitment and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions
and intends to increase its lease of office space following an improvement in the COVID-19 situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5. Shareholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In March 2019, the Company
sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued 213,510
shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future Equity (SAFE)
agreements. See Note 6. In connection with the sale and issuance of the Series A preferred stock in March 2019, the Company issued
warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price of $3.13 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In July 2019, the Company
sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with the issuance
of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series A preferred stock
at an initial exercise price of $3.13 per share.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2019,
the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred Stock
were issued and outstanding. The holders of Series A Preferred Stock were entitled to receive dividends when, as and if declared
by the Company&rsquo;s Board of Directors, payable in preference and priority to any declaration or payment of dividends on Common
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Effective January 15,
2020, as a result of the reincorporation in the state of Delaware, the par value of the Company&rsquo;s preferred stock was changed
from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein as reflective of
this change</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Upon the Company&rsquo;s
IPO, all shares of the Company&rsquo;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of September 30,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On June 15, 2020, the
Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750 and
other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in its IPO
at a price of $15.00 per share. In connection with the IPO, all shares of the Company&rsquo;s Series A Preferred Stock were converted
into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of
the fractional shares adjustments that occurred in connection with the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion of
the preferred stock that took place in connection with the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the three and
nine months ended September 30, 2020, the Company issued zero and 50,460 shares of common stock, respectively, relating to the
exercise of stock options. The shares were issued at a purchase price of $1.03 for total proceeds of $52,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of September 30,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,217,577 shares were issued and outstanding. As of
December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company had warrants
to purchase 332,014 shares of common stock outstanding and exercisable as of September 30, 2020 at a weighted average exercise
price of $6.42 per share. The Company had warrants to purchase 273,900 shares of Series A Preferred Stock outstanding and exercisable
as of September 30, 2019 at a weighted average exercise price of $3.13 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
IPO, the Company granted the underwriters warrants (the &ldquo;Underwriters&rsquo; Warrants&rdquo;) to purchase an aggregate of
70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price. The
Underwriters&rsquo; Warrants have a five-year term and are not exercisable prior to December 7, 2020. All of the Underwriters&rsquo;
Warrants were outstanding at September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
Series A Preferred Stock financing transactions discussed above, during the nine months ended September 30, 2019, the Company issued
warrants to purchase an aggregate of 137,514 shares of Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company recorded
stock-based compensation of approximately $167,000 and $54,000 related to stock options during the nine months ended September
30, 2020 and 2019, respectively, and approximately $43,000 and $32,000 of stock-based compensation during the three months ended
September 30, 2020 and 2019, respectively. These amounts are included in general and administrative expenses in the accompanying
condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">A summary of stock option
activity under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the &ldquo;Plan&rdquo;) during the
nine months ended September 30, 2020 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<BR>
Average<BR> Exercise Price Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Outstanding December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">607,491</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.03</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,460</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(43,166</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.03</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Outstanding September 30, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">820,608</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6.25</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Options were exercisable
for 515,695 shares of Common Stock at September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2019, options to purchase 1,342 shares of Common Stock were granted, no options were exercised, and no options
expired or were canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6. SAFE Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In December 2018, the
Company entered into SAFE agreements (the &ldquo;SAFE Financing&rdquo;) with five investors pursuant to which the Company received
funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent
financing of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&rsquo; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The SAFE agreements
were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in full satisfaction of
these agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 7. Notes and Loan Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed was
approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of September 30, 2020, there is no remaining loan balance on
the Company&rsquo;s condensed consolidated balance sheet related to the First Insurance financing arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On May 1, 2020 (the
&ldquo;Origination Date&rdquo;), the Company received $108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;) from JPMorgan
Chase Bank (the &ldquo;Lender&rdquo;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &ldquo;PPP Loan Agreement&rdquo;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past
two years. The Company is tracking further development and guidance related to the Paycheck Protection Program terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company has from
time to time obtained preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. The Company
recorded expenses of approximately $11,000 and $23,000 related to Biological Mimetics, Inc. during the three and nine months ended
September 30, 2019, all of which is included in research and development. No expenses related to Biological Mimetics, Inc. were
recorded during the three and nine months ended September 30, 2020. Approximately $2,000 was owed to Biological Mimetics, Inc.
at December 31, 2019, all of which is included in accounts payable and accrued expenses in the accompanying condensed consolidated
balance sheet. Nothing was owed to Biological Mimetics, Inc. at September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company has previously
engaged Intuition Systems (&ldquo;Intuition&rdquo;) to provide services relating to development of the Company&rsquo;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&rsquo;s former Chief Executive Officer, President and Director. No expenses
were recorded related to Intuition Systems during the three and nine months ended September 30, 2020 or during the three and nine
months ended September 30, 2019. At both September 30, 2020 and December 31, 2019, approximately $9,000 remained unpaid relating
to Intuition and is included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2018, the
Company entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with BioNumerik Pharmaceuticals, Inc. (&ldquo;BioNumerik&rdquo;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&rsquo;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. The Company recorded no expense related to BioNumerik during the three and nine months ended
September 30, 2020 and September 30, 2019. Amounts payable to BioNumerik as of both September 30, 2020 and December 31, 2019 totaled
approximately $11,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9. Loss Per Share of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt">Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included
in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due to being
anti-dilutive&nbsp;include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding at <BR>
September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Warrants to purchase Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">332,014</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Warrants to purchase Series A Preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">820,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,402</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,152,622</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,343,168</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_009"></A>Item 2. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>You should read the following discussion
and analysis of our financial condition and plan of operations together with our condensed consolidated financial statements and
the related notes appearing elsewhere in this Quarterly Report. In addition to historical information, this discussion and analysis
contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially
from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified
below, and those factors discussed in the Risk Factors section of the final prospectus, dated June 10, 2020, for our initial public
offering, on file with the Securities and Exchange Commission.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We are a clinical stage
biopharmaceutical company, focused on leveraging artificial intelligence (&ldquo;A.I.&rdquo;), machine learning and genomic data
to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies.
Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized
drug, as well as new compounds that we are developing with the assistance of our A.I. platform and our biomarker driven approach.
Our A.I. platform, known as RADR<SUP>&reg;</SUP>, currently includes more than one billion data points, and uses big data analytics
(combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from
trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures
correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. This data-driven,
genomically-targeted&nbsp;and biomarker-driven&nbsp;approach allows us to pursue a transformational drug development strategy that
identifies, rescues or develops, and advances potential small molecule drug candidates at what we believe is a fraction of the
time and cost associated with traditional cancer drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our strategy is to both
develop new drug candidates using our RADR<SUP>&reg;</SUP>&nbsp;platform, and other machine learning driven methodologies, and
to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted in
development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant for
the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or for
strategic reasons by the owner or development team responsible for the compound. Importantly, these historical drug candidates
appear to have been well-tolerated&nbsp;in many instances, and often have considerable data from previous toxicity, tolerability
and ADME (absorption, distribution, metabolism, and excretion) studies that have been completed. Additionally, these drug candidates
may also have a body of existing data supporting the potential mechanism(s) by which they achieve their intended biologic effect,
but often require more targeted trials in a stratified group of patients to demonstrate statistically meaningful results. Our dual
approach to both develop de-novo, biomarker-guided&nbsp;drug candidates and &ldquo;rescue&rdquo; historical drug-candidates by
leveraging A.I., recent advances in genomics, computational biology and cloud computing is emblematic of a new era in drug development
that is being driven by data-intensive&nbsp;approaches meant to de-risk&nbsp;development and accelerate the clinical trial process.
In this context, we intend to create a diverse portfolio of oncology drug candidates for further development towards regulatory
and marketing approval with the objective of establishing a leading A.I.-driven, methodology for treating the right patient with
the right oncology therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">A key component of our
strategy is to target specific cancer patient populations and treatment indications identified by leveraging our RADR<SUP>&reg;&nbsp;</SUP>platform,
a proprietary A.I. enabled engine created and owned by us. We believe the combination of our therapeutic area expertise, our A.I.
expertise, and our ability to identify and develop promising drug candidates through our collaborative relationships with research
institutions in selected areas of oncology gives us a significant competitive advantage. Our RADR<SUP>&reg;</SUP> platform was
developed and refined over the last four years and integrates millions of data points immediately relevant for oncology drug development
and patient response prediction using artificial intelligence and proprietary machine learning algorithms. By identifying clinical
candidates, together with relevant genomic and phenotypic data, we believe our approach will help us design more efficient pre-clinical&nbsp;studies,
and more targeted clinical trials, thereby accelerating our drug candidates&rsquo; time to approval and eventually to market. Although
we have not yet applied for or received regulatory or marketing approval for any of our drug candidates, we believe our RADR<SUP>&reg;</SUP>&nbsp;platform
has the ability to reduce the cost and time to bring drug candidates to specifically targeted patient groups. We believe we have
developed a sustainable and scalable biopharma business model by combining a unique, oncology-focused big-data platform that leverages
artificial intelligence along with active clinical and preclinical programs that are being advanced in targeted cancer therapeutic
areas to address today&rsquo;s treatment needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our current portfolio
consists of three active compounds in development: two drug candidates in clinical phases and, one in preclinical studies. All
of these drug candidates are leveraging precision oncology, A.I. and genomic driven approaches to accelerate and direct development
efforts. We currently have two drug candidates in clinical development, LP-100&nbsp;and LP-300, where we are leveraging data from
prior preclinical studies and clinical trials, along with insights generated from our A.I. platform, to target the types of tumors
and patient groups that would be most responsive to the drug. Both LP-100 and LP-300 showed promise in prior clinical testing,
but failed pivotal Phase III trials where the overall results did not meet the required clinical endpoints due to what we believe
was a lack of patient stratification driven by an inability to develop biomarker-driven, precision oncology trials. Additionally,
we have one new drug candidate, LP-184, in preclinical development for two potentially distinct indications where we are leveraging
machine learning and genomic data to streamline the drug development process and to identify the patients and cancer subtypes that
will best benefit from the drug, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our development strategy
is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence and genomic
data can help us provide biological insights, reduce the risk associated with development efforts and help clarify potential patient
response. We plan on strategically evaluating these on a program-by-program&nbsp;basis as they advance into clinical development,
either to be done entirely by us or with out-licensing partners to maximize the commercial opportunity and reduce the time it takes
to bring the right drug to the right patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">To date, except for
a prior research grant, we have not generated any revenue, we have incurred net losses and our operations have been financed primarily
by sales of our equity securities. Our net losses were $1,701,488 and $669,652 for the three months ended September 30, 2020 and
September 30, 2019, respectively. Our net losses for the nine months ended September 30, 2020 and September 30, 2019 were $3,012,186
and $1,753,018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our net losses have
primarily resulted from costs incurred in licensing and developing the drug candidates in our pipeline, planning, preparing and
conducting preclinical studies, early stage clinical testing and general and administrative activities associated with our operations.
We expect to continue to incur significant expenses and corresponding increased operating losses for the foreseeable future as
we continue to develop our pipeline. Our costs may further increase as we conduct preclinical studies and clinical trials and potentially
seek regulatory clearance for and prepare to commercialize our drug candidates. We expect to incur significant expenses to continue
to build the infrastructure necessary to support our expanded operations, preclinical studies, clinical trials, commercialization,
including manufacturing, marketing, sales and distribution functions. We have experienced and will continue to experience increased
costs associated with operating as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our operations, including
the development of our drug candidates, could be disrupted and materially adversely affected in the future by a pandemic, epidemic
or outbreak of an infectious disease like the recent outbreak of COVID-19. For example, as a result of measures imposed by the
governments in regions affected by COVID-19 businesses and schools have been suspended due to quarantines or &ldquo;stay at home&rdquo;
orders intended to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the Director General
of the World Health Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC),
based on the advice of the Emergency Committee under the International Health Regulations (2005), and on March 12, 2020, the President
of the United States imposed international travel restrictions between the U.S. and Europe to supplement the existing international
travel restrictions between the US and certain Asian countries and on March 13, 2020, declared a national emergency in response
to the likely spread of COVID-19. COVID-19 continues to spread globally and, as of September 30, 2020, has spread to over 150 countries,
including the United States. U.S. and international stock markets continue to experience fluctuations and to be impacted from time
to time by uncertainty associated with the impact of COVID-19 on the U.S., Chinese, European and other economies and the reduced
levels of international travel experienced since early 2020. The Dow Industrial Average and other domestic and international stock
indices have experienced substantial fluctuations during 2020 largely attributed to assessments and expectations regarding the
adverse effects of the pandemic on the world&rsquo;s economies. We are continuing to assess our business plans and the impact COVID-19
may have on our operations and plans, including the ability to advance the development of our drug candidates, but no assurances
can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19 or its consequences,
including downturns in business sentiment generally or in our sector in particular. The extent to which COVID-19 impacts our operations
and plans will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the
duration of the outbreak, new information which may emerge concerning the severity and treatment of COVID-19, and preventative
or protective actions that governments, businesses, and organizations performing research and clinical trials may take in respect
of COVID-19, among others. The existence and spread of an infectious disease, including COVID-19, may also result in the inability
of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our collaborators
and out-license partner&rsquo;s ability to perform and advance preclinical and nonclinical studies and clinical trials. For example,
Allarity Therapeutics (formerly known as Oncology Venture) has informed us that continuing enrollment in the Phase II clinical
trial for LP-100 (Irofulven) has slowed during the pandemic. The timing of non-clinical research studies for our drug candidates
by collaborators and service providers also slowed during the second and third quarters of 2020 in connection with the pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Components of Our Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We did not recognize
revenues for any of the three or nine month periods ended September 30, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and Administrative</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">General and administrative
expenses consist of our operating expenses that are not included in the direct costs of production or cost of goods sold which
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">corporate
office overhead expenses such as salaries of administrative staff and corporate officers;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
expenses;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounting
expenses; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance,
rent, utilities and supplies.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
expenses consist primarily of costs incurred for the research and development of our preclinical and clinical candidates, which
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
incurred towards consultants, laboratories and investigators that conduct our preclinical or clinical research activities; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 24pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost of acquiring and developing preclinical study materials and lab supplies.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We expense research
and development costs to operations as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our research and development
costs by project category for the three months ended September 30, 2020 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended September&nbsp;30,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">LP-300</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">149,028</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>LP-184</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">248,083</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">RADR<SUP>&reg; </SUP>Platform</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62,391</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">600,769</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As a private company,
we did not track our research and development costs by project category primarily because research and development salary expenses
were not further allocated to each project. As a result, our tracking of research and development costs by project category commenced
in the second calendar quarter of 2020 in connection with the Company&rsquo;s IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We expect that our research
and development expenses will continue to increase as we progress toward our commencement of clinical trials of LP-300 and LP-184.
We expect this increase to include additional expenses associated with research and service provider agreements for the advancement
of our drug candidates and research and development efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Because of the numerous
risks and uncertainties associated with product development, we cannot determine with certainty the duration and completion costs
of these or other current or future clinical trials of LP-184 and LP-300 or our other therapeutic candidates. We may never succeed
in achieving regulatory approval for LP-184 and LP-300 or any of our other drug candidates. The duration, costs and timing of clinical
trials and development of our therapeutic candidates will depend on a variety of factors, including the uncertainties of future
clinical and preclinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation.
In addition, the probability of success for each drug candidate will depend on numerous factors, including competition, manufacturing
capability and commercial viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and Administrative</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">General and administrative
expenses consist primarily of salaries and related costs for employees in executive, finance and administration, corporate development
and administrative support functions, including stock-based compensation expenses and benefits. Other significant general and administrative
expenses include accounting and legal services, insurance, the cost of various consultants, occupancy costs and information systems
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our general and administrative
expenses have increased upon our becoming a public company and we expect this increase to continue. We also expect increased administrative
costs resulting from our anticipated clinical trials and the potential commercialization of our drug candidates. We believe that
these increases in our general and administrative expenses will include increased costs for director and officer liability insurance,
hiring additional personnel to support future market research and future product commercialization efforts and increased fees for
outside consultants, attorneys and accountants. We also expect to incur increased costs to comply with corporate governance, internal
controls, investor relations and disclosures and similar requirements applicable to a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Results of Operations for the
Three Months and Nine Months Ended September 30, 2020 and 2019 (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,100,719</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">441,251</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,117,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">977,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">600,769</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">228,401</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">894,896</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">775,718</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,701,488</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">669,652</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,012,186</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,753,018</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,701,488</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(669,652</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3,012,186</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,753,018</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison of the Three Months Ended
September 30, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">To date, except for
a prior research grant, we have not generated any revenue since our inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and Administrative Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">General and administrative
expenses increased $659,468 or 149%, from $441,251 for the three months ended September 30, 2019 to $1,100,719 for the three months
ended September 30, 2020. The increase was primarily attributable to increases in labor expense of approximately $177,000, increases
in business development expense of approximately $72,000, and corporate insurance expense increases of approximately $451,000.
This was partially offset by a decrease in travel and relocation expense of approximately $45,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
expenses increased $372,368, or 163%, from $228,401 for the three months ended September 30, 2019 to $600,769 for the three months
ended September 30, 2020. The increase was primarily attributable to increases in research study expenses of approximately $85,000,
increases in product candidate manufacturing related expenses of approximately $74,000, and an increase in research and development
employee associated expenses of approximately $206,000. Expenses for annual licensing fees and development milestone extension
payments did not change substantially for the three months ended September 30, 2020 as compared to the three months ended September
30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison of the Nine Months Ended
September 30, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">To date, except for
a prior research grant, we have not generated any revenue since our inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General and Administrative Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">General and administrative
expenses increased $1,139,990 or 117%, from $977,300 for the nine months ended September 30, 2019 to $2,117,290 for the nine months
ended September 30, 2020. The increase was primarily attributable to increases in labor expense of approximately $340,000, increases
in Nasdaq and other filing fees of approximately $61,000, business development expense increases of approximately $71,000, corporate
insurance expense increases of approximately $604,000, and stock option compensation expense increases of approximately $113,000.
This was partially offset by a decrease in travel and relocation expense of approximately $103,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
expenses increased $119,178, or 15%, from $775,718 for the nine months ended September 30, 2019 to $894,896 for the nine months
ended September 30, 2020. The increase was primarily attributable to increases in research study expenses of approximately $21,000,
increases in non-manufacturing related consulting expenses of approximately $62,000, increases in research and development employee
associated expenses of approximately $159,000, and increases in annual licensing fees and development milestone extension payments
of approximately $14,000. These increases were offset in part by reductions in product candidate manufacturing related expenses
of approximately $136,000 reflecting completion of process development and scale-up studies conducted in the prior year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt">On September 3, 2018
Lantern Pharma Limited, our wholly owned subsidiary, was awarded a grant by the UK government in the form of state aid under the
Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &ldquo;General Block Exemption&rdquo;), Article 25 Aid for research
and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and development activities
for the prostate cancer biomarker analysis of our LP-184 drug candidate. Following our research and development activities in Northern
Ireland, the grant will reimburse 50% of our research and development expenses not exceeding GBP 24,215 of vouched and approved
expenditures within specific categories and will remain in force for a period of five years. No revenue has been recognized from
this grant through September 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We incurred net losses
of $3,012,186 and $1,753,018 for the nine months ended September 30, 2020 and September 30, 2019, respectively. As of September
30, 2020, we had working capital of approximately $21,661,000 and as of December 31, 2019 we had working capital of approximately
$744,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On June 10, 2020, our
registration statement on Form S-1 relating to our IPO was declared effective by the Securities and Exchange Commission (&ldquo;SEC&rdquo;).
The IPO closed on June 15, 2020, and we issued and sold 1,750,000 shares of common stock at a public offering price of $15.00 per
share. Gross proceeds totaled $26,250,000 and net proceeds totaled $23,419,721 after deducting underwriting discounts and commissions
of $1,968,750 and other offering expenses of $861,529.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On May 1, 2020 (the
&ldquo;Origination Date&rdquo;), we received $108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;) from JPMorgan Chase
Bank (the &ldquo;Lender&rdquo;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security
(CARES) Act. As of September 30, 2020, we expect to meet the requirements of loan forgiveness under the stipulations of the program.
In the event we do not meet the requirements of loan forgiveness, the PPP Loan bears interest at a fixed rate of 1.0% per annum.
Payments of principal and interest are deferred for the first six months following the Origination Date, and the PPP Loan will
mature two years after the Origination Date. Following the deferral period, we will be required to make payments of principal plus
interest accrued under the PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined
by the Lender based on the principal balance of the PPP Loan outstanding following the deferral period and taking into consideration
any portion of the PPP Loan that may be forgiven prior to that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We have not yet generated
any revenues from operations, other than revenues from a research grant, and we have not yet achieved profitability. We expect
that general and administrative expenses and our research and development expenses will continue to increase and, as a result,
we will need to generate significant product revenues to achieve profitability. We may never achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sources of Liquidity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Since our inception,
our operations have been financed primarily through the sale of equity securities, and, to a much lesser extent, funds received
by us from the PPP Loan and a 2017 grant from the Massachusetts Life Sciences Center. We plan to apply for grant funding in the
future to assist in supporting our capital needs. We may also explore the possibility of entering into commercial credit facilities
as an additional source of liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of September 30,
2020 and December 31, 2019, we had cash and cash equivalents of approximately $20,803,000 and $1,232,000, respectively. We believe
that our existing cash and cash equivalents as of September 30, 2020, and our anticipated expenditures and capital commitments
for the remainder of calendar year 2020 and for calendar year 2021, will enable us to fund our operating expenses and capital
expenditure requirements for at least 12 months from the date of this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The following table
summarizes our cash flow for the periods indicated:</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Nine Months Ended<BR> September 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash flows used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,083,564</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,419,047</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash flows used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,145</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,717</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,665,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,920,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">19,570,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,495,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operating Activities</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">For the nine months
ended September 30, 2020, net cash used in operating activities was $4,083,564 compared to $1,419,047 for the nine months ended
September 30, 2019. The increase in net cash used in operating activities was primarily the result of the increase in the net loss
together with increases in prepaid expenses.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing Activities</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">For the nine months
ended September 30, 2020, net cash used in investing activities was $11,145 compared to $5,717 used in investing activities during
the nine months ended September 30, 2019.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financing Activities</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Net cash provided by
financing activities was $23,665,221 during the nine months ended September 30, 2020, attributable primarily to net proceeds from
our initial public offering. Net cash provided by financing activities during the nine months ended September 30, 2019 was $2,920,507.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Operating Capital and Capital Expenditure
Requirements</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We expect to continue
to incur significant and increasing operating losses at least for the next several years as we commence our clinical trials of
LP-300 and LP-184, pursue development of our other drug candidates, and seek potential future marketing approval for our drug candidates
which could be several years in the future, if at all. We do not expect to generate revenue, other than possible license revenue,
unless and until we successfully complete development and obtain regulatory approval for our therapeutic candidates. Our net losses
may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our planned clinical trials and
our expenditures on other research and development activities.</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We have based our projections
of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources
sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization
of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. We anticipate that
our expenses will increase substantially as we:</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">continue the development of our drug candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">initiate preclinical studies and clinical trials for any additional indications for our current drug candidates and any future drug candidates that we may pursue;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">continue to build our portfolio of drug candidates through the acquisition or in-license&nbsp;of additional drug candidates or technologies;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">continue to develop, maintain, expand and protect our intellectual property portfolio;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">continue to develop, maintain, and expand our RADR<SUP>&reg;</SUP> platform;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">pursue regulatory approvals for those of our current and future drug candidates that successfully complete clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ultimately establish a sales, marketing, distribution and other commercial infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">hire additional clinical, regulatory, scientific and accounting personnel; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">incur additional legal, accounting and other expenses in operating as a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We expect that we will
need to obtain substantial additional funding in order to complete our clinical trials. To the extent that we raise additional
capital through the sale of common stock, convertible securities or other equity securities, the ownership interests of our existing
stockholders may be materially diluted and the terms of these securities could include liquidation or other preferences that could
adversely affect the rights of our existing stockholders. In addition, debt financing, if available, would result in increased
fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific
actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our
ability to conduct our business. If we are unable to raise capital when needed or on attractive terms, we could be forced to significantly
delay, scale back or discontinue the development or commercialization of LP-184 and LP-300 and/or other drug candidates, seek collaborators
at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available, and
relinquish or license, potentially on unfavorable terms, our rights to LP-184 and LP-300 or other drug candidates that we otherwise
would seek to develop or commercialize ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Contractual Obligations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We did not have during
the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We prepare our consolidated
financial statements in accordance with generally accepted accounting standards in the United States of America. Our significant
accounting policies are described in Note 3 to our condensed consolidated financial statements appearing elsewhere in this Quarterly
Report. We believe the following critical accounting policies involve the most significant judgments and estimates used in the
preparation of the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The preparation of financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities
at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant
areas of estimation include determining the deferred tax asset valuation allowance and the inputs in determining the fair value
of equity-based&nbsp;awards and warrants issued. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
expenses are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development
and that have no alternative future use are expensed when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock-based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We have granted stock
options to our employees under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the &ldquo;Plan&rdquo;).
Stock-based compensation expense from awards granted under the Plan is allocated over the required service period over which those
stock option awards vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The stock option awards
are valued at fair value on the date of grant and that fair value is recognized over the requisite service period. The estimated
fair value of stock option awards was determined using the Black Scholes option pricing model on the date of grant. Some of these
grants occurred at a time when we were not a public company. Significant judgment and estimates were used to estimate the fair
value of these awards, as they occurred when our stock was not publicly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our estimation of fair
value of the awards made prior to the time we became a public company considered our recent transactions, relevant industry and
comparable public company data. Since, at the time of the grants, we were a non-public entity, the majority of the inputs used
to estimate the fair value of the common stock option awards are considered level 3 due to their unobservable nature. Each option
award is subject to specified vesting schedules and requirements. Compensation expense is charged to us over the required service
period to earn the award which is expected to be up to four years, subject to the achievement of time and event-based vesting requirements.
For the three months ended September 30, 2020 and September 30, 2019, we incurred share-based compensation expense related to equity
awards totaling approximately $43,000 and $32,000, respectively. For the nine months ended September 30, 2020 and September 30,
2019, we incurred share-based compensation expense related to equity awards totaling approximately $167,000 and $54,000, respectively.
We have recorded these charges as general and administrative expense in our statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">The
Company considered the applicability and impact of recent accounting pronouncements and determined them to be either not applicable
or expected to have minimal impact on our consolidated balance sheets or statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and Qualitative Disclosure
About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our primary exposure
to market risk is interest expense sensitivity, which is affected by changes in the general level of U.S. interest rates. Historically,
we have raised capital through the issuance of equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We do not believe that
our cash has significant risk of default or illiquidity. While we believe our cash does not contain excessive risk, we cannot provide
absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash at one or more financial institutions that are in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We do not participate
in any foreign currency hedging activities and we do not have any other derivative financial instruments. We did not recognize
any significant exchange rate losses during the nine months ended September 30, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Inflation generally
affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect
on our results of operations during the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>JOBS Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On April 5, 2012, the
Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an &ldquo;emerging
growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act
of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an &ldquo;emerging
growth company&rdquo; can delay the adoption of certain accounting standards until those standards would otherwise apply to private
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We are in the process
of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject
to certain conditions set forth in the JOBS Act, as an &ldquo;emerging growth company,&rdquo; we intend to rely on certain of
these exemptions, including without limitation, (i) providing an auditor&rsquo;s attestation report on our system of internal
controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley&nbsp;Act and (ii) complying with any requirement
that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing
additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain
an &ldquo;emerging growth company&rdquo; until the earliest of (i) the last day of the fiscal year in which we have total annual
gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the
completion of this offering; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous
three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_010"></A>Item 3. Quantitative and Qualitative
Disclosures About Market Risk.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt">Our balance sheet
as of September 30, 2020 includes cash and cash equivalents of approximately $20,803,000. Our primary exposure to market risk is
interest expense sensitivity, which is affected by changes in the general level of U.S. interest rates. Historically, we have raised
capital through the issuance of equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We do not believe that
our cash has significant risk of default or illiquidity. While we believe our cash does not contain excessive risk, we cannot provide
absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain
significant amounts of cash at one or more financial institutions that are in excess of federally insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We do not participate
in any foreign currency hedging activities and we do not have any other derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Inflation generally
affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect
on our results of operations during the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_011"></A>Item 4. Controls and Procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial
officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2020. The term
&ldquo;disclosure controls and procedures,&rdquo; as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure
that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by
a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&rsquo;s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding
required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The closing of our initial
public offering occurred on June 15, 2020. Consequently, as a newly reporting company under the Exchange Act, we are not required
to evaluate the effectiveness of our internal controls over financial reporting until the end of the fiscal year after we file
our first annual report on Form 10-K, which will occur on December 31, 2021. However, in connection with the audit of our financial
statements for the years ended December 31, 2019 and 2018, prior to our initial public offering, we observed material weaknesses
in our internal controls over financial reporting during those periods because we did not have a formal process for period end
financial closing and reporting, and also because we historically had insufficient resources to conduct an effective monitoring
and oversight function independent from our operations. We believe we are addressing these weaknesses through measures including
implementation of additional internal control processes and procedures regarding the financial close and reporting process, the
recruitment of a full time Chief Financial Officer, and the allocation of additional personnel and resources to support our finance
function, including, but not limited to, enhanced scrutiny of accounting entries in the areas where we have observed material weaknesses
in our internal controls over financial reporting. Our management intends to continue to monitor these weaknesses and evaluate
whether the remedial actions taken by the Company have remediated these weaknesses when it completes its first evaluation of the
Company&rsquo;s internal controls over financial reporting for the fiscal year ended December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Based on the evaluation
of our disclosure controls and procedures as of September 30, 2020, our Chief Executive Officer and Chief Financial Officer concluded
that, as of such date, our disclosure controls and procedures, as defined above, are effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_012"></A>PART II &ndash; OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_013"></A>Item 1. Legal Proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">From time to time in
the future, we may become involved in litigation or other legal proceedings that arise in the ordinary course of business. We are
not currently party to any legal proceedings, and we are not aware of any pending or threatened litigation against us that we believe
could have a material adverse effect on our business, operating results or financial condition. In the event we are subject to
a legal proceeding, it could have a material adverse impact on us because of litigation costs and diversion of management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_014"></A>Item 1A. Risk Factors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As a Smaller Reporting
Company we are exempted from the requirements of Item 1A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_015"></A>Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Unregistered Sales of Equity Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of Proceeds.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On June 10, 2020, our
registration statement on Form S-1, as amended (File No. <FONT STYLE="background-color: white"><B>333-237714) </B></FONT>was declared
effective by the SEC in connection with our initial public offering of common stock, pursuant to which we issued and sold, on June
15, 2020, 1,750,000 shares of common stock at a public offering price of $15.00 per share for total gross proceeds of $26,250,000.
On June 15, 2020 we received net proceeds of $23,419,721, after deducting underwriting discounts and commissions of $1,968,750
and other offering expenses of $861,529 borne by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of September 30,
2020, we estimate that we have used approximately $3.1 million of the net proceeds from our IPO for advancing and developing our
drug candidates and RADR<SUP>&reg;</SUP> platform, and for working capital and other general corporate purposes, including payment
of director and officer liability insurance premium amounts of approximately $1.8 million, approximately $557,000 of which have
been expensed through September 30, 2020 and approximately $1.25 million of which are included as part of prepaid expenses and
other current assets on the Company&rsquo;s condensed consolidated balance sheet at September 30, 2020. Substantially all of the
unused net proceeds from the offering are held in interest bearing accounts. There has been no material change in our use of the
net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the
SEC on June 10, 2020. Other than payments in the ordinary course of business for compensation of officers and to non-employee directors
as compensation for board or board committee service, none of the net proceeds from our IPO used by us were direct or indirect
payments to any of (i) our directors or officers or their associates, (ii) persons owning 10 percent or more of our common stock,
or (iii) our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_016"></A>Item 3. Defaults Upon Senior Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_017"></A>Item 4. Mine Safety Disclosures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_018"></A>Item 5. Other Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_019"></A>Item 6. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 89%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1***</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0920ex10-1_lantern.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">API Services Project Agreement, dated July 10, 2020, between Patheon API Services, Inc. and Lantern Pharma Inc.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10q0920ex31-1_lantern.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10q0920ex31-2_lantern.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10q0920ex32-1_lantern.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.2**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="f10q0920ex32-2_lantern.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</A></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Schema</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Calculation Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Definition Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Label Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL Taxonomy Extension Presentation Linkbase</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">**Furnished with this report</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>***</B>Certain confidential portions of this Exhibit were
omitted by means of marking such portions with an asterisk (the Mark) because the identified confidential portions (i) are not
material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lantern Pharma Inc.,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 63%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Delaware Corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;October 29, 2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Panna Sharma</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna Sharma, Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:&nbsp;&nbsp;October 29, 2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David R. Margrave</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David R. Margrave, Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">27</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0920ex10-1_lantern.htm
<DESCRIPTION>API SERVICES PROJECT AGREEMENT, DATED JULY 10, 2020, BETWEEN PATHEON API SERVICES, INC. AND LANTERN PHARMA INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.85pt"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT,
MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 5pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="width: 721px; height: 1020px"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 77%; font-size: 11pt"><FONT STYLE="font-size: 8pt"><B>[***]</B></FONT></TD>
    <TD STYLE="width: 23%; font-size: 11pt; text-align: right"><FONT STYLE="font-size: 8pt"><B>Lantern Pharma</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1.65pt; font-size: 11pt"><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD>
    <TD STYLE="padding-top: 1.65pt; font-size: 11pt; text-align: right"><FONT STYLE="font-size: 8pt"><B>Page 2 of 27</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: right; font: 8.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 8.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; background-color: #545658">
    <TD STYLE="border-top: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-bottom: 7pt; width: 50%; padding-top: 7pt; padding-left: 5.85pt; font-size: 11pt"><FONT STYLE="font-size: 10.5pt; color: white"><B>Patheon API Services, Inc. (&ldquo;Patheon&rdquo;)</B></FONT></TD>
    <TD STYLE="border-top: gray 1pt solid; border-right: gray 1pt solid; border-bottom: #008542 1pt solid; padding-bottom: 7pt; width: 50%; padding-top: 7pt; padding-left: 6pt; font-size: 11pt"><FONT STYLE="font-size: 10.5pt; color: white"><B>Patheon API Services, Inc. (&ldquo;Patheon&rdquo;)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 7pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 134.3pt 0pt 5.85pt">101 Technology Place <BR>
Florence,</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">SC 29501</P></TD>
    <TD STYLE="padding-bottom: 7pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid">
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 127.85pt 0pt 5.6pt">101 Technology Place <BR>
Florence,</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt">SC 29501</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-left: gray 1pt solid; padding-top: 15.2pt; padding-left: 5.85pt; font-size: 11pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;/s/ </FONT>[***]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; padding-top: 15.2pt; padding-left: 5.6pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;/s/ </FONT>[***]<FONT STYLE="font-size: 10pt">&#9;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.85pt; text-align: left; border-right: gray 1pt solid; border-left: gray 1pt solid; vertical-align: middle">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Name: </FONT>[***]</P></TD>
    <TD STYLE="border-right: gray 1pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt"><FONT STYLE="font-size: 10pt">Name: </FONT>[***]</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-left: gray 1pt solid; padding-top: 8.4pt; padding-left: 5.85pt; font-size: 11pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Title:&#9;Sr.
Business Manager</FONT>&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; padding-top: 8.4pt; padding-left: 5.6pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">Title:&#9;Executive Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">Date: July 10, 2020</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">&nbsp;</P></TD>
    <TD STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt">Date: July 10, 2020</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; background-color: #545658">
    <TD COLSPAN="2" STYLE="padding-bottom: 7pt; border-top: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-top: 7pt; padding-left: 5.85pt; font-size: 11pt"><FONT STYLE="font-size: 10.5pt; color: white"><B>Lantern Pharma (&ldquo;Client&rdquo;)</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: gray 1pt solid; border-right: Gray 1pt solid; border-bottom: #008542 1pt solid; padding-bottom: 7pt; padding-top: 7pt; padding-left: 6pt; font-size: 11pt"><FONT STYLE="font-size: 10.5pt; color: white"><B>Lantern Pharma (&ldquo;Client&rdquo;)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-bottom: 7pt; border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid">
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 102.25pt 0pt 5.85pt">1920 Mckinney Ave 7th Floor <BR>
Dallas, Texas
        75201</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">United States</P></TD>
    <TD COLSPAN="2" STYLE="border-right: Gray 1pt solid; border-bottom: gray 1pt solid; padding-bottom: 7pt">
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 95.85pt 0pt 5.6pt">1920 Mckinney Ave 7th Floor <BR>
Dallas, Texas
        75201</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt">United States</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid; width: 6%">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">By:</P></TD>
    <TD STYLE="border-right: gray 1pt solid; width: 44%">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>/s/ David Margrave&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </U></P></TD>
    <TD STYLE="width: 6%">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt">By:</P></TD>
    <TD STYLE="border-right: Gray 1pt solid; width: 44%">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">Name:</P></TD>
    <TD STYLE="border-right: gray 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>David Margrave&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
        </U></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt">Name:</P></TD>
    <TD STYLE="border-right: Gray 1pt solid">
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid; padding-top: 8.4pt; padding-left: 5.85pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><FONT STYLE="font-size: 10pt"><U>Chief Financial Officer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-top: 8.4pt; padding-left: 5.6pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-right: Gray 1pt solid; padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid; padding-top: 8.4pt; padding-left: 5.85pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-right: gray 1pt solid; padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><FONT STYLE="font-size: 10pt"><U>July
    10, 2020 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="padding-top: 8.4pt; padding-left: 5.6pt; font-size: 11pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-right: Gray 1pt solid; padding-top: 8.4pt; padding-left: 0; font-size: 11pt"><B><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: gray 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 1pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.85pt"><FONT STYLE="font-size: 1pt">&nbsp;</FONT></P></TD>
    <TD STYLE="border-right: gray 1pt solid"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 1pt"><B>&nbsp;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.05pt"><FONT STYLE="font-size: 1pt">&nbsp; </FONT></P></TD>
    <TD ROWSPAN="2" STYLE="border-bottom: gray 1pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.6pt">&nbsp;</P></TD>
    <TD ROWSPAN="2" STYLE="border-right: Gray 1pt solid; border-bottom: gray 1pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 5.05pt; text-indent: 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: gray 1pt solid; border-bottom: gray 1pt solid; border-left: gray 1pt solid; padding-top: 9.35pt; padding-left: 5.85pt; font-size: 11pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt"><B>Effective Date: <U>July 10, 2020</U></B><U> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Proposal when executed
by Patheon and the Client will become a contract binding on the parties (the &ldquo;Contract&rdquo;). The Term of the Contract
will be from the Effective Date until completion by Patheon unless specified otherwise. This Proposal is a time-limited offer,
which will remain open for acceptance by the Client for 14 days from the issue date above. Following the expiry of this offer,
Patheon may, at its sole option, waive the time limit or rescind this offer without further notice to the Client.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date of Confidentiality Agreement:
March 11, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; background-color: #D9D9D9">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>Peace of Mind</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 31.35pt 0pt 14.35pt; color: #4B4D4B">Our global quality systems
        are proven by a regulatory track record that&rsquo;s second to none.<BR>
&nbsp;<BR>
<BR>
<BR>
<BR>
<BR>
<BR>
</P>



<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 31.35pt 0pt 14.35pt; color: #4B4D4B"></P></TD>
    <TD STYLE="width: 50%; background-color: #F1F1F1">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>Unmatched Capabilities</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 32.25pt 0pt 14.35pt; color: #4B4D4B">The most services across
        all phases, dosage forms and scales for drug substances and products.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #F1F1F1">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>Experience</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 50.05pt 0pt 14.35pt; color: #4B4D4B">We work with companies in
        more than 70 countries.<BR></P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 50.05pt 0pt 14.35pt; color: #4B4D4B"><BR>
<BR>
<BR>
&nbsp;</P></TD>
    <TD STYLE="background-color: #D9D9D9">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>Trust</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 14.75pt 0pt 14.35pt; color: #4B4D4B">We understand the unique
        needs of small companies. More than 75% of our clients are emerging and mid-size biopharma organizations.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="background-color: #D9D9D9">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>True Partners</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 14.35pt; color: #4B4D4B">Our Business Management
        approach nurtures client relationship, and the Voice of client program enables smooth issue resolution.<BR>
&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 14.35pt; color: #4B4D4B">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 14.35pt; color: #4B4D4B">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 26.65pt 0pt 14.35pt; color: #4B4D4B">&nbsp;</P></TD>
    <TD STYLE="background-color: #F1F1F1">
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 15pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.35pt; color: #ED3034"><B>Results</B></P>
        <P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 24.65pt 0pt 14.35pt; color: #4B4D4B">We manufacture 117 products
        having received NDA approval from 2008-2017.</P></TD></TR>
</TABLE>
<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 22pt; color: #ED3741"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10.5pt; font-weight: bold">Part A: Project Overview</TD>
    <TD STYLE="text-align: right; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">6</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-top: 3.3pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 85%; padding-top: 3.3pt; text-indent: 0in; font-size: 10pt">Proposal Introduction</TD>
    <TD STYLE="text-align: right; width: 10%; padding-top: 3.3pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">7</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 7.7pt; font-size: 10.5pt; font-weight: bold">Part B: Project Activities</TD>
    <TD STYLE="text-align: right; padding-top: 7.7pt; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">8</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3.3pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3.3pt; text-indent: 0in; font-size: 10pt">1. Technology Transfer and Process Evaluation</TD>
    <TD STYLE="text-align: right; padding-top: 3.3pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">8</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">2. Analytical Methods Implementation and Associated Services</TD>
    <TD STYLE="text-align: right; padding-top: 2.9pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">8</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">3. Manufacture of GMP Material</TD>
    <TD STYLE="text-align: right; padding-top: 3.15pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">10</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">4. Stability Studies</TD>
    <TD STYLE="text-align: right; padding-top: 2.9pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">11</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">5. Raw Materials</TD>
    <TD STYLE="text-align: right; padding-top: 3.15pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">12</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2.9pt; text-indent: 0in; font-size: 10pt">6. Additional Services</TD>
    <TD STYLE="text-align: right; padding-top: 2.9pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3.15pt; text-indent: 0in; font-size: 10pt">7. Project Management</TD>
    <TD STYLE="text-align: right; padding-top: 3.15pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">13</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 7.7pt; font-size: 10.5pt; font-weight: bold">Part C: Budget Summary</TD>
    <TD STYLE="text-align: right; padding-top: 7.7pt; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">14</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 8.1pt; font-size: 10.5pt; font-weight: bold">Part D: High Level Timeline</TD>
    <TD STYLE="text-align: right; padding-top: 8.1pt; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">17</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 7.85pt; font-size: 10.5pt; font-weight: bold">Part E: Standard Assumptions</TD>
    <TD STYLE="text-align: right; padding-top: 7.85pt; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">18</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 8.1pt; font-size: 10.5pt; font-weight: bold">Part F: Legal Terms and Conditions</TD>
    <TD STYLE="text-align: right; padding-top: 8.1pt; font-size: 10.5pt; font-weight: bold; vertical-align: bottom">22</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 3.25pt; text-indent: 0in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-top: 3.25pt; text-indent: 0in; font-size: 10pt">Project Team Profiles</TD>
    <TD STYLE="text-align: right; padding-top: 3.25pt; text-indent: 0in; font-size: 10pt; vertical-align: bottom">25</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Part A: Project Overview</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Lantern is currently evaluating it&rsquo;s
API LP-300 in a Phase 2 clinical trial. They have requested that Patheon provide a proposal to transfer the previously validated
manufacturing process and analytical methods and produce [***] of final API under cGMP.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Technical Expertise</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Reduced Timelines</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Price</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 29.9pt 0pt 30.3pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 29.9pt 0pt 30.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #ED3034">Proposal
Introduction</P>

<P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patheon is an industry
leading API Contract Development and Manufacturing Organisation (CDMO) with extensive experience of successfully undertaking programs
of work for many established and emerging pharmaceutical companies. The R&amp;D and manufacturing facilities at Patheon&rsquo;s
global network of sites are well- positioned to deliver on Lantern&rsquo;s requirements for LP-300. The services covered by this
proposal will be undertaken at the Florence facility in South Carolina.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10.5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10.5pt">This FDA
approved facility [***] is primarily engaged in API process development and manufacture for early clinical phases. [***]</FONT></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 30.05pt 0pt 30.3pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 30.05pt 0pt 30.3pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Part B: Project Activities</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">1.
Technology Transfer and Process Evaluation</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Goal</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">To reproduce the Client&rsquo;s documented
procedures on laboratory scale</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Complete a non-GMP demonstration batch in a glass reactor.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">To carry out process improvement activities to
enable safe and robust manufacture on the desired scale</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Deliverables</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Weekly updates. Format as per Patheon standard.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Samples of any material produced</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">One final report detailing work carried out. Format as per Patheon standard.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 13pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Estimated Duration</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Approximately 6 weeks after receipt of materials</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Scope</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; text-align: justify">Patheon will begin the
project by undertaking laboratory activities to implement and evaluate the process provided by Lantern. This work will be carried
out in the chemical and analytical R&amp;D laboratories.</P>

<P STYLE="text-align: justify; text-indent: 0; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0; text-align: justify">As the transfer and
evaluation of each stage of the process is completed, Patheon will carry out a non-GMP demonstration batch in a glass reactor.</P>

<P STYLE="text-align: justify; text-indent: 0; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-indent: 0; margin: 0pt 0; text-align: justify">Wherever possible, the
conditions already established by Lantern will be implemented for scale-up. Sometimes the process supplied by a Client needs to
be improved or formally developed in order to be safe and robust for the requested scale-up.</P>

<P STYLE="text-align: justify; text-indent: 0; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Assumptions</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0; color: #ED3034">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Lantern technical personnel will be available as required to answer questions and generally support
the implementation process.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">The process provided by Lantern works reasonably similar as described</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">2.
Analytical Methods Implementation and Associated Services</P>

<P STYLE="text-align: justify; font: 8.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Goals</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">To transfer validated analytical methods from the Client or other third party to support the
cGMP manufacture, release, and stability testing of Product</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">To develop suitable methods to support testing of non-GMP development activities, and to validate
the developed methods to support cGMP manufacture release of cGMP batches</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">To perform verification of USP methods to support release and stability testing of the Product</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">To generate/procure intermediate and impurity markers
for analytical method development</TD>
</TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Deliverables</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Patheon format documents providing details of the final analytical methods developed</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Estimated Duration</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Approximately 6 weeks</TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt; color: #ED3034">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Scope</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Patheon will carry out analytical method transfer
in our R&amp;D laboratories. Once the methods have been qualified in-house, they will be transferred to the Quality Control laboratory/personnel.
Impurity/intermediate markers will be either produced in-house or procured if commercially available. [***]. The remaining markers
will be produced in-house except for [***].[***] Procurement of this material will be captured as a pass-through cost once a source
is identified. All markers will be tested and a Certificate of Testing will be issued.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Assumptions</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Already fixed specifications
for key raw materials, intermediates, and final product will be provided by the Client prior to commencement of work. If fixed
specifications are not available, timelines may be impacted and additional costs may be incurred and will be captured via the Change
of Scope process.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Client-stated available
analytical methods, reference standards / marker substances will be provided by the Client to Patheon in good time prior to the
start of laboratory process familiarisation. If methods and standards are not provided or prove to be inadequate for the required
purpose, timelines may be impacted and additional costs may be incurred and will be captured via the Change of Scope process.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patheon standard specifications
and release testing will be applied to all non-contributory or standard raw materials. If Client-defined specifications are required,
timelines may be impacted and additional costs may be incurred and will be captured via the Change of Scope process.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: #ED3034">Methods to be
Transferred </FONT><FONT STYLE="color: red">or Evaluated</FONT><FONT STYLE="color: #ED3034">:</FONT></P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">[***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Other Analytical Services</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other analytical services
may include the following. Modify/delete as appropriate, including addition of appropriate scope text.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Impurity identification</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Genotoxic assessments in conjunction with chemical development</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Forced degradation study</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Characterisation of reference standards</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Specification generation</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">3.
Manufacture of GMP Material</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Goal</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in">To manufacture approximately [***]
of LP-300 under cGMP conditions</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Deliverables</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Target Quantity: Approximately
[***] of LP-300 to the agreed upon specifications on a campaign basis. Lantern will receive all material generated from the campaign
(except retains, QC samples, etc)</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Campaign Report. Format
as per Patheon standard. A report will be issued four to six weeks after release, containing detailed process descriptions, commented
scale-up results, and information on key raw materials used for the scale-up. Key analytical data for intermediates and final product
will be included.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GMP Documentation: Copies
of all GMP Executed Batch Operating Procedures will be provided (incl. deviation/OOS reports, CoA and releases of all raw materials,
printouts of all IPC and release tests, cleaning records and temperature charts, and QA sign-off). Master Batch Operating Procedures
(BOP) (equivalent to Master Batch Records (MBR)) and Executed Batch Operating Procedures (equivalent to Executed Batch Records
(EBR)) in local language (English).</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">QA-approved TSE/BSE
certificate, certificate of compliance/conformity, release for intended application, and batch tree for the GMP batch.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Estimated Duration</P>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10.5pt">Approximately </FONT>[***] <FONT STYLE="font-size: 10.5pt">after receipt of materials</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt; color: #ED3034">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Scope</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patheon will transfer
the manufacturing process established during the Technology Transfer and Process Evaluation phase of work to the production facility
and carry out a production campaign. The target quantity of this campaign will be [***]. This campaign shall be performed under
cGMP conditions using water for injection.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Assumptions</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">The final product will be tested against the following
specifications (tentative; to be discussed in good faith):</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.3pt">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">[***]</P>

<P STYLE="font: 14.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">4.
Stability Studies</P>

<P STYLE="font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Goal</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">To provide re-test data for LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Deliverables</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Data summaries will be provided to the Client at
intermediate time points, and a stability summary report will be provided to the Client following completion of the study.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Estimated Duration:</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">See table below</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Scope</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Patheon shall design a stability program to monitor:</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Single batch from the GMP campaign under ICH conditions</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Samples will be placed on storage concurrently and also tested concurrently at each test point.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Unless indicated in the stability protocol, the analytical data from each batch manufactured
at Patheon will be used as initial time point (T=0) data.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 11.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">The following storage conditions and time points
are suggested for testing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: White 1pt solid; border-left: Black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: White"><B>Storage</B></FONT></TD>
    <TD STYLE="border-bottom: White 1pt solid; padding-right: 0; text-align: center; background-color: #545658; padding-top: 0; padding-left: 0"><FONT STYLE="font-size: 8pt; color: White"><B>Number</B></FONT></TD>
    <TD COLSPAN="12" STYLE="border-bottom: White 1pt solid; border-right: black 1pt solid; padding-right: 0; background-color: #545658; padding-top: 0; padding-left: 0"><P STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: white"><B>Time points</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; text-indent: 0; width: 22%; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B></B></FONT>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>
<FONT STYLE="font-size: 8pt; color: white"><B>conditions</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: center; padding-right: 0; width: 6%; background-color: #545658; padding-top: 0; padding-left: 0; text-indent: 0; vertical-align: middle; border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt; color: white"><B></B></FONT>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; color: white"></P>
<FONT STYLE="font-size: 8pt; color: white"><B>of<BR>
batches</B></FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-left: 0; text-indent: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt; color: white"><B>0 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 8pt; color: white"><B>1 M</B></FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-left: 0; text-indent: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt; color: white"><B>2 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>3 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>6 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>9 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>12 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>18 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-indent: 0; width: 6%; border-right: black 1pt solid; background-color: #545658; padding-top: 0; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt; color: white"><B>24 M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; background-color: #545658; width: 6%; border-right: black 1pt solid; padding-top: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 8pt; color: White"><B>36
    M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; background-color: #545658; width: 6%; border-right: black 1pt solid; padding-top: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 8pt; color: White"><B>48
    M</B></FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; background-color: #545658; width: 6%; border-right: black 1pt solid; padding-top: 0; padding-left: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 8pt; color: White"><B>60
    M</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">Freezer -20&deg;C</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: center; padding-right: 0; border-bottom: black 1pt solid; border-left: Black 1pt solid; background-color: #FFFFCC; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-left: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt">R</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">Refrigerator 5&deg;C</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: center; padding-right: 0; border-bottom: black 1pt solid; border-left: Black 1pt solid; background-color: #FFFFCC; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt">R</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">Long term 25&deg;C/60% R.H.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: middle; padding-left: 0; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">1</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt">R</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">M</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; text-align: center; padding-left: 0"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; text-align: center; padding-left: 0"><FONT STYLE="font-size: 8pt">M</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">M</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">Intermediate 30&deg;C/65% R.H.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: middle; padding-left: 0; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-top: 1.85pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">1</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-left: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt">R</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">C</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">C</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">C</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; text-align: center; padding-left: 0"><FONT STYLE="font-size: 8pt">C</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 1.85pt; text-align: center; padding-left: 0"><FONT STYLE="font-size: 8pt">C</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; vertical-align: middle; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">Accelerated 40&deg;C/75% R.H.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; vertical-align: middle; padding-left: 0; border-bottom: black 1pt solid; border-left: Black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">1</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; vertical-align: middle"><FONT STYLE="font-size: 8pt">R</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-left: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-right: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 2.05pt; padding-left: 0; text-align: center"><FONT STYLE="font-size: 8pt">X</FONT></TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 0; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; padding-right: 0; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center; padding-left: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">R = release test data</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">C = contingency (storage; testing only in
case of &quot;significant change&quot;)</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">X = characteristics, assay &amp; purity (HPLC),
water, XRPD</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">M = characteristics, assay &amp; purity (HPLC),
water, XRPD, microbiology</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Assumptions</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">The Client provided analytical method is stability
indicating, confirmed via a forced degradation study. If no forced degradation study has been undertaken, Patheon can arrange at
additional cost under a change of scope</P>

<P STYLE="text-align: justify; font: 15.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">5.
Raw Materials</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">The amounts of raw materials have been calculated on the current yields. A contingency of [***]%
has been considered.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">All raw materials, reagents, solvents, and auxiliary chemicals will be purchased by Patheon
and assumed to be available within the required quality and quantity and assumed lead time.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Commercial raw materials and starting materials will be released based on supplier CoA and identity
test. Starting materials and key raw materials will be additionally subjected to a use-test on lab scale.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Supplier of starting materials and raw materials will not be qualified by Patheon at this stage.</TD></TR></TABLE>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Raw materials supplied by the client must be accompanied by the appropriate documentation (CoA,
BSE/TSE or GMO certificate).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Import and forwarding costs for materials supplied by Clients will be passed through to the
Client in line with the rules for reimbursable items as set forth elsewhere in this document. Client or Client&rsquo;s suppliers
have to make sure that shipment paperwork shows realistic commercial value of the material for the purpose of import.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Raw material pricing and lead times will be confirmed upon PO initiation.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">6.
Additional Services</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following items
are formally considered out of the scope of this proposal, but could be offered as additional services:</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Further development and/or revalidation of analytical methods</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Preparation of analytical reference standards</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Assessment and/or analysis of potential genotoxic impurities (pGTI)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Long-term storage and costs for special packaging and transportation (if required); Florence
standard bulk packaging assumed (double PE bag in screw-lid HDPE drum)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Micronization/particle size reduction.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Certified translation of Master Batch Records and Executed Batch Records</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Analysis of solid state properties</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 17pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; color: #ED3034; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">7.
Project Management</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patheon will provide
dedicated project management support to monitor the progress of the project against the agreed scope of work and timelines and
will provide Lantern with routine updates while there are ongoing billable activities in progress (excluding stability).</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon award of this project,
Patheon will form its project team. A Project Manager / Leader will be assigned to lead the team and be the primary client point
of contact from raw material procurement through process implementation, development and production, to shipment of the product.
The Project Manager / Leader typically has university degree (Ph.D. or BSc) qualifications in chemistry and significant prior experience
with chemical process research and development and API manufacturing</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">The core team typically consists of the Project Leader, API Business Manager and Chemical and
Analytical R&amp;D Scientists</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Other members join the core team on an as-needed basis (e.g. the Client Business Development
Executive, Process Safety Expert, Chemical Engineer, Plant personnel, Quality Control, and Quality Assurance representatives)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Each team member reports into their own functional area but reports to the Project Manager /
Leader for direction on each specific project</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">On a weekly basis, the Project Manager / Leader reports progress to the site management team
who oversee performance on the wider portfolio of site projects</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Project Manager / Leader
will typically organise:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Up to two, one-hour teleconference meetings per month. Other calls can be arranged as agreed
between the parties and <I>ad hoc </I>calls accommodated as needed. The frequency of meetings can be increased during peak activity
times and the Project Manager / Leader is available via e- mail/phone for discussions outside of scheduled meetings</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Minutes of teleconferences and other meetings. These can generally be customised to meet Client
or project requirements</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">A quarterly Patheon site face-to-face project review / update meeting</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; padding-right: 0; width: 0.75in"></TD><TD STYLE="text-align: justify; padding-right: 0; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify; padding-right: 0">Delivery of project documentation. Documentation may include protocols, reports, master batch
records or executed batch records, Certificates of Analysis, BSE/TSE statements, summary data and analytical methods</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The team will also be
made up of Lantern personnel as agreed. A formal project kick-off (KO) meeting will be arranged prior to start of work to review
the provided technical information and re-confirm that the scope of the project remains as per this proposal.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #ED3034">Part C:
Budget Summary</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #ED3034">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #ED3034">Price
Quotation</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.9pt; padding-right: 35.1pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.15pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 2.1pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 2.1pt; padding-right: 35.1pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.1pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.3pt; padding-left: 34.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.2pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.65pt; padding-right: 5.15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-top: 0.65pt; padding-right: 35.8pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt">[***]</P></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.45pt; padding-left: 60.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-top: 0.45pt; padding-right: 35.6pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.45pt; padding-left: 60.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.45pt; padding-right: 5.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-top: 0.45pt; padding-right: 35.75pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.6pt; padding-right: 5.3pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-top: 0.6pt; padding-right: 35.6pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.6pt; padding-right: 5.55pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-top: 0.6pt; padding-right: 35.7pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 1.2pt; padding-right: 4.8pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 1.2pt; padding-right: 35.3pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.1pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0.65pt; padding-right: 5.15pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-top: 0.65pt; padding-right: 35.8pt; padding-left: 35.65pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt">[***]</P></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.2pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.95pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.95pt; padding-right: 35.3pt; padding-left: 34.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 1.15pt; padding-right: 4.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 1.15pt; padding-right: 35.25pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 5.05pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-top: 0.9pt; padding-right: 35.25pt; padding-left: 35.15pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costs which cannot be
quantified upfront e.g. analytical columns/reagents, external analytical testing, API packaging, shipping charges, custom fees,
etc. that must be purchased to run the project will be passed through at [***].</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Payment and Delivery Terms</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 92%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #545658">
    <TD STYLE="padding-right: 0.1in; width: 30%; border-top: #151733 1pt solid; border-right: white 1pt solid; border-bottom: black 1pt solid; border-left: #151733 1pt solid; padding-top: 1.9pt; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: White">Amount</FONT></TD>
    <TD STYLE="padding-right: 0.1in; width: 33%; border-top: #151733 1pt solid; border-right: white 1pt solid; border-bottom: black 1pt solid; padding-top: 1.9pt; padding-left: 5.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: White">Invoicing</FONT></TD>
    <TD STYLE="padding-right: 0.1in; width: 37%; border-top: #151733 1pt solid; border-right: #151733 1pt solid; border-bottom: black 1pt solid; padding-top: 1.9pt; padding-left: 5.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: White">Deliverable</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.1in; padding-left: 5.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]
    </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 0.1in; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.1in; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.2pt; padding-right: 0.1in; padding-left: 5.25pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10.5pt Times New Roman, Times, Serif">[***]</FONT></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.2pt; padding-right: 0.1in; padding-left: 5.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt">[***]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Payment terms: [***]</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Where applicable, please issue purchase orders,
referencing Proposal Number [***], to the legal entity which will perform the services covered by this proposal:</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Patheon API Services, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>
<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Please send the purchase order to the following
addresses:</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">E-mail: [***]@thermofisher.com</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">E-Mail: [***]@patheon.com</P>

<P STYLE="text-align: justify; font: 8pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">E-Mail: [***]@patheon.com</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Shipping Options</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #545658">
    <TD STYLE="width: 20%; border: black 1pt solid; padding-top: 3.1pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt; color: white">Service Selection</FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.1in; width: 80%; padding-top: 3.1pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt; color: white">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 18.05pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt"><B>(A) Courier Management through Total Transportation Management (&ldquo;TTM&rdquo;)</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.1in">
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 5.25pt">TTM is a service whereby Patheon will manage the
        couriers for all shipments and lanes, such selection being based on data relating to courier performance across all shipments executed
        across the Patheon logistics network. The TTM fees will be based on actual shipment characteristics and provides for the following
        services:</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 40.3pt; text-indent: -0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Patheon
        will select the courier from a broad array of vendors managed and qualified through TTM&rsquo;s quality management system</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-indent: -0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Patheon
        will coordinate the dispatch of the shipment with selected carrier</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-indent: -0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Patheon
        will support the facilitation and coordination of necessary documentation as required by a receiving country, including the generation
        and creation of such documents</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-indent: -0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All
        shipments will be tracked and traced via the Global Logistics Help Desk from origin to final destination</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.3pt; text-indent: -0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Patheon
        will assist with the resolution of shipment issues arising during transit and will escalate such issues to the Client in accordance
        when necessary</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">The TTM fees will be quoted at the time of
        shipment in a TTM Freight Quote. Client will be responsible for any charges with respect to services that were not contemplated
        in this quote including, but not limited to, charges for supplementary services such as detention or demurrage. The Terms and Conditions
        specified in the applicable TTM Freight Quote issued at the time of shipment will apply.</P>
        <P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt"><B>If you want to make use of this service, please
        contact:</B></P>
        <P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">[***]<FONT STYLE="font-size: 10.5pt">@thermofisher.com</FONT></P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">Tel: North America [***]</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">Tel: Europe [***]</P>
        <P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt"><B>(B) Client Managed Shipping (Client Carrier)</B></FONT></TD>
    <TD STYLE="text-align: justify; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.1in; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt">Client will select the couriers for all shipments and lanes and manage the shipment from origin to destination. All Client carriers will bill any and all freight charges and other costs associated with all Client shipments directly to Client using the Client&rsquo;s account number(s), and Client shall be solely responsible for the payment of all such charges and other costs.<BR>
&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #ED3034">Part D:
High Level Timeline</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The timeline below and
any estimated activity durations stated above are presented at this stage as a non- binding projected estimate of the milestone
durations and deliverables envisioned at the time of issuing this proposal. Patheon will use commercially reasonable efforts to
adhere to timeline estimates shown below by initiating the project as soon as a Lantern award by signature is received. All project
timelines are however subject to resource and production asset availability at the time the project is awarded. Once awarded, timelines
will be reviewed and updated and an updated project plan provided.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 9.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 24pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Part E: Standard Assumptions</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Financial</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">All prices presented in the Price Quotation are
NET of VAT.</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">All prices quoted are based on Patheon API Services
Inc Tariff 2020.</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Any analytical columns/reagents, external
analytical testing, API packaging, shipping, and filter media that must be purchased will be charged additionally as pass through
costs.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Validity</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">This offer is valid until July 25, 2020.</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Regulatory Management</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To support the proposed
project and eventual product filing, it is anticipated that Lantern will conduct an audit of Patheon&rsquo;s site for Quality Assurance
purposes. It is assumed that the audit will require one Patheon QA team member for up to two days. If additional resources and/or
time are required, these will be considered changes of scope and priced as per the table below.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The regulatory support
requirements of Clients vary from project to project. Patheon can provide support for activities such as:</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Provision of documentation not typically provided as part of routine project activities</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Regulatory body interactions associated with the regulatory applications or registration of Client
products, such as Pre-Approval Inspections and remote desk-top audits</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Third party due diligence activities towards the potential sale / licensing of the Clients Product
or company</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Translation of documentation</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">General regulatory guidance or support for compilation of regulatory documentation</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the extent of regulatory
support can be uncertain, hourly rates are normally defined for any required services as per the table below.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 60%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #545658">
    <TD COLSPAN="2" STYLE="border: black 1pt solid; padding-top: 1.75pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10pt; color: white">Regulatory Filing/Audit Assistance Fee</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 59%; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt"><B>Level of Support</B></FONT></TD>
    <TD STYLE="width: 41%; border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 30.7pt; padding-left: 31.25pt; text-align: center"><FONT STYLE="font-size: 10.5pt"><B>Fee</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.7pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt">First audit (two days)</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.7pt; padding-right: 30.85pt; padding-left: 31.1pt; text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.7pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt">Additional Audit Time per Person</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.7pt; padding-right: 30.85pt; padding-left: 31.25pt; text-align: center">[***]</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.7pt; padding-left: 5.25pt"><FONT STYLE="font-size: 10.5pt">Miscellaneous Regulatory Suppor</FONT><FONT STYLE="font-size: 8pt">t</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.7pt; padding-right: 30.85pt; padding-left: 31.15pt; text-align: center">[***]</TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Out of Scope</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following activities
are not within the normal scope of project activities and may incur additional costs if required:</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Extended Client site visits, for example, to observe manufacturing activities first hand</TD></TR></TABLE>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Additional raw material, intermediate, or final Product sampling that is outside the typical
scope of the activities proposed</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">OEL</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise stated
above, Patheon assume that the OEL of the raw materials, intermediates and / or product have an OEL of &gt;10 &micro;g/m3. If the
OEL is confirmed as lower than &gt;10 &micro;g/m3 after project commencement, a further assessment of the handling requirements
will be made which may impact timelines and cost.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Fees include a single revision of documentation.
Patheon will invoice the Client on issue of draft report.</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For Analytical Out Of
Specification (OOS) investigations, Patheon will conduct investigations according to Patheon&rsquo;s Standard Operating Procedure
and report findings to the Client, the costs for which will be borne by the Client should the OOS be a result of the nature of
the product rather than Patheon error in processing or testing.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the Client request,
issued documents may need to be updated throughout the life of the project. The requirement for update could be based on, but is
not limited to, new stability data or new storage conditions. Documents requiring update may include Certificate of Analysis, specifications,
test methods, reports or any other document already issued by Patheon. Any additional costs for the update will be communicated
to the Client via the Change of Scope process prior to initiating the documentation change.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Client requests
Patheon to provide a quarantine release (provisional batch release pending full release for shipment), the Client shall pay Patheon
a fee of [***] per-quarantine released batch (fee not included within the Price Quotation) to cover the additional administrative
and QA requirements necessary to meet such a request. Patheon makes no warranty of any kind, either expressed or implied of fitness
for a particular purpose or warranty of merchantability in respect to the quarantine release.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Deliveries</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to tax law,
VAT or customs may have to be charged on the product price in case of delivery destination changes (from 3rd party country to Europe
or the other way). This is valid for inbound materials as well as outbound materials. The potential changes have to be evaluated
case by case between the Client and Patheon. Delivery destinations have to be communicated well in advance.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Storage</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that the
Client does not take delivery of a product at the agreed time, Patheon have the option but not the obligation to store the product
at its site or through carefully selected external partners. In such a case, the product is deemed delivered by transferring it
into the storage facility. Any storage will be subject to a fee and certain terms and conditions which will be discussed and agreed
at the time any storage need becomes known.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Client
and Patheon have to evaluate the customs situation if products are not delivered to the Client within six months after the invoice
date. For quantities produced in commercial buildings customs needs to be evaluated immediately upon invoicing.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Product Release by Client</P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: justify; font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event it will
be agreed that a product shall be released by the Client, the Client is obliged to carry out such release within the agreed time.
Otherwise, Patheon are entitled to release and ship the product.</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Provided Goods</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">Provided goods have to fulfil specifications and
other agreed quality criteria and they have to be fit for use.</P>

<P STYLE="text-align: justify; font: 12.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Cancellation Terms</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; color: #ED3034">Intellectual Property</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term &ldquo;Intellectual
Property&rdquo; includes, without limitation, rights in patents, patent applications, formulae, trade- marks, trade-mark applications,
trade-names, trade secrets, inventions, copyright, industrial designs, data and know-how.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***].</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[***]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #ED3034">Part F:
Legal Terms and Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Unless otherwise specified
in this proposal, the Patheon API Services Inc. General Terms and Conditions of Sale (provided separately with this proposal) apply
to the transaction covered by this proposal.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In case of any discrepancies
between this proposal and the General Terms and Conditions of Sale the conditions of this proposal shall prevail.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This proposal has been
made to the best of Patheon&rsquo;s knowledge. It is based upon the information available at the time of offering and the assumptions
specified in this proposal. Patheon are entitled to adequately amend this proposal, if determining factors have been subject to
change.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This proposal is subject to
Patheon Management approval.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<div style="float: left; width: 32%">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>GENERAL</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.1.</TD><TD STYLE="text-align: justify">These General Terms and Conditions of Sale (&ldquo;Conditions&rdquo;)
govern the offering, sale and delivery of all goods and/or services (hereinafter jointly referred to as the &ldquo;Product(s)&rdquo;)
from or on behalf of Patheon API Services,Inc., Florence, South Carolina (&ldquo;PATHEON&rdquo;), to client (&ldquo;Client&rdquo;)
and apply to all transactions between PATHEON and Client.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.2.</TD><TD STYLE="text-align: justify">By contracting on the basis of the Conditions, Client
agrees to the applicability thereof in respect of all future dealings, even if this is not explicitly stated.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.3.</TD><TD STYLE="text-align: justify">PATHEON explicitly rejects the applicability of any general
terms and conditions of Client. Furthermore, the Conditions supersede any and all terms of prior oral and written quotations,
communications, agreements and understandings of the parties in respect of the sale and delivery of the Products and shall apply
in preference to and supersede any and all terms and conditions of any order placed by Client and any other terms and conditions
submitted by Client. Failure by PATHEON to object to the terms and conditions set by Client shall in no event be construed as
an acceptance of any of the terms and conditions of Client.Neither PATHEON&rsquo;s&#9;commencement&#9;of performance nor PATHEON&rsquo;s
delivery shall be deemed as acceptance of any of Client&rsquo;s terms and conditions. If the Conditions differ from any of the
terms and conditions of Client, the Conditions and any subsequent communication or conduct by or on behalf of PATHEON, including,
without limitation, confirmation of an order and delivery of Products, constitute a counter-offer and not acceptance of such terms
and conditions submitted by Client. Any communication or conduct of Client which confirms an agreement for the delivery of Products
by PATHEON, as well as acceptance by Client of any delivery of Products from PATHEON shall constitute an unqualified acceptance
by Client of the Conditions.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.4.</TD><TD STYLE="text-align: justify">PATHEON reserves the right to amend the Conditions at
any time. PATHEON will notify Client of any such amendments by sending the amended Conditions to Client, posting them on the aforementioned
Internet sites or otherwise. The amended Conditions
will take effect on the date of notification of these amendments. The amended Conditions shall apply to all transactions concluded
between Client and PATHEON after the date of such notification.</TD>
</TR></TABLE>

</div>
<div style="float: left; width: 2%;">
<P STYLE="margin: 0">&nbsp;</P>
</div>
<div style="float: left; width: 32%; left:20pt;">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.5.</TD><TD STYLE="text-align: justify">Any electronic communication between PATHEON and Client
shall be effective as originals and shall be considered to be a &ldquo;writing&rdquo; between the parties. The electronic communication
system used by PATHEON will serve as sole proof for the content and the time of delivery and receipt of such electronic communications.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>QUOTATIONS,&#9;ORDERS&#9;AND CONFIRMATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.1.</TD><TD STYLE="text-align: justify">Unless stated otherwise by PATHEON, quotations made by
PATHEON in whatever form are not binding to PATHEON and merely constitute an invitation to Client to place an order. All quotations
issued by PATHEON are revocable and subject to change without notice. Orders are not binding until accepted by PATHEON in writing
(&ldquo;Confirmed Order&rdquo;). PATHEON shall be entitled to refuse an order without indicating the reasons.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.2.</TD><TD STYLE="text-align: justify">Price quotations based on estimated or projected quantities
are subject to increase in the event that actual quantities purchased during the specified period are less than the estimated
or projected quantities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.3.</TD><TD STYLE="text-align: justify">Each delivery shall stand as a separate transaction and
any failure to deliver shall have no consequences for other deliveries.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>PRICES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.1.</TD><TD STYLE="text-align: justify">Prices and currencies of PATHEON&rsquo;s Products are as set out in the Confirmed Order.
                                                                                 Unless otherwise agreed, PATHEON&rsquo;s prices include standard packaging but do not include Value Added Tax or any other
                                                                                 similar applicable taxes, duties, levies or charges in any jurisdiction levied in relation to the Products or the delivery
                                                                                 thereof (&ldquo;Taxes&rdquo;). The amount of any Taxes levied in connection with the sale of Products to Client shall be for
                                                                                 Client&rsquo;s account and shall either be added to each invoice or separately invoiced by PATHEON to Client. If PATHEON grants
a discount, this discount only relates to the delivery specifically mentioned in the Confirmed Order.</TD>
</TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</P>
</div>
<div style="float: right; width: 32%">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.2.</TD><TD STYLE="text-align: justify">Unless the prices have been indicated as firm by PATHEON
in the Confirmed Order, PATHEON is entitled to increase the price of the Products still to be delivered if the cost price determining
factors have been subject to an increase. These factors include but are not limited to: raw and auxiliary materials, energy, products
obtained by PATHEON from third parties, wages, salaries, social security contributions, governmental charges, freight costs and
insurance premiums. PATHEON shall notify Client of such increase which shall not exceed the increase in the determining cost factors.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>PAYMENT AND CLIENT&rsquo;S CREDIT</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.1.</TD><TD STYLE="text-align: justify">Unless stated otherwise in the Confirmed Order, payment
shall be made on the basis of net cash, to be received by PATHEON within [***] following the date of PATHEON&rsquo;s
invoice. All payments shall be made without any deduction on account of any Taxes and free of set-off or other counterclaims except
for set-offs with uncontested&#9;and/or&#9;enforceable counterclaims.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.2.</TD><TD STYLE="text-align: justify">With regard to payment for the Products, time is of the
essence. PATHEON may, without prejudice to any other rights of PATHEON, charge interest on any overdue payment at [***] per annum from the due date computed on a daily basis until all outstanding amounts are paid in full. All costs and expenses
incurred by PATHEON with respect to the collection of overdue payments (including, without limitation, reasonable attorney&rsquo;s
fees, expert fees, court costs and other expenses of litigation) shall be for Client&rsquo;s account.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.3.</TD><TD STYLE="text-align: justify">Every payment by Client shall in the first place serve
to pay the judicial and extra- judicial costs and the accrued interest and shall afterwards be deducted from the oldest outstanding
claim regardless of any advice to the contrary from Client.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.4.</TD><TD STYLE="text-align: justify">Any complaint with respect to the invoice must be notified
to PATHEON in writing within 20 (twenty) days
after the date of invoice. Thereafter, Client shall be deemed to have approved the invoice.</TD>
</TR></TABLE>
</div>
<div style="clear:both"></div>

<P STYLE="margin-left: 0.25in; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>
<div style="float: left; width: 32%">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>DELIVERY AND ACCEPTANCE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.1.</TD><TD STYLE="text-align: justify">Unless stated otherwise in the Confirmed Order, all deliveries
of Products shall be [***]. The term [***] shall have the meaning as defined in the latest version of INCOTERMS
published by the International Chamber of Commerce in Paris, France, at the time of the Confirmed Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.2.</TD><TD STYLE="text-align: justify">Unless stated otherwise in the Confirmed Order, any times
or dates for delivery by PATHEON are estimates and shall not be of the essence. PATHEON is entitled to deliver the Products as
stated in the Confirmed Order in parts and to invoice separately. Delay in delivery of any Products shall not relieve Client of
its obligation to accept delivery thereof, unless Client cannot reasonably be expected to accept such late delivery. Client shall
be obliged to accept the Products and pay the rate specified in the Confirmed Order for the quantity of Products delivered by
PATHEON.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>CANCELLATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">6.1.</TD><TD STYLE="text-align: justify">Client&rsquo;s wrongful non-acceptance or rejection of
Products or cancellation of the Confirmed Order shall entitle PATHEON to recover from Client, in addition to any other damages
caused by such action:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">[***]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: left"><B>EXAMINATION AND CONFORMITY TO SPECIFICATIONS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.1.</TD><TD STYLE="text-align: justify">On delivery and during the handling, use, commingling,
alteration, incorporation, processing, transportation, storage, importation and (re)sale of the Products (the &ldquo;Use&rdquo;),
Client shall examine the Products and satisfy itself that the Products delivered meet the agreed specifications for the Products
as stated in the Confirmed Order or, in the absence of agreed specifications, to the most recent specifications used by PATHEON
at the time of delivery of the Products (the &ldquo;Specifications&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.2.</TD><TD STYLE="text-align: justify">Complaints about the Products shall be made in writing and must
reach PATHEON not later than [***] from the date of delivery in respect of any defect, default or shortage which would be apparent
from a reasonable inspection on delivery, and [***] from the date on which any other claim (e.g. hidden defects) was or ought to
have been apparent, but in no event later than (i) [***] from the date of delivery of the Products or (ii) the expiry of the Products&rsquo;
shelf-life whichever is the earlier. Any Use of the Products shall be deemed to be an unconditional acceptance of the Products
as of the date of delivery and a waiver of all claims in respect of the Products.</TD>
</TR></TABLE>

</div>
<div style="float: left; width: 2%;">
<P STYLE="margin: 0">&nbsp;</P>
</div>
<div style="float: left; width: 32%; left:20pt;">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.3.</TD><TD STYLE="text-align: justify">A determination of whether or not delivered Products
conform to the Specifications shall be done solely by PATHEON analysing the samples or records retained by PATHEON and taken from
the batches or production runs in which the Products were produced in accordance with the methods of analysis used by PATHEON.
In case of a disaccord between the parties concerning the quality of a batch or production run of Products supplied by PATHEON
to Client, PATHEON will submit representative samples of said batch or run to an independent laboratory reasonably acceptable
to Client to have determined whether or not the batch or run in question has met the Specifications. The results of such analysis
shall be binding upon the parties and the party unable to uphold its position shall bear the related costs of the laboratory.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">7.4.</TD><TD STYLE="text-align: justify">Defects in parts of the Products do not entitle Client
to reject the entire delivery of the Products, unless Client cannot reasonably be expected to accept delivery of the remaining
non defective parts of the Products. Complaints, if any, do not affect Client&rsquo;s obligation to pay as defined in Article
4.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>TRANSFER OF RISK AND PROPERTY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">8.1.</TD><TD STYLE="text-align: justify">The risk of the Products shall pass to Client according
to the applicable Incoterm (see Article 5.1).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">8.2.</TD><TD STYLE="text-align: justify">The title to the Products shall not pass to Client and
full legal and beneficial ownership of the Products shall remain with PATHEON unless and until PATHEON has received payment in
full for the Products, including costs such as interest, charges, expenses etc.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">8.3.</TD><TD STYLE="text-align: justify">In the event of termination on the basis of Article 16,
PATHEON shall, without prejudice to any other rights of PATHEON, be entitled to require immediate return of the Products, or to
repossess the Products, for which it may invoke a retention of title.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>LIMITED WARRANTY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>[***]</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>
</div>
<div style="float: right; width: 32%">


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B>LIMITED LIABILITY</B></TD>
</TR></TABLE>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">10.1.</TD><TD STYLE="text-align: justify">PATHEON&rsquo;s liability for any and all claims arising out
of or in connection with the Products and the Use thereof shall per occurrence be limited to [***].</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">10.2.</TD><TD STYLE="text-align: justify">PATHEON shall under no circumstances be liable to Client
or any other person for any kind of special, incidental, indirect, consequential or punitive damage or loss, cost or expense,
including without limitation, damage based upon lost goodwill, lost sales or profit, delay in delivery, work stoppage, production
failure, impairment of other goods or based on any other cause, and whether arising out of or in connection with breach of warranty,
breach of contract, misrepresentation, negligence or otherwise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B>FORCE MAJEURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">11.1.</TD><TD STYLE="text-align: justify">Neither party shall be liable in any way for any damage,
loss, cost or expense arising out of or in connection with any delay, restriction, interference or failure in performing any obligation
towards the other party caused by any circumstance beyond its reasonable control, including, without limitation, acts of God,
laws and regulations, administrative measures, orders or decrees of any court, earthquake, flood, fire, explosion, war, terrorism,
riot, sabotage, accident, epidemic, strike, lockout, slowdown, labour disturbances, difficulty in obtaining necessary labour or
raw materials, lack of or failure of transportation, breakdown of plant or essential machinery, emergency repair or maintenance,
breakdown or shortage of utilities, delay in delivery or defects in goods supplied by suppliers or subcontractors (&ldquo;Force
Majeure&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">11.2.</TD><TD STYLE="text-align: justify">Upon the occurrence of any event of Force Majeure, the party
suffering thereby shall promptly inform the other party by written notice thereof specifying the cause of the event and how it
will affect its performance of its obligations under the Confirmed Order. In the event of any delay, the obligation to deliver
shall be suspended for a period equal to the time loss by reason of Force Majeure. [***]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>12.</B></TD><TD STYLE="text-align: left"><B>MODIFICATIONS AND INFORMATION; INDEMNITY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">12.1.</TD><TD STYLE="text-align: justify">Unless the Specifications have been agreed to be firm
for a certain period of time or quantity of Products, PATHEON reserves the right to change or modify the Specifications and/or
manufacture of Products and to substitute materials used in the production and/or manufacture of Products from time to time without
notice. Client acknowledges that data in PATHEON&rsquo;s catalogues, product data sheets and other descriptive publications distributed
or published on its websites may accordingly be varied from time to time without notice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
</div>
<div style="clear:both"></div>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<div style="float: left; width: 32%">
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">12.2.</TD><TD STYLE="text-align: justify">Client must utilise and solely rely on its own expertise,
know-how and judgment in relation to the Products and Client&rsquo;s Use thereof. Consultation provided by PATHEON shall not give
rise to any additional obligations. Client shall indemnify
and hold PATHEON harmless from and against any and all damages, losses, costs, expenses, claims, demands and liabilities (including
without limitation product liabilities) arising out of or in connection with the Products and Client&rsquo;s Use thereof.</TD>
</TR></TABLE>
<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>13.</B></TD><TD STYLE="text-align: justify"><B>COMPLIANCE WITH LAWS AND STANDARDS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">13.1.</TD><TD STYLE="text-align: justify">Client acknowledges that the Use of the Products may
be subject to requirements or limitations under any law, statute ordinance, regulation, code or standard (&ldquo;Laws and Standards&rdquo;).
Client shall be exclusively responsible for (i) ensuring compliance with all Laws and Standards associated with its intended Use
of the Products; and (ii) obtaining all necessary approvals, permits or clearances for such Use.</TD>
</TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>14.</B></TD><TD STYLE="text-align: justify"><B>INDEPENDENT CONTRACTORS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">14.1.</TD><TD STYLE="text-align: justify">PATHEON and Client are independent contractors, and the
relationship created hereby shall not be deemed to be that of principal and agent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>15.</B></TD><TD STYLE="text-align: justify"><B>NON-ASSIGNMENT AND CHANGE OF CONTROL</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">15.1.</TD><TD STYLE="text-align: justify">Neither party may assign any of the rights or obligations
under the Confirmed Order without the prior written consent of the other party, except that either party may assign such rights
and obligations to any of its affiliates or to a third party acquiring all or a substantial part of its assets or business relating
to the Products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">15.2.</TD><TD STYLE="text-align: justify">PATHEON shall have the right to terminate the Confirmed Order
with immediate effect if at any time during the term of the Confirmed Order a person or group of persons, who are unrelated to
the persons controlling Client as of the date of the Confirmed Order, acquires control, through ownership of voting securities
or otherwise, over Client. Client must notify PATHEON of such acquisition within [***] thereof. PATHEON may exercise its right
to terminate the Confirmed Order by giving Client written notice of such exercise within [***] after the date of receipt of such
notice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>16.</B></TD><TD STYLE="text-align: justify"><B>SUSPENSION AND TERMINATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt"><B>[***]</B></FONT></P>

</div>
<div style="float: left; width: 2%;">
<P STYLE="margin: 0">&nbsp;</P>
</div>
<div style="float: left; width: 32%; left:20pt;">


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>17.</B></TD><TD STYLE="text-align: justify"><B>WAIVER</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">17.1.</TD><TD STYLE="text-align: justify">Failure by PATHEON to enforce at any time any provision
of the Conditions shall not be construed as a waiver of PATHEON&rsquo;s right to act or to enforce any such term or condition
and PATHEON&rsquo;s rights shall not be affected by any delay, failure or omission to enforce any such provision.</TD>
</TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-left: 0.25in; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">No waiver by PATHEON of
any breach of Client&rsquo;s obligations shall constitute a waiver of any other prior or subsequent breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>SEVERABILITY AND CONVERSION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">18.1.</TD><TD STYLE="text-align: justify">In the event that any provision of the Conditions shall
be held to be invalid or unenforceable, the same shall not affect in any respect whatsoever, the validity and enforceability of
the remaining provisions between the parties and shall be severed therefrom. The pertaining provisions held to be invalid or unenforceable
shall be reformed to meet the legal and economic intent of the original provisions to the maximum extent permitted by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>19.</B></TD><TD STYLE="text-align: justify"><B>LIMITATION OF ACTION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">19.1.</TD><TD STYLE="text-align: justify">Unless otherwise stated hereunder, no action by Client shall
be brought unless Client first provides written notice to PATHEON of any claim alleged to exist against PATHEON within [***] after
the event complained of first becomes known to Client and an action is commenced by Client within [***] after such notice.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>20.</B></TD><TD STYLE="text-align: justify"><B>GOVERNING LAW AND VENUE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">20.1.</TD><TD STYLE="text-align: justify">The parties&rsquo; rights and obligations arising out
of or in connection with the Confirmed Order and/or the Conditions shall be governed, construed, interpreted and enforced according
to the laws of South Carolina, without regard to the conflict of laws provisions thereof. The United Nations Convention on Contracts
for the International Sale of Goods dated 11 April 1980 (CISG) shall not apply.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>21.</B></TD><TD STYLE="text-align: justify"><B>SURVIVAL OF RIGHTS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">20.2.</TD><TD STYLE="text-align: justify">The parties&rsquo; rights and obligations shall be binding
upon and inure to the benefit of the parties and their respective successors, permitted assigns, directors, officers, employees,
agents and legal representatives. Termination of one or more of the parties&rsquo; rights and obligations, for whatever reason,
shall not affect those provisions of the Conditions which are intended to remain in effect after such termination.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>22.</B></TD><TD STYLE="text-align: justify"><B>HEADINGS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">22.1.</TD><TD STYLE="text-align: justify">The headings contained in the Conditions are included
for mere convenience of reference and shall not affect the latter&rsquo;s construction or interpretation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
</div>
<div style="float: right; width: 32%">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>23.</B></TD><TD STYLE="text-align: justify"><B>LANGUAGE</B></TD>
</TR></TABLE>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">24.1.</TD><TD STYLE="text-align: justify">The original version of the Conditions is made in the
English language. In the event of any inconsistency or contradiction between the English version and any translation thereof,
the English version shall prevail.</TD>
</TR></TABLE>



<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Version: August, 2018</P>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
</div>
<div style="clear:both"></div>

<P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 13.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034">Project
Team Profiles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10.5pt">[***]</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="ex10-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 20pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034"><B>Pharma Services - Global Site
Network</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="vertical-align: bottom; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; background-color: Gainsboro; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><IMG SRC="ex10-1_003.jpg" ALT="" STYLE="width: 110px; height: 126px"></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; vertical-align: bottom"><IMG SRC="ex10-1_004.jpg" ALT="" STYLE="width: 110px; height: 126px"></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; vertical-align: bottom"><IMG SRC="ex10-1_005.jpg" ALT="" STYLE="width: 110px; height: 126px"></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; vertical-align: bottom"><IMG SRC="ex10-1_006.jpg" ALT="" STYLE="width: 110px; height: 126px"></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; vertical-align: bottom"><IMG SRC="ex10-1_007.jpg" ALT="" STYLE="width: 110px; height: 126px"></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; width: 20%; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Ahmedabad, India</B></FONT></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; width: 16%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; width: 16%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; width: 16%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; width: 16%"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-top: #FEFEFE 1pt solid; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; width: 16%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Allentown, PA</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Basel, Switzerland</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Beijing, China</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Bend, OR</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Bogota, Colombia</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Bourgoin, FR</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Brisbane, AU</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Buenos Aires, Argentina</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Cincinnati, OH</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Ferentino, IT</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Florence, SC &ndash; West</B></FONT></TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Florence, SC &ndash; East</B></FONT></TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Greenville, SC</B></FONT></TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Greenville, NC</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Groningen, NL</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>High Point, NC</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Horsham, UK</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Indianapolis, IN</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Lima, Peru</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Linz, AT</B></FONT></TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Manat&iacute;, PR</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Mexico City, Mexico</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Milton Park, UK</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Monza, IT</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Moscow, Russia</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Mt. Prospect, IL</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Pretoria, South Africa</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Princeton, NJ</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Regensburg, DE</B></FONT></TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Santiago, Chile</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>S&atilde;o Paulo, Brazil</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Seoul, Korea</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Singapore</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>St. Louis, MO</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Suzhou, China</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Swindon, UK</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Tilburg, NL</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Tokyo, Japan</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Toronto, ON</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Weil am Rhein, Germany</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #F1F1F1">
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; border-left: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt; color: #4B4D4B"><B>Whitby, ON</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD>
    <TD STYLE="text-align: center; border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-right: #FEFEFE 1pt dashed; border-bottom: #FEFEFE 1pt dashed; text-align: center"><FONT STYLE="font-size: 7pt"><B>&bull;</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><IMG SRC="ex10-1_002.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034"><B>Your truly integrated pharma
services partner</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 14pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Built on a proven foundation of quality systems
and commitment to continuous improvement, Thermo Fisher Pharma Services has the capabilities and expertise to help you achieve
success at every milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; width: 15%">
        <P STYLE="text-align: center; font: 4pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_008.jpg" ALT="">&nbsp;</P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; width: 14%">
        <P STYLE="text-align: center; font: 5.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_009.jpg" ALT="">&nbsp;</P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; width: 16%">
        <IMG SRC="ex10-1_010.jpg" ALT="" STYLE="width: 124px; height: 103px"><P STYLE="text-align: center; font: 3.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 2pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="text-align: center; font: 1pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; width: 16%">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_011.jpg" ALT="">&nbsp;</P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; width: 16%">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex10-1_012.jpg" ALT=""></P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-top: #D9D9D9 6pt solid; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; width: 23%">
        <IMG SRC="ex10-1_013.jpg" ALT=""><P STYLE="text-align: center; font: 4pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Create or source your ingredient</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Design the ideal formulation</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Scale to your next milestone</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Develop clinical supply chain strategy</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Accelerate clinical research</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Develop successful commercial launch</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<B>Route
Scouting</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Quick to Clinic</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 10.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pre-clinical</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Clinical Supply Optimization</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Primary &amp; Secondary
        Packaging</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>95%+ Right <BR>
First Time <BR>
Performance</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Cell Line Development</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Complex Formulations</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Early Phase Development</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Compliance
        Management</B></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&amp; Risk Mitigation</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Labeling</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 6.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="text-align: center; font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>75% of all <BR>
Dosage Forms</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Analytical Methods</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Solubility Enhancement</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Clinical Trial Material Manufacture</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Comparator Sourcing</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Storage &amp; Distribution</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Oral Solid Dose</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Process Development</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Analytical Methods</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Late Phase Trials</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Label Translation &amp; Planning</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Global Network</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Sterile <BR>
Injectables</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Commercial Manufacturing</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Process Development</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="text-align: center; font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commercialization</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Cold Chain Material Management</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Flexible <BR>
Business Models</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Oral Solid &amp; Sterile</B></P>
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Development</B></P></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt"><FONT STYLE="font-size: 7pt"><B>Logistics &amp; Transportation</B></FONT></TD>
    <TD STYLE="padding-top: 4pt; border-right: #F1F1F1 1pt dashed; border-bottom: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="border-right: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; border-bottom: #D9D9D9 2.25pt solid">
        <P STYLE="font: 7pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034"><B>More
        than <BR>
1,000</B></P>
        <P STYLE="font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034"><B>molecules
        <BR>
developed 40+ <BR>
dosage forms</B></P></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>185 technology</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed">&nbsp;</TD>
    <TD ROWSPAN="6" STYLE="border-right: #F1F1F1 1pt dashed; vertical-align: middle; text-align: center; border-bottom: #D9D9D9 2.25pt solid">
        <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>
        <P STYLE="font: 8.5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #ED3034"><B>More
        than 400,000 <BR>
clinical shipments <BR>
completed in 2017</B></P></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>More than 250</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>transfers in 2017:</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>11,000+</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>large &amp; small</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>44 Drug</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>unique clinical</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>117 NDAs</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>APIs developed</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>substance 3</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>packaging lots in</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>2008&ndash;2017</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; border-left: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>or manufactured</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>Development</B></FONT></TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>2017</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-bottom: #D9D9D9 2.25pt solid; border-left: #F1F1F1 1pt dashed">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; border-right: #F1F1F1 1pt dashed; border-bottom: #D9D9D9 2.25pt solid; text-align: center"><FONT STYLE="font-size: 8.5pt; color: #ED3034"><B>138 Commercial</B></FONT></TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-bottom: #D9D9D9 2.25pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center; border-right: #F1F1F1 1pt dashed; border-bottom: #D9D9D9 2.25pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 7pt">+1 919 226 3200 &bull;
thermofisher.com/patheon &bull; </FONT><FONT STYLE="font-size: 7.5pt">doingbusiness@patheon.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&copy;
</FONT>2018 Thermo Fisher Scientific Inc. All rights reserved.</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Published 6/18 PATH0712</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-top: Red 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="padding-top: 3pt; width: 50%"><FONT STYLE="font-size: 8pt"><B>[***] <BR> </B></FONT><FONT STYLE="font-size: 10.5pt">Project</FONT><FONT STYLE="font-size: 8pt"><B>Confidential</B></FONT></TD><TD STYLE="padding-top: 3pt; width: 50%; text-align: right"><P STYLE="margin: 0pt 0; font: 8pt Times New Roman, Times, Serif"><B>Lantern Pharma <BR> Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></B> <B>of 27</B></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 6pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>f10q0920ex31-1_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT
TO SECTION 302 OF THE SARBANES-</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Panna Sharma, certify that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">1.</TD><TD STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q of Lantern Pharma Inc.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: October 29, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ Panna Sharma</U></FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Chief Executive Officer (Principal Executive Officer)</TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>f10q0920ex31-2_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULES 13a-14(a) AND 15d-14(a)
UNDER THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT
TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, David R. Margrave, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q
of Lantern Pharma Inc.</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Date: October 29, 2020</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ David R. Margrave</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer <I>(Principal Financial Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>f10q0920ex32-1_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>18 U.S.C. SECTION
1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Lantern Pharma Inc. (the &ldquo;Company&rdquo;) hereby certifies,
to his knowledge, that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD><TD STYLE="text-align: justify">the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2020 (the &ldquo;Report&rdquo;)
fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934,
as amended; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 40%"><FONT STYLE="font-size: 10pt">Date: October 29, 2020</FONT></TD>
    <TD STYLE="text-align: justify; width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ Panna Sharma</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer <I>(Principal Executive Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>f10q0920ex32-2_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>18 U.S.C. SECTION
1350, AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Lantern Pharma Inc. (the &ldquo;Company&rdquo;) hereby certifies,
to his knowledge, that:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD><TD STYLE="text-align: justify">the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended September 30, 2020 (the &ldquo;Report&rdquo;)
fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934,
as amended; and</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Date: October 29, 2020</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ David R. Margrave</U></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer <I>(Principal Financial Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>ltrn-20200930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ltrn="http://laternpharma.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="ltrn-20200930.xsd"/>
  <context id="c0_From1Jan2020To30Sep2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c1_AsOf28Oct2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-10-28</instant>
    </period>
  </context>
  <context id="c2_AsOf30Sep2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c4_From1Jul2020To30Sep2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c5_From1Jul2019To30Sep2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c6_From1Jan2019To30Sep2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c7_AsOf31Dec2018_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c12_From1Jan2019To31Mar2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2019To31Mar2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2019To31Mar2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2019To31Mar2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c16_From1Jan2019To31Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c17_AsOf31Mar2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Mar2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c19_AsOf31Mar2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c20_AsOf31Mar2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c21_AsOf31Mar2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c22_From1Apr2019To30Jun2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c23_From1Apr2019To30Jun2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c24_From1Apr2019To30Jun2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c25_From1Apr2019To30Jun2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c26_From1Apr2019To30Jun2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="c27_AsOf30Jun2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c28_AsOf30Jun2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c29_AsOf30Jun2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c30_AsOf30Jun2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c31_AsOf30Jun2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c32_From1Jul2019To30Sep2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c33_From1Jul2019To30Sep2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c34_From1Jul2019To30Sep2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c35_From1Jul2019To30Sep2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c36_AsOf30Sep2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="c37_AsOf30Sep2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="c38_AsOf30Sep2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="c39_AsOf30Sep2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="c40_AsOf30Sep2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="c41_AsOf31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c43_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c44_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c45_From1Jan2020To31Mar2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c46_From1Jan2020To31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c47_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jan2020To31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jan2020To31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c50_AsOf31Mar2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c51_AsOf31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c53_AsOf31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c54_AsOf31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c55_From1Apr2020To30Jun2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c56_From1Apr2020To30Jun2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c57_From1Apr2020To30Jun2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c58_From1Apr2020To30Jun2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c59_From1Apr2020To30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c60_AsOf30Jun2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c61_AsOf30Jun2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c62_AsOf30Jun2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c63_AsOf30Jun2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c64_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c65_From1Jul2020To30Sep2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c66_From1Jul2020To30Sep2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c67_From1Jul2020To30Sep2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c68_From1Jul2020To30Sep2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c69_AsOf30Sep2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c70_AsOf30Sep2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c71_AsOf30Sep2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c72_AsOf30Sep2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c73_AsOf15Jan2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-15</instant>
    </period>
  </context>
  <context id="c74_AsOf15Jan2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-15</instant>
    </period>
  </context>
  <context id="c75_AsOf30Sep2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c76_AsOf31Jan2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="c77_From1Jan2020To30Sep2020_BioNumerikPharmaceuticalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ltrn:BioNumerikPharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c78_From1Jan2020To30Sep2020_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c79_AsOf30Sep2020_BioNumerikPharmaceuticalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ltrn:BioNumerikPharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c80_From1Jul2020To30Sep2020_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c81_From1Jan2020To30Sep2020_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c82_From1Jul2020To30Sep2020_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c83_From1Jan2020To30Sep2020_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c84_From1Jul2019To30Sep2019_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c85_From1Jan2019To30Sep2019_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c86_From1Jan2020To30Sep2020_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c87_From1Jan2020To30Sep2020_LP184Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c88_From1Jul2020To30Sep2020_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c89_From1Jan2020To30Sep2020_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c90_From1Jul2020To30Sep2020_LP100Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ltrn:ProductOrServicesAxis">ltrn:LP100Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c91_From1Jan2020To30Sep2020_LP100Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ltrn:ProductOrServicesAxis">ltrn:LP100Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c92_From1Jan2019To30Sep2019_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c93_From1Jul2019To30Sep2019_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c94_From1Jan2019To30Sep2019_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c95_From1Jul2020To30Sep2020_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c96_From1Jan2020To30Sep2020_EUGrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:EUGrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c97_From1Jan2019To30Sep2019_PatheonAPIServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:PatheonAPIServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c98_From1Jan2020To30Sep2020_SouthwestResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:SouthwestResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c99_AsOf30Sep2020_SouthwestResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:SouthwestResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c100_From1Aug2019To31Aug2019_PropertySubjectToOperatingLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c101_From1Mar2019To31Mar2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c102_AsOf31Mar2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c103_From1Jul2020To31Jul2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="c104_AsOf31Jul2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="c105_AsOf31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c106_From1Jun2020To15Jun2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c107_AsOf15Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-15</instant>
    </period>
  </context>
  <context id="c108_From1Jun2020To15Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c109_From1Jun2020To15Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c110_From1Jun2020To15Jun2020_SeriesAPreferredStockMember_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSmAkPxKOFTq/FWK6AvrHlBc=] CSR-->
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c111_From1Jan2020To30Sep2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c112_From1Jan2020To30Sep2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c113_AsOf30Sep2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c114_From1Jan2019To30Sep2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c115_From1Jan2020To30Sep2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c116_AsOf31Dec2019_EquityIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ltrn:EquityIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ltrn:EquityIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c118_AsOf30Sep2020_EquityIncentivePlan2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ltrn:EquityIncentivePlan2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c119_AsOf31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-01-31</instant>
    </period>
  </context>
  <context id="c120_From1Jan2020To31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="c121_From25Apr2020To1May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-04-25</startDate>
      <endDate>2020-05-01</endDate>
    </period>
  </context>
  <context id="c122_From1Jul2019To30Sep2019_BiologicalMimeticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BiologicalMimeticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c123_From1Jan2019To30Sep2019_BiologicalMimeticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BiologicalMimeticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c124_From1Jan2019To31Dec2019_BiologicalMimeticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BiologicalMimeticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c125_AsOf30Sep2020_IntuitionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:IntuitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c126_AsOf31Dec2019_IntuitionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:IntuitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c127_AsOf30Sep2020_BioNumerikMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BioNumerikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="c128_AsOf31Dec2019_BioNumerikMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BioNumerikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c129_From1Jan2020To30Sep2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c130_From1Jan2019To30Sep2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c131_From1Jan2020To30Sep2020_WarrantMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c132_From1Jan2019To30Sep2019_WarrantMember_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c133_From1Jan2020To30Sep2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="c134_From1Jan2019To30Sep2019_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="gbp">
    <measure>iso4217:GBP</measure>
  </unit>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To30Sep2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To30Sep2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To30Sep2020">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To30Sep2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To30Sep2020">2020-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2020To30Sep2020">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To30Sep2020">0001763950</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To30Sep2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To30Sep2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To30Sep2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To30Sep2020">001-39318</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To30Sep2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To30Sep2020">TX</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To30Sep2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To30Sep2020">Lantern Pharma Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To30Sep2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2020To30Sep2020">true</dei:EntitySmallBusiness>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf28Oct2020" decimals="INF">6217577</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">20802542</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">1232030</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">1672802</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">788</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">22475344</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">1232818</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">17608</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">8758</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" xs:nil="true"/>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">191000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">22492952</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">1432576</us-gaap:Assets>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">814557</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">489292</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">814557</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">489292</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">108500</us-gaap:AccountsPayableCurrentAndNoncurrent>
  <us-gaap:AccountsPayableCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Liabilities unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">923057</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">489292</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c2_AsOf30Sep2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c2_AsOf30Sep2020" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">244</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">622</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">198</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">31333164</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">7694547</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">-9763891</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">-6751705</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">21569895</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">943284</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">22492952</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">1432576</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf30Sep2020" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2019" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">3480000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">2438866</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">2438866</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf30Sep2020" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2019" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">12180000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">6217577</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">1978269</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">6217577</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2019" decimals="INF">1978269</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">1100719</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">441251</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">2117290</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">977300</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">600769</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">228401</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">894896</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">775718</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">1701488</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">669652</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">3012186</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">1753018</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">-1701488</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">-669652</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">-3012186</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">-1753018</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c4_From1Jul2020To30Sep2020" decimals="2">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c5_From1Jul2019To30Sep2019" decimals="2">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To30Sep2020" decimals="2">-0.82</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c6_From1Jan2019To30Sep2019" decimals="2">-0.89</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jul2020To30Sep2020" decimals="INF">6217577</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c5_From1Jul2019To30Sep2019" decimals="INF">1978269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To30Sep2020" decimals="INF">3661942</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c6_From1Jan2019To30Sep2019" decimals="INF">1978269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c7_AsOf31Dec2018_PreferredStockMember" decimals="INF">1292952</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2018_PreferredStockMember" decimals="0">129</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c8_AsOf31Dec2018_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2018_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="0">4121395</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31Dec2018_RetainedEarningsMember" decimals="0">-4323520</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31Dec2018" decimals="0">-201798</us-gaap:StockholdersEquity>
  <ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants unitRef="shares" contextRef="c12_From1Jan2019To31Mar2019_PreferredStockMember" decimals="INF">804153</ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c12_From1Jan2019To31Mar2019_PreferredStockMember" decimals="0">81</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c13_From1Jan2019To31Mar2019_CommonStockMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c14_From1Jan2019To31Mar2019_AdditionalPaidInCapitalMember" decimals="0">2384919</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c15_From1Jan2019To31Mar2019_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c16_From1Jan2019To31Mar2019" decimals="0">2385000</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c12_From1Jan2019To31Mar2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c13_From1Jan2019To31Mar2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c14_From1Jan2019To31Mar2019_AdditionalPaidInCapitalMember" decimals="0">15531</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c15_From1Jan2019To31Mar2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c16_From1Jan2019To31Mar2019" decimals="0">15531</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c12_From1Jan2019To31Mar2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c13_From1Jan2019To31Mar2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c14_From1Jan2019To31Mar2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c15_From1Jan2019To31Mar2019_RetainedEarningsMember" decimals="0">-453973</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c16_From1Jan2019To31Mar2019" decimals="0">-453973</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c17_AsOf31Mar2019_PreferredStockMember" decimals="INF">2097105</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Mar2019_PreferredStockMember" decimals="0">210</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c18_AsOf31Mar2019_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Mar2019_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c19_AsOf31Mar2019_AdditionalPaidInCapitalMember" decimals="0">6521845</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c20_AsOf31Mar2019_RetainedEarningsMember" decimals="0">-4777493</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c21_AsOf31Mar2019" decimals="0">1744760</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c22_From1Apr2019To30Jun2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c23_From1Apr2019To30Jun2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c24_From1Apr2019To30Jun2019_AdditionalPaidInCapitalMember" decimals="0">6029</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c25_From1Apr2019To30Jun2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c26_From1Apr2019To30Jun2019" decimals="0">6029</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c22_From1Apr2019To30Jun2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c23_From1Apr2019To30Jun2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c24_From1Apr2019To30Jun2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c25_From1Apr2019To30Jun2019_RetainedEarningsMember" decimals="0">-629393</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c26_From1Apr2019To30Jun2019" decimals="0">-629393</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c27_AsOf30Jun2019_PreferredStockMember" decimals="INF">2097105</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf30Jun2019_PreferredStockMember" decimals="0">210</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c28_AsOf30Jun2019_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c28_AsOf30Jun2019_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c29_AsOf30Jun2019_AdditionalPaidInCapitalMember" decimals="0">6527874</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c30_AsOf30Jun2019_RetainedEarningsMember" decimals="0">-5406886</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf30Jun2019" decimals="0">1121396</us-gaap:StockholdersEquity>
  <ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants unitRef="shares" contextRef="c32_From1Jul2019To30Sep2019_PreferredStockMember" decimals="INF">341761</ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c32_From1Jul2019To30Sep2019_PreferredStockMember" decimals="0">34</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants unitRef="shares" contextRef="c33_From1Jul2019To30Sep2019_CommonStockMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c33_From1Jul2019To30Sep2019_CommonStockMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c34_From1Jul2019To30Sep2019_AdditionalPaidInCapitalMember" decimals="0">1070473</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c35_From1Jul2019To30Sep2019_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">1070507</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c32_From1Jul2019To30Sep2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c33_From1Jul2019To30Sep2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c34_From1Jul2019To30Sep2019_AdditionalPaidInCapitalMember" decimals="0">32796</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c35_From1Jul2019To30Sep2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">32796</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c32_From1Jul2019To30Sep2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c33_From1Jul2019To30Sep2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c34_From1Jul2019To30Sep2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c35_From1Jul2019To30Sep2019_RetainedEarningsMember" decimals="0">-669652</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">-669652</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c36_AsOf30Sep2019_PreferredStockMember" decimals="INF">2438866</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c36_AsOf30Sep2019_PreferredStockMember" decimals="0">244</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c37_AsOf30Sep2019_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c37_AsOf30Sep2019_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c38_AsOf30Sep2019_AdditionalPaidInCapitalMember" decimals="0">7631143</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c39_AsOf30Sep2019_RetainedEarningsMember" decimals="0">-6076538</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c40_AsOf30Sep2019" decimals="0">1555047</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c41_AsOf31Dec2019_PreferredStockMember" decimals="INF">2438866</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c41_AsOf31Dec2019_PreferredStockMember" decimals="0">244</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c42_AsOf31Dec2019_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c42_AsOf31Dec2019_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c43_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">7694547</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c44_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-6751705</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c46_From1Jan2020To31Mar2020_CommonStockMember" decimals="INF">50460</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c46_From1Jan2020To31Mar2020_CommonStockMember" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c47_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">51995</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c48_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c49_From1Jan2020To31Mar2020" decimals="0">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c46_From1Jan2020To31Mar2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c47_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">18460</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c48_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c49_From1Jan2020To31Mar2020" decimals="0">18460</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c46_From1Jan2020To31Mar2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c47_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c48_From1Jan2020To31Mar2020_RetainedEarningsMember" decimals="0">-477276</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c49_From1Jan2020To31Mar2020" decimals="0">-477276</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c50_AsOf31Mar2020_PreferredStockMember" decimals="INF">2438866</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c50_AsOf31Mar2020_PreferredStockMember" decimals="0">244</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c51_AsOf31Mar2020_CommonStockMember" decimals="INF">2028729</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c51_AsOf31Mar2020_CommonStockMember" decimals="0">203</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c52_AsOf31Mar2020_AdditionalPaidInCapitalMember" decimals="0">7765002</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c53_AsOf31Mar2020_RetainedEarningsMember" decimals="0">-7228981</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c54_AsOf31Mar2020" decimals="0">536468</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c55_From1Apr2020To30Jun2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" decimals="INF">1750000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" decimals="0">175</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c57_From1Apr2020To30Jun2020_AdditionalPaidInCapitalMember" decimals="0">23419546</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c58_From1Apr2020To30Jun2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c59_From1Apr2020To30Jun2020" decimals="0">23419721</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <ltrn:StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares unitRef="shares" contextRef="c55_From1Apr2020To30Jun2020_PreferredStockMember" decimals="INF">-2438866</ltrn:StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c55_From1Apr2020To30Jun2020_PreferredStockMember" decimals="0">-244</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <ltrn:StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares unitRef="shares" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" decimals="INF">2438848</ltrn:StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" decimals="0">244</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c57_From1Apr2020To30Jun2020_AdditionalPaidInCapitalMember" decimals="0">-261</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c58_From1Apr2020To30Jun2020_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c59_From1Apr2020To30Jun2020" decimals="0">-261</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c55_From1Apr2020To30Jun2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c57_From1Apr2020To30Jun2020_AdditionalPaidInCapitalMember" decimals="0">105363</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c58_From1Apr2020To30Jun2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c59_From1Apr2020To30Jun2020" decimals="0">105363</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c55_From1Apr2020To30Jun2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c56_From1Apr2020To30Jun2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c57_From1Apr2020To30Jun2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c58_From1Apr2020To30Jun2020_RetainedEarningsMember" decimals="0">-833422</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c59_From1Apr2020To30Jun2020" decimals="0">-833422</us-gaap:ProfitLoss>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c60_AsOf30Jun2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c61_AsOf30Jun2020_CommonStockMember" decimals="INF">6217577</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c61_AsOf30Jun2020_CommonStockMember" decimals="0">622</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c62_AsOf30Jun2020_AdditionalPaidInCapitalMember" decimals="0">31289650</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c63_AsOf30Jun2020_RetainedEarningsMember" decimals="0">-8062403</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c64_AsOf30Jun2020" decimals="0">23227869</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c65_From1Jul2020To30Sep2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c66_From1Jul2020To30Sep2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c67_From1Jul2020To30Sep2020_AdditionalPaidInCapitalMember" decimals="0">43514</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c68_From1Jul2020To30Sep2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">43514</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c65_From1Jul2020To30Sep2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c66_From1Jul2020To30Sep2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c67_From1Jul2020To30Sep2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c68_From1Jul2020To30Sep2020_RetainedEarningsMember" decimals="0">-1701488</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">-1701488</us-gaap:ProfitLoss>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c69_AsOf30Sep2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c70_AsOf30Sep2020_CommonStockMember" decimals="INF">6217577</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c70_AsOf30Sep2020_CommonStockMember" decimals="0">622</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c71_AsOf30Sep2020_AdditionalPaidInCapitalMember" decimals="0">31333164</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c72_AsOf30Sep2020_RetainedEarningsMember" decimals="0">-9763891</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">2295</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">1091</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">167337</us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">54356</us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">1672014</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">25950</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">431004</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">304474</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">-4083564</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">-1419047</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">11145</ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment>
  <ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">5717</ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">-11145</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">-5717</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">26250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">2920507</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <ltrn:IncreaseDecreaseIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">2745279</ltrn:IncreaseDecreaseIssuanceCosts>
  <ltrn:IncreaseDecreaseIssuanceCosts unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">52000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">169049</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">-169049</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">108500</ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable>
  <ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">23665221</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">2920507</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">19570512</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">1495743</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c11_AsOf31Dec2018" decimals="0">445163</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c40_AsOf30Sep2019" decimals="0">1940906</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" xs:nil="true"/>
  <ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">-535000</ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock>
  <ltrn:ApplicationOfDeferredOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">-456437</ltrn:ApplicationOfDeferredOfferingCosts>
  <ltrn:ApplicationOfDeferredOfferingCosts unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" xs:nil="true"/>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 1. Organization, Principal Activities,
and Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Lantern Pharma Inc.,
and Subsidiary (the &amp;#x201c;Company&amp;#x201d;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence
(&amp;#x201c;A.I.&amp;#x201d;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&amp;#x2019;s portfolio of therapies consists of small molecule
drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds
that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company&amp;#x2019;s A.I. platform,
known as RADR&lt;sup&gt;&amp;#xae;&lt;/sup&gt;, uses big data analytics (combining molecular data, drug efficacy data, data from historical studies,
data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning.
The Company&amp;#x2019;s data-driven, genomically-targeted&amp;#xa0;and biomarker-driven&amp;#xa0;approach allows it to pursue a transformational
drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January&amp;#xa0;15, 2020. The Company&amp;#x2019;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017. All intercompany balances and transactions have been eliminated in
consolidation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;LP-100&amp;#xa0;(irofulven), out-licensed&amp;#xa0;to Allarity Therapeutics (formerly known as Oncology Venture), in a phase II trial for the treatment of prostate cancer;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;LP-300&amp;#xa0;(Tavocept) in planning stages for phase II trial for the treatment of non-small&amp;#xa0;cell lung cancer; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24pt&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;LP-184&amp;#xa0;in preclinical studies for treatment of solid tumors including prostate, liver and pancreatic cancers and glioblastoma.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In connection with the
Company&amp;#x2019;s reincorporation in the state of Delaware on January&amp;#xa0;15, 2020, the par value of the Company&amp;#x2019;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying condensed consolidated financial statements. Additional funds have been reclassified
from Common Stock and Series A Preferred Stock to additional paid-in&amp;#xa0;capital to reflect the change in par value associated
with the reincorporation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company&amp;#x2019;s
fiscal year ends on December 31 of each calendar year. The accompanying interim condensed consolidated financial statements are
unaudited and have been prepared on substantially the same basis as the Company&amp;#x2019;s annual consolidated financial statements
for the fiscal year ended December&amp;#xa0;31, 2019. In the opinion of the Company&amp;#x2019;s management, these interim condensed consolidated
financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair
statement of the Company&amp;#x2019;s financial position, results of operations and cash flows for the periods presented. The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of
expenses during the reporting periods. Actual results could differ from these estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The December 31, 2019
year-end condensed consolidated balance sheet data in the accompanying interim condensed consolidated financial statements was
derived from audited consolidated financial statements. These condensed consolidated financial statements and notes do not include
all disclosures required by U.S. generally accepted accounting principles and should be read in conjunction with the Company&amp;#x2019;s
audited consolidated financial statements as of and for the year ended December 31, 2019 and the notes thereto included in the
Company&amp;#x2019;s final prospectus, dated June 10, 2020, for the Company&amp;#x2019;s initial public offering, on file with the Securities
and Exchange Commission.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The results of operations
and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative
of the results to be expected for any future period or the entire fiscal year.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;)
of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;). To date, the Company has operated its business as one segment.
The Company&amp;#x2019;s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary,
Lantern Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Effective June 11, 2020,
in connection with the Company&amp;#x2019;s initial public offering (&amp;#x201c;IPO&amp;#x201d;), the Company completed a forward stock split
of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&amp;#x2019;s preferred stock converted into common
stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying condensed
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying condensed consolidated financial statements
and in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the
forward stock split.&lt;/p&gt;&lt;br/&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c73_AsOf15Jan2020_MinimumMember" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c73_AsOf15Jan2020_MinimumMember" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c74_AsOf15Jan2020_MaximumMember" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c74_AsOf15Jan2020_MaximumMember" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 2. Liquidity &lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company incurred
a net loss of $3,012,186 and $1,753,018 during the nine months ended September 30, 2020 and September 30, 2019, respectively. As
of September 30, 2020, the Company had working capital of $21,660,787, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 5). The Company had working capital of $743,526 as of December 31, 2019. The Company
has received funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in
supporting its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional
source of liquidity. As of December 31, 2019, there was substantial doubt about the Company&amp;#x2019;s ability to continue as a going
concern in the absence of additional funding. We believe that our existing cash and cash equivalents as of September 30, 2020,
and our anticipated expenditures and capital commitments for the remainder of calendar year 2020 and for calendar year 2021, will
enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this quarterly
report.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <ltrn:WorkingCapital unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">21660787</ltrn:WorkingCapital>
  <ltrn:NetProceed unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">23420000</ltrn:NetProceed>
  <ltrn:WorkingCapital unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">743526</ltrn:WorkingCapital>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 3. Summary of Significant Accounting
Policies&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Use of Estimates and Assumptions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The significant areas of estimation include determining deferred tax asset
valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could
differ from those estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the
potential risk of business failure.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&amp;#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted.
If the Company&amp;#x2019;s operations are impacted by this outbreak for an extended period, the Company&amp;#x2019;s results of operations
or liquidity may be materially adversely affected.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In conjunction with
the Company&amp;#x2019;s IPO, costs incurred related to the IPO were capitalized as deferred equity issuance costs in other non-current
assets until the time of completion of the IPO. Upon completion of the IPO, these costs have been offset against proceeds received.
Offering costs include direct and incremental costs related to the offering such as legal fees and related costs associated with
the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;During the nine months
ended September 30, 2020, the Company classified deferred offering costs of $456,437 as a reduction to additional paid-in capital
upon completion of the Company&amp;#x2019;s IPO on June 15, 2020. As of December 31, 2019, the Company recorded deferred offering costs
of $191,000 and as of September 30, 2020, there were no deferred offering costs recorded on the Company&amp;#x2019;s condensed consolidated
balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&amp;#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Prepaid expenses and
other current assets as of September 30, 2020 totaled approximately $1,673,000 and included approximately $357,000 of upfront payments
for contractor and academic research studies and services, approximately $48,000 of licensing and other fees to AF Chemicals, LLC,
approximately $6,000 associated with receivables and undeposited funds, and approximately $1,262,000 of prepaid annual insurance
fees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Loan Pursuant to Paycheck Protection
Program&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company received
$108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan Chase Bank (the &amp;#x201c;Lender&amp;#x201d;) pursuant to
the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan is evidenced
by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;) by and between the Company and the Lender. This
amount is recorded as a loan payable on the Company&amp;#x2019;s condensed consolidated balance sheet at September 30, 2020.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Use of Estimates and Assumptions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The significant areas of estimation include determining deferred tax asset
valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could
differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the
potential risk of business failure.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&amp;#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted.
If the Company&amp;#x2019;s operations are impacted by this outbreak for an extended period, the Company&amp;#x2019;s results of operations
or liquidity may be materially adversely affected.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In conjunction with
the Company&amp;#x2019;s IPO, costs incurred related to the IPO were capitalized as deferred equity issuance costs in other non-current
assets until the time of completion of the IPO. Upon completion of the IPO, these costs have been offset against proceeds received.
Offering costs include direct and incremental costs related to the offering such as legal fees and related costs associated with
the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;During the nine months
ended September 30, 2020, the Company classified deferred offering costs of $456,437 as a reduction to additional paid-in capital
upon completion of the Company&amp;#x2019;s IPO on June 15, 2020. As of December 31, 2019, the Company recorded deferred offering costs
of $191,000 and as of September 30, 2020, there were no deferred offering costs recorded on the Company&amp;#x2019;s condensed consolidated
balance sheets.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c75_AsOf30Sep2020_IPOMember" decimals="0">456437</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c3_AsOf31Dec2019" decimals="0">191000</us-gaap:DeferredOfferingCosts>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&amp;#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <ltrn:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Prepaid expenses and
other current assets as of September 30, 2020 totaled approximately $1,673,000 and included approximately $357,000 of upfront payments
for contractor and academic research studies and services, approximately $48,000 of licensing and other fees to AF Chemicals, LLC,
approximately $6,000 associated with receivables and undeposited funds, and approximately $1,262,000 of prepaid annual insurance
fees.&lt;/p&gt;</ltrn:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
  <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">1673000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
  <ltrn:UpfrontContractorFees unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">357000</ltrn:UpfrontContractorFees>
  <ltrn:PatentLicenseFees unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">48000</ltrn:PatentLicenseFees>
  <ltrn:UndepositedFunds unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">6000</ltrn:UndepositedFunds>
  <us-gaap:InsuranceCommissionsAndFees unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">1262000</us-gaap:InsuranceCommissionsAndFees>
  <ltrn:LoanPursuantToPaycheckProtectionProgramTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Loan Pursuant to Paycheck Protection
Program&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company received
$108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan Chase Bank (the &amp;#x201c;Lender&amp;#x201d;) pursuant to
the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan is evidenced
by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;) by and between the Company and the Lender. This
amount is recorded as a loan payable on the Company&amp;#x2019;s condensed consolidated balance sheet at September 30, 2020.&lt;/p&gt;</ltrn:LoanPursuantToPaycheckProtectionProgramTextBlock>
  <us-gaap:ProceedsFromLoans unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">108500</us-gaap:ProceedsFromLoans>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">0</us-gaap:DeferredOfferingCosts>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 4: Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;BioNumerik
Pharmaceuticals.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In January 2018, the
Company entered into an Assignment Agreement (the &amp;#x201c;Assignment Agreement&amp;#x201d;) with BioNumerik Pharmaceuticals, Inc. (&amp;#x201c;BioNumerik&amp;#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300&amp;#xa0;(Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced a License Agreement
that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling $25,000 in connection
with entry into the Assignment Agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In the event the Company
develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related&amp;#xa0;payment recipients
designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million,
with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million
and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;If the Company enters
into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients a specified
percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300&amp;#xa0;that are not otherwise reimbursed from such third
party transaction.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In addition, the Assignment
Agreement provides that the Company will use commercially diligent efforts to develop LP-300&amp;#xa0;and make specified regulatory
filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that the Company
will provide TriviumVet DAC (&amp;#x201c;TriviumVet&amp;#x201d;) with (i) specified data and information generated by the Company with respect
to LP-300, and (ii) an exclusive license to use specified LP-300-related&amp;#xa0;patent rights, trademark rights and related intellectual
property to support LP-300&amp;#xa0;development in non-human&amp;#xa0;(animal) treatment indications.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company is also
required to pay all patent costs on covered patents related to LP-300. These patent costs are fully recoverable at the time of
any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In addition to the recovery
of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection with entry into the Assignment
Agreement, which payments are recoverable prior to making any royalty or third party transaction sharing payments. The Company
also has the right to recover previously incurred LP-300&amp;#xa0;development and regulatory costs, with up to a mid-single&amp;#xa0;digit
percentage of net revenue amounts to be applied towards repayment of development and regulatory costs until such costs are fully
recovered.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;There is approximately
$11,000 payable to BioNumerik as of September 30, 2020 and December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;font&gt;&lt;b&gt;&lt;i&gt;AF Chemicals&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&amp;#x201c;AF Chemicals&amp;#x201d;) for the treatment of cancer in humans for the compounds LP-100&amp;#xa0;(Irofulven) and LP-184. In
February 2016, the Company and AF Chemicals entered into an Addendum providing for additions and amendments to the Technology License
Agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Pursuant to the Technology
License Agreement and Addendum (collectively, the &amp;#x201c;AFC License Agreement&amp;#x201d;) the Company is obligated to make annual
licensing fee payments to AF Chemicals in the amount of $30,000 per year relating to LP-184. The Company paid $0 and $30,000 to
AF Chemicals relating to the LP-184 annual fee&amp;#xa0;during the three and nine months ended September 30, 2020, $7,500 and $22,500
of which was expensed during the three and nine months ended September 30, 2020, respectively. The Company paid $0 and $30,000
to AF Chemicals relating to the LP-184&amp;#xa0;annual fee during the three and nine months ended September&amp;#xa0;30, 2019, $7,500 and
$22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively. Such amounts are included
in research and development expenses in the accompanying condensed consolidated statements of operations. In addition, the Company
is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application (&amp;#x201c;IND&amp;#x201d;)
filing relating to LP-184&amp;#xa0;and also upon reaching additional specified milestones in connection with the development and potential
marketing approval of LP-184&amp;#xa0;in the United States, specified countries in Europe, and other countries.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In the event of a sublicense
of the LP-184&amp;#xa0;rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income and
fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double digit
percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184&amp;#xa0;and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company
to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development
time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three
and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing
milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September
30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements
of operations. The Company paid AF Chemicals $37,500 during the year ended December&amp;#xa0;31, 2019 in connection with extension
of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts
of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension
payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.
The Company is also obligated to make annual licensing fee payments to AF Chemicals relating to LP-100&amp;#xa0;as described below
under &amp;#x201c;Oncology Venture.&amp;#x201d;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Nothing was accrued
or payable to AF Chemicals as of September 30, 2020 and December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Allarity Therapeutics (formerly known
as Oncology Venture)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In May 2015, the
Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics A/S (&amp;#x201c;Allarity&amp;#x201d;) entered into
an addendum and an amendment providing for additions and amendments to the Drug License and Development Agreement. In
connection with the Drug License and Development Agreement, as amended (collectively, the &amp;#x201c;Allarity License and
Development Agreement&amp;#x201d;), Allarity agreed to directly pay to AF Chemicals on behalf of the Company amounts owed to AF
Chemicals with respect to LP-100&amp;#xa0;under the AFC License Agreement. Amounts paid by Allarity to AF&amp;#xa0;Chemicals on
behalf of the Company are then deducted from amounts owed by Allarity to the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The amounts owed to
AF Chemicals with respect to LP-100&amp;#xa0;are in many ways similar to the amounts owed with respect to LP-184&amp;#xa0;as described
above under &amp;#x201c;AF Chemicals&amp;#x201d;. In the event any such amounts relating to LP-100&amp;#xa0;are not paid to AF Chemicals by Allarity,
the Company is obligated to pay such unpaid amounts. In addition to the payments to be made by Allarity, the Company is obligated
to make annual licensing fee payments to AF&amp;#xa0;Chemicals in the amount of $30,000 per year relating to LP-100. The Company paid
$0 and $30,000 to AF Chemicals relating to the LP-100 annual fee&amp;#xa0;during the three and nine months ended September 30, 2020,
respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2020, respectively.
The Company paid $0 and $30,000 to AF Chemicals relating to the LP-100&amp;#xa0;annual fee during the three and nine months ended September
30, 2019, respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively.
Such amounts are included in research and development expenses in the accompanying condensed consolidated statements of operations.
In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in
clinical trials, and file a potential NDA with respect to LP-100. During the three and nine months ended September 30, 2020, the
Company paid AF Chemicals $25,000 relating to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately
$4,000 of which was expensed during the three and nine months ended September 30, 2020 and included under research and development
expenses in the accompanying condensed consolidated statements of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;There is nothing accrued
or payable related to the Allarity License and Development Agreement as of September 30, 2020 and December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;font&gt;&lt;b&gt;&lt;i&gt;EU
Grant&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In September 2018, Lantern
Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form of state
aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &amp;#x201c;General Block Exemption&amp;#x201d;), Article 25
Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and development
activities for the prostate cancer biomarker analysis of the LP-184&amp;#xa0;drug candidate. Following the Company&amp;#x2019;s research
and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development expenses
not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting and
consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made under
the grant as of September 30, 2020 and December 31, 2019. No revenue has been recognized from this grant through September 30,
2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;&lt;i&gt;Patheon API Services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In July 2020, the Company
entered into an agreement with Patheon API Services, Inc. (&amp;#x201c;Patheon&amp;#x201d;) for the manufacture and supply of cGMP material
to support the Company&amp;#x2019;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300
API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer previously
validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used to support
non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing milestones
are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700 pharmaceuticals
for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated global network of
facilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company paid approximately
$194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was
expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services
received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying
condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid
expenses on the Company&amp;#x2019;s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;&lt;i&gt;Southwest Research Institute&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;As
part of the Company&amp;#x2019;s research and development activities, the Company has engaged Southwest Research Institute (&amp;#x201c;SwRI&amp;#x201d;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&amp;#x2019;s product candidates.
Approximately $4,000 and $21,000 was expensed with respect to SwRI during the three months ended September 30, 2020 and September
30, 2019, respectively, and approximately $5,000 and $221,000 was expensed with respect to SwRI during the nine months ended September
30, 2020 and September 30, 2019, respectively. All of such expensed amounts are included in research and development expenses in
the accompanying condensed consolidated statements of operations. Approximately $99,000 was payable to SwRI as of September 30,
2020, and approximately $21,000 was payable to SwRI as of September 30, 2019. In September 2020, the Company entered into an agreement
with SwRI for the non-GMP synthesis of LP-184 material and related analytical development to assist with preclinical studies. Approximately
$97,000 relating to the SwRI agreement is included under prepaid expenses on the Company&amp;#x2019;s condensed consolidated balance
sheet for the period ended September 30, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company
expects to pay additional amounts to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;The Research
Institute of Fox Chase Cancer Center&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&amp;#x201c;FCCC&amp;#x201d;)
as part of the Company&amp;#x2019;s research and development activities, with a focus on &lt;font&gt;advancing
the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.&lt;/font&gt; Approximately $6,000 was expensed with
respect to the FCCC agreement during the three months ended September 30, 2020, which amount is included in research and development
expenses in the accompanying condensed consolidated statements of operations. As of September 30, 2020, approximately $71,000 was
payable to FCCC. Approximately $65,000 relating to the FCCC agreement is included under other current assets on the Company&amp;#x2019;s
condensed consolidated balance sheet as of September 30, 2020. The Company expects to pay additional amounts to FCCC in future
periods in accordance with the payment schedule specified under the FCCC agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;Other Research
and Service Provider Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company leased office
space in Dallas, Texas under month-to-month lease arrangements during the nine months ended September 30, 2020 and the year ended
December 31, 2019. In connection with the Company&amp;#x2019;s employees working remotely due to COVID-19, the Company in August 2020
reduced its monthly lease commitment and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions
and intends to increase its lease of office space following an improvement in the COVID-19 situation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <ltrn:UpfrontPayments unitRef="usd" contextRef="c76_AsOf31Jan2018" decimals="0">25000</ltrn:UpfrontPayments>
  <us-gaap:OtherCommitmentsDescription contextRef="c77_From1Jan2020To30Sep2020_BioNumerikPharmaceuticalMember">In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.</us-gaap:OtherCommitmentsDescription>
  <ltrn:NetRevenuePercentage unitRef="pure" contextRef="c78_From1Jan2020To30Sep2020_PatentsMember" decimals="2">0.50</ltrn:NetRevenuePercentage>
  <ltrn:UpfrontPayments unitRef="usd" contextRef="c79_AsOf30Sep2020_BioNumerikPharmaceuticalMember" decimals="0">25000</ltrn:UpfrontPayments>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent unitRef="usd" contextRef="c79_AsOf30Sep2020_BioNumerikPharmaceuticalMember" decimals="0">11000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
  <ltrn:Annualfees unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">30000</ltrn:Annualfees>
  <ltrn:Annualfees unitRef="usd" contextRef="c80_From1Jul2020To30Sep2020_LP184Member_AFChemicalsMember" decimals="0">0</ltrn:Annualfees>
  <ltrn:Annualfees unitRef="usd" contextRef="c81_From1Jan2020To30Sep2020_LP184Member_AFChemicalsMember" decimals="0">30000</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c82_From1Jul2020To30Sep2020_LP184Member_AFChemicalsMember" decimals="0">7500</us-gaap:OtherExpenses>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c83_From1Jan2020To30Sep2020_LP184Member_AFChemicalsMember" decimals="0">22500</us-gaap:OtherExpenses>
  <ltrn:Annualfees unitRef="usd" contextRef="c84_From1Jul2019To30Sep2019_LP184Member_AFChemicalsMember" decimals="0">0</ltrn:Annualfees>
  <ltrn:Annualfees unitRef="usd" contextRef="c85_From1Jan2019To30Sep2019_LP184Member_AFChemicalsMember" decimals="0">30000</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c84_From1Jul2019To30Sep2019_LP184Member_AFChemicalsMember" decimals="0">7500</us-gaap:OtherExpenses>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c85_From1Jan2019To30Sep2019_LP184Member_AFChemicalsMember" decimals="0">22500</us-gaap:OtherExpenses>
  <us-gaap:OtherCommitmentsDescription contextRef="c86_From1Jan2020To30Sep2020_AFChemicalsMember">the ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.</us-gaap:OtherCommitmentsDescription>
  <ltrn:Annualfees unitRef="usd" contextRef="c87_From1Jan2020To30Sep2020_LP184Member" decimals="0">30000</ltrn:Annualfees>
  <ltrn:Annualfees unitRef="usd" contextRef="c88_From1Jul2020To30Sep2020_AFChemicalsMember_LP100Member" decimals="0">0</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c89_From1Jan2020To30Sep2020_AFChemicalsMember_LP100Member" decimals="0">30000</us-gaap:OtherExpenses>
  <ltrn:Annualfees unitRef="usd" contextRef="c90_From1Jul2020To30Sep2020_LP100Member_AFChemicalsMember" decimals="0">7500</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c91_From1Jan2020To30Sep2020_LP100Member_AFChemicalsMember" decimals="0">22500</us-gaap:OtherExpenses>
  <ltrn:Annualfees unitRef="usd" contextRef="c92_From1Jan2019To30Sep2019_AFChemicalsMember_LP100Member" decimals="0">0</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c92_From1Jan2019To30Sep2019_AFChemicalsMember_LP100Member" decimals="0">30000</us-gaap:OtherExpenses>
  <ltrn:Annualfees unitRef="usd" contextRef="c93_From1Jul2019To30Sep2019_AFChemicalsMember_LP100Member" decimals="0">7500</ltrn:Annualfees>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c94_From1Jan2019To30Sep2019_AFChemicalsMember" decimals="0">22500</us-gaap:OtherExpenses>
  <ltrn:MilestoneExtensionPaid unitRef="usd" contextRef="c95_From1Jul2020To30Sep2020_AFChemicalsMember" decimals="0">25000</ltrn:MilestoneExtensionPaid>
  <ltrn:MilestoneExtensionPaid unitRef="usd" contextRef="c86_From1Jan2020To30Sep2020_AFChemicalsMember" decimals="0">25000</ltrn:MilestoneExtensionPaid>
  <ltrn:IncludedUnderResearchExpensed unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">4000</ltrn:IncludedUnderResearchExpensed>
  <ltrn:IncludedUnderResearchExpensed unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">4000</ltrn:IncludedUnderResearchExpensed>
  <ltrn:ResearchAndDevelopmentExpensesPercentage unitRef="pure" contextRef="c96_From1Jan2020To30Sep2020_EUGrantMember" decimals="2">0.50</ltrn:ResearchAndDevelopmentExpensesPercentage>
  <ltrn:ManufacturingAgreementDescription contextRef="c97_From1Jan2019To30Sep2019_PatheonAPIServicesMember">The Company paid approximately $194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid expenses on the Company&amp;#x2019;s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.</ltrn:ManufacturingAgreementDescription>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">4000</ltrn:ProductCandidates>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">21000</ltrn:ProductCandidates>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">5000</ltrn:ProductCandidates>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">221000</ltrn:ProductCandidates>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c98_From1Jan2020To30Sep2020_SouthwestResearchInstituteMember" decimals="0">99000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">21000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c99_AsOf30Sep2020_SouthwestResearchInstituteMember" decimals="0">97000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">6000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <ltrn:ApproximatelyPayable unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">71000</ltrn:ApproximatelyPayable>
  <us-gaap:OtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">65000</us-gaap:OtherAssetsCurrent>
  <us-gaap:LesseeOperatingLeaseDescription contextRef="c100_From1Aug2019To31Aug2019_PropertySubjectToOperatingLeaseMember">the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.</us-gaap:LesseeOperatingLeaseDescription>
  <ltrn:ResearchandDevelopmentExpensesNotExceedingGbp unitRef="gbp" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">24215</ltrn:ResearchandDevelopmentExpensesNotExceedingGbp>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 5. Shareholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Preferred Stock &lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In March 2019, the Company
sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued 213,510
shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future Equity (SAFE)
agreements. See Note 6. In connection with the sale and issuance of the Series A preferred stock in March 2019, the Company issued
warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price of $3.13 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In July 2019, the Company
sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with the issuance
of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series A preferred stock
at an initial exercise price of $3.13 per share.&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;As of December 31, 2019,
the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred Stock
were issued and outstanding. The holders of Series A Preferred Stock were entitled to receive dividends when, as and if declared
by the Company&amp;#x2019;s Board of Directors, payable in preference and priority to any declaration or payment of dividends on Common
Stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Effective January 15,
2020, as a result of the reincorporation in the state of Delaware, the par value of the Company&amp;#x2019;s preferred stock was changed
from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein as reflective of
this change&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Upon the Company&amp;#x2019;s
IPO, all shares of the Company&amp;#x2019;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of September 30,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;On June 15, 2020, the
Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750 and
other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in its IPO
at a price of $15.00 per share. In connection with the IPO, all shares of the Company&amp;#x2019;s Series A Preferred Stock were converted
into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of
the fractional shares adjustments that occurred in connection with the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion of
the preferred stock that took place in connection with the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;During the three and
nine months ended September 30, 2020, the Company issued zero and 50,460 shares of common stock, respectively, relating to the
exercise of stock options. The shares were issued at a purchase price of $1.03 for total proceeds of $52,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;As of September 30,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,217,577 shares were issued and outstanding. As of
December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and outstanding.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company had warrants
to purchase 332,014 shares of common stock outstanding and exercisable as of September 30, 2020 at a weighted average exercise
price of $6.42 per share. The Company had warrants to purchase 273,900 shares of Series A Preferred Stock outstanding and exercisable
as of September 30, 2019 at a weighted average exercise price of $3.13 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In connection with the
IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In connection with the
IPO, the Company granted the underwriters warrants (the &amp;#x201c;Underwriters&amp;#x2019; Warrants&amp;#x201d;) to purchase an aggregate of
70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price. The
Underwriters&amp;#x2019; Warrants have a five-year term and are not exercisable prior to December 7, 2020. All of the Underwriters&amp;#x2019;
Warrants were outstanding at September 30, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In connection with the
Series A Preferred Stock financing transactions discussed above, during the nine months ended September 30, 2019, the Company issued
warrants to purchase an aggregate of 137,514 shares of Series A Preferred Stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company recorded
stock-based compensation of approximately $167,000 and $54,000 related to stock options during the nine months ended September
30, 2020 and 2019, respectively, and approximately $43,000 and $32,000 of stock-based compensation during the three months ended
September 30, 2020 and 2019, respectively. These amounts are included in general and administrative expenses in the accompanying
condensed consolidated statements of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;A summary of stock option
activity under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the &amp;#x201c;Plan&amp;#x201d;) during the
nine months ended September 30, 2020 is presented below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt;
Average&lt;br/&gt; Exercise Price Per Share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;306,743&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(50,460&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(43,166&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Outstanding September 30, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;820,608&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6.25&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Options were exercisable
for 515,695 shares of Common Stock at September 30, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;During the nine months
ended September 30, 2019, options to purchase 1,342 shares of Common Stock were granted, no options were exercised, and no options
expired or were canceled.&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c101_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="INF">590643</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c101_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="0">1850000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c102_AsOf31Mar2019_SeriesAPreferredStockMember" decimals="INF">213510</us-gaap:PreferredStockSharesIssued>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c101_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="INF">96499</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c102_AsOf31Mar2019_SeriesAPreferredStockMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c103_From1Jul2020To31Jul2020_SeriesAPreferredStockMember" decimals="INF">341761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c103_From1Jul2020To31Jul2020_SeriesAPreferredStockMember" decimals="0">1070000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c103_From1Jul2020To31Jul2020_SeriesAPreferredStockMember" decimals="INF">41015</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c104_AsOf31Jul2020_SeriesAPreferredStockMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c105_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">3480000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c105_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">2438866</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c106_From1Jun2020To15Jun2020_SeriesAPreferredStockMember" decimals="INF">2438851</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <ltrn:CommonStockTotalProceedsValue unitRef="usd" contextRef="c107_AsOf15Jun2020_IPOMember" decimals="0">23419721</ltrn:CommonStockTotalProceedsValue>
  <us-gaap:OtherUnderwritingExpense unitRef="usd" contextRef="c108_From1Jun2020To15Jun2020_IPOMember" decimals="0">1968750</us-gaap:OtherUnderwritingExpense>
  <ltrn:OtherOfferingExpenses unitRef="usd" contextRef="c108_From1Jun2020To15Jun2020_IPOMember" decimals="0">861529</ltrn:OtherOfferingExpenses>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c108_From1Jun2020To15Jun2020_IPOMember" decimals="INF">1750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c107_AsOf15Jun2020_IPOMember" decimals="2">15.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockholdersEquityNoteStockSplit contextRef="c109_From1Jun2020To15Jun2020">In connection with the IPO, all shares of the Company&amp;#x2019;s Series A Preferred Stock were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of the fractional shares adjustments that occurred in connection with the IPO.</us-gaap:StockholdersEquityNoteStockSplit>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c110_From1Jun2020To15Jun2020_SeriesAPreferredStockMember_CommonStockMember" decimals="INF">2438851</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c111_From1Jan2020To30Sep2020_SeriesAPreferredStockMember" decimals="0">261</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c66_From1Jul2020To30Sep2020_CommonStockMember" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c112_From1Jan2020To30Sep2020_CommonStockMember" decimals="INF">50460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c2_AsOf30Sep2020" decimals="2">1.03</us-gaap:SharesIssuedPricePerShare>
  <ltrn:CommonStockTotalProceedsValue unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">52000</ltrn:CommonStockTotalProceedsValue>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c111_From1Jan2020To30Sep2020_SeriesAPreferredStockMember" decimals="INF">332014</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c113_AsOf30Sep2020_SeriesAPreferredStockMember" decimals="2">6.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants unitRef="shares" contextRef="c114_From1Jan2019To30Sep2019_SeriesAPreferredStockMember" decimals="INF">273900</ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c40_AsOf30Sep2019" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c115_From1Jan2020To30Sep2020_IPOMember" decimals="INF">70000</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c2_AsOf30Sep2020" decimals="2">18.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:WarrantsToPurchasePercentage unitRef="pure" contextRef="c0_From1Jan2020To30Sep2020" decimals="2">1.25</ltrn:WarrantsToPurchasePercentage>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c6_From1Jan2019To30Sep2019" decimals="INF">137514</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To30Sep2020" decimals="0">167000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c6_From1Jan2019To30Sep2019" decimals="0">54000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jul2020To30Sep2020" decimals="0">43000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c5_From1Jul2019To30Sep2019" decimals="0">32000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c2_AsOf30Sep2020" decimals="INF">515695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c6_From1Jan2019To30Sep2019" decimals="INF">1342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-&lt;br/&gt;
Average&lt;br/&gt; Exercise Price Per Share&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;306,743&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(50,460&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(43,166&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Outstanding September 30, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;820,608&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6.25&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c116_AsOf31Dec2019_EquityIncentivePlan2018Member" decimals="INF">607491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c116_AsOf31Dec2019_EquityIncentivePlan2018Member" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="INF">306743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="2">15.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="INF">50460</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="INF">43166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c117_From1Jan2020To30Sep2020_EquityIncentivePlan2018Member" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c118_AsOf30Sep2020_EquityIncentivePlan2018Member" decimals="INF">820608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c118_AsOf30Sep2020_EquityIncentivePlan2018Member" decimals="2">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <ltrn:SafeAgreementsDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 6. SAFE Agreements&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In December 2018, the
Company entered into SAFE agreements (the &amp;#x201c;SAFE Financing&amp;#x201d;) with five investors pursuant to which the Company received
funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent
financing of preferred stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&amp;#x2019; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The SAFE agreements
were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in full satisfaction of
these agreements.&lt;/p&gt;&lt;br/&gt;</ltrn:SafeAgreementsDisclosureTextBlock>
  <ltrn:AgreementDescription contextRef="c0_From1Jan2020To30Sep2020">the Company entered into SAFE agreements (the &amp;#x201c;SAFE Financing&amp;#x201d;) with five investors pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent financing of preferred stock.</ltrn:AgreementDescription>
  <us-gaap:InvestmentOwnedPercentOfNetAssets unitRef="pure" contextRef="c2_AsOf30Sep2020" decimals="2">0.80</us-gaap:InvestmentOwnedPercentOfNetAssets>
  <us-gaap:DebtDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 7. Notes and Loan Payable&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed was
approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of September 30, 2020, there is no remaining loan balance on
the Company&amp;#x2019;s condensed consolidated balance sheet related to the First Insurance financing arrangement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;On May 1, 2020 (the
&amp;#x201c;Origination Date&amp;#x201d;), the Company received $108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan
Chase Bank (the &amp;#x201c;Lender&amp;#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past
two years. The Company is tracking further development and guidance related to the Paycheck Protection Program terms.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;During the nine months
ended September 30, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of September 30, 2020.&lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentAnnualPrincipalPayment unitRef="usd" contextRef="c119_AsOf31Jan2020" decimals="0">66000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c120_From1Jan2020To31Jan2020" decimals="4">0.0664</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c120_From1Jan2020To31Jan2020">ten months.</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:ProceedsFromLoanOriginations1 unitRef="usd" contextRef="c121_From25Apr2020To1May2020" decimals="0">108500</us-gaap:ProceedsFromLoanOriginations1>
  <us-gaap:DebtInstrumentDescription contextRef="c121_From25Apr2020To1May2020">the PPP Loan bears interest at a fixed rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past two years.</us-gaap:DebtInstrumentDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c2_AsOf30Sep2020" decimals="0">103000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 8. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company has from
time to time obtained preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. The Company
recorded expenses of approximately $11,000 and $23,000 related to Biological Mimetics, Inc. during the three and nine months ended
September 30, 2019, all of which is included in research and development. No expenses related to Biological Mimetics, Inc. were
recorded during the three and nine months ended September 30, 2020. Approximately $2,000 was owed to Biological Mimetics, Inc.
at December 31, 2019, all of which is included in accounts payable and accrued expenses in the accompanying condensed consolidated
balance sheet. Nothing was owed to Biological Mimetics, Inc. at September 30, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;The Company has previously
engaged Intuition Systems (&amp;#x201c;Intuition&amp;#x201d;) to provide services relating to development of the Company&amp;#x2019;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&amp;#x2019;s former Chief Executive Officer, President and Director. No expenses
were recorded related to Intuition Systems during the three and nine months ended September 30, 2020 or during the three and nine
months ended September 30, 2019. At both September 30, 2020 and December 31, 2019, approximately $9,000 remained unpaid relating
to Intuition and is included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt&quot;&gt;In January 2018, the
Company entered into an Assignment Agreement (the &amp;#x201c;Assignment Agreement&amp;#x201d;) with BioNumerik Pharmaceuticals, Inc. (&amp;#x201c;BioNumerik&amp;#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&amp;#x2019;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. The Company recorded no expense related to BioNumerik during the three and nine months ended
September 30, 2020 and September 30, 2019. Amounts payable to BioNumerik as of both September 30, 2020 and December 31, 2019 totaled
approximately $11,000.&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c122_From1Jul2019To30Sep2019_BiologicalMimeticsIncMember" decimals="0">11000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c123_From1Jan2019To30Sep2019_BiologicalMimeticsIncMember" decimals="0">23000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c124_From1Jan2019To31Dec2019_BiologicalMimeticsIncMember" decimals="0">2000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c125_AsOf30Sep2020_IntuitionMember" decimals="0">9000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c126_AsOf31Dec2019_IntuitionMember" decimals="0">9000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent unitRef="usd" contextRef="c127_AsOf30Sep2020_BioNumerikMember" decimals="0">11000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent unitRef="usd" contextRef="c128_AsOf31Dec2019_BioNumerikMember" decimals="0">11000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Note 9. Loss Per Share of Common Shares&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt&quot;&gt;Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included
in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due to being
anti-dilutive&amp;#xa0;include the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Outstanding at &lt;br/&gt;
September 30,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Warrants to purchase Common Stock&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;332,014&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Warrants to purchase Series A Preferred stock&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;273,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;820,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;630,402&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Series A preferred stock&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,438,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,152,622&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,343,168&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To30Sep2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Outstanding at &lt;br/&gt;
September 30,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Warrants to purchase Common Stock&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;332,014&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Warrants to purchase Series A Preferred stock&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;273,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;820,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;630,402&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Series A preferred stock&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,438,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,152,622&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,343,168&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c129_From1Jan2020To30Sep2020_WarrantMember" decimals="INF">332014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c130_From1Jan2019To30Sep2019_WarrantMember" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c131_From1Jan2020To30Sep2020_WarrantMember_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c132_From1Jan2019To30Sep2019_WarrantMember_SeriesAPreferredStockMember" decimals="INF">273900</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c133_From1Jan2020To30Sep2020_EmployeeStockOptionMember" decimals="INF">820608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c134_From1Jan2019To30Sep2019_EmployeeStockOptionMember" decimals="INF">630402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c111_From1Jan2020To30Sep2020_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c114_From1Jan2019To30Sep2019_SeriesAPreferredStockMember" decimals="INF">2438866</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jan2020To30Sep2020" decimals="INF">1152622</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c6_From1Jan2019To30Sep2019" decimals="INF">3343168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ltrn-20200930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://laternpharma.com/20200930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ltrn="http://laternpharma.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20200930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20200930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20200930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20200930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet" id="ltrn_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="ltrn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement" id="ltrn_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3" id="ltrn_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedCashFlow" id="ltrn_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation" id="ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation">
        <link:definition>006 - Disclosure - Organization, Principal Activities, and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/Liquidity" id="ltrn_r_Liquidity">
        <link:definition>007 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies" id="ltrn_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/CommitmentsandContingencies" id="ltrn_r_CommitmentsandContingencies">
        <link:definition>009 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquity" id="ltrn_r_ShareholdersEquity">
        <link:definition>010 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SafeAgreements" id="ltrn_r_SafeAgreements">
        <link:definition>011 - Disclosure - Safe Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/NotesandLoanPayable" id="ltrn_r_NotesandLoanPayable">
        <link:definition>012 - Disclosure - Notes and Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/RelatedPartyTransactions" id="ltrn_r_RelatedPartyTransactions">
        <link:definition>013 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LossPerShareofCommonShares" id="ltrn_r_LossPerShareofCommonShares">
        <link:definition>014 - Disclosure - Loss Per Share of Common Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy" id="ltrn_r_AccountingPoliciesByPolicy">
        <link:definition>015 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityTables" id="ltrn_r_ShareholdersEquityTables">
        <link:definition>016 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables" id="ltrn_r_LossPerShareofCommonSharesTables">
        <link:definition>017 - Disclosure - Loss Per Share of Common Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails" id="ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails">
        <link:definition>018 - Disclosure - Organization, Principal Activities, and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LiquidityDetails" id="ltrn_r_LiquidityDetails">
        <link:definition>019 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSrp+ex+nBio4y/YIokWQ+Co=] CSR-->
      <link:roleType roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" id="ltrn_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>020 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails" id="ltrn_r_CommitmentsandContingenciesDetails">
        <link:definition>021 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityDetails" id="ltrn_r_ShareholdersEquityDetails">
        <link:definition>022 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable" id="ltrn_r_ScheduleofstockoptionactivityTable">
        <link:definition>023 - Disclosure - Shareholders' Equity (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SafeAgreementsDetails" id="ltrn_r_SafeAgreementsDetails">
        <link:definition>024 - Disclosure - Safe Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails" id="ltrn_r_NotesandLoanPayableDetails">
        <link:definition>025 - Disclosure - Notes and Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails" id="ltrn_r_RelatedPartyTransactionsDetails">
        <link:definition>026 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable" id="ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
        <link:definition>027 - Disclosure - Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="SafeAgreementsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDisclosureAbstract"/>
  <xs:element name="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
  <xs:element name="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
  <xs:element name="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
  <xs:element name="StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares"/>
  <xs:element name="IncreaseDecreasePurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
  <xs:element name="IncreaseDecreaseIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreaseIssuanceCosts"/>
  <xs:element name="IncreaseDecreaseInBorrowingsOnLoanPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
  <xs:element name="ConversionOfSafeAgreementsToSeriesPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
  <xs:element name="ApplicationOfDeferredOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ApplicationOfDeferredOfferingCosts"/>
  <xs:element name="SafeAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDisclosureTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
  <xs:element name="LoanPursuantToPaycheckProtectionProgramTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofstockoptionactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems"/>
  <xs:element name="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <xs:element name="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
  <xs:element name="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
  <xs:element name="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WorkingCapital"/>
  <xs:element name="NetProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_NetProceed"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="UpfrontContractorFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UpfrontContractorFees"/>
  <xs:element name="PatentLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PatentLicenseFees"/>
  <xs:element name="UndepositedFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UndepositedFunds"/>
  <xs:element name="ProductOrServicesDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ProductOrServicesDomain"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UpfrontPayments"/>
  <xs:element name="NetRevenuePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_NetRevenuePercentage"/>
  <xs:element name="Annualfees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_Annualfees"/>
  <xs:element name="MilestoneExtensionPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_MilestoneExtensionPaid"/>
  <xs:element name="IncludedUnderResearchExpensed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncludedUnderResearchExpensed"/>
  <xs:element name="ResearchAndDevelopmentExpensesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ResearchAndDevelopmentExpensesPercentage"/>
  <xs:element name="ManufacturingAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ManufacturingAgreementDescription"/>
  <xs:element name="ProductCandidates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ProductCandidates"/>
  <xs:element name="ApproximatelyPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ApproximatelyPayable"/>
  <xs:element name="ResearchandDevelopmentExpensesNotExceedingGbp" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="WarrantsToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WarrantsToPurchaseShares"/>
  <xs:element name="CommonStockTotalProceedsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockTotalProceedsValue"/>
  <xs:element name="OtherOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_OtherOfferingExpenses"/>
  <xs:element name="WarrantsToPurchasePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WarrantsToPurchasePercentage"/>
  <xs:element name="SafeAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_SafeAgreementsDetailsTable"/>
  <xs:element name="SafeAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDetailsLineItems"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_AgreementDescription"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="ProductOrServicesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="ltrn_ProductOrServicesAxis"/>
  <xs:element name="AFChemicalsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_AFChemicalsMember"/>
  <xs:element name="BioNumerikMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BioNumerikMember"/>
  <xs:element name="BioNumerikPharmaceuticalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BioNumerikPharmaceuticalMember"/>
  <xs:element name="BiologicalMimeticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BiologicalMimeticsIncMember"/>
  <xs:element name="EUGrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_EUGrantMember"/>
  <xs:element name="EquityIncentivePlan2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_EquityIncentivePlan2018Member"/>
  <xs:element name="IntuitionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IntuitionMember"/>
  <xs:element name="LP100Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LP100Member"/>
  <xs:element name="LP184Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LP184Member"/>
  <xs:element name="PatheonAPIServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PatheonAPIServicesMember"/>
  <xs:element name="SouthwestResearchInstituteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SouthwestResearchInstituteMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ltrn-20200930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSrd8uw15+4OjTarDT4x08aU=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ltrn-20200930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityType2or3" roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_Liquidity" roleURI="http://laternpharma.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SummaryofSignificantAccountingPolicies" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_CommitmentsandContingencies" roleURI="http://laternpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquity" roleURI="http://laternpharma.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SafeAgreements" roleURI="http://laternpharma.com/role/SafeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_NotesandLoanPayable" roleURI="http://laternpharma.com/role/NotesandLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_RelatedPartyTransactions" roleURI="http://laternpharma.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LossPerShareofCommonShares" roleURI="http://laternpharma.com/role/LossPerShareofCommonShares"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_AccountingPoliciesByPolicy" roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityTables" roleURI="http://laternpharma.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LossPerShareofCommonSharesTables" roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ScheduleofstockoptionactivityTable" roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable" roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LiquidityDetails" roleURI="http://laternpharma.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_CommitmentsandContingenciesDetails" roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityDetails" roleURI="http://laternpharma.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SafeAgreementsDetails" roleURI="http://laternpharma.com/role/SafeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_NotesandLoanPayableDetails" roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_RelatedPartyTransactionsDetails" roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#DocumentAndEntityInformation" roleURI="http://laternpharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" xlink:href="ltrn-20200930.xsd#ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20200930.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20200930.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreements">
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDisclosureAbstract" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonShares">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonSharesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_EquityIncentivePlan2018Member" xlink:href="ltrn-20200930.xsd#ltrn_EquityIncentivePlan2018Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ltrn_EquityIncentivePlan2018Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSrT2R+Nzg34rRkvYC8+S1/o=] CSR-->
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WorkingCapital" xlink:href="ltrn-20200930.xsd#ltrn_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ltrn_WorkingCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceed" xlink:href="ltrn-20200930.xsd#ltrn_NetProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ltrn_NetProceed" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontContractorFees" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontContractorFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_UpfrontContractorFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatentLicenseFees" xlink:href="ltrn-20200930.xsd#ltrn_PatentLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_PatentLicenseFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UndepositedFunds" xlink:href="ltrn-20200930.xsd#ltrn_UndepositedFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_UndepositedFunds" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceCommissionsAndFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissionsAndFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InsuranceCommissionsAndFees" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductOrServicesAxis" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="ltrn_ProductOrServicesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductOrServicesDomain" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ltrn_ProductOrServicesAxis" xlink:to="ltrn_ProductOrServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductOrServicesDomain_0" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ltrn_ProductOrServicesAxis" xlink:to="ltrn_ProductOrServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP100Member" xlink:href="ltrn-20200930.xsd#ltrn_LP100Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ProductOrServicesDomain" xlink:to="ltrn_LP100Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikPharmaceuticalMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ltrn_BioNumerikPharmaceuticalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP184Member" xlink:href="ltrn-20200930.xsd#ltrn_LP184Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ltrn_LP184Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_AFChemicalsMember" xlink:href="ltrn-20200930.xsd#ltrn_AFChemicalsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ltrn_AFChemicalsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_AFChemicalsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_AFChemicalsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_LP100Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_EUGrantMember" xlink:href="ltrn-20200930.xsd#ltrn_EUGrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_EUGrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatheonAPIServicesMember" xlink:href="ltrn-20200930.xsd#ltrn_PatheonAPIServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_PatheonAPIServicesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_SouthwestResearchInstituteMember" xlink:href="ltrn-20200930.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_SouthwestResearchInstituteMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontPayments" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_UpfrontPayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetRevenuePercentage" xlink:href="ltrn-20200930.xsd#ltrn_NetRevenuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_NetRevenuePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_Annualfees" xlink:href="ltrn-20200930.xsd#ltrn_Annualfees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_Annualfees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_MilestoneExtensionPaid" xlink:href="ltrn-20200930.xsd#ltrn_MilestoneExtensionPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_MilestoneExtensionPaid" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncludedUnderResearchExpensed" xlink:href="ltrn-20200930.xsd#ltrn_IncludedUnderResearchExpensed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_IncludedUnderResearchExpensed" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20200930.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ManufacturingAgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_ManufacturingAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ManufacturingAgreementDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductCandidates" xlink:href="ltrn-20200930.xsd#ltrn_ProductCandidates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ProductCandidates" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApproximatelyPayable" xlink:href="ltrn-20200930.xsd#ltrn_ApproximatelyPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ApproximatelyPayable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" xlink:href="ltrn-20200930.xsd#ltrn_ResearchandDevelopmentExpensesNotExceedingGbp"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchaseShares" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_WarrantsToPurchaseShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockTotalProceedsValue" xlink:href="ltrn-20200930.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_CommonStockTotalProceedsValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_OtherOfferingExpenses" xlink:href="ltrn-20200930.xsd#ltrn_OtherOfferingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_OtherOfferingExpenses" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchasePercentage" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_WarrantsToPurchasePercentage" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="23" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_SafeAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_SafeAgreementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_AgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_AgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="ltrn_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BiologicalMimeticsIncMember" xlink:href="ltrn-20200930.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_BiologicalMimeticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IntuitionMember" xlink:href="ltrn-20200930.xsd#ltrn_IntuitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_IntuitionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_BioNumerikMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="18" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ltrn-20200930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">CHANGE IN CASH FOR THE PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH, BEGINNING OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">CASH, END OF PERIOD</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:href="ltrn-20200930.xsd#ltrn_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDisclosureAbstract_lbl" xml:lang="en-US">Safe Agreements Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureAbstract" xlink:to="ltrn_SafeAgreementsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:href="ltrn-20200930.xsd#ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule of diluted loss per share due to being anti-dilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:to="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">PPP loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 4)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock - Par Value (1,000,000 authorized at September 30, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding at September 30, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Series A preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Series A Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock &#8211; Par Value (25,000,000 authorized at September 30, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,217,577 shares issued and outstanding at September 30, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock, shares par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of common shares, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average number of common shares outstanding, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl" xml:lang="en-US">Preferred stock and warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl" xml:lang="en-US">Preferred stock and warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl0" xml:lang="en-US">Preferred stock and warrants issued, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Number of Shares, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl" xml:lang="en-US">Preferred stock conversion to common stock and fractional shares adjustments from stock split and conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" xlink:href="ltrn-20200930.xsd#ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares_lbl" xml:lang="en-US">Preferred stock conversion to common stock and fractional shares adjustments from stock split and conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" xlink:to="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of common and preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from stock option exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Borrowings from notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Payments on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl" xml:lang="en-US">Borrowings on PPP loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20200930.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl" xml:lang="en-US">Application of deferred offering costs to initial public offering proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseIssuanceCosts" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20200930.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl" xml:lang="en-US">Conversion of SAFE agreements to Series A preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted- Average Exercise Price Per Share, Cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">SAFE Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureTextBlock" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes and Loan Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of diluted loss per share due to being anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-diluted loss share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares, Cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_EquityIncentivePlan2018Member" xlink:href="ltrn-20200930.xsd#ltrn_EquityIncentivePlan2018Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_EquityIncentivePlan2018Member_lbl" xml:lang="en-US">2018 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EquityIncentivePlan2018Member" xlink:to="ltrn_EquityIncentivePlan2018Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A preferred stock {Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductOrServicesAxis" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ProductOrServicesAxis_lbl" xml:lang="en-US">Product Or Services Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductOrServicesAxis" xlink:to="ltrn_ProductOrServicesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WorkingCapital" xlink:href="ltrn-20200930.xsd#ltrn_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WorkingCapital" xlink:to="ltrn_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceed" xlink:href="ltrn-20200930.xsd#ltrn_NetProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_NetProceed_lbl" xml:lang="en-US">Net proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceed" xlink:to="ltrn_NetProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expense and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontContractorFees" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontContractorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UpfrontContractorFees_lbl" xml:lang="en-US">Contract fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatentLicenseFees" xlink:href="ltrn-20200930.xsd#ltrn_PatentLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PatentLicenseFees_lbl" xml:lang="en-US">Licensing and other fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UndepositedFunds" xlink:href="ltrn-20200930.xsd#ltrn_UndepositedFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UndepositedFunds_lbl" xml:lang="en-US">Undeposited funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceCommissionsAndFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissionsAndFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InsuranceCommissionsAndFees_lbl" xml:lang="en-US">Prepaid annual insurance fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissionsAndFees" xlink:to="us-gaap_InsuranceCommissionsAndFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Aggregate loan proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontPayments" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UpfrontPayments_lbl" xml:lang="en-US">Upfront payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Commitments and contingencies, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetRevenuePercentage" xlink:href="ltrn-20200930.xsd#ltrn_NetRevenuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_NetRevenuePercentage_lbl" xml:lang="en-US">Net revenue, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl" xml:lang="en-US">Amounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_Annualfees" xlink:href="ltrn-20200930.xsd#ltrn_Annualfees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_Annualfees_lbl" xml:lang="en-US">Annual fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_MilestoneExtensionPaid" xlink:href="ltrn-20200930.xsd#ltrn_MilestoneExtensionPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_MilestoneExtensionPaid_lbl" xml:lang="en-US">milestone extension paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_MilestoneExtensionPaid" xlink:to="ltrn_MilestoneExtensionPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncludedUnderResearchExpensed" xlink:href="ltrn-20200930.xsd#ltrn_IncludedUnderResearchExpensed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_IncludedUnderResearchExpensed_lbl" xml:lang="en-US">Included under research expensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncludedUnderResearchExpensed" xlink:to="ltrn_IncludedUnderResearchExpensed_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20200930.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl" xml:lang="en-US">Research and development expenses percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ManufacturingAgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_ManufacturingAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ManufacturingAgreementDescription_lbl" xml:lang="en-US">Manufacturing agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ManufacturingAgreementDescription" xlink:to="ltrn_ManufacturingAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductCandidates" xlink:href="ltrn-20200930.xsd#ltrn_ProductCandidates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ProductCandidates_lbl" xml:lang="en-US">Product candidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApproximatelyPayable" xlink:href="ltrn-20200930.xsd#ltrn_ApproximatelyPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ApproximatelyPayable_lbl" xml:lang="en-US">Approximately payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApproximatelyPayable" xlink:to="ltrn_ApproximatelyPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" xlink:href="ltrn-20200930.xsd#ltrn_ResearchandDevelopmentExpensesNotExceedingGbp"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl" xml:lang="en-US">Research and development expenses not exceeding GBP (in Pounds)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" xlink:to="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchaseShares" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WarrantsToPurchaseShares_lbl" xml:lang="en-US">Warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted into shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockTotalProceedsValue" xlink:href="ltrn-20200930.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockTotalProceedsValue_lbl" xml:lang="en-US">Total proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockTotalProceedsValue" xlink:to="ltrn_CommonStockTotalProceedsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting discounts and commissions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OtherOfferingExpenses" xlink:href="ltrn-20200930.xsd#ltrn_OtherOfferingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_OtherOfferingExpenses_lbl" xml:lang="en-US">Other offering expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OtherOfferingExpenses" xlink:to="ltrn_OtherOfferingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Stockholders&apos; equity stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued relating to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchasePercentage" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WarrantsToPurchasePercentage_lbl" xml:lang="en-US">Warrants to purchase percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchasePercentage" xlink:to="ltrn_WarrantsToPurchasePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Common stock, shares granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_AgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_AgreementDescription_lbl" xml:lang="en-US">Agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AgreementDescription" xlink:to="ltrn_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Triggering equity financing, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Annual amount</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSow+cPJ+434ZxEKoGlvbLgg=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Description of maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xml:lang="en-US">Aggregate loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Description of notes payable and loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related party transactions expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Amounts owed to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Remaining unpaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl" xml:lang="en-US">Loan Pursuant to Paycheck Protection Program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikPharmaceuticalMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BioNumerikPharmaceuticalMember_lbl" xml:lang="en-US">BioNumerik Pharmaceutical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikPharmaceuticalMember" xlink:to="ltrn_BioNumerikPharmaceuticalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP184Member" xlink:href="ltrn-20200930.xsd#ltrn_LP184Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LP184Member_lbl" xml:lang="en-US">LP-184 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP184Member" xlink:to="ltrn_LP184Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_AFChemicalsMember" xlink:href="ltrn-20200930.xsd#ltrn_AFChemicalsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_AFChemicalsMember_lbl" xml:lang="en-US">AF Chemicals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AFChemicalsMember" xlink:to="ltrn_AFChemicalsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP100Member" xlink:href="ltrn-20200930.xsd#ltrn_LP100Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LP100Member_lbl" xml:lang="en-US">LP-100 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP100Member" xlink:to="ltrn_LP100Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_EUGrantMember" xlink:href="ltrn-20200930.xsd#ltrn_EUGrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_EUGrantMember_lbl" xml:lang="en-US">EU Grant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EUGrantMember" xlink:to="ltrn_EUGrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatheonAPIServicesMember" xlink:href="ltrn-20200930.xsd#ltrn_PatheonAPIServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PatheonAPIServicesMember_lbl" xml:lang="en-US">Patheon API Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatheonAPIServicesMember" xlink:to="ltrn_PatheonAPIServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SouthwestResearchInstituteMember" xlink:href="ltrn-20200930.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SouthwestResearchInstituteMember_lbl" xml:lang="en-US">Southwest Research Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SouthwestResearchInstituteMember" xlink:to="ltrn_SouthwestResearchInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember_lbl" xml:lang="en-US">Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BiologicalMimeticsIncMember" xlink:href="ltrn-20200930.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BiologicalMimeticsIncMember_lbl" xml:lang="en-US">Biological Mimetics, Inc., [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BiologicalMimeticsIncMember" xlink:to="ltrn_BiologicalMimeticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IntuitionMember" xlink:href="ltrn-20200930.xsd#ltrn_IntuitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_IntuitionMember_lbl" xml:lang="en-US">Intuition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IntuitionMember" xlink:to="ltrn_IntuitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BioNumerikMember_lbl" xml:lang="en-US">BioNumerik [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikMember" xlink:to="ltrn_BioNumerikMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of stock option activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of stock option activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable_lbl" xml:lang="en-US">Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems_lbl" xml:lang="en-US">Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductOrServicesDomain" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ProductOrServicesDomain_lbl" xml:lang="en-US">ProductOrServices [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductOrServicesDomain" xlink:to="ltrn_ProductOrServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="ltrn_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="ltrn_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDetailsTable_lbl" xml:lang="en-US">Safe Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDetailsTable" xlink:to="ltrn_SafeAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDetailsLineItems_lbl" xml:lang="en-US">Safe Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_SafeAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_RelatedPartyTransactionsDetailsTable" xlink:to="ltrn_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="ltrn_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_Annualfees_lbl0" xml:lang="en-US">Annual fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl0" xml:lang="en-US">Amount of application of deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ApproximatelyPayable_lbl0" xml:lang="en-US">Approximately payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApproximatelyPayable" xlink:to="ltrn_ApproximatelyPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl0" xml:lang="en-US">Conversion of SAFE agreements to Series A preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_IncludedUnderResearchExpensed_lbl0" xml:lang="en-US">Included under research expensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncludedUnderResearchExpensed" xlink:to="ltrn_IncludedUnderResearchExpensed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl0" xml:lang="en-US">IncreaseDecreaseInBorrowingsOnLoanPayable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_NetRevenuePercentage_lbl0" xml:lang="en-US">Percentage of net revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PatentLicenseFees_lbl0" xml:lang="en-US">Patent license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl0" xml:lang="en-US">The entire policy of prepaid expenses and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ProductCandidates_lbl0" xml:lang="en-US">Product candidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl0" xml:lang="en-US">Research and development expenses percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl0" xml:lang="en-US">Research and development expenses not exceeding GBP.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" xlink:to="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UndepositedFunds_lbl0" xml:lang="en-US">The amount represents uneposited funds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UpfrontContractorFees_lbl0" xml:lang="en-US">The amount represents upfron contractor fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UpfrontPayments_lbl0" xml:lang="en-US">Upfront payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_WarrantsToPurchaseShares_lbl0" xml:lang="en-US">Warrants to purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BioNumerikPharmaceuticalMember_lbl0" xml:lang="en-US">BioNumerikPharmaceuticalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikPharmaceuticalMember" xlink:to="ltrn_BioNumerikPharmaceuticalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_Annualfees_lbl1" xml:lang="en-US">Annualfees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UndepositedFunds_lbl1" xml:lang="en-US">UndepositedFunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ProductCandidates_lbl1" xml:lang="en-US">ProductCandidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BiologicalMimeticsIncMember_lbl0" xml:lang="en-US">BiologicalMimeticsIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BiologicalMimeticsIncMember" xlink:to="ltrn_BiologicalMimeticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_NetRevenuePercentage_lbl1" xml:lang="en-US">NetRevenuePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ManufacturingAgreementDescription_lbl0" xml:lang="en-US">ManufacturingAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ManufacturingAgreementDescription" xlink:to="ltrn_ManufacturingAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl1" xml:lang="en-US">ResearchandDevelopmentExpensesNotExceedingGbp</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp" xlink:to="ltrn_ResearchandDevelopmentExpensesNotExceedingGbp_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SouthwestResearchInstituteMember_lbl0" xml:lang="en-US">SouthwestResearchInstituteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SouthwestResearchInstituteMember" xlink:to="ltrn_SouthwestResearchInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ProductOrServicesAxis_lbl0" xml:lang="en-US">ProductOrServicesAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductOrServicesAxis" xlink:to="ltrn_ProductOrServicesAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WarrantsToPurchaseShares_lbl1" xml:lang="en-US">WarrantsToPurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_EquityIncentivePlan2018Member_lbl0" xml:lang="en-US">EquityIncentivePlan2018Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EquityIncentivePlan2018Member" xlink:to="ltrn_EquityIncentivePlan2018Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl1" xml:lang="en-US">ResearchAndDevelopmentExpensesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LP100Member_lbl0" xml:lang="en-US">LP100Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP100Member" xlink:to="ltrn_LP100Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl0" xml:lang="en-US">LoanPursuantToPaycheckProtectionProgramTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_NetProceed_lbl0" xml:lang="en-US">NetProceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceed" xlink:to="ltrn_NetProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_EUGrantMember_lbl0" xml:lang="en-US">EUGrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EUGrantMember" xlink:to="ltrn_EUGrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock_lbl0" xml:lang="en-US">SafeAgreementsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureTextBlock" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares_lbl0" xml:lang="en-US">StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" xlink:to="ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OtherOfferingExpenses_lbl0" xml:lang="en-US">OtherOfferingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OtherOfferingExpenses" xlink:to="ltrn_OtherOfferingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_AFChemicalsMember_lbl0" xml:lang="en-US">AFChemicalsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AFChemicalsMember" xlink:to="ltrn_AFChemicalsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WarrantsToPurchasePercentage_lbl0" xml:lang="en-US">WarrantsToPurchasePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchasePercentage" xlink:to="ltrn_WarrantsToPurchasePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PatheonAPIServicesMember_lbl0" xml:lang="en-US">PatheonAPIServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatheonAPIServicesMember" xlink:to="ltrn_PatheonAPIServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl0" xml:lang="en-US">StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PatentLicenseFees_lbl1" xml:lang="en-US">PatentLicenseFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl1" xml:lang="en-US">ApplicationOfDeferredOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncludedUnderResearchExpensed_lbl1" xml:lang="en-US">IncludedUnderResearchExpensed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncludedUnderResearchExpensed" xlink:to="ltrn_IncludedUnderResearchExpensed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UpfrontPayments_lbl1" xml:lang="en-US">UpfrontPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl0" xml:lang="en-US">StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts_lbl0" xml:lang="en-US">IncreaseDecreaseIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseIssuanceCosts" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UpfrontContractorFees_lbl1" xml:lang="en-US">UpfrontContractorFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockTotalProceedsValue_lbl0" xml:lang="en-US">CommonStockTotalProceedsValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockTotalProceedsValue" xlink:to="ltrn_CommonStockTotalProceedsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WorkingCapital_lbl0" xml:lang="en-US">WorkingCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WorkingCapital" xlink:to="ltrn_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_MilestoneExtensionPaid_lbl0" xml:lang="en-US">MilestoneExtensionPaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_MilestoneExtensionPaid" xlink:to="ltrn_MilestoneExtensionPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl0" xml:lang="en-US">IncreaseDecreasePurchaseOfPropertyAndEquipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl1" xml:lang="en-US">IncreaseDecreaseInBorrowingsOnLoanPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_AgreementDescription_lbl0" xml:lang="en-US">AgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AgreementDescription" xlink:to="ltrn_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BioNumerikMember_lbl0" xml:lang="en-US">BioNumerikMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikMember" xlink:to="ltrn_BioNumerikMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IntuitionMember_lbl0" xml:lang="en-US">IntuitionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IntuitionMember" xlink:to="ltrn_IntuitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ApproximatelyPayable_lbl1" xml:lang="en-US">ApproximatelyPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApproximatelyPayable" xlink:to="ltrn_ApproximatelyPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl1" xml:lang="en-US">ConversionOfSafeAgreementsToSeriesPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LP184Member_lbl0" xml:lang="en-US">LP184Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP184Member" xlink:to="ltrn_LP184Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl0" xml:lang="en-US">Proceeds from Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl0" xml:lang="en-US">Proceeds from Loan Originations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl0" xml:lang="en-US">Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl0" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl0" xml:lang="en-US">Other Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember_lbl0" xml:lang="en-US">Property Subject to Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InsuranceCommissionsAndFees_lbl0" xml:lang="en-US">Insurance Commissions and Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceCommissionsAndFees" xlink:to="us-gaap_InsuranceCommissionsAndFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl0" xml:lang="en-US">Proceeds from Stock Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0" xml:lang="en-US">Investment Owned, Percent of Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ltrn-20200930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Oct 29 02:43:15 EDT 2020 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityType2or3" roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_Liquidity" roleURI="http://laternpharma.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SummaryofSignificantAccountingPolicies" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_CommitmentsandContingencies" roleURI="http://laternpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquity" roleURI="http://laternpharma.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SafeAgreements" roleURI="http://laternpharma.com/role/SafeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_NotesandLoanPayable" roleURI="http://laternpharma.com/role/NotesandLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_RelatedPartyTransactions" roleURI="http://laternpharma.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LossPerShareofCommonShares" roleURI="http://laternpharma.com/role/LossPerShareofCommonShares"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_AccountingPoliciesByPolicy" roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityTables" roleURI="http://laternpharma.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LossPerShareofCommonSharesTables" roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ScheduleofstockoptionactivityTable" roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable" roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_LiquidityDetails" roleURI="http://laternpharma.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_CommitmentsandContingenciesDetails" roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_ShareholdersEquityDetails" roleURI="http://laternpharma.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_SafeAgreementsDetails" roleURI="http://laternpharma.com/role/SafeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_NotesandLoanPayableDetails" roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#ltrn_r_RelatedPartyTransactionsDetails" roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20200930.xsd#DocumentAndEntityInformation" roleURI="http://laternpharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" xlink:href="ltrn-20200930.xsd#ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="IncreaseDecreasePurchaseOfPropertyAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IncreaseDecreaseIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20200930.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IncreaseDecreaseInBorrowingsOnLoanPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20200930.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfSafeAgreementsToSeriesPreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20200930.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ApplicationOfDeferredOfferingCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreements">
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDisclosureAbstract" xlink:to="SafeAgreementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonShares">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20200930.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LoanPursuantToPaycheckProtectionProgramTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonSharesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="ltrn-20200930.xsd#ltrn_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareholdersEquityDetailsScheduleofstockoptionactivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="EquityIncentivePlan2018Member" xlink:href="ltrn-20200930.xsd#ltrn_EquityIncentivePlan2018Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="EquityIncentivePlan2018Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityTable" xlink:to="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:href="ltrn-20200930.xsd#ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20200930.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:to="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPZRXtAdTIbdpmbkqj8OwosvPxVGoYOUJOKWTDuEce1cJEOE37wCxUPrJrogfDU5GpHEkxdd3fEvBAHJuIkYPMG6+dTAwGohKB4Nu+zAUNBVSryf7VLQxJn1gmjrWwc1l4g=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="ltrn-20200930.xsd#ltrn_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="WorkingCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceed" xlink:href="ltrn-20200930.xsd#ltrn_NetProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NetProceed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontContractorFees" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontContractorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="UpfrontContractorFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentLicenseFees" xlink:href="ltrn-20200930.xsd#ltrn_PatentLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PatentLicenseFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UndepositedFunds" xlink:href="ltrn-20200930.xsd#ltrn_UndepositedFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="UndepositedFunds" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InsuranceCommissionsAndFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceCommissionsAndFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_InsuranceCommissionsAndFees" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ProductOrServicesAxis" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="ProductOrServicesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductOrServicesDomain" xlink:href="ltrn-20200930.xsd#ltrn_ProductOrServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServicesAxis" xlink:to="ProductOrServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LP100Member" xlink:href="ltrn-20200930.xsd#ltrn_LP100Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServicesAxis" xlink:to="LP100Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioNumerikPharmaceuticalMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="BioNumerikPharmaceuticalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember" xlink:href="ltrn-20200930.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AFChemicalsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember_0" xlink:href="ltrn-20200930.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AFChemicalsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LP100Member_0" xlink:href="ltrn-20200930.xsd#ltrn_LP100Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LP100Member_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EUGrantMember" xlink:href="ltrn-20200930.xsd#ltrn_EUGrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EUGrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatheonAPIServicesMember" xlink:href="ltrn-20200930.xsd#ltrn_PatheonAPIServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PatheonAPIServicesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SouthwestResearchInstituteMember" xlink:href="ltrn-20200930.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SouthwestResearchInstituteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LP184Member" xlink:href="ltrn-20200930.xsd#ltrn_LP184Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="LP184Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember_1" xlink:href="ltrn-20200930.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="AFChemicalsMember_1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayments" xlink:href="ltrn-20200930.xsd#ltrn_UpfrontPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="UpfrontPayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetRevenuePercentage" xlink:href="ltrn-20200930.xsd#ltrn_NetRevenuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="NetRevenuePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Annualfees" xlink:href="ltrn-20200930.xsd#ltrn_Annualfees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="Annualfees" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneExtensionPaid" xlink:href="ltrn-20200930.xsd#ltrn_MilestoneExtensionPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MilestoneExtensionPaid" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncludedUnderResearchExpensed" xlink:href="ltrn-20200930.xsd#ltrn_IncludedUnderResearchExpensed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="IncludedUnderResearchExpensed" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20200930.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ResearchAndDevelopmentExpensesPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManufacturingAgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_ManufacturingAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ManufacturingAgreementDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductCandidates" xlink:href="ltrn-20200930.xsd#ltrn_ProductCandidates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ProductCandidates" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ApproximatelyPayable" xlink:href="ltrn-20200930.xsd#ltrn_ApproximatelyPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ApproximatelyPayable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchandDevelopmentExpensesNotExceedingGbp" xlink:href="ltrn-20200930.xsd#ltrn_ResearchandDevelopmentExpensesNotExceedingGbp"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ResearchandDevelopmentExpensesNotExceedingGbp" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseShares" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockTotalProceedsValue" xlink:href="ltrn-20200930.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CommonStockTotalProceedsValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOfferingExpenses" xlink:href="ltrn-20200930.xsd#ltrn_OtherOfferingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OtherOfferingExpenses" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20200930.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchasePercentage" xlink:href="ltrn-20200930.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchasePercentage" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDisclosureAbstract" xlink:to="SafeAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsTable" xlink:to="SafeAgreementsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="ltrn-20200930.xsd#ltrn_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="AgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20200930.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BiologicalMimeticsIncMember" xlink:href="ltrn-20200930.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiologicalMimeticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntuitionMember" xlink:href="ltrn-20200930.xsd#ltrn_IntuitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="IntuitionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioNumerikMember" xlink:href="ltrn-20200930.xsd#ltrn_BioNumerikMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioNumerikMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="ltrn-20200930.xsd#ltrn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex10-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  8&!@8'!@<(" <*"PH+"@\.# P.
M#Q80$1 1$!8B%1D5%1D5(AXD'AP>)!XV*B8F*C8^-#(T/DQ$1$Q?6E]\?*<!
M!@8&!@<&!P@(!PH+"@L*#PX,# X/%A 1$!$0%B(5&145&14B'B0>'!XD'C8J
M)B8J-CXT,C0^3$1$3%]:7WQ\I__  !$("2$&=0,!(0 "$0$#$0'_Q #4  $
M @,! 0$              @,!! 4'!@@0 0 " 0,! P4- P@'!@,##0 ! @,$
M!1$&$B$Q!Q-159,4%187(C(S07%RDL+14V&B(S9"5'2!D;(U4F)S@K&S"#0W
M0Z'2)'64)3A$5H/!8V1FA--EHZ2TX@$!  (# 0$               0% 0,'
M!@(1 0 " @ "! H) @0$!00# 0 ! @,$!1$&$B&!$S$T-4%2<8*QLA06(C)1
M5&&1H3-R(W.2P14V8G0D0D-3T6.3HL(E@[-$_]H # ,!  (1 Q$ /P#]4@
M
M              $SQ"F]^046NT\V:. <O)D[5N(7X<,UD'2IBF6_2H+0
M
M
M       + ->]_J4VGN!S\N?L\N?DM.2>X%^#!X3+JXZ1,@W:UBJV(
M
M
M      F5-I!KVF(:&?/$ YEIG);CTMK!@F =*F'P;U*@N
M
M                                                         1GN
M!5?)W*+7X@'/SZCB)<VTS>0;>'!WQ+I8\7(-VE>(71
M
M                                                      ' ,3W*
M+S(->W/I:.;/%8F.0<JUK9+<0W<.#B.^ =+%BGF&]6(@%P
M
M                                                         !,@
MU\F3GA1?)Q .;GU/$.9;M9+ WL&"(XEU,>+N!N8J+HJ
M
M                                  !R!R             Q\H[P.3M@
MQ.6$)RP!YR$XR0#///A+,^ (Q*C)E!JVY\>7/SZGCNY!SIFV2>(;V##Z8!T<
M>'OAT,=> 6@
M
M 3: 0\["'G:\@G%ZIP            !RKFX(3=7-I!7,H3((S;ACSL@E3/,-
MJN:)\00RYH[N&O?)$1SR#EY]9,1PYOR\MP=73X(KWNCCQ_N!O5KW+H@
M
M                                            YD!";@A.:RB;3(*Y
M5SX@=N878]7-8[/(-S'FB4P          !5:5-I!#ECF00E"8!%"8!'P8G)(
M(^=XB>7.U&LB.[D&E$VS3#JZ?3Q$0#JXL/I;M*Q +N
M
M                               !BW<"N;*)F019X[@53*BUN^046NJM
M;Z^078-1V9\77QYHO', V*R         7E1-P5S9@$.)2B 1M"BP(<H3(*[2
MJM8$..TY6IT]K7[@=#28(K$.SBQ@Z-:]R<5
M
M                         %5K@IF>4(F>06<0C:T U;W:U[ U+W:ULL>D
M%<9Z<^+KZ'4\?)GZY!W.9B(X3BT@SR<@<G('(  <G(')R"F]VO,S((S,I5F9
M!;QW*Y!7-E%I!7,JIL"JUU4W!BMED1 -O!B^5XNS2D14%D<@
M           ^2^,SHSUE;V.7]#XS.C/65O8Y?T1OIFOZ_P#$O1?5/CWY./\
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M;B8YC[)&R)B8B85V3'?%DOCO'*U;368_6 9?
M                                   $M.]@5]I.)@$+9>&O?+ -6^2&
MM?- -#+F<[/FFL<@T[Y^S$6;VAU.:^2MHYX!]_ILO:Q1ROB:@ES4YJ!S4YJ!
MS4YJ#/:@F8!CFIS4#FK$S7@&I-N49!F.)3CB )O"JUX!K7OWRIM<%=KJ9N#7
MO?O0[4@E6>)7=H'5T,Q-IY]#K3QP#,                        \*^)S>
M/6>D_P +OE.JNB-;TU@TN74:K#EC->:Q%.>[A3Y-.^.EKS:)Y.L\/Z6ZN]N8
M=:FMEK;),Q$S,/BZQVK1'IEZ_P#$YO'K/2?X7:\&O;-UN5HCDL.-<=P<)G!X
M3#>_A>MRZOHZKO;5T-KNFMMZDSZC5X<L9=IU%(BD6]'+P%];&*<5<59GGV2C
M< XCCXCFXCLTI:E;7QQRG]*OUCY._P"9NT?<R?\ 4L^D6V'^EC_LAR[BOG3?
M_P"YR_-(-B            \_\K?\UL7]NQ_Y;-.Q_0R?VK?@'GG0_P ZK\U/
M7M-Y(MRSZ?!FC=-/$9,=;Q$TM]:HP8)S3;E;ER=3XUQO%PFN"U\-LGA)M$<I
MY<N2^/(WN7K;3_@L^QZMZ"U>]QMF#2:S%@TVCP=BE+5E-KIVKCR5Z\<[<GD-
MCI=KYM[1S_1<D5P>$GJ\X[9O')Q-@\EV?:]YT6NU6OPY<>#)V^Q6D\S:/!ZT
MD:V"<-)B9YS,J+C_ !BO%MK%EICM2M,?5Y3//MY@D*%R>L_YJ;W_ &2[\@*K
M?_J4_M=-Z#>0[?\ G_[/UYT1_-+9?[-5V5EC_IT_MAS[B'E^Y_GY/F!]H8
M                                                       $6 R7
M[,-">)!KVM%4)S@UKYI:MLT@UK99:]\D]X-;M=J>&;X:=W:L#EVPSGU5<=?#
ME]OI-#CQ8JQV>\'1I6:QQ$)_* ^5Z3Y7I ^5Z3Y7I!+BWI.+>D&?E,3V@8XL
M?+ XMZ4;3: 8KW,6L!'VELD HMD53D!1;*IMF!5.;]R$W!B*S>5WF+ SYBR4
MXI@&UIK36SO8_E5!.(                        >4^63_ $?M'^_R(^UY
M/D7O1GS[H_W6^67@>/Z2GWH?M)%X?_ZO<]+T\\?#?9E__5K=1_S>WK^P:C_I
MR_&;YXA]_'[$CH+Y+N_YE7VV/K7?J;+HMHVZ]\&/!CMV[XOI+S-IMX_5#DZ;
MJKJ72W[>+>=9$\\]^6UH_P +(TY\OV>5IB(B(CN>BQ<#X7$;$9-?%EOER7O>
MUHB;?;GF]_Z"ZUOU!I<^'5Q2NLP1S;LQQ%Z3X6:G6O75-@O&CTV&N766ISW_
M #<43Z5E])Y:T9/3XN]SN.CW7Z17X=%IC%6>OUO3&/QO(<6_==[]EO33:W7Y
MK1WVK@YI%8GT]A=?JSKK8M7[FU.NU-,E.)G%GB,G,?;97^&VHCPG6MRY]SW<
M\)Z.7O.AX#!X6*=;JQ]^(_'F]VZ.ZOTO4FBO-<?FM3AB(S8OM^NLO$-_ZPZH
MT>^[MIL.[9JX\6MS4I6..ZM;I>QL6G#BO2W+F\QP/@>M7B_$=/<Q5RQBK$UF
M?PGQ2Z&R^4K>-%MFZ6U6IG5:JU\-=-&3PIS%^W9T.@^JNH-VZMP8];N.7)CO
MCRS.+PIW5]$---G):^"O6]/VOU[5GN]'>'Z^MQC9C!7^E/@8]%(BD=L=[XGX
M=]7>N<[Z3%Y2M]ILN'28,M\VX7R7F^>U>U-:?5%8:Z;>:.?.TSV=BPW.C'"<
MD88IKTQUC+%LEHF8^Q$3V/E+]8=5><[5MZUD6B?#SDQ'X7H.S>5G58-JU=-Q
MQQGU=*Q[GO$<1D^_PSAV\E+3U[3:.37Q3HMH;6OCKK8:8<E;U^U7LYUF>WF^
M%W+K'JW6W\[FW/58J7[ZUQ6G%3^%U>G?*-OVVZS%[LU>75Z6;1&2F69O:(]-
M;/FNUFC)%IM/ZPDY^CG"<NA;7Q:^.LQ68IDB/M1:/QE^D[:_25T$ZZV6(T\8
M?.^<GNCL<<\OS]O_ )4]WUEYQ;7'N/!6>ZW=;+=/V]B<=:Q7QV>(Z,<"IO[.
M;)LUGP6">4T]:SY2-]ZSRTG65W#<YQU\<M;Y.Q#O['Y3^H=OS1[LR^[<'UTR
M=UX^[9 ILYZ6B9M,Q/HE[;;Z/\&W=?)BQ8<..]?LQ?'$<Z6_7D_1&R[EH]TV
M[3:[2WF<>:G/[XGPFL_OA\)Y6_YK8O[=C_RV6>:T6UKVCQ35SC@^&^#C^IAO
M'VJ;/5M[8E^:GZVV[JOIG'M^CI?>=%%JX,<6B<U>8F*H.C>E)OUK1'B>SZ9Z
M>WM8]*-?7R9>K:_/J5FW)V-NW;:-?.3W%K\&HG'$3?S=XMV>7CWE)ZEWS:M_
MPX-!N&7#BG1TO-:^F;V3-G+,8.OCMZ?'#R_1WAM,G&?HV[K3V8[3..\3#4\G
MW5/4.Y=3:;3:S<LV;#;%EF:6_=5T^M_*)J]!KLNV[5Q3)AGLYL]HBW%O12$:
MNS>NM-IGG:;<H7NQT>TL_2/'KTQ1CUZ:T9,E:^GMF'G6'<NNMUKDSX-5NV>E
M)^5;%;)-:_@6;=U_U7M^6)]\<F>OUX\_\I"-&;8I,7FUN4_CXI>CR<'X#M4R
MZU=?7BU.RW@XB+TF?8]JUF^Z;?O)_NNNP8YISI,E;TG^C>'YA;=RT7G%:/31
M7=$=:^KCXEKVGG./:FLS[(?<9.MM_OM.BVS07R:?!IL$5M;%S&2WIF;1X0Y&
MDZLZET=XOAWC5^//%LDWK_A9IML9N=9BTQ$1RA:8> \+KCS4R:^/+?)>U\EK
M1$VYVGGW/T1T+UA'46@R^?K6FLP3$9JU\+1/A:'&ZVZ_KL.6=!H,=<FMFG-[
MV[Z8N5E;9Y:T9/3/Q<]P]'IR=(<O#^M,8\=NM:WI\'XX>38-ZZ]W[)>FEUNX
MYYKWVC#,TK'V]CB%OPOZYV+6SI]5KM1&3%,=O#J.+J^,VS$1DZUN4SW/=VX3
MT<RWMH1@P1EK3K36OWXC\>;WGI'JG1=0Z"^HICG%FQ3%<V*>_LS,>,?NEX1O
M'6?56GW?<L&+=\]:8]7FI6.[NBMYA+V,]_!8KTF8ZSS' .!ZT<4XEJ;F&N7P
M,5ZO-OZ+RE;WI=DU>.^KMFUN7-$8LE^_S5..^7VWDKWK<]QG?+Z_79\\UG!V
M/.6FT5Y[?/#XP;&2^;%6;3RY3S_5+XUP+1TN$\4STP5B]LE/!_\ 17K5CL>I
M"S<X                                                    "([P
M4YI[G-D%4Q,HY,?9@'/O:8E5(->RB\ UZ_/1U<S/$0"K;LU<>JCM/LL>MKQ(
M+8UU6?=E9 ]U42KJJ G[JQD:K&#/NK&S&IH"7NBI[HJ#/NBI[HJ#$ZBJ$Y8D
M&(LA:P*K7E5-[ HMEGE3;+(*IO,H3,@B VM/,M^9D$JI\1P#$5B+0[>G^:#(
M                       #RGRR?Z/VC_?Y$?:\GR+WHSY]T?[K?++P/'])
M3[T/VDB\/_\ 5[GI>GGCX;[,O_ZM;J/^;V]?V#4?].7XS?/$/OX_8D=!?)=W
M_,J_4'DTT>ETG2>CS4I'G=1-[Y;>GB\UAXUY2-'@TO5NMC#2*UR5QY)B/3:K
MZV*Q&GA[O@T\"V,M^E?%.=IY6\+'^B\1#I>2;)-.J+]_%9T66+?XU?!;MKK[
MAN>MU=[S:<V>]^9]$SW(MI_\/CC_ *K/2Z^*/K!OY>7;&MACG[9G_P"'I70W
M7&P=.[3?3ZC2ZRV?)GF^2^*E)B8\*^-H<KK[JG8^H[:'+H=+J,>;%%ZWOEK2
MO-)\(^3:6VVQBG6C%U;<^4*S!P+B./I%?B4YL/@K7OSKSGK=68Y1'B4>3379
M=+U;HJ5MQ345OBR1Z8[,VAP>K/YS[Y_;\_\ GEJF>>M7],D_!9X\<5Z1[%HC
M[^C29]L7F&YT=TMEZDW2=-YV<6''3MYLD1S,1Z(?H38N@=@V/5XM7I8SVSTK
M:(O>_/=9)T]>MJQDMX^?9W/-=+./;&'-DX?ABL5G%RRS,<YGK^A^3WZ$\D.C
MTN/9M;K9I'GKZJ<7:^OLTK$M&E$3GC](E==+\EJ<$RQ$_>R4K+Y'RN:+!@W_
M $N?%2*SGTW.3]]J6XY?(]%Z+!K>J=IP9Z1;'.;FU9\)[$38R5CZ7,>B;P^N
M';&3ZJUR\YZU-/)RG^R)B'Z,Z]T.#5=);I6]*SYK#YVG^S:G?W/R6V;\?XE9
M_P"E7]!\EIX=LTF>RN?L[XA[1U5N.7'Y->F]/&2>=1&*+_OICJ\BV_3>Z]?H
M]-SQY[/3'S]^W#5L3ULM(_Z:PL^ UC!P[;R17Q[.>W[3R_V?L?!I\&GT^/3X
ML5:8:4BE:1'=%8[N'Y/ZMV_%MO4FZZ3%6*XZ9YFE?16_RHA+WZQX.D_A/)Y;
MH1GR6W]VEK3/7Q=>?;%GJ/D<UUYC=M#:W-8\WFI7_P!+/HO*W_-;%_;L?^6S
M-)YZ$_VR^=O'&/IMCY1V3GQV_>L/S4^@ITIU->E;TV76S6T1,3&&RMK2]_NU
MF71-G=U-6*SL;&/%UO%U[1'/D]X\FVR:C:-CRVU6"^'4ZG/-KUO'9M6E.ZL/
M.?*[_.?!_8,?^>ZPS5FFE2)_1X+A&S79Z8;6:EHM68R168],5[(:'DN_GAI/
M]SF_R.5USM.;:^IMPQWFTUS9)SX[3]=<L\HO5YZD3^&1Z6N>M.E&3%/CR:-9
MCVUM+L]%=?VZ<T^31YM'Y_3WRSDYK;B])F.'>Q:+R:=1:_/J;[IK=)J-1EF]
ML62U,=>;^B9K,-N/)ARXZ8LLS7EXI5N]H<6X;O;?$>'5QYHS1_B8[1,S'LY3
M'-]MKNF]!T]T1O\ I]%FSWQY<%\O\K:MN^:\=W9B'YD8W*12<=8\45;>B6UD
MW,?$-C)6L7R;'.8KXONOU7T!I--HNE-NG%CB+YL<Y<EOKM:TO ^O-'@T75N[
M8,%(I2+TO%8\(G)2+MNU6(U</=\%9T;SY<G27BW6M/VHR3/NWB(?5>2'+YO>
M=SYMQ2-!:T_W7J\QU^KRZW6ZG59;3:^;+:\S/?/RIY1;S_X?#'ZV>CT\4?\
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MM/"=G;:?O.L+!X4
M        :^>)B',F_:!&MN]')EBT U9BJJU8!K6B$)KS -;S?%N6OJ*7O;Y,
M T\..:9XM:'T&,%O="<< =QS '/VL\Q ,]NI%ZP#/GH])YZ/2!YZ/2Q.>/2"
MOW1$.ABM$UBW(-A"P,5KQXJ\W$0#GV5S$@BQR#",R#<TO,Q+?F02JNKP#,U[
MX=3%/%03                        >4^63_1^T?[_ "(^UY/D7O1GS[H_
MW6^67@>/Z2GWH?M)%X?_ .KW/2]//'PWV9?_ -6MU'_-[>O[!J/^G+\9OGB'
MW\?L2.@ODN[_ )E7ZQ\G?\S=H^YD_P"I9XIY4_YW9_\ <86S8\CQ>ROP0NC_
M /S9Q+VY_G6>2KCX46Y\/<>5YYJL$Z?59\,^./):GX9X0K1_@8_[K/8:UO\
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M5(_ZGD>@U)GB.S?\-?E^]H??^1K2S.KW?5?53%CQ_CGE]7Y6_P":V+^W8_\
M+9C''+0GV2V;U^MTVQ1ZN7%'_P",/S4_:FU_Z,T/]FQ?Y8?'#_'D]D)G3O\
MI:']V3_9E^?/*[_.?!_8,?\ GND;O]"?;"CZ&^>J_P"5=H>2[^>&D_W.;_(]
M<W?JGR>;A3)I-QU.')%+3$Q;#DYK/X6C6OBKKS&2>R;2N.D.GQ/8X]3)H4M.
M3%KXYYQ:(F.<S^+XG+Y-MFWG1WUW3FZVMCFUHK3+69K,Q]46[I>/:O2:G1ZG
M-IM3BMCS8K36]+>,3"-L8(Q]6])YTMXGHN!\9R[ML^MM8HQ[6#LO$3V2]=Z8
MW?5:SR?=3:/->;QI,'&.9^JEXGN>-,9[3:F"9]3X2^^#X*8-SC-*1RCZ5%O]
M=(L_7G1'\TME_LU7Y\\I/\]=V_\ S'_1HE[?DN+VU^#RW1?_ )EXG_9F_P#]
M(=[R14C)O>Y4GPMM]H_QO5Y;GQ6PY\N*WC2]JS]M9X0[^3X9_6SUFG;_ /G.
M*U_^EKS_ !+V?I'H#IS>>GM'K]1FU7GKS>,D4O6(B:V7;YT?Y.MBRX<6X:_7
MX[Y:S:D1/;_RT2XUM>,-<EYMXHF>]YF_2'CV3BVQHZN'!:U<N2M(F/12?:OZ
M2T7D]C?]';:-PUV365[<XZWB8K\R>>>:0\>ZBCCJ#>?[?J/\\M.>,48:>#F9
MCKSXUMP?)Q._%]G_ (ABQTRQJTY13Q=7K3^LO8_(S$>Y-ZGTY<+UI8:GD^/O
M>$Z4>?=WVT^2 2%
M        $ AEF)K+Y_-,TD$/.QPJ\Y ';A7:P*9F%=O %45F6S2L1W< KOIN
M9YB&QAQ6[H!MSH[V9C1Y(!GW)E]![ER>@#W+?T,3I;?7 ,>Y?W,3I9] (SI9
M]"'N6?0!.FMZ)0G36] *K:>>UQQ+IX*Q6G$P"?*< E,PIR\3 -.:H36 0FL(
M34"*P=B ;&".SRVY!;6.Y;6 6Q'?#?I'R02JR
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M>XIFI_3C'2E/967L?D:_[GO/^^Q/64_4\GQO$])_/N][:_+ )"A
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MXK'*L6F9Y,C+4    U<VS[+EM,WVO1WMSXVPTE?ATVETT37!@Q8HGZJ5BO\
MR?,4I$\XK$2D9-O:R4BE]C+:GJS:9A,?2.  ".IV_;]13_XG1Z?-]_'6_P#S
M8P:/1Z6)C3Z;#BCT8Z13_D^>K7GSZL<_Q;IV-B<7@IS9/!^IUIZO[)CZ:0
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MSX_)QO-M'^W^7'Y >G]#]?[/UGMV;6Z#!JL,8;^;RTSX^.+OJ0
M                                          &+W@&K:>9:V7)% <#5
MZN;3W2TJ89RSS(.A&FYKQ%5=-'EQ<S:O +8KS*Z,8+8Q)]@%U:3Z&SCP6F.>
M ;N/%PM DJ       $<H9:<UD'$O$UF>54@HO5JVBP(3:T*+Y)!1?),-/-EF
ML<R#6C+EO/-/!?7'JI](-O3^?I/>^CTT]J ;]*\+ZQS(-^D<0
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MX^UV*5KVK3:>(XYF?K
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MW>V                                                     (7F
M42U\F:*0#@:S5S:>(EJ8L,Y)[X!W-/IXB.Z'5P8(I -GLI1$2!$23$ QW>AG
MD            &..U6>7,S8;=KNJ#GVCOE3,2"FU55J U,V*T\KMOQ\6[X!]
M'ACB..6Q:.X&EEKW2IP?.!VL>..%\=P,Q                          \
MYZ_Z7Z^W+4Z#7=+]2UT-]+BO$Z:T3%,LV^NT]\6!\334_P#:0P1&*=#M.?\
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MU<5*=V#[MN*ON@
M    D%-K<*N^9Y!KY<W8AP-9JYF>(!K8L<Y)B7:T^ '8P8HAL@
M      (S -+-I8XF8<ZV&\2"$TA5;' (6P\PEAP\6!TZ=S:YY@&K>K5B.+@[
MFFO$PL
M                                                     !"\P#7G
MQ:N7-V <75:KGF(EJ4P^<GO!U]/IXKQ'#M8<,1 +HCA,
M$4@8BJN^.MOJ!1.C56T8(>Y)9G2V@$.S-)XE?20+QWM/+'$@Z&W9*Q-NU+;
M
M                                              $+9&OSS/(*,N:*
M1+@ZO5=J> :F/%-[19V<&G!V,&'B&T                       -/55_E9
MX54GB076[VGD@%>*>SDAV(GGB03
M
M            $,E@:L6YF5&3-%>0<35ZGF)B&G3'.2>0=?3X>)K'#MXL,1 -
MBL<,@                      "C/',S+1B?E VH[X:V2 :=YXF)=?36YQQ
M(-F
M                                            #D[4 39CGD#P.00R
M9>&KVIF049,T4</4ZGM3Q -:F*;3$NII]+SP#N:?#%8AM
M          AE[X<V8XD%U)9OX T,D-K1VXD'2CQ9
M
M                   &+74VR JF\S+':D&>U)YW@%N//7ZV;Y(F :DS,S+7
MOGBD2#BZK5\]S7QXIR3R#KX<$3Q5V<.'LU!M49
M  !B>^7/SQQ8"LIV\ :>6%>&_%P=[#WQS(
M
M            393-@5S97,@BQ((3*$R!RKFUH^L$;YXB'&U>KB9XK(-7#7MV
M[W:T^FGNX!W,&&*Q'<V@                         "WBU=76..X&I7ZF
MQXP#7O#3\+@[6GO$UA>
M                                                         IM*
MF; @S%03[/<JL"FRN9!";<*[W[@:66+6I9Q<.&\9I[8.[IM-$W[GT&'%V:@V
MJ,@                         'UJKQVHD'/\ "TK:R!DCP:.6.)!L:3+,
MS,.M3P
M                                           57O/U2"B;2P"<5C@[
MH!&;*;6!3:8Y5S: 57M"B;0 IMABUH[@=_18*UK$\-_@
M           #LP#0U5(IDXA")[@76XFD.?F@%>*TUO7B7<K/=' +/K
M
M                             !5>>%$VY!7RL@&9MPIMD!1;(JMD!5-U
M-L@*+Y%<9 3B\Q,+ZW[X!]%H\G-8B%X                            -
M?5QSS+2B>X%U9YK#7RU!HS/$NUI;]J@-NH
M
M         -?-/#7!"9X)R\1W2"J<L_7+7OE!5.6%=LT JG/'*B^29GND$>Q>
M4II, E%+3X+J5MSW@[.CR?*X=29[@(                          "6.\
M%66LS6>7,GM1/ -BD]R&2>8!SLE9;NBRVCY,@ZU9[TN0.0
M
M                   !I9K*.T"C+:943V^ 46O*BV2053=7:X*IMWHQD^4#
MIX.)KWIWXY!92L1"V*0#8T_%;NO7OJ"4                          !*
M/;B 0OEB6I>L3(*Y[D.0)K"%)BD\\ WJ:BLMNEJV!G@
M
M                 <_-XM<&.%=[3Z(!S<EK=NRB>9!5;GE5,2"$UE"L6[0.
MKBGC'+-)FUN\&]59R"S%7Y;L4^8#+(                        !,\ A-
MU%I!2R"%H4SR#',L3((+L>>U0=*E^U"T")
M
M       <_.TYD&>WW*;W!J6B)F946X!7/"$\ QW(\1$@V(O'=#8I7@&W5,&S
MIXYNZL=U09J                         *[R"GM(@C,<LQ (VF%-I@%-I
M538$)OPAYP&W@U'RH=K%DBT R
M                                                          T=
M368<Z9Y!7-N%%[ JFRBT@KF8A3;+ $7B8YY5S?F0;&+OGET:3R#9K"=NX&[I
M*S-N72                          ):^2P*?JY8B9F06]T0KM: 46NIM8
M%5K*;7!KWR]R$6!;6TQ+MZ/+SQ$@Z,R
M
M    KRTBU9<3+'%I@&K>9:E[2"OSG<IOE!J9,O>UYR S%VUBKR#>I7AN8@;E
M4ZUFUH!V<%(K58                          A>>&E>_,@CVF8M$2#-LD
M2U[W@%%LBJV4%5LK7MD!B*S9?3"#;IAA?AKV; Z].)CO2
M
M                 !AR]1AF)Y!S;PTLE0:UZ3Z6AFYK]8.=DRQ$^*GST^@%
MV/-$SXNO@[X\0;V/EO8HD&W7N;^#%]8-ZO=*0
M  "C//9AH6D&+2U[9)] *IR3"FV604SDE5-Y!";2A]8.A@;< NA.D3V@=+'$
MS$+0
M                                    88R8^8!Q,^"T3/#FS28D&OD:
MDX)R2"_!L]+6[5H;V;:M-&/NJ#YO4[=-,O-/!?IXM$\ [&*G$-['4&_AQ=J7
M2QTX@$P                         !J:JW<T+6 F>4>P#3U'=:.&K/((3
M$HS$@A,,3$\@Z&GAN1 +HA;2.\'1QQW0F
M
M     !,$\\ KFD6CARM3IICO@'*RX9B/!+3XOE ZU:S59EIS0'%SXN]13!7G
MP!NTQ3/U.I@TX-^F.M4P(B>0                         !HZWF(<VUNZ
M (O"5KQP#6M\J>4)B(!"TU0[@8[)YOD&YCB(CAL5!?6%M:]X-_'/$)
M
M                            ,3W,3V;>(*,FGI9I3INQ/, G$<+I[Z Y
MN:C&FQ1:P.O3#2K8KQP#,0                           #6UL=N'"O/U
M HG)Q*49>0.VA,@B E"VL NK'>V*P#8JV*1R#;H
M
M             (\2SV /"4,O@#26U[X!I:B)5::W9OW@[M8BU>68@
M                     $,E9M67S.?^3O/:!I7O"F,G>"V+K.W $7A*)B06
M4\5]8D%]:ROK +ZPVL< O
M                                                         E"\
M<U!I6CA93P!KYHYEI4[L@.]AGFL)@                            QSW
MRY.KT\7GD&G[AB8<S4Z>,?@#0Q6B;=\NCV(FO<#..DSROKC!;6G"^E07Q5=6
M@-FM&S2H,@
M                                             2<=P-+-W6,?@".2
M.8ES9B8N#MZ2T<+@                           )F(!1DO'U-;M3/B"G
M+:(^MP]7/;Y[P<BNEM>_:K/@ZF.DTXY!MUX^I;6 6Q65U8!L4CO;-:@OK5(
M
M                                    !J9X^5*O'()7<_+W6!OZ.W=+
M>D                           /!KY+@JY49+Q .9GS<3^YH<6RW[@=+#
MIZTCCCQ2R8H] (5K^Y?2/W OK6;+Z8@;$8^%L0"8
M
M                  U\\=S5Q^(+K3#0S^(+=';OF'6Y
M           %-[M>049+<.9GS?O!I_*RSQQW.E@PQ0'2PX^9[X;M]-7@%,8*
M1]2<8:>@$XQ52[,0#(
M                                                         *\\
M=SGUGB07\1,-+,"&DO$97=B/ ")[P                        &)[E-[@
MHF5&3)P#G9\_C#0CF]@='3X9BO#JXL(-^E>S
M
M                    (Y(<NW=<&SQW*,F+D&OCPS&6KJQDXF 7TR1:3F
M                       47LI\04Y,D1RY6HS@T8YR3RZ6# #JX<3>B.(!
MFL\@
M                                              <P"%[0U)\0$9!"
M0"+3"499!97-WMNF6)!**]_(                    #'S5-[@JFS7OEX!R
ML^I[YAJQ$Y)!OXL,Q$0ZN#"#?K7B
M
M            1F5,V!#M(R#",@A+ ,2A-@1[2=,TUD&]AS=JT0V0
M            :][JO$%&3)$0Y.?4\2#3K6<D\NE@P=D'4Q8H[I="L16 (
M
M                                       !'D%5I[T)!#DY!CL\G9!&
MU55H!!&9!"TH<@L[?#=P:B/"0;];1,                  !X0U[W!5$<-;
M+EB <O/J(MW0TZ4FT@Z6'%X=SK8L7<#>I6(J
M
M                   !*BT@KY1F08XY3B@+..%=I!7-E5K IO95,@A,J9L"
M5;]Z=<G%@=?39HGB&X                  HO=1X@HS9N(<;/GF9!KX\<VL
MZF'#$0#IXL4<1+?I6(@
M
M   $,EFKS/($L LB.Y($;64VL"JUE5K IM93:P*)R*;9 1\Y/I2KEXD'2T^7
MY59Y=V+=NL<2"?U0R               "B]P:[6R9HKSW@X^?43;PE1CK-I[
MP=+'BYXX=7#@GCO!T*TB(@
M
M      !JVGF95R"/*=03YX5S<%5KJK6!5:RFU@56LU<EP:MLBJ;2!VN(Y0[<
M\@WL&;PA]+H<LV@'0\99         )G@%=KJ_. >=9C+P"7GH(S0"<7B4I!1
MDR-:9!JY<\4AQ<^>;2"G'BM:74PX>(!T\.&8=&.Z 2@
M
M                          &)GO1R6XCN!IS*,V!CM0QYS@&)R3/UH3<%
M5K\*;9 5VRPIME@%-\T-7+D!16)LE&.X,6X\);%,%)@%U,5:][J:&_%^ =[Z
MHF$@        5VNJF\S]8*YF4)!"9E&9D$>6.U,3X@G&6\?6M]U<QV>08BTS
M/>U-1J(IX X>HU-K^%D,-)M\X'4Q8N^.(=?!@CCO@'0K2.
M
M                               $949K=P-69[E-K A-D)F05SDX0G*"
MJ^2>5$WD%5KJK6!5-E5K0#;P]GAM<UX!S,G?D;5+=FOB"V+<_6OTN3C) /J<
M4\TA:       (VE3:X*ILQR 3 (3"$P"N4+ QRCX3%@5Y]9V*R^>SZVV6TQ
M&#':9[W9PX? '9P8.&_W0"4
M
M        '#2S@UIE#LQ('9JC:L T\O$6:UI!"953(*K2JL"J957\.0;NFGY"
M67+%8[@<WW1/G.9E.^II$<\@MT^6;S\EUM/CM%XF0?48+1V(A?S^\$HEB;<@
M<RSR!R  $R<]P->]_0HYF?$& $HB4^ 0E58%4RKY!79#FP*=1BB^/][B1I9K
M?F8!U,&'GPAV]-@CNY!U(I#/8
M
M           &EJ :<R1('*-I!H9?GRIFL@A:LJ;5D$.S*JU9!3>LJ;UGL@W,
M'=BESL]YFT@YV6ZK21?/FBH/N]'M]<5:RZE<,0"Z.:LQ:_I!+MW9C//H!;&I
M3]T0![HA;7/'9!GST'G8D&.80O;CN!J3,\L\@E$)Q ',(6L"FUE4V!3-D)L"
M%LBN,D<@SVYFR.6L3X W]#BCAUHI$ L
M
M                 !I:J.R#G6OW,5N"<S"NUP46B)GE$$+*+0"$H2"F]54T
MC@$JVK%9JY>HM%9F8!RLT]J.6YM5XC+$@^ZPZN)B(EMUU5 61J,<I]O']4@S
MVF8F/1 )Q$,>;!F,1YN?2"/8LEQ:( [5X0F\S('/) +8+6D%-KRKFX*YNJFX
M*YLJM/<"B;0AS +J3/H7Q6T@Z&GF:3PZM?
M
M                      &OJ8Y@'$O/?*KM\ SV^81Y 8F05VE3:001D$)4
M9)!K3S:>"=-%H!H:G1\4F85[=BFE^\'U.+)CCNELQDQ MB^-+GCPD#MY/2G&
M6_I!=7+9/W3()QJ971G@$XSU2C-69!C)DK,-;D$HEGM< ><A"<D JMDA7-X!
M3:\*IR0"N<L(6RQP"-:S=MTTX-BN.(7QP"5>ZSJ8K=P)@
M
M                               Q?'VH!\]GIV;V^UIVYD"+\+(M$@Q,
M]Z$R#'BKFH*YB85S8%=Y]"B>U/U SCQ]Z[L@C;'VHX58M/V+>'(.A3!S'AWI
MQIK^@$O,WCZCLW]('R_2S&2P)^>M"49Z^@$XST3C-3T@EVZ3_23B?18$HF?2
MMB9\)!/PA1>\\@K[<JO.3W@KMD56N"J;3Z5<S((3,H\@WM+;M-[O!F(E=4$I
M[N]T,'?2)!L
M                                                           Y
M&X8HI6;0X-,_?Q()6MWRKF\@E6_<3<"+G:!7DOQPHYF9!;6GI.S )Q5.* E&
M-L4Q0#HX,,=NO<ZD8*>@$;8*>A"='B!5.AQJIV\%,[>UIT=H_H@JG2W_ -5K
MS@R1((>;NA;SL1X@NTU[]KOEU.>\$XMR=D$9IQ#GY9XD&M:TH<@C,RA-N 5S
M=B+=X-_1SWRZ$3W@LA; )V\(;^G^C@&P
M
M                  #$WX!RM5,Y.8?.ZK%YKF>048LG:K"T&2:R#'9E96D@
ME-(^MCL5!/B&.P"40LB 75\?!?2G-@=C#CXB); $PCV9!([P#B/0",TCT0S&
MEQS'RH!KVT=)^I3?;JS -.V@C'W\J^ 2A9R"%[]W#GWK/(*+50[((S"$U!'L
M0QV ;6FB:2Z%06U75@&;3]3HX(^1 +P
M
M                !7,]AK9+3<&GFO%:OE]RS3,3P#BZ;4VBW9EW<5NWP#:[
M+/9 BBR*@S,,=D&8JE%03BG"VM>07UQ\RZ.'! -N.YD       :^HK\F7)GN
M!7VDNV"NUE5@4VX56D%<RB S'B"^DPVZR"^K8J#/'-G2Q1W0"T
M
M            #D                      +7B :-KS91>\4!Q-9J>>>)<6
M]9MWR"&/2UFW,0Z.+3Y:_4#=B)3[,@1'"0,\2SV9!F*2LK206=A=CQ WL>'B
M6U6)@&>)       !#+',.+FB:WF)!K3$H=O@&.W"N]_0"BTRKF01E7-XJ#,9
M*EK=W<">*9=#'/@#;I+8CP!;BK-I=&(X@$@
M                                                       ">\!B
M8.) B.]D                    "UHB&I>X-?+>M8<+4ZN>>Z0<RW:O/*_%
MAF?J!UM+I.^.:N]33XXKWU@&MET5+VFT-+)I[5\(!3%+?7"45_<"40E$ G%5
ME<<R#8QX._O;-<<0"Z)@        !B[FZK'SS8'+GE"8[ID&I:TQ)%@5VR0J
M[<2#6ODB/K43DCT@5O\ [3;QQX3R#<QQ#<I'@#;HVZP#;PTX;,@R
M
M          !VH!&;1RCVX!&U_0AYR0(RREYV02IE^5WK8O4#D
M       "^2L TYOVO!3:]:^,@X>HU'/,1+F3$VD&W@Q6GCN=O2Z3F>9@'8KC
MK6(XAGO BLI=B 1MIZ7GGA#W'605SI:P1IJ@LC3UA97%$ R<0!P        ?
M6 KO3M5F <7/CBDM/D%%Z0IFH-:]9:EXM$ U8Q9,MN*][;C:M5>/F@U;[=GQ
MSWK\6/)7CO!T<,RZF..> ;=8XEO8L=IX[@;\4
M                                                        !&T\
M2KFP(\H3((\HS((\G: [:49 74R\S$-B+0!,L@                JO>:J)
MF; IR9(QU<34ZKF0<_BTMK%AY!V-/I?!UJT[$ MKX                 ",
M\Q(*,V&N2O[W$R8;4F0:UE-@:]VG>)D'3V_31VN9?1=BD1W TL^GK9RKX(K8
M$J8XY=#'7N!O8L4V=+'3@$@
M                                         .U7T@IR3S;F%4R"/+$R
M#"$@A,L<@<P<@QS,+\>6?KD&Y6>5@'(              %[U[,]X-.UILU;Y
MHISS(.-J-3-O"6E6)M/>#:Q8[6GYKMZ;2]W? .MCQ\,R!
M   >,@C,<3W*LF*EP<K/I;1//9:%Z< U[T:LXY[4=P.QI:S$1W.K6.X%=X<S
M/6.)!#!3M2[6+!X<P#=KCBJ8
M                                           A:5,V!";(<@S$<I=@
M#LJ[5!#A"T J\#M QV^3F>0;&+-,3#HUR<@S*0             "%[UAJ6MS
M(*<F:*0XFIU':D&EQ,MS#AF0=K3:;CATXCL0"<                    ,6
M\08M6+>+4R:2D@T\FB]$-*^COW<0"^E;4XB70Q\=D"[G9J\\@AI>[(^AKWQ
M)
M                     U[S\J5,R"*<5!/C@!&9538%4V538%4V5VL"OM\2
MLC),@G%^^'2T]^?K!O@       '(',':KZ0.U7TG,  ".3+6M9!IS/;[^5&3
M)%*SW@X>IU$SX-.O-I!N8L7,^#N:?3]T<P#IQ6*L^(,@
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MF]N9!5FR12'%SZGF9@&I',RW<6*9X!V]-I^S+J1W0"0
M      !;Q!1GCF&G3NL#8^IJY0<RT<7=[1W^2#:   !Y%Y9?H]B^]J/R/#%+
MM^47[O@ZGT:\S:OO_/((R]
M                       'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0"
M2H@       !1ED&MRC,@AVN)9G)(*YO,H3<$9NJFP*K7:][@T[W4S,@<]Q&.
MUI!M8L5ZS$S+H4L#MZ._,=[<      0M*F;@A,H<@C,H3W@PQ:8@$.TA:9B.
M05X\DVMQ,I9LT8^Z <?4:J;3QRU*UFT\@Z&'!S+Z#3Z:L5CD'1BD06
M                    0M',.=X90;,>"C)'<#FYXX;V@MS .L   #R+RR_1
M[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
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MBGH[<7!WJSS5FH   \B\LOT>Q?>U'Y'ABEV_*+]WP=3Z->9M7W_GD$9>@
M                                                         #VO
MR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40       !?P<O+/R@0[CLP!-
M8X:&3B :\V4VL"N;*ID%-Y4VOP">#)$Y%^7/$1,<@Y5\L1?M2LPY_/7BM0?1
M:?3<1'/UMRFCKR#<T]*X[2WHR@NBZ0   -;+/RY!3R0"V(2D%5I56L"FUE<V
M!795(*^>]JZG!6]9B(!K8<,Q:*OJ-'I(K6)!TZTB"09
M         $6CJ(X!C'/<E8&AECQ:VGM,90?189YA8#(  \B\LOT>Q?>U'Y'A
MBEV_*+]WP=3Z->9M7W_GD$9>@
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M7W_GD$9>@
M         #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40       !'A+
MDZGNN#6[7>GR"NUN]1: 05VX!5958%:J\0"B9BO>YV:>U,\ YN7!>77VK-2D
M]FP/IL=JS/,6;5;3'U@V*Y[PLC/(+(SPGVL<@EQ26.P!V)2XL"N;6.UW A.0
MC*",Y49R KM=5:\ JFZC)D[@:_/*79D%U(;5:5 CNL[.FMS4&V
M                  :GOK .7X67_P!$&MEAS,GB#J:&[JR   /(O++]'L7W
MM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
M                               ]K\C?T^]_<P?F>RKK4\GIW_%RSI+Y
MYVO<^2 25$        C,=[G:VOU@YDV[V8M($RA,@KF4)!5=4#$PU<EN :E^
M92ICIQWU OBK,<1#G^Y[5R<P#LX/.1$=\NACMDCQF07>Z;1,-F-17T G&6DI
M]J/2"7?_ *R49LD MC46]"?NGF/ %<WY)MW IF5=YD$(R*;Y)Y[I!1;);TJI
MR6]((3>?2A:T@V-+-;3Q,-Z]*Q'= *:5GM-S@$;NIH.\&\
M              6B)@',O'%UG/<"G(YF;ZP7Z&\Q>.]WY^;4$@ !Y%Y9?H]B
M^]J/R/#%+M^47[O@ZGT:\S:OO_/((R]
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MZ->9M7W_ )Y!&7H
M                ]K\C?T^]_<P?F>RKK4\GIW_%RSI+YYVO<^2 25$
M   <1*%YK6. ?.ZNU*YK>AI3>L^ (QDEF+@3=";@QVE5^05Q$S/>LBH)=E*(
MF0611MXZ]P-C'2'3T^+@&[/=W,@<03@QSXP",Z#33'-JRY]]!$\\0#3OH+_4
MH]QY:R"=:VIXK8L"<V4Y.^L@Y\U[T)J"JU54T!CS<,>;@&QCCL^#,S,R#=Q<
M\+HB8D&;.KH8X!N@                            -341W-7'S$@LOWPY
MV6 :5)XR0^ETUIFD V@&.9.T#Q_RO_0;#][4?D>(*7;\HOW?!U/HUYFU??\
MGD$9>@
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MP=3Z->9M7W_GD$9>@
M                 #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40
M   !SZ0:F?+]3G9;16LR#Y_69IOVH<#S5XOVH!U]-EGB(NZ,168[@3BLP2#,
M1!P#,52BH+*TYE;&,%M:=[?PX8GQ!NQ6*QPD   !P!V3@&CJL<<2XT]P*NW+
M%IB05S/"BT^@$)0F:P#/:HHR6Y^:">.);] 7UJVJ OQ4YN[%>Z(!(
M                    #ECM JO;EIVK4"+(SP 3'('+/(,Q:5L9; \C\K.3
MMXME^]G_ "/&%+M^47[O@ZGT:\S:OO\ SR",O0
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M:OO_ #R",O0
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M":H2"*,@QV0'DWE1GFFT?;F_*\B4NWY1?N^#J?1KS-J^_P#/((R]
M                                                     'M?D;^G
MWO[F#\SV5=:GD]._XN6=)?/.U[GR0"2H@    !&9BK4R9)^H&O?-%8<74ZB;
M3W2#2YF6QBPS8'8TVD[HF8=C'CK6 6  !,,<?O \&.^02CM<@        #$]
MP-/4:6N6)M$.'GPWI/' -*\=S1M'9BTR#G9/.Y9[-5F'9LU^9N#&7:9I'BT\
M>#)BR>,@[VGYF(=7%2W=W ZF'3<Q$RZ>*L5C@%@
M     %O$%=K*)N",RB# #,53BL 3PIG@%2,@A-D)L#RCRG3S3:?MS?E>2J7;
M\HOW?!U/HUYFU??^>01EZ
M                      /:_(W]/O?W,'YGLJZU/)Z=_P 7+.DOGG:]SY(!
M)40     U,E^U#3M>*^,@Y.HS]KF(:$1,R#:QXIMP[6FTP.M3'$5X2[$^D
M )@[, =F#LR!$3Z0          [,^GN59=/6T=_B#CY]!:.>''S:3)Z 0TVF
MXOWP^AK2)I$ T=1AB8EQ\N&M9YX!T=)INW#NX-+' -V,?$)1'
M                 %P:MY4\ $R"45Y3BG$@E*$@KE5((3*N; K0D'E'E+MS
M3:_O9ORO*5+M^47[O@ZGT:\S:OO_ #R",O0
M                                   ![7Y&_I][^Y@_,]E76IY/3O\
MBY9TE\\[7N?) )*B     ')ODBL./J,TS/=(-'O;.&LR#MZ;3<Q676K2*P"0
M                 Q//(,\1,*\N'%X Y>7#6MNY;6/D@U\U>YR<]0=C:^S-
M>]UZ]P)                            (9)!JS*,@P MJ3((S9"; JFRJ
M; A-E4V!#M*;7!Y7Y1YYKMGVYORO+E+M^47[O@ZGT:\S:OO_ #R",O0
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M8B(],MB^V;E2.;Z'45CTSCM#1)K:/'$P^,>7%DCGCR5M[)B08;
M                               ![7Y&_I][^Y@_,]E76IY/3O\ BY9T
ME\\[7N?) )*B     'P5;3+:P4YGP!W-/I8[IX=2*]B 3@
M      GQ!IZF.]33P!#)#G9O %VWV^6[\]]@9
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M                      M$]KD&KJ(YKRHQ 7JYF>.X#0]V1]%7OX!(
M                       %&;NAI<@PQ-H@%-K(=J8!&<AVY\01G)"%LD<
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ML\_T3R37B=J>B^&T/3O)'_-G4_V_)_DH^HZV_FGO/]FE]X_)(_L1MW_F._\
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MBP*LT3-.YHT!;/@TLW'$@U,'=D?28IYK )@
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MBR8\\9(O:T3]4Q,/,6O/EC+DZT1R[$KA&ADT-.,%\D7F+3/./U!I6@
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MWMV>;?/QV]%GGBESXO!9)K^SJW"M^-_2Q9^7*T]EX_"T TK$
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M%;FMZ^Q8?@=NWG(CNI28^]VXX?E1\;_]6O\ :D]$.?\ P_/_ )\_+ (+U@
M               ]#Z"M-9W+[,7YGWTYI76IY/3O^+EG27SSM>Y\D,XM9$6C
MFW#[#:]5YR(CGE)43O     .+IZ\Y78!(                      8O\QR
MICB\@NCP59? '(R3_*._HYYI -T                           $,D<UE
MQ,OR+ IM"N+<2"R+<I@A,H\@,2"$H A,(  /,O*-\S:_MS?E>7J7;\HOW?!U
M/HUYFU??^>01EZ  #[SR<[3&X]3::]Z\XM+$Y[_;7YK]*+;1KRPS/XV<XZ6Y
MNOQ*F/T8\4?O/:_+76VZSNG4NX9XMS2E_-8_NX^Y\HK<MNMDO/XVE[S0Q>!T
M=7'ZN*D3[>0_0_DFW2-3LNIV^]N;:7-VJ_<R-^E;EGB/QB85'2G%U^$WM_[>
M2EO]O]WW'4VT5W38=QT41S;)AF<?WZ?*J_(=8F+Q$QWQ9MWZ_;I;\85_0_-S
MU=O%ZN2+?ZHY?[/V:\3\L7^D-I_W%TK<\GMW*#HSYXP?VW^5XV*5U$ ?H_R1
M_P V=3_;\G^2CZCK;^:>\_V:5UC\DC^QRW=_YCO_ -W7XP_) I74AT]GW75;
M1N6FUVFMQDQ6YX^JT?76?W2^JVFMHM'HEJSXJ9L.7%?[MZ36?9+]4].]4[7O
MVDKETV6(RQ$>=P3/RZ2Z6KT>BU>+S6ITV+-3_5R5B\?X2OJVKDI$^.)AQ_8P
M;&CMWQVFU,F.W9:.SV3#DTZ.Z5[?;C9M+^".'7P8,&GQ1CPX:8L=?"E*Q6(_
MN@KCQT^[6(-C>W-F(C/L9+Q'BBT\X?#]8];Z'8]-FTVDS4S;A>LUB*]\8?\
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MKX*LG@#C9NZ[NZ">:P#H@                           =W#CZZDQ:LQ
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M\\[7N?)#[?18,.&E>/1#?BE)GE)42WL1Z3L1Z02BL'$ <0<0!Q4!+3UX;0
M                  #$\\@<R Q%HB.'.S=]P2K/<A>0<G4UM,NEMUIB8@'8
MY.0                           X:^JFO8F ?*WO;%DE+SG:[P.TE%N 6
M1;E(& "49@$0$>).)!YEY2>ZFU?;F_*\K4NWY1?N^#J?1KS-J^_\\@C+T
M                                                          ?>
M]$>.X?9C_,^SQS:N?F%UJ>3T[_BY9TE\\[7N?)#ZK3ZR_$-R-9=)42Z-98]V
M6!*-99GW98#W98]V6!*NL =ZM>(8^L$@                   "UX@%5LD*
MYR HOEE5SV@8Y.08\W6R=.,5N8!MTS<MF)B0
M  ^L%66_#GY)MEG[ :&IPU[,RXT7XO: 75E; )0EVP8[9VP61*7 ,<' ,\'9
M!Y?Y2_H]I^W-^5Y0I=ORB_=\'4^C7F;5]_YY!&7H
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MR52[?E%^[X.I]&O,VK[_ ,\@C+T
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M0^9M'VYORO(U+M^47[O@ZGT:\S:OO_/((R]
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M_P">01EZ
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M3Z->9M7W_GD$9>@
M               #UCR75YR;M]F'\SV;'@Y76IY/3O\ BY9TE\\[7N?)#?K$
M1PFDJ(                        0RSW U.Y&>01[UU*QP"?"-IX!"95S(
M*K2JM8%4V5S, HO>?JE3.2?2"$WA93M\QP#;KS];JZ7(#H@
M     Q$2#*N]X!JSS,]ZNUNR#G:C/'?WN3DR=J0,>&9EO4P3W [6FT]8B)[+
MHQQ'<!P   !V*G8J!V*G9@ !X]Y8:13%L?WM1^1X@I=ORB_=\'4^C7F;5]_Y
MY!&7H
M      ]A\DM(OEWG[N#\SVSL\1W+K4\GIW_%RSI+YYVO<^2$^($E1
M                 #4S6!162; QVED7 \XA>X*INA:X*9NKFP*;74SD!1:Z
M/:!=2D6;M*UJ"5YXA/!>>U .[2W*P                  )D%-\K6GF;<@K
MOEB'.SZCB9!R;Y)O*6/#/B#IX<,RZF#3S',S .A7B(X(CO!D       'D7EE
M^CV+[VH_(\,4NWY1?N^#J?1KS-J^_P#/((R]
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M^CV+[VH_(\,4NWY1?N^#J?1KS-J^_P#/((R]
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MB^]J/R/#%+M^47[O@ZGT:\S:OO\ SR",O0
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M@          #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
M                                                    /:_(W]/O
M?W,'YGLJZU/)Z=_Q<LZ2^>=KW/D@$E1                        *-1X2
MYDR#,2LY!&9:>:?E U;3*OO!7;E7,3((3655HD%<\JKQ,P#?QW[.-I7OS8&G
M;+-+J,NLM:T5K]8/H=OT%[TBUW5KHZ4[^ ;^GR5QMV-14%WG*2SS )
M  HO=5-Y!&9E"00E"002F00[;%HX\)!",\U;%)CQY!')FBKF9=5X@Y]KVO*S
M'2>X'4T^&9=G#AB*P#;XX@J           /(O++]'L7WM1^1X8I=ORB_=\'4
M^C7F;5]_YY!&7H
M               ]K\C?T^]_<P?F>RKK4\GIW_%RSI+YYVO<^2 25$
M                 3:8D%.>)FG+DVG@&*V[UG:!";*KSS(*9B$>S (36%=J
M@JFJNU> 5]EB: C;NJT<D\<@YV:\<2U]+':S5GT2#T30Y><41/<Z-)KX>($X
MJRQYL&.+0S&2\?4#:IK;UKQV87QJ8GQ!+SE3M     3*J^60:\SRB#':)!!&
M8!6Q(*IJ1(*;U0\[,>(-//J8CP[VA$S>9D&UBIWNK@Q<\=P.UAPQ6&U
M        /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
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MRB_=\'4^C7F;5]_YY!&7H
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M@             !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_/((R]
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M_P#/((R]
M         'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0"2H@
M             M', XNKP6K,V<Z>^ 5=Z7(+89D&$> 8[*,UD#LH]CB02X9B
M@+(QPV*T!OX,;H5KP#-L=947TF*9!J9-#,-6=+> 0FEH^I">T#$Q65<T!'B8
M/.3 +*ZB8;%-1^\&Q74UB.\\YV@2.01BT<L]N08[2,R"N;(S8%4RKM: 4S:%
M,5F0;=*\>*VMJQ(-GZF)^5 -K2WXCLRZ-8X@             !Y%Y9?H]B^]
MJ/R/#%+M^47[O@ZGT:\S:OO_ #R",O0
M                               ![7Y&_I][^Y@_,]E76IY/3O\ BY9T
ME\\[7N?) )*B                        $05YJUFO>^6U5XIGM6/ %47Y
M3!.DROD&.#@#@X X.R!%$XH"R*2W,6*>8!TJ8^RG,@ ,,?)] (S2L_4HMI:R
M#5OHIYGAK7T]Z@IFDQW3",Q^X$)I"N:3]4@C$VK:'2Q3\D%U9+> *)YB4>W(
M'G$;904VRJIS C.55.0$.U+:T_$@W;1'#6CGM WZ_-9B 3P?/=8
M    !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO\ SR",O0
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MP=3Z->9M7W_GD$9>@
M                 #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40
M  U\>;M-B;                  ',0T\V;GFL YMIXGO<W59HCG@'S&HQ6S
M7[I;NCQ9,-.S/I!W,%Y;@'9Y9BD@EV"* GYM** MKB;-,/? -RM(B
M  "8B4;XL7AQR#5RZ>EH[H:EJ]F.R#$=T+*V Y:N8'/MXHR"NRJ01 %VGF8N
M#IQ/,K 3A.(!;ACY3IU\              'D7EE^CV+[VH_(\,4NWY1?N^#J
M?1KS-J^_\\@C+T
M               >U^1OZ?>_N8/S/95UJ>3T[_BY9TE\\[7N?) )*B     '
M$QWF)=/%DBT>(-@               !B;=D&GER<_-:D]W?,@YVISQZ7'RVM
M?N!/!IJQWS+?QX.UX0#JX-%/UU=&V@B(!1.DF/"$(TV6/Z$@S[GR_P"I).FR
MS_1D$ZZ6WUPV*Z>(D%L8HA+C@#F?0         'B#$QQ+G9HXN#6O/>1(%I4
MSW@KFL*YK (6K'"J:P"/9@[ '864I$6!M1/>NY!9"R.. ;&&/E-\
M     !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_ #R",O0
M                                               ![7Y&_I][^Y@_
M,]E76IY/3O\ BY9TE\\[7N?) )*B     '!7X,G$@Z])B8ACGB09
M      #NAJ7R\S, U+WBK1SYXXD'*M;MRLKB[@;>'#VI=;!IN =2D<0
M            -+40#0O]1 (VE7,@A,H3((3*L$$@$X!=5? +86 W,,-L
M         !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_ #R",O0
M                                                   ![7Y&_I][
M^Y@_,]E76IY/3O\ BY9TE\\[7N?) )*B     'S%;3]:^D@ZV#)S];:F
M         #D!CM1$ T\N2?J:UYXCF0<[-G_>Y]K6M,@GCQMW%BF>.X'6P:>(
M=&E8@ B                 )\5.HIW YEHE"052KD$)E"011!!(!. 757P"
MV%M(YD'0QUX7              /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_
MYY!&7H
M       ]K\C?T^]_<P?F>RKK4\GIW_%RSI+YYVO<^2 25$     /E[,TL#HZ
M6_%G6CT@            $0!:W#0ODFP-><G9:&?/X@YWSY713B ;6'',NOAP
M=T2#H4KP0                  6GO)[X!S]128X:-I!!"P*F+ IE&; A-R+
M NB4X@%T+X@%U:MO#0&]]17P              >1>67Z/8OO:C\CPQ2[?E%^
M[X.I]&O,VK[_ ,\@C+T
M                    >U^1OZ?>_N8/S/95UJ>3T[_BY9TE\\[7N?) )*B
M    'S']%1CGY8-_#;BSN5GY )U\(        Y@Y@#F/2<QZ0.8 &+V!IY,C
M5O:*P#FYL[3[[2"VM.&YBIVI@'7PZ>(ANQ'9@")                   !C
M-2+./FI,6\ 4*K K1L"FW@U[2#7FRRE@;=&S +H7U!MTJZ&.G= ,@
M      #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
M                                               /:_(W]/O?W,'Y
MGLJZU/)Z=_Q<LZ2^>=KW/D@$E1     #Y*+QRAS_ "@-_!\Z'>I\P$X
M$9!'M<(6R JFZ$W!";H]O@#S]H6TU7$=X-G'J(F)[VMER]H&I?)V7/SY^T#3
MCO3CQ!O8<<V=;#AXX!OQ'$                     "G+3F <G-AM7OAK36
M/K!#B.5-O$%-[1SPT,N>(G@&G?-Q+$:J*2#HX-56[I4M -ND-S'BF0;]<?97
MQX               #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
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M?7$J_;P1CM%J_=E[7HYQ>^]AOBS3SS8_3ZU5@AO2@
M                /:_(W]/O?W,'YGLJZU/)Z=_Q<LZ2^>=KW/D@$E1
M#YFN"(GP6^8I(+<./L2Z^.\3' +.R3W S   %O#D&IDMRJ 1D$& $+ JE58&
MGDY<S-J)F>)!BL=W+:I .CAPVL[6'#V8CN!O>$
M   &;%6U..(<W)HXD'.R[?V>;3'@ACQ\2">6D.7FJ#9T;OZ2M?1 -_B
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M:C1VGYGRZ?9/BW;/*^MUO9,*S@4VU./1AF?_ #9,5NY]X*=TP
M                        ![7Y&_I][^Y@_,]E76IY/3O^+EG27SSM>Y\D
M DJ(     <KG';P.Q$ Q,25O:H+HS675S0#:I,6KR  $PUKY/J!3+ ''+,4!
M.*(VB 4VX56!5+7O(*IAS=3INU':J#4Q3,3V9=K3X^U, ^BT^"*PW.ZH(\\I
M0                        !("C45YQVAR.Q,2#-ZSPT<U.X$-/W2^@T@-
MX                !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_ #R",O0
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M [N$(CF.. :U]+'/,0W]OXI/%@?11QQRD!Q
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MTQ/&^Z+[U_\ )*QQ^1^Y+Q6YV=*(_P"[Q?&'LHIW3
M                 'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0"2H@
M !\W2\QXKXO$@3$216T G&286^=K()1QP< S$,]J8!&^298H!/BG6P)VOW0J
MFP(]I7:P*ILKM(*;6[I4]H%M&Y6D Q>JFO=> =[%;M8UT
M            !>.:N7DCBP(3X-/) -;PF'4PSWP#K1\V$@
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MD_=VYG\$K"GD?_\ 7+Q>S]KI3'_>8_XF'L0IW3
M              'M?D;^GWO[F#\SV5=:GD]._P"+EG27SSM>Y\D DJ(
M<2,$6^HG2W@%4Q>K,9;1X@GS$]\G%/J YM"49> 61EK*?=/A((37TI<<1W I
M[4PCYR?2"478FP(]M&;P"NUX4VL"JTS/,1*=,-N.\$JQQ+<K()2ICQ!UM-X-
ML                           +>#G9H[P5-;(#1MXNC@GNB0=?'/-(6@
M               \B\LOT>Q?>U'Y'ABEV_*+]WP=3Z->9M7W_GD$9>@  /S_
M )?I<GWI6.AX\G<\1TR^[H^W)_L^YZ)U.GP5U_G<V.G,XN.U:*^E]W[X[?\
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M0\II6C;Z35O7MB=B]X]E><O3A3NF@
M    /:_(W]/O?W,'YGLJZU/)Z=_Q<LZ2^>=KW/D@$E1     #4PXYB>]MS6)
M!5."DM7)I:@U[8+*)I:L@QYR8[DNU$@C:O,\D3,?6"^LS*_CN!KWI+5MS (]
MM&;@A;(KF\@A-Y1FX)4M\N'2YYJ#5F+=IMU!.4(CO!T=/+=
M              !IYX!J*LD=P-"\=[:T]NX';P_,A<                #R
M+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ   _/^7Z7)]Z5CH>/)W/$=
M,ONZ/MR?[*Q9/##?VK_2F@_M.+_-#YO]RWLENUO*<'^97XO9-X_T3N']FR?Y
M7AB%H?<O[7JNF/E6K_E3\7K71O\ H:/]]=]4@['];)_=+UW!_-6E_DU!I60
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M:Z[9H:8.8F\SVLEH^NTH6]DB*UIZ9GG+U/1'2M;/EV[1]FE>I7VRZXJWOP
M                                 'M?D;^GWO[F#\SV5=:GD]._XN6=
M)?/.U[GR0"2H@      .S!-8D#LP6TV*WCR#0R:2.U/9\&K?%:OU HMSSWJN
M9[0-VD=RV)D"6CG!JS*$R"$RA,@@ E7QATZ3\CO!BD\RV(B 2XA">Z ='31'
M8Y;<                            U,_@#2B90N#1R+]-P#M89[HAL
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MAIYN\%$TGA7-)!":H3608BD\I>;D$JT^5#8M(+,4\+^03Y..8!T\$<8U\
M                        !+7S1S4&AQQ*-H!I9(,%N =C3VY;P
M         /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
M                                                  ]K\C?T^]_<
MP?F>RKK4\GIW_%RSI+YYVO<^2 25$         ' "-J]Y;YH.1ECOE74&+*Y
M@"?!"00F$> (K'*79 X.SW@LB%L LB%M8[^ =+''%.%D
M           !;P5W[Z@YMOG,6!JY*M;'W6X!V--W3$.D
M#R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??\ GD$9>@
M                                          #VOR-_3[W]S!^9[*NM
M3R>G?\7+.DOGG:]SY(!)40          $L3WU!SL]>]JP",H2"*,@A+ $)@)
M< G$+(@%L0VL-.9!O1'$                            6\&+_-!S+1WH
M2#7NU*_2 ZF"?E0ZT>$                 \B\LOT>Q?>U'Y'ABEV_*+]WP
M=3Z->9M7W_GD$9>@
M                #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40
M       "C/A[G,XXD$+*Y!%&00E@!,&8A9P"<0G6 7UJZ.+%V8\03
M                     +3,Q, YN7Y,J9!1=J1W6Y!OX;=_+MTMS$ 1(
M            /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
M                                                     ]K\C?T^
M]_<P?F>RKK4\GIW_ !<LZ2^>=KW/D@$E1            ,3',M'4XN_F :4P
MA, CPC, CP=D"*IQ4$HJLBH)Q5/L@V\.-M@
M    -'/5J@INTK]P-K3V=K#;F 7?6R               /(O++]'L7WM1^1X
M8I=ORB_=\'4^C7F;5]_YY!&7H
M                          ]K\C?T^]_<P?F>RKK4\GIW_%RSI+YYVO<^
M2 25$            3",TYCO!S\^GM2S6F 0X0D&(CO2X X3B 2A. 3B&S3%
M, VZ59                             (!J:B6C,@KM#2RU!;IG:TX-N0
M               >1>67Z/8OO:C\CPQ2[?E%^[X.I]&O,VK[_P \@C+T
M                                                         >U^
M1OZ?>_N8/S/95UJ>3T[_ (N6=)?/.U[GR0"2H@             O6):.33]_
M, U+4F$>R!-3L@15/@#B5U,8-JN*%L5!,
M  (!K9ZN=/B"-FIE!'3V[W:TU@;S(               \B\LOT>Q?>U'Y'AB
MEV_*+]WP=3Z->9M7W_GD$9>@
M                        #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(
M!)40              (7PU56TTSX0"B^FO6.9A7YJP,UPVF8A?&EM'B"V,,0
MLC&"0                              ' (Y:SV)EQKSQ((VGEJYO %.&
M>+.SIY[,@Z<>#(               \B\LOT>Q?>U'Y'ABEV_*+]WP=3Z->9M
M7W_GD$9>@
M         #VOR-_3[W]S!^9[*NM3R>G?\7+.DOGG:]SY(!)40
M    !9$"$@                                 "_P V7$S]T@IB563P
M!J5GBSL8;=]0=>OS4@              !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT
M:\S:OO\ SR",O0
M              ![7Y&_I][^Y@_,]E76IY/3O^+EG27SSM>Y\D DJ(
M                                              GP<75QQ(-6D\H7
MGN!HSSRZ^">^H.YBF.(2               'D7EE^CV+[VH_(\,4NWY1?N^#
MJ?1KS-J^_P#/((R]
M                 'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0"2H@
M                                                ";1PYFIK%@:E
M<7"?FJR"/N:DKJ8^S(-VF3A=&: 9YY3@             !Y%Y9?H]B^]J/R/
M#%+M^47[O@ZGT:\S:OO_ #R",O0
M                           ![7Y&_I][^Y@_,]E76IY/3O\ BY9TE\\[
M7N?) )*B                                                  Y
MF>Y3:T@IF\J9GD%<H@QS*V+ E%H 3C):&]ASTBO?X@S%HD            !Y
M%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_/((R]
M                                       'M?D;^GWO[F#\SV5=:GD]
M._XN6=)?/.U[GR0"2H@ .0
M         E&>)!5:_#7M<$.6 11 8 2BP)Q8[7>#9I=M4M' !$@
M #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
M                                          /:_(W]/O?W,'YGLJZU
M/)Z=_P 7+.DOGG:]SY(!)40<@Q;)"N;U!CSO!YX#SX"X
M                           "W"B]^ 42K XA'F 89XD#A &$.02B3D%D
M7_>V,>3P@&[$Q,%0          !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO
M_/((R]
M       'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0"2HE=K*IO(*IF9E">
M01Y8Y [0#J                                          !8!5>>Y1
M,@A/>QX KGOE** LBK,R"$RJF00Y1!'ECD&:_.;/'?R#9QY/J;4
M  #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
M                                           /:_(W]/O?W,'YGLJZ
MU/)Z=_Q<LZ2^>=KW/D@\%-[I*B5<H\@KF>\Y!&4) @!U@
M                           E"P*+2KD$)E#M2"RM5H'*J9!"953((22"
MF9*R"ZD?*;<@A7NETM->.)F09          'D7EE^CV+[VH_(\,4NWY1?N^#
MJ?1KS-J^_P#/((R]
M                 'M?D;^GWO[F#\SV5=:GD]._XN6=)?/.U[GR0UKW4\\I
M*B91!F*\L]@$9A"8!"0'6
M   !"]H!J68!7,E9!L1:.$9L",V538$)E7,@C-D9L"BT\E([P;U/!;R"4K,4
M\2#<F>68          >1>67Z/8OO:C\CPQ2[?E%^[X.I]&O,VK[_ ,\@C+T
M
M>S>2&\UR;W]S!^9[#>RZU/)Z=_Q<LZ2^>=KW/DA0)*B9B4XKR"?A",R"N956
MD%<]X#L                                           U\D@U[>"/(
M*Y 2[2,V!&;(S((3*$R"'*%[=P*HGF6U2 ;=3ZP701W7!NQX)P
M\B\LOT>Q?>U'Y'ABEV_*+]WP=3Z->9M7W_GD$9>@
M                                        #V#R33Q?>ONX/S/8N5UJ
M>3T[_BY9TE\\[7N?)"(DJ).*K([@1F4)!"94V!7-@';
M                         "6GE\05(V!K6B>4>U, G%^XF\ A-H1FT A-
MH1G) *IR0A-P3P\39T.(Y!.&03AF ;N+P6QX@         /(O++]'L7WM1^1
MX8I=ORB_=\'4^C7F;5]_YY!&7H
M                           ]<\E7=?>/NX/S/8HE=:GD]._XN6=)?/.U
M[GR03"5825$OCP8Y!5:RF; KFZN<@*^V ^A
M                 "6GE\046\" )JHOCY!J6M-91FX(3>54Y+ AV[,=J0.6
M 6X+\6=6)Y!.&02A9'@#9PKP         'D7EE^CV+[VH_(\,4NWY1?N^#J?
M1KS-J^_\\@C+T
M              >M>2SY^[_9@_,]@A=:GD]._P"+EG27SSM>Y\D)=I*+I*B)
MRH3E!7-U5K AVU<W@%4Y(@!]4
M       $M++X@H9@$E5^8@'.R3WJY@%4H3((3)V@.T E3YSJX_F0"Z$X!*$@
M;6%L1X@         /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
MR"?FLG^I;_!CS>3_ %+?X,\I?/6KZT(##Z    '5T^Q;WJL-,VGVO5Y<5OFW
MIAM:L_9,0^JUM:>5:S+3FV,&"L6S9:8ZS/*)M,5CFHUFV[CH9I&LT>?!-^>Q
MYVEJ<\>CEHL36:SRF)B7UBRXLM(OCO6])\5JSSB08;
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MVS->V:05^<F?K0F\^D$9L ^W
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MJO7B&G-N\%5K=\JI!'GA&; KFP#[\
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MFN7,6Y!7:)Y0XD$>)1F)!"8D!Z"
M         %E.:O=(.<2"#$@K1L"J400ED!F(!.(2@%E5L MA?2.9!OXX[@
M       !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S:OO_/((R] !;@P9=1GQ8<5
M>UDR7K2D>'-K3Q$=[,1S8M:*UFT^*(YR].VOR6[AJL,7U>L]RS,<Q7L5R_\
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MVEUJ>3T[_BY9TE\\[7N?)"_M]R,W25$HO?EJS$ A,0A,0"N4)!CN ?=@
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M/8L$<K6QY(COQPLT'7/1^ET&DT\;GW8L%*?0Y?Z%>/JJV;^4/I**S--S[_\
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MR>G?\7+.DOGG:]SY(4SW,=M)42$W53(*YE"9!&;*YR A.4!Z"
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MEG27SSM>Y\D*I^4UKQV4E1*.W/*?:@%5KPJG("F^6G][7G) *?.\@/4@
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M>&*7;\HOW?!U/HUYFU??^>01EZ
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MW=6E?-X:=W\GBB9FM.8B.>.?%R&F]IM:;3Z5EKX*X,&/%7Q5CD#Y;@
M  ![1Y'JS;-O7W<'YGL>?3><KSSPNM3R>G?\7+.DOGG:]SY(<')2U>>Y1"2H
ME-HGF5-I!KWAI7CO!;I\,7O#ZK!IL=<?S02\S6?J@!V@
M                             F.05VPQ,-:V"8!1:DPAV9 [,G9D$XK*
M<8Y!?7$V(QQP#/9X9            !Y%Y9?H]B^]J/R/#%+M^47[O@ZGT:\S
M:OO_ #R",O0
M           ![7Y&_I][^Y@_,]E76IY/3O\ BY9TE\\[7N?)#7RX:Y(<?-@G
M'*2HFI:):]H!KWK+5G',R#HZ+%Q$3^]]%CX[()=D!T
M                             [S@&)QPK\S 'F8/,P"48JI>;@&>#O
M            >1>67Z/8OO:C\CPQ2[?E%^[X.I]&O,VK[_SR",O0
M                                                    ![7Y&_I]
M[^Y@_,]E76IY/3O^+EG27SSM>Y\D$0CEPULDJ)RLNDGF9<_)B[/U U[8YGZE
M,XN ;NGCBL.GCY!LQ #<
M                          'D7EE^CV+[VH_(\,4NWY1?N^#J?1KS-J^_
M\\@C+T
M       >U^1OZ?>_N8/S/95UJ>3T[_BY9TE\\[7N?) )*B8F(E3.GI/U IOH
MH:M]$"/N?L0G2W$@VX ;8
M                           \B\LOT>Q?>U'Y'ABEV_*+]WP=3Z->9M7W
M_GD$9>@
M       #VOR-_3[W]S!^9[*NM3R>G?\ %RSI+YYVO<^2 25$'$@1R IS4[I<
MN.8N#?CP@!M@
M                 #R+RR_1[%][4?D>&*7;\HOW?!U/HUYFU??^>01EZ
M                                                          /:
M_(W]/O?W,'YGLJZU/)Z=_P 7+.DOGG:]SY(!)40  (Y(YB7+O'%P;5.^ &X
M
M     /(O++]'L7WM1^1X8I=ORB_=\'4^C7F;5]_YY!&7H
M                                              ]K\C?T^]_<P?F>
MRKK4\GIW_%RSI+YYVO<^2 25$  !+G9J\6 K;N =$
M                                               >1>67Z/8OO:C\
MCPQ2[?E%^[X.I]&O,VK[_P \@C+T
M                             >U^1OZ?>_N8/S/95UJ>3T[_ (N6=)?/
M.U[GR0"2H@  /K:6>H*(D!U
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M%5NWK#2_Q'Q4[MZPTO\ $?0,GKU/KAI_ELW\'Q5;KZPTO\2/Q6;KZPTO\1]
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M?6HU'?W@T8D!U@
M     .2;P",Y(0F]09B]5D6B0               E7D^8#ESXR1()<DR#4S3
MW0U+2"J953(*YE78%4RIFT@IM:>);.GOQ0&OER_*EHVR]FDS((Z/+?/E[,^#
M[/2X^(CN!T*Q,+HF 3BTK(R2"ZN;A.,D2"<9*\)1> .U !WHVGB.\&GSS),@
M)1'>"Q&9!5:RJ; A-U,V!795-H!#MH\@Q:.WW-;S'\K /I=+IHBL2W^> 9
M                              59(^2#FSW3(#K@
M                                  KFX*IO*N; A,_O1YD$HF4ZWX!=
M%UU+<@R             3XJ\GS <FTQS*,2"9,@ULG?$-:U05]E":@KFJNU0
M5315:D IFD=Z5(XH#F9)^5+GZB\V@&]M4?*\'VFGSQ'$3 .C7-1;VJ2!V>?"
M4XI/ '",\\@<RSVY@%E<BV,H,^=5Y,G, HJ3X@G59S$0"NUU<WD%5K*IL"N;
M*YL"NUVM?)($660#-IM''$-CCNBP.UH\TSCB&S, D
M            !)>.X')RQ,6 =8
M               .>00M:*M>U@4]M7-IF08XD[X [4I18$XE;2_ -NG$][,3
MW@            ?TE=N^)!QKQV;61B06=KN5VD%<RA,@A,JID%5E4@A*J:@J
MF%66T17@'-FMIF6I?!::S(+]NS^:R<2^LQZFD@W:WI,+8D%D7O"<9\L G&IC
MZUD:BD@LBV*4IC']0,36"* 3'"N9 Y0F_ (^</.Q((S>$9R0"%KU4SDJ"F<D
M(SD@&M?+S*44FT G-.S$+<7%I!N1'#%@;>DGY3K3X0
M                T]53^4 ;@
M              C/R8!IY+\J^>X"*\IQ6(@#F(5VM'(*;7AB+<@G$DSWP#;Q
M9&Y6/K            !B?G2C'>#E:N.+M&9!F+'(%I5S((3*J05RA((J[R#4
MM9KS6;6!LQCK6JNU:S$UX!S<FEFENU#=P1?N!U\7;X;,7O +JY[0NC4QP"7G
M,<IQV)\ 2X2B+>D$O.35.NH!.<T2AVN9!B94S,R"%E7:GD&+746R2"NUY53>
M?2",WE";@Q%N]UL/'9!7FKRCAK,2#=8L"[2S\MV02
M              0R5YL F
M          -;-8&E:RN+Q )SF1\\",YD)N"JUT/. E7)+8I;M OI/?#JX^^H
M             #3UV/F)F(<"])D&8MQ7ACM<@S*,R"'*,R"%E4@C$]ZO+$ U
M)BQ7%(-B,<GF02\QRWL&*(^H&Y7%#<KH^8B0+;=RU[Z*].Z(!K6PYJ_4KXRU
M!.,MX3C4V@%U=1RM[=+ =JJ4 LB4IXX!"W'#G99[P46F%5I@%<V0FP*INC-P
M1B_RH=K%;Y $VYEL5^:"=6;^ ,Z>/EN[3P!(
M                                                           !
MSL]@:5K-2\VCO!1[HX)U, KG4D:CD%D7Y;&.O(-F,<+*QP"R/%T\4\U@%@
M          #&68O'#YK53YO+, U;(=K@$ZWY9D$49!"55P43*=(F06S2K'9!
M*(2K4%]:-BE)!NX<<S+K8Z<5@%I-8D&)PU4WT^.9\ :E]%6?!K6V^?J!K7T6
M6&O.#-7Q!&G;B>]OUGN!95.T]P(6GN<[)WR"BU)5S605S"$P",XT)Q@Q7'\I
MT9GLXP0I?F70CYH+*)7\ 6Z6/E0[?'%0(
M                                                         <K5
M3W@UXXFK6SWCL@XM[=ZJ; QVDXD&UAEU,?@#:JS;Q@"/%U<,=T M
M    )C@&IGS<=SYS5Q,VFTR#2KEB>>]+F9 B>%T6Y@%,\\L3,@CWS*7FY \T
MS%02[+,5!9%5M:@OK5M4KR#HX<?9;8    '$%\5)CYL T\FEK_JPYLU[-I!'
MGO6=KY(*K64SP"JTPIM, KE  !F)J3/(+<56]]0)T)\0;FGK\IU8\ 9
M
M                   <G61P#G^<XJULEXF <O),<RU;Y(@&,>2)EL\@V<,N
ME2W$ VJW3[7/ +J1WPZV*/D@R           !,\=[6R9HX!S\M^9Y<779>Z>
M ?-3GO3([.#-6]07=B9E96O +.QRA.,&(IQ*S@#@[()]DBH+8HMK4%]:M_#A
MX[P;W'$     !('U.3J*\3R#GVGO2[7<"%I56D%-I5S((3*'(')R"CM][8Q=
MX-VL<+JR"^B?'>#I:>G=#9D$X
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M+908K2>6WCC@&U$ROJ"ZG=+8QUFU@=C#2(K"?$
M           $WX!5.2 %H
M          7IS2>0?.:O!-;3+C9]/.3P!MZ3;,58YO7O;=L&'P[$ Y^IVW!>
M)F*N9333BMV8!U,-9B&[2H-FM5]*@Z&+&V            \%&7*#4M,3',N=
MGSQ$3P#C7O:\RI['(+*X9F8X=33Z"V28[@=VNAQ5I$<1RT\VBF/" :<XLE9[
MT>) 9[('96=@$XHLKCD&S7#+=KBK4%GV,@       6CF)@'#U.+L6F6C/>#3
MR5F)5QD^H"UX46R1Q(->V11-I [2VO$@WZS"V ;%8;-8!?%73T^+B.0;@
M                             "NU^)F%%K<@A #>
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M9=+'_G8_Q01DTL^.>GXH!*N;31_YV/\ %![HT_[;'^* /=&G_;8_Q0>Z-/\
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M_P!MC_%![HT_[;'^* /=&G_;8_Q0>Z-/^VQ_B@#W1I_VV/\ %![HT_[;'^*
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MF\(^<@#SD)1> 61,<,1$0"%[\-2_>#7XEB00[*,XID%E,,MB,,@V:8N&Q6
M        'G'E0^9M'VYORO)&&!"9!"95VL#7F6 3B%]* V(C@!D
M        5VKR#6O685S (2A(*;3,LQ@M($X95]B8!=29;%06Q"ZM071#(
M                         /5?)?\ 3;K]S#^9Z:RR  !>T0T[VY!6  .@
M                                            6MP"F<DJIL"N6.9!
MGF3D$HR2L[8(VMRJXX!7,JYD%N*G;GO;]=/7@$XQ1#/9@     D")F0    '
MF_E.M6U-IX].;\KR5AA";0A,@JM91,@PG$ NI1LQ ,@
M# #$Q$J+XP:]JRJM$@G2D-J([@5VJHM4"L+ZTD%\4A; ,@
M              /5?)?]-NOW,/YGIK+( $R#7O/,RJX!&6  '0
M                                  R3Q5JS<%<RP!Q*N>00[4L]H#M'
M:D$XN3(*IDI3F0='%C[*X       .6.U ',', =ID !YCY2JVK3:N?3F_*\H
MF6&%<JK6!3,L G%6Q2@+XAD                    & $9K$J[8H!7%>)6@
MA95: 1I'>WHCN!(                              >J^2_Z;=?N8?S/3
M660 56D%$RA,@P < .@
M !,@U\EYF.&N"452X Y1M, IGA1V@0G),)QDY!E*M^>X#QEOX</R8GD&R1
M  $S, QS)R!VD)N"$V0F01Y8[<@E&99&: 61DB?"4YO$0#RKRD9NW3;(]%LW
MY7E?+#"JUE,SR#"=:@V*47Q ,@                     # "BWBE (S"J0
M0KXMZO@"0                              ]5\E_TVZ_<P_F>FLL@!,]
MS3MDF9X!&40& 65@!N@
M IR6X!K39#M0"<7CAB<@(3D4SE!5.5KWS1 *?/1)YX%U,O+8BP-W!CY[Y=&L
M<0      3,0JM;N!3-I1[4@39#M Q-D.T#$H3,@JKFMCELSGG)4'F?E!^9MO
MVY?RO,;6884S+ )Q5L4H"_AD                        %-H[V8\ 8E3(
M*X\6[3P!,                              >J^2_Z;=?N8?S/3660!7E
MGB&E(,<G((S+-9!?%H@!N
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MZ+U\]:VIRQ;BTWO/-N&CU_L^BG2:7=])2M?.36,G9[HM%XYK8'1W7_PWT_\
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MX 5^:Q,@IM/>KFT@QVI ?1
M    !?P<G)W7!GQA5>>(!S[QS*FU+ IM66K:D@U[TX:67MU\9!V]LIQ6+/H:
M7B/J!.+3RMK/ID#ZUO(';3B\ LB\+8R1(',$R"FUE%I!#MI1\H$XJES$ C-X
M0F\ KM95-@53WJ+@KF5%J<@\UZZQ36-#]N3_ /0^!I###<QT7@R  #VW4?\
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MN\;S_>O],;G_ &O-_GEAAR;H5!)7(*I7XI!>
M      /5?)?]-NOW,/YGIK+( YN:?E2J^H&(\#B9 [",XP/- .T
M                             ',0  !,@A-G-S^(*(M,(6GD%$Q"JP*)
M46B.0:V7AS,\\R#K[;FB(BLOH:Y*R"SCE#BP)Q:5D9 2BY,@E$IQ:02BTIQ?
M@%=KJ^01Y2BW ,^<8G("N;H]L$)NIFX*YR*K9.00[:7:!YWUWWUV_P"W+^5Y
MW-6&&SBGN7@   [=NH]YMMOO=.KYTO8BGF^Q3PC]_'(.(^BVGJK>MJQ^:T^H
MYQ?5CO':K ,[KU9O>ZXO,ZC41&+Z\=([,2^K\F/_ '[<?]Q3_F#0UG5^][7N
MFZ:7!FI;%769NQ7)7M=GY;X[<=RUNY:FVHU>:<F2?\(CT1 -O+U!N^;;:[=D
MU7.EK6M8Q]BGA7OCOXY0VK?-SVG):^CSS2+?.K/?6P.MN'6N_P"OP6P7SUQT
MM'%HQU[,V?)@1,Q/,/L-)UUU%IL,8O=%,L1'$3DKS8'$W7>MRW;+7)K-1-^S
M\VOA6OV1"S;^H=XV[2Y=+I-5YO#DM-K5[%+<S:.)[[1(.,MP9LFGSXLV*W9R
M8[UO2?'BU9YB>\'1W3?-UW;S/N[4^=\UVNQ\BM>.U]V(<D'2VS>-QVK+DR:+
M/YJ]Z]FT]FMN8_XHEIZG49M3GRY\UNUDR6FU[<1',S]@.CM._;IM%[3H]1-(
MMWVI/?6WVQ+KZWKCJ'5X;89U%<5;1Q;S=>S,@="_SIV_[,O_ $[/J.JNH]UV
M;J/-&DRQV+X,<VQWCM5Y!\%N^_[IO%Z6UF?M5K\VE8XK5K;;NVX;7G\]H]1;
M':>ZWUQ:/WQ(/I,_7W4>;%..,^/'SXVI3BSXZ<N2<GG9O;M]KM=OGOY\>>0?
M7Z?KWJ/#CBDZBF3B/&](F7&W;J#==WFONS43:M9YK2(BM8!O[9UCONVZ6NFP
MYZ6Q5^9%Z]KLHTZQZDQY<^2NX6BV68FW-*6\/1S'<#0T&_;KMV;49M)J(Q7S
M3SDF*4F)_NF.(<S-FR9\V7-DMS?)>;WGPYFT\R"BW@JJ":$@IE=B!L
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M      W-'N&NT-KVTNIR89M'%II::\P#6RY<F;)?)DO-KWM-K6GOF9E
M       7:?4Y]+FKFP9;8\E>>+UGB8YCA/5:S5:S+YW4Y[Y<G$1VKSS/$ U@
M     !&W@ICQ!8A(*;+,4@V0                             !ZKY+_I
MMU^YA_,]-99 ')S]UY53/$ C$I1()@'(#L
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MFLL@#F:N.+-2T]P*YE.E@6]I&; A-@'?
M      %=IAK6D%4VA">0(K;CP1F)!7W\K:U!9Q4F00[4QXJ[9 53>90[0!P!
MPA:H*IJCV)!F*$8Y!=7&V<= ;V+',>,-V )I65-]+6>9!K7TGHAJWTUXGYH*
M;4M7QA#MV@$HR2G%XD%T3$>*<S $VB8<_-;@&I:ZJ;@A-I0FT\ AVCM GBGY
M3H3DB*^(&+O; //>O_F;;]N7\KS1AA.OBV09
M & )\%/U@DQ(*+,T!MPR                              ]5\E_TVZ_<
MP_F>FLL@#1UM>>^([G,YY!5;QDK8%O;@Y @!]"
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M3660!1FCFDPXD_(F8!"58)U\%D 3(#Z(
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MEP==6U<G='<#7B>2P*^TE%P3BP#Z<
M  ^IS\L\V!K7K*FTS6 5QE[F)R@JMEGEJ9<L@UZ9^+\2WZWY^L%]9Y\5T6B(
M!FMXFS:Q3\N =2OU,@            %_ '(ST[VJ"%I53(*K656L"$V1Y@&.
MTA:>Z055GF6[C\ ;$+:^ //^O/F;=]N7\KSJ(887UA,
M          856 @D%=E4 W*>"0,@                            /5?)
M?]-NOW,/YGIK+( C:/0T-=QYJ?2#YNN2U9XE;YSF (ED#M< /KP
M                       #)/<YEY^4#$V4YN.R#G2A((JKP#0RX+VOVH3I
M;)68CO!T*6M,+XYF 3I$Q9O8/GP#LU\(             "WB#4SU[G(M\Z05
M2IM(*;2K!7?N:ULD@KC+*<6Y!M4QQ"_P!?"ZH/@.O?F;;]N7\KSRL,,+F0
M                      & 8F4>T!RC(, $<,=F 3K/"<2"0
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M*%Y[-0<G49>ZSYO)EXR\@Z6'+%XB6S$@OB)D!]>
M            6EI:FL1 .=:R$2#$RA,@A+ ''*44@":I5H#8I5T=/4&X
M          $*LE(N#D:C3\2Y]XX@&I=J9+\1(.=FU$QX-2V2\Q,@IC43RZFG
MSUG@'3I+=I -FE);=,4@^%\H>'L8MJGTSE_*\S88
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MXU-;TO2,E[SVHBWZ/B081!$Y!'DY B4HD%M97@   P  R
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M++F9<TRUHB;2#9QXYAT<6/M Z^#3Q%:S,-V(X
M                #B   .( [,'                    C$J-1X2#3KXEX
M!IYO!1BCO!]%@^B61X D \X\J'S-H^W-^5Y(PP
M"NQ$<@SV68K '91Y!'DY!'ECD&.6 88!"91!CE*(Y!.*Q"0,+Z=T M
M             !D  $)D$6)D'WW0F3LSN7V8OS/M,N;F?%EE1%)F>]MTP^@'
M0Q8>>.YUL."L?4#<B.
M                     )!&JC4>$@U*^)<&EF\%&+Q!]%@^B61X D \X\J'
MS-H^W-^5Y(PP                      "-O KX 6MPA%IY@%JB9[P88!A@
M&& 81F00F3O!GAF)!9R +>>)K]@+X                   !D 8!&90 F55
MK ^UZ*O,6W#[,?YGW5:3:666]7',<.AAQ3(.KBPQ''<VP
M                                                )!&JC/X2#5K'
M>7@&GFCN48H[P?08/HEGU D \X\J'S-H^W-^5Y(PP    P ,@
M    P#%O!F 4WGO*?.!=,\1,M:+ <H\@<H\@QVF.01Y1F0(71$ C95R"VL]R
M0"V?&)_<"^OA#(,@                   *YL"),@JFRBT@^[Z&KVKZ_P"S
M'_\ I>EX<<0RRWZ8N9\'3PX8B ;G
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M_*?1@             *^>;0L!3*5(\0,D_)4=GN!!@&$0 $9E'D")7P#%I5
MLCN.0.>Y=2>W3CZX!L4YB(3 8!D      &     8Y8[0':.T!VB+ ES #("N
MUD0)E3-@4VE&(!Z+T%7F^X?9B_,]1P8+2RRZV+#V6UQ$0
M                                                   5AJYY\0:U
M/%*\ TL_@U\7B#Z#!]$L^H$@'G'E0^9M'VYORO)&&    'PVZ?SYZ>_W&?\
MR6=3J38J[QAP8XQ8(MYVL9,UH_E*8O&8H!T[L5-KT>;3Y<&GF9O:OG*U^5EQ
M?5YQ\]3HJ8W.-;.#1S6=5/.EX_DHP?\ O!]!U%L%-VP:?#7#@B8R5B^:T?+I
MBCOF,:?3>R>]&ER8;8L';\Y:(S4CB^3'_1F_[P<K9OYY]2?<P?Y8?<
M       *K3((\\,]N089BTQ (7F5?:D&& 11!ACD&.6 %T> (6E")X!/M(S>
M 9B;2NQ\U!N4[X2            !CE'D&)1   #EF+@G%XE&UN>X&$9D%=K*
M)D"(61 /2_)W3M9-Q^S%^9Z]AI%(99;
M                                      0U-1]8->GBG8&AG48O$'T&
M#Z)9]0) /./*A\S:/MS?E>2,,    /AMT_GST]_N,_\ DL^Y   'P^S?SSZD
M^Y@_RP^X             4W\00(!(!"RL& $408X8X!CA@&..];SQ *N4)D%
M5[S$+\&/M=\@WHI#/ )]J82BP)\L\@         ,, P2"+  #"/( "/@G $R
MJM8%-K3)$ LB%M:@]5\FU(\YN?V8?S/5YKZ&660
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M+(
M       %@8GQ:>I\ :V/Q77!S=3*G#(/H=/]$N^H&0'G'E0^9M'VYORO)&&
M   ',UVS;7N%Z7U>DQY;5CBLV^J&]APXL&''AQ4BN.E8K6L>$1 +0!3GP8=1
MAR8<U(OCO6:VK/A,2#3T.S[9M]KVTFDQX9O$1::_7$.D             KO
M*&.09  && 88!@!%@!"00F%5H!1];<H#:A.)D$XLEV@2Y@ X8X!CB3O!*+)=
MH&>U"0   C,H\@PP R SP## (L PB##$P"B\2C4%T0NI4&S%>$@>J^2_Z;=?
MN8?S/3660
M              + Q/BT]3X UL?BML#FZF%. 'T6G^B7?4#(#SCRH?,VC[<W
MY7DC#                      (SX UOK1GQ!F&0 && 88!@!A$$#@!&T<@
MUYI\I?0&S25@)<' #/:!+M,\@ER CP ',@SVD^T#/("$RB  RD P",L PQ((
ML PP!,<JIKP"['7EMUC@$@'JODO^FW7[F'\STUED
M                                             "P,3XM+5]U0:F*>
M]L6!S=5*C!(/H]/]$N^H&0'G'E0^9M'VYORO)&&
M  :^2JH!GD#E@ !@!A@!&01[+/ '#' (33O65H"V*G ,\L\@SV@#@ BR46!*
M+)<P < QP< =[/(,<@#(,@"((\L (R"+'( "56;0"6-L@ /5?)?]-NOW,/YG
MIK+(
M         %@)CO<_6SQ4&EA\6Y/? .5JY48)XD'TVF^B71X R \X\J'S-H^W
M-^5Y(PP                      "-HYAJSW2",L )  , # , '!P!P< S$
M+(@%U:)32 0G&A-)!#B8 #D!@#DB9!*+I1<$NTER#*(, #, 3(!RC,@B CR
MC*()1#()Q#(,1XMF 9 >J^2_Z;=?N8?S/3660
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MI1^._P"H+:]+[#_48_'?]3X+;#_48_'?]0/@ML/]2C\=_P!3X+;#_4H_'?\
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M6FC%YSB+\6M;GL_>F6X
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M,< NMWJO-VY!LTB8A9 )V\&YI; VP
M                                   .05WNU[7Y!#D!&81F 8)!%GM
M<G()X\LQ/>WJY*VCN!8                     %^>8X!&]HBKDY\TW^34'
M.R8:3$S+BZB\8[=P)X=7BOQ7GO=&E>?&0;-:0EP!P< <' ,]D[()15** MBD
M\+\6/D&_3%Q5..X&0      E&:4GZ@4VT])^IK7T<?5 -.^EO"BU;5^H%7//
MC#?K'= )+:R#%I5S4&E>(BRNT@JM97R",RCR",RCSW@S,MO33W@W6:^(+82!
M*?!M:4&Z
M              (V46N"N90D&#D$9E&9 Y.01F4)D&>U#/($LUO:G@#KX=13
MS=?2                    <@,9+16 <W+EM:>(:MH['>#G9\GCWOGM3,WF
M8@%&GTEZ9.UR[^*UN:@Z%+<K@.#@#@X!9V3@$XA=&.T^$ V*8I^N&SV(B 3K
MSP         <L SQ$QX*IP4O]0-6^DKSW0UY@$)65D&+']$'.RS/:4S(*I1!
M&4>01E@"6[I?G WF:^(+82!*?!M:8&Z
M                                    %I!KVNJD&.6)D$.6.)D#LRQV
M9 [+$P"N4 8E*)!GM':!/'DXET<62+ N                  !B?$$;6BL-
M/)DFP*)[G-U&8'(S9)M*%,',\@W*X8X;>'3=J8!U<6A[D[:28!7.&T*_-V!+
ML3Z#L3Z 61BLLC!,@OK@B&U3'$              #E7^3,@ILS6P)397-P:]
MJ\J^Q$ C-856I'(*YHC- 8[!V 9BB_#'9L#;B5D LA. 3EM8*@VP
M                                                        !3FO
MWQP"B4)D&&8B9!+LI17@$F.X$;1"FW *90Y!&TPAVH!GDY!F?!LZ?), ZV.T
M34                  &+VB :&3),RIM,5@&CDU'#EY<G:D%=<?,MRM.X&Y
MBP3/'<[&#3Q$1(-N(F&9!#B)8\W4&>Q7T'8KZ 9XB$HF(^H
M  ',U,<2#6GYJ%9!F90 5V\05S"((2A(, )0G +J+_J!.J^.. 2AO88X@%P
M
M  !/S@1O9JS((3+ ,Q5='<!-D>T",V1[0(3*FU@53*J; Q:57(,3D9KE!;%E
MM; Z6FO\F(;D@                 (Y+\-+)DFT@HO/$-#-F!S,F3M2Q3%]
M8-JE(;N'#VK Z^#%V6V                     U-14&CXJY!"6.01F4)D$
M)E"9!7,HR  G"V 656P"=86Q +\=6_3N@$P
M                                      "0:][*)D$9E#D%U92FP(S9
M'D$9E#D$)E5-@4S*N; IMD5]N01Y2KR#9K,\0MK(-K3W^7P[->^
M        $;VX!I6R3,J+SV0:&;4N=:\VD$:X^9;E:<P#:PX>9=C#@BG$@V8X
MAD                    !"]>U .9>.S91((2A((3*$R"$RA,@A,L ,@G"V
M 656U!=5=6 ;>*K:F.
M                       &,D]P-'E#GCD%4W8[8,Q9*; QVF)L"$S*$S((
M3,H3(*YM$0U,EP4\IP"S'6.6[6L< 751/>#9Q3Q:'<PVYH"R         !'O
M YE+F .8   Y!"^3AIWOV[<@IR6BL.?ESP#GWGM24@&S2LRW<6&;2#JX<79A
MM                       #4SUY<R>Z00GO8!59$$+*I!5:54V B5M9!?5
M;]0+*0NB 6TALTI/, W\<)R
M                            IS2#3B4;@UI1F> 8BR4V!CM,3?@$9RPA
M.6 0G+"$Y8!KWR*X^4"^,2C)W QCM/+>I:> 61//+7Y_E ;$3Q9V]+;FH-L
M        1FX*IR0EYR@'G*)Q('*4 *<EN.0:5LDV47OV <_-J9GN:?,S()UJ
MV,=.0;^##$NMBPQ4%W@                       !:G:<[-@XYD&A,<2C(
M*K(@KLKD&MDE1-@(E?BGOD&W1= +J0V*1W@NK'>W\=(X@%P
M                                                    U]3/RP::
M4 A:(56KW2#5\))MR"$RKM/<"J90F00F4)D$9GN2Q3W@Z'C#0S=P*\4=[=BW
M$ SVT+S\J ;6+Q=K1_-D&[4       $9E7.0%4W0FX(3='M@CR><M'U@G&?A
ML8]76>Z9!9?)2(YY:-[]JTVY!JY,D0T<N;]X-/GF5D0#8QUF71P8>?J!U<6.
M(A=]8                        #$QR#GY\//A#GS6:S,2"NU853 (6:]K
M< TLV:C3MJ/0#%=1,)8M=\J8!T\.;M.ACKS(-FL<-JE)L#>Q8^/%L\<
M
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MN
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MD.YI<-9KS, W(K$>$'
M                          -/6_2 T.4HD&)LKFP*IJCV01FB$T!7-$)H
M"$T0F@(]E&8X!JY>YS\V7@&KIZ3FR=[[?0X<=*1$ Z?FH0FEH\ .)B.]?3)-
M8!;7/W=Z^N6 61,2R   #7R7!KR ,< SV$>P!V&)J"J55H!0JMQ(*,V+M5[G
M$R4FEY@%F.71PUYC@'9TNF=G'BBL L                            8Y
M!D[,@3$-744K-9D')BL=I.:_)!J6HT,M>+0#IZ?B*0[^DO$4!:
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MQP"_3=]7<T?CP#;
M                       ,U8FO .'?Y-YA"9!"98@$F)!7,H@Q*$@@A((3
M",P"BT<M//C!K:3'-;3]KZ#2Y(Y!UN*3'+$U] ,QVH6QEF 3C)$IQV9!&U&.
M)@&8O:%U<L@MG,S3("G)D1CO!&_@Q0&Q'#,V@%<W538$9LJFP*ILA-@0G)"'
M:Y!E.M9F00R8*S+.#G%ECCP!]'2_;K$I@
M    QEGF <K)7O1B 49(:F2.Z06:?P=C13\L&\
M                                              2#D:FG%^6MW Q/
M"/<!RQ,@@P#",P"$PA, A*((357;'%@5TP\2WL6'CO!MQ%E]+S +8OREQ608
MFGH(M-03KFGZUT6I('9CZCB8!B2+< AXSS*R)X!&;$6!.+L3<%<RA-P0FZN;
M A-E=[ UIGE..T#8QQRV8B(@$+QW<JZ=]0=G1SS$-JOU@
M                Q> <[-'>K@%.2&G?PD$<-IBW#KZ>TTMS .G$\U(F0
M
M     :^;'%JN/:DUF04V0[0)1*4@PQ((@(S"/ (S5&:@EV&?-@LKAAM5QP"Z
MN+E*=+8%4X;PA/:J#-<D\)Q,2"45KPAQ, G&2T)QE!96:V8MQ *XGF4I!1-N
M\BX)Q=B;@AVV)M (3:$)M (=J%%IY!*E.5]J]F ,=N]M\@6CN45!T=-;AT8
M                               \9!I9Z][6!"\-2]>Z048_GNGBGO@'
M4I/R4X!D
M              "W,@CW1#CZN]*VC@&EVILA,0#$3,+>>8 )@$>#@#ACL@<'
M8@$HJLB@+:T717T W,6/B(EMU@&9Q5E&VW5MXV!S<VCM6W%?!JVI>H*^9Y3B
MX,Q:$^S$@KF+1WQ+-.U,=X+L<KN.047QQPHM'9@%<78F\@A.254WD$)O*':D
M&.3M@W]//->4LO@"G'1N5\ 6>,*9KQ<&WIH^4ZE0
M           )\0:V:.8:,^($M7+W0#4\+.AB[^)!U\7?5;P
M                                                      !,\ TM
M1F[IX?-ZB\VYF0:>+75I;LS+H1:+?*CZP61'*Z( X. .R=D#LG9!'LIQ4$HH
MMK0%D4EN8L0-CLIQ  !/*J<=;>(*+Z2EO!J9--,> -;S=ZL=J8 MDF(3QWYJ
M"ZD<0MB01E1F\ :$>),@A,H3((3* #'/<#H::?D+[3S$ S2O<L!*$9^>#:TT
M?*=(                                %&6.YH6\08EK90:=_%NX9[@=
MC!*\
M          .0&OJ<_'=$ X^6_/,RXFJR@^?RTO?)S$\.SI<UJUBM@=K#>+0V
M .#B099X@ X BDIQ0%D4A;%)!MTT_=$\KXKP   !P!PQ,1(%]/%FADT@-3)I
M[5CP8QTF.Z8!=]7'+, C*G)WP#2F.$)!"4)!">4>) XDBL@WL/R:\)=OOX!L
M4GN6Q'<"3'U\@V]/X\M\                                %63PESY[
MYD$949(!I9/%MZ?O!U<$ML
M                            1F>\%&;+'#FWR\^(.9J<T1W./:ELD@E3
M3MFN'GP!U=-IK]SI3II[(*YQ3"/ '9J=P'%3B 2CF5L8K2#8K@F&S6L1 )
M      Q/8GZFIJ*Q6 :'?XIQ8$+6[E((]F$9J"'9A&: C-&.P!V&8I )Q!%>
M\&S5.+ G$D@W]/7N;<                                 C>/DN=,<3
M((2IR TLL+-/;O!UM//>WP
M                           "9B&MERQ$S -#)=S<^7O[@<R];7LOKC[H
M!;3#,RZ&#3\R#M8<,5A=QW\ 3BJC?35B 4SI6/<@,^Y6?<O +(PU612( [P
M       "8:^ICY(.;XQPQP",H2"# (@(G ' "<,Q +(.)!;6$XCFW .EAKQ5
M=7ZP                                +N?DKQ(*)5Y :>7O0PSQ<'7P
M3V9ATX
M           )M$ U<V5I6R Y^;,TIGM2"<8X74H#=PXN9=6F*(@&S6.X
M           "_P!2-Z]JH.5>LULA((2A((H@B  #' )1"<0"<0E$ MB%^.G,
M\@WZQQ5*H                                %FEG\8!JRAD\(!J7A33
MNO .KCGOAUJ3W
M                  3+5RY([^ :%\G?WM+-FKS/ -&9FTK*4[@7TQV;V+!V
M@=3%BK6(7@                $1(-34XIB.UPT)D$)E"011D$.0 !GA+@$H
MA. 61"45D%M*S+>PX^*]X+@                               "8[P&K
MJ8F)@&CSRQ8&KD:\3\H'1Q3SQ+K8I[4=P+
M                                     )MP#4R96GDR0#GY<K5GOL"R
M,:RE)!O8<4S,.G3'V8!?6&0                 #)7M5<K-CF)!K\(S (\(
MR"OAD!G@$HA+@$HA*(!;6%D1(-O%1LQ
M      JU4=X.9QWL2#6RM4&]IY^2ZVFGN!L
M                                !S ','(':@  )M$-/)ECO[P:5LM?
MKES\V:)M,1(-;BTRMK7N!L4K+<QX;3WQ .GBQ1$+@
ME5?'S .?DI-5' (3"'(!V0.R< E$) G$)< LK#<QXYX@&SV>((
M                        $<W>#F6[I5 U\D-2W<#;TUHF.'7T\\=P-L
M                                                       8Y_<!
MS^XY_<#"0"-IX!I9,C5R7C@'+RY>]3'?W@OI5?%)D&YAQ3+ITIV8!=
M              %@%-\7::M\' -2U98[ ,<0SV0.RCV03BJ<1 ,IQ7D&SCQM
MNL<0                                   #&2.X'+S>*F)!5D:>0%FG
MGBSM8+?+@&]R
M         Q?)7CQ4^>@&//U//P"49Z<KHM6?"0)F(<_+G\8@'/OF[^]H9<_,
MS$2"B.^5]8!LTK+?P8;3$?)!TJ8XK"V )(                     8M7D%
M-\'R9GAJ6Q3Z 4S26> .&. 3BJ<8K>@&Q7"LKCB 7<<$
M                    6\ <K/W2UZSX@A=J7!C#/RG9P3\J =&J0
M                                               C-@5S=5>\@H[4
M\DR"')R!RC&:] 1MK&G?/$<R#F9M1RC3O!L5HV\=/ '3PX(=/%6*TX!D
M                   !B8K(*YPQ*/F( \Q",8(!9&*$HJ"<0
M                           .9JJM+G@"T\PT\D KQ3Q=U\5O '6Q3W)@
M                                                     %IAKWD%
M$V8F01E"018Y Y1FT6@'/S5GZG(S9K1W2"&..VW\=? &]CHZ&'!,\3P#JTQQ
M$)                         2CV0$@#B089
M                 &EJH<FX'U*+ U*SQD=?%/= .OAGY*^
M                                        .2?#D&M:ZJ9!6SWR!V9.
MP#$QW*9!5*,@JLYFHT_G.\&O2./DM_!$@ZV#!-I=K%7LTB
M                                                       "8YD&
MKJ?FN+D\0(\%=@:4Q\MU<%NZ(!U\#9 )
M                       "T*;WX!J3/><@E6.96=T =J$9D%-K*9!5* '"
MN:=T@Y^3!,6Y=;18.UP#N5I6B8
M                                  !,]\ HU'%JN1DQ]\ G3&>:K]8,
M>8IRMC'6O@#8QVX;$9.0619,
M               +VXAI7OW@UIMWLQ8$^T=H&)MW*YL"$RKFW *INSX@E7',
MI\< A,<NIHN.. ;D$
M                         3 (3?A3?("FUN54Q (H@S"<2"?)R"43,+:Y
M> 71DY3CO!D                                                !
M#.YT^(*+]R,6!+M,]H#M(3((\JKR!6G*8+Z3!> 5QWM[1SWV!OU^MD
M
M $,EN)!JWLIFW (S/+$<@$ 2CR#/+,3W@L[<'()UEL5N"\
M                                 "W@Q4&KFGO4=P(7B)AIW[I!'MHS
M8$)M/I0[<^D#ME;_ "@="LQV54]X+:1PG(,1#:T\=X-\
M                                                  #CO!"]VK:W
M(*;%:\@=T,<@PP < Q*(,IQ()=I.M@7X\C9B0
M                        MX(U!J9_&&OR!RT<T@H1F01F4> ."L?*!T:>
M"=(X!;QRP##<P0#=D@
M                        1O<&K:W,JI ([@8GO1[()11/L A,*P8E'ZP)
M1Y [25; NK,PW,>0%X
M    $Q$0#1S_ %-208F>Y1:(D%4PA- 1[/>GV8 [,+(I7T MAD%D3)7D#OY=
M##'$0#:(\
M               "TM6\]X*Y0D!B08CF97UJ"7<C,@ILK!&4 .6)X!'ZDJ>(
M-F82K/ -ZEH[D[ 0
M  -7/'=#0L"JTH QPQ/ (G ,\) G"R(!+AF(X!9CKS9TZ4[H!D
M                                                        57EK
M3/>"$RQ ,LQ7D%D4X9Y!B90F04VE7R",RCR",RKFX+(GN6XX[P;,3RC, MQ7
M[V['? ,@                                             "&:D3#D
MWY[7>"J4)!&40&022B 2B%D G"41(-O%2&T
M                                         $@U+VGE7((\0C/<#%9G
MEL1Q $W0F01FRN; A,H3((3*/(*[2J!9CFTMZD1 )QW)@C'=/<Z..>Z 2
M                                           !HZC%]8-"5<@B< <,
M\ G$)1 )1"R(!*(;..@-NM&0
M                             !&9\0:5Y^4A,]X'*,@QX)18&)LCV@8F
MRN; A,H\@Q,H3(*YDB.0;>*G"^0(E*)!)LX; V0
M                         GQ@R5BU0<O+AB&K:L@CV9.) X 33XD$HB5L
M5!;&.6Y7'$1 )
M                    AD[@:5N]CCD$5-[3$@CVY(L#/+'((S9CF)!&>$9X
M@$)M"N;0"$RV,-8GB0;K(,)0"SZD\/=8&\
M                    $QR Q;'7ZVIDP1]0-.U+1/@A-9!#B>4XJ"<53BL@
MMBDKZXP;$1#(
M                   (9? &G* "%J@U[UE3S-0.VQ-P0G(A.600G-*/G9D&
M)M*$VD#EOZ>W<#;Y.02A($JSRLIW2#?K\V
M                      +1R1 (WQUE1;# *IP0Q[GL"489YAM1AB 3BL'
M'9D
M          !7F[H!I3*L$ZI6!5,-+-XP"E&X*IE'D$9E&)[P2Y1D#EM8)!T&
M> 3A(&:0MB.\&_3YL
M       !-6.\#O9
M                         %><&C* ,Q/#,V[@0Y[FEE\043/"NU@5S*'(
M(S+'(,\@$^#8T]N^ =1($D@3HLKX@WJ_-@
M                       DB)
M                                       1S4F8!SK3Q/"((S+':!&;
M->\<R#7M65,UD$9K*/9D$9K*/9D#B6>)!F:S*S%$UM .I%ED3 )PE )5[EE.
M^0;]?"
M
M         +> .;DCY2L$400E&00F(0FH(36$.R",U8[('8@[$ DG' +(F5L2
M"Z)3Y!*LK\4=X-X
M
M                  &CFCO:W/(,(@A*N08[V+ KE$#LRQV9@&6)!A. 61"R
M 6)P"RL2V\-9!M
M
M                  U\M.6E,<2""(*Y0 1L"MB 28D$0"(3B 6Q"<0"R(2B
M 75CENXZ@M
M
M              M'+G9JS%Y!1*(*Y0D&$; @Q '),@P GPG$ MA. 60G$ NQ
MUGENQW R
M
M            JRX^>9!S+UF)8!"85V@$>&)@$)A'@#@X!+@X!.(3X!*(6Q ,
MKJ1(-NE>%T^ ,P
M
M                  3S(-7+C:<UF/& 0E7: 1X1D$4> .#@$N"(!/A.(!.*
MRLB 3K3EN8\8+^"(
M
M                      0M#7R8^>\&C>)B48!B80M (\' '!$ EPSP"40G
M$ LA.(D&Q2C:@
M
M                    #@%.3#$M*^.8GP!5,(< <' '!$ EP< E'"<0"^M%
M]<8+HKP
M
M                %J18&MDPM6V&\ AV;(\ <' $1*7$R"=<4MFN$%\4X3B>
M
M
M            )F/K@$)I6RJ<$ C[G/, E&&$XQ0"SS<0SR
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUQH?;T_4#X0[!ZXT/MZ?J?"'8/7&A]O3]0/A#L'KC0^WI^I\(=@]<:'V]/U
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M]F>GZ@/PN,,
M
M                           .IMO_ )W_  @.6
M
M                                                          ZF
MV_\ F_\ " Y8
M
M                            #J;;_P";_P (#E@
M
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MIAQYK:?+&*\\4R328K:?1$MOWDWKU7K/8W!I9]/J-/DG'GPWQ7B.^MZS6?\
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MZVBW;34TLZC)."DSBYKCFWR8[Z.+Y,]RC3[3UCK]?'G8KFC+J>Z/E>,W!O\
M1G3U-CZZW6N">WHM3M5L^CR?5;%?)1\;Y-^K>H;;]LNSVU\^X.;U\SV*>$4M
M8'+Z]ZJW_4[MO.T9M=-M%CUMZTP]BG=%+=SSO%BG+?LQ+XO>*4M:?1"1J:UM
MK:PX*S$3DM%><^@RXIQW[,R]EZ;SUZ7\GFJW_2XZ3N&KU,X<66T<]BL3PS2T
M7I6T>F#;U[:NSFP6F)G'>:\W"IY1=3K]EW/;>H,,Z^,U/_A\O%*6PW=??/\
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M-8KW1'?:.U8'@        .IMO_F_\(#E@
M
M                                                 .IMO_F_\(#E
M@
M
M                 .IMO_F_\(#E@
M
M                                             .IMO_F_\(#E@
M
M
M             .IMO_F_\(#E@
M
M                                         .IMO_F_\(#E@
M
M
M         .IMO_F_\(#E@
M
M                                     .IMO_F_\(![Q[UZKUGL;GO'
MO7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKU
MGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![
MQ[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO
M6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;G
MO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZ
MKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN
M![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7
MJO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL
M;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[
MUZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>
MQN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'
MO7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKU
MGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![
MQ[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO
M6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;G
MO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZ
MKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN
M![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7
MJO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL
M;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[
MUZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>
MQN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'
MO7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKU
MGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![
MQ[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO
M6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;G
MO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZ
MKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN
M![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7
MJO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL
M;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[
MUZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>
MQN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'
MO7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKU
MGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![
MQ[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO
M6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN![Q[UZKUGL;G
MO'O7JO6>QN![Q[UZKUGL;GO'O7JO6>QN#I;=LN\5\[SMFKCP\<-P'[(&60
M
M
..              !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex10-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  N +$# 2(  A$! Q$!_\0
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M!6L+B^2#3K.ZL[P36,DC"*3S/BC]K7_@IQ^V-X"^"?[%7A[POXWD\#7OQD^
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MILT,&M:5>Z5<SVR^#-)C6:**^@@EE@$HE19%5HQ()%!W!A7Z'?M*_P#!1?\
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M4GFZ7\6-2^ /PHOOB7ILI^VYDL/'=UX3E\4V<A_M'4/GM]5C;_3[WG_2I_,
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M@WXUQ:'#<SZYX/NX?$%YHNH:DE_XF\/_ -!G_!#W_E$+_P $ZO\ LU+X4?\
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M)MO$6BZ;K=OI?B'1I3/I&O:=#J=M=1V6M:5.S3:;JELL5]8RDR6L\3DM704
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=?#FGZ;IL3+!#%"ICME(BBCC&$15 !W%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex10-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MT:+[EWXV\1IL_P!ETBC_ /:=>?)<S^?X',U>1Y!X_P#VD/&7Q0\._P!C:MK
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IQ10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex10-1_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M23;\C&)S_P !I -S?X]ZWY_@_P",(=0U2WF\*>(8KK1XQ/?1264BO91D9#R
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1>YP_PWCZ.,C.45;7JNQ__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex10-1_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#XOHK:_P"%7>*O^A5\4?\
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M]0!Y'_PGGC3_ *'SQC_X,&_PH_X3SQI_T/GC'_P8-_A7KG_##.J?]%'^%/\
MX4MG_P#'J/\ AAG5/^BC_"G_ ,*6S_\ CU 'B7V6/_GFOY4?98_^>:_E4E%
M$?V6/_GFOY4?98_^>:_E4E% $,UG$R-^[7H>U=Q\:[6,Z=\/_P!VO_(HVAZ?
M]-)JXN3[C?0UW'QJYT[P!_V*-I_Z-FH K?LZ>&--\1_&G2[/4M.M-4LELM5N
MVM;@'RIG@TRZGC#;2#M$D:' (SBJEG\5X9K2-V\$?#TEE#$_V?/][_O]6W^R
MR<?'W3?^P3KO7_L"WM><::[?V?;K\V-B]J!GJWQ UZ'Q/^ROX7D&BZ'I*Q>*
M[U/+TVW>-'_T:$[FWLQSVXKRW[%&K#]VOY5Z%K/_ ":=X=]_%UY_Z30UP?\
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M_B9H6OV_A/Q3!:KK3:]K%@1I\<9F-I);C[.8XE>3[^=\K[MH(H5@T/ESP/\
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I_P#/Y;_]]"@1^^U%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10-1_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MB_%#6&F\1?&MM861CE[O2[V1@IZX7[H^@XK);X>_##18(POQ$U2?C!6U\.N
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D4:H?4:JX]C0!CI2[:4C-/<7J)]W\3DXI101D44@"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ex10-1_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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D/':1S3P%_")8F-E&[%[!C.5/3/'3J>O;GQ'P6/4R?_>XG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ex10-1_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !C $8# 2(  A$! Q$!_\0
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M%IX&AFN9YKF-?,<RS/%PIRP.$PWJ/_#3'_!13_GX_P""8W_A]O&O_P L*/\
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M 5ZDONK_ ():?\H__P!F+_L1+S_U*O$-%?<^A:!H7A;2+#P_X9T72?#N@:5
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@8G$U*2Y$E"U*IB*E-<B24+4UR))1Y4DEH44451SG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ex10-1_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> $$# 2(  A$! Q$!_\0
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M<\K_ +.>-5+]VL6\2H>ZD%%%%:'FA1110!\3_P#!1_\ Y,3_ &I_^R/^)_\
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DSH9;EU*K5G7K2E5QF8YECJF(S3.LUS;-<7B<:RBBBNP^+/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ex10-1_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !G 'P# 2(  A$! Q$!_\0
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M75S^B/H]\-<%9S/QAXAXZX6I<999X<^#/$''67Y!B,\SSA["XW/,%Q/P/DN
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M?_13/VG/_"S^%?\ \Y>O)O\ @D-\'?#'P4_;@_X* ?#3P7?Z[J?A7X5RZ)X
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M _+?_@LOK^L>'_\ @GM\9VT;4+C3I-7U#X>:!J,MLPCEN-'U7X@>'(=3T\R
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M+UBEG8+JOB'P!I.C6DUU(!#;F_U&UCEG>.!'::6-'[[_ (=\?L._]&I_ O\
M\-YX?_\ D.OR!_;*^!'P9^!?_!2+_@FEIWP<^&/@KX9V/B#XB:=>ZW:>#- L
M-!@U6[LO'WAF"TN+Z.QBB6XEMH9I8H7D#&-)'5<!CGNQN,XGRVE2Q.*JY#6H
M/&8##5:>'PN90K..,QE#"N4)5<4Z:E%5G).2:T6CV?P/ O!7T4/%'-<WX6X4
MROZ0V2\04N"/$'BC*\?Q'Q5X7XW)88G@O@GB'BRG1Q^%RCA6CF%:CBIY-2PT
MHX>M1DXU:EZM*\:D?Z0J***^O/XL"BBB@#^>[_@L/^V!\/?B/X$\;_L)?"+P
M_P".?BU\<+W6/">H^)[7P%X<O-=TGP6/"^O:3XEN]+U%[))]2U776@AMHI[/
M1--O;'2FNFCU;5++4;9],;[D_P""<_[<GP>_:3^'NA_"'0X?$/@OXQ?!CP)X
M9\.^-OAOXUL$TW6UA\+Z;IGAB^\0:*\<LL6I:,FIQ1VE['*MCK6CWEQ!;ZOI
M%G'=6%S>_)G_  17LK/4?%/[?'C:]M+:X\5ZS^TAJ-EJ.O20QMJ5S9C4?%.K
MFT:Y*^:MLVI:E>7DD*,L<D\HD=6:.,I0^*=G:>'O^"_7[-<NB6UOIDGC?]G[
M7[SQ8]G#' ^O7=M\._C_ &D-SJ31JK75Q';>$O#=NLTI:00:/8Q;O+@C5?@,
M-B\>JV#XEG7HRI9QC\+DM3+EAE%4,#+,<?AL'.GBO:NI+$TJL)5ZTIT_9U55
ME2C&"A"1_HWQ1P?X<ULEXX^BQ@\@SW"YIX*^'O%GCIEOB35XGGB:F>\>X?PT
M\/>)^-,#F/"CRJGEN&X7S?*,=A\BR/#X/,7F64U\IP^:5\3BZN.QM ZGX>P0
MZA_P7E^.DE[&MT^A_LJZ1/I#3#>=.FFT[X.6TLEJ3_JF>#6-4B8CJE]<C_EH
M:YC_ (+Q11P^!?V2]7B18]4T[]H..*QOU4"ZM([C1TNIT@E^]&LMQIMA-(JG
M#26D#')C7'6?#'_E/%^T3_V:AHG_ *2_ JN6_P""\W_),_V5_P#LX:U_]1^Z
MJ,9_R3/%3Z_V[FCOUNLURNSOO=65GNK*S5CMX+E)?2N^B+34I*G_ ,2^^$E+
MDN^3V=?PA\5Y5Z?)?E]G6E.<JT.7DJN<W4C-RDY?O57X??\ !"3_ )-^_:(_
M[.O\=?\ J$_#ROW!K\/O^"$G_)OW[1'_ &=?XZ_]0GX>5]%CO^2AX>_[!L^_
M]1<"?S)P!_RC5])'_LJ?H\?^M7XA'[@T445] ?SD%%%% !7X*_\ !2#_ )27
M_P#!+O\ ['JW_P#5A^%*_>JOP5_X*0?\I+_^"7?_ &/5O_ZL/PI7SO%'_(KI
M_P#8UR/_ -6^"/Z:^B5_R=K,/^S0>/7_ *YGCH_>JBBBOHC^90HKYY_:3_:E
M^"W[)7@K2?B!\<?$MYX9\,ZYXEM?".E7-AX?USQ'<W>O7FFZKK$-H++0;"_N
M8D_L[1=1N'N;A(K9/($1E\Z:&.3XE_X?7_\ !/3_ **KXH_\-9\0_P#YGJ\[
M$YOE6#JNAB\QP6&K*,9NE7Q-*E449IN$G"3NE))N+ZI-H_3.%O!?Q=XXRBGG
M_!OACQWQ3D=7$8K"4LXR#AG-,TRVIBL%.G2QF'AC,+3=&=;"U*M.GB*<6Y4I
MSC&=I.QX3_P1)_YOE_[.:U+_ -S=9WQL_P"4^W[(/_9NWB;_ -0/]J&O:=#_
M ."PW_!,WPS]O_X1OQE=>'O[4NC?:G_8?P5\9Z3_ &C>MNW7E_\ 8/"UO]KN
MCN;-Q<>9*=S9?DY2?_@L)_P3,N?$%GXLN?&-S<>*M.MFL]/\2S_!3QG+X@L;
M1X[J)[6SUF3PLVHVUL\5]>Q-!!<I$T=Y=(5*W$P?Y2$\DAE>5Y=_K'E+EE^9
MX7,)5?K%-1JQPV88K&NE&'M+PE-8A4U-RDDX.3BTTE_8..R_QZQGBWXK^)B^
MC+XP4Z'B3X5\6^'%#)WP]F,J^45^)O#GA3@2GFU?&K+E1QE#!UN&ZF95,'1H
M4*U:EBX86%>G5HSK3\]^&/\ RGB_:)_[-0T3_P!)?@57+?\ !>;_ ))G^RO_
M -G#6O\ ZC]U7MT7_!8C_@F?!K]SXJA\9WD/BB\M%L+OQ)%\%O&D>OW5BH@"
MV5SK">%QJ,]HHM;4+;2W#0@6T "#R8]K-?\ ^"PG_!,SQ7%:0>*/&-SXDAL+
MD7EC#K_P4\9:Q%9W84H+JTCU'PM<I;W(0E1/"$E"DKNP<4ZU3)*N59MERXBR
MF,LSQ^+QL:KQ%-QHK$XO"8E4Y0]HI3<%AG!RC**DYJ2246G.1Y9X]91XO>#G
MB?+Z,WC!7P_A9X=\&<#8C)H\/9C3KYU6X4X,XMX4J9EA\;++I4,#2QM3B:GC
M:>&KT,15H4\'.A4JU*E:%2G^O]?A]_P0D_Y-^_:(_P"SK_'7_J$_#RO8?^'U
M_P#P3T_Z*KXH_P##6?$/_P"9ZL/0?^"Q'_!,_P *V]S:>&/&=YX<M+R[DO[N
MUT'X+>--'M[J^E2.*6]N8=/\+V\<]W)'##')<RJTSI%&C.510/2Q&9Y%6S++
ML>L^RN*P%+,*;I/%4FZOUZEAZ2:DII1]G[%MII\W,DK6=_RWAWPH^D#D?AAX
MF^'D_H]^+6)K^(.;>&^94<UAPEFU*CE<> \WXCS.M1K826$G6Q<LSCGL*-&=
M*M1CA98:<ZL:T:L8P_7RBOR?_P"'U_\ P3T_Z*KXH_\ #6?$/_YGJ/\ A]?_
M ,$]/^BJ^*/_  UGQ#_^9ZO0_P!8LA_Z'.6?^%M'_,_-/^):?I#_ /1C_%3_
M ,0C//\ Y4?K!17Y/_\ #Z__ ()Z?]%5\4?^&L^(?_S/4?\ #Z__ ()Z?]%5
M\4?^&L^(?_S/4?ZQ9#_T.<L_\+:/^8?\2T_2'_Z,?XJ?^(1GG_RH_6"OP5_X
M*0?\I+_^"7?_ &/5O_ZL/PI7T5_P^O\ ^">G_15?%'_AK/B'_P#,]6!J7_!8
M3_@F9K.IZ5K>L>,;G5M9T*02Z)J^I?!3QE?:GH\HD282:5?W7A:6ZT^031QR
MA[26%O,1'SN52/-S7,LBS+"1PT<^RNBXXO 8KGEBJ4TU@\90Q3ARQG%WJ*BX
M*5[1<E)II-/]2\'_  M^D!X7<88CBC$?1Z\6LYIU^#?$'A58*APGFV"J1J<;
M\$Y_PC2QKKU\)B(.GEU3.H8ZK05-5,33P\L/2J4JE2-2/Z_T5^=?P=_X*J?L
M4_';XD^%?A+\.OB3KFI>-_&E[/IWAS3K_P"'WCC2+:^OK>QNM1:V?4K_ $*&
MQM'>VL[@QO=SP0O(JQ>8'D0-^BE?0X7&X/'0E5P6*P^+IPG[.4\/5A5A&?*I
M<DI0;2ERM2L];-/8_FKB_@3C7P_Q^&RKCGA/B+@_,\9@UF&$P'$F4XS)\7B<
M"Z]3#+&4*&,A&=7#/$4:M#VT+P]K3G3=I1:.&^('PP^&GQ8T:#PY\4_AYX&^
M)?AZUU"'5K;0?B!X2T#QEHUOJMO!<6T&IP:7XCT_4K&'4(+:\N[>&\C@6YC@
MNKB))%CGE5O'/^&)_P!C/_HT?]F/_P ,)\*__F4HHJJF$PM:7/6PN%K3LESU
M<-AJL[+9<]7#U9V5W9<]E=V2N[\V6<7\7Y+A5@<EXMXLR; QJ5*T<#D_%7$^
M48*-:LXRK58X+*>)<KP<:M:4(2JU5A%5JRC%U:E5QBXG_#$_[&?_ $:/^S'_
M .&$^%?_ ,RE'_#$_P"QG_T:/^S'_P"&$^%?_P RE%%1_9^ _P"@# _^$."_
M^8SO_P"(B^(G_1PO$#_Q/>.O_HV#_AB?]C/_ *-'_9C_ /#"?"O_ .92C_AB
M?]C/_HT?]F/_ ,,)\*__ )E***/[/P'_ $ 8'_PAP7_S&'_$1?$3_HX7B!_X
MGO'7_P!&P?\ #$_[&?\ T:/^S'_X83X5_P#S*4?\,3_L9_\ 1H_[,?\ X83X
M5_\ S*444?V?@/\ H P/_A#@O_F,/^(B^(G_ $<+Q _\3WCK_P"C8/\ AB?]
MC/\ Z-'_ &8__#"?"O\ ^92C_AB?]C/_ *-'_9C_ /#"?"O_ .92BBC^S\!_
MT 8'_P (<%_\QA_Q$7Q$_P"CA>('_B>\=?\ T;!_PQ/^QG_T:/\ LQ_^&$^%
M?_S*4?\ #$_[&?\ T:/^S'_X83X5_P#S*444?V?@/^@# _\ A#@O_F,/^(B^
M(G_1PO$#_P 3WCK_ .C8/^&)_P!C/_HT?]F/_P ,)\*__F4H_P"&)_V,_P#H
MT?\ 9C_\,)\*_P#YE***/[/P'_0!@?\ PAP7_P QA_Q$7Q$_Z.%X@?\ B>\=
M?_1L=+X0_9:_9C^'WB'3_%W@+]G/X$>"/%>DM,^E>)_"'PA^'_AKQ#ICW%O+
M:7#:?K6C>'K+4K)I[6>>VF:VN8C+;S2PN6CD=3[O116]*C1H1<:-&C1BWS.-
M&E2HQ<K)<SC2I4HN5DES.+=DE>R27@YKG6=9[7ABL\SG.,\Q5.DJ%/%9WF^;
D9UBJ=",Y5(T*>)SC-,VQ-.A&I.<XT*>(A1C.<YJBISG.?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ex10-1_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: $$# 2(  A$! Q$!_\0
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M>GTY7Y__  P_Y20_M7?]F[_LS?\ I\^+5?H!7Y__  P_Y20_M7?]F[_LS?\
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MO5PW)5P>6YE[6%66<XGVL:D*=E3I*,M)'S#_ ,-5>%?^B3_M/?\ B,WQF_\
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@IG:P].OB\FRZ5=PP$ZDZ=!THU*4:DY,HHHKTC\M/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ex10-1_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !6 (D# 2(  A$! Q$!_\0
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MHNN6FC_V3H/Q.UG1H8+WQ-\,-8&B:RVNKKEQX$LO$GA.R35H_P JO@+^T_\
M\%OOB/\ #C0_!7A#X#6MU>0B0?\ "[OC#X)_X0[6[K2BD*V,BR>,=>\)^&=:
M%JJR--JT'AGQ'J&J*ZES/>13-<>U)_P3:_X*&?M(36,W[9_[< C\(RZEIVJZ
MS\*_AU:ZCJ?AS6K>RO;>^72-8T32+?X7^"8)5> (EV-'\416KXEM_.D'F'VY
M9P\R=#$Y;P_FF*KNG&$I8W X?"X/V4Y1G*C6KX]IR]G)RE3K82E-QDY<JJTZ
MDJ;_  7#>"5/PMCQ#POXH?2-\)N%>':>98K&8>AP'Q_Q)Q;QK_:F"PV)P>%S
MK(N'_#ZC5IT'F>'AA<+F&2<8YI@J.*P\,-]:GE699;A\SI_>G[.WP;^"GAV\
M\3_LZ_$'X-?##4/B!\+'N=1\.^(-<^&G@R>X^)/P=UK6;X^!O&=E?RZ-(^HW
MNAVSQ>!/&JO))=V'B?1#=W6+37](FNO'O@=H_P"S]\./V)?AY\0O$_P-^&GC
M?QCK%_XF\,>#/#__  KKPCJ/B?XA_$#6/B+XOTOP=X/TV>;0[FYDNM0FMX89
MKN020:+H=E?:O>>7INE7+Q^]>.OV / 7BJ3P_>>'OC/^TM\/]5\'F9_!NK:5
M\7]4\::MX8^T36D]Q9Z-XB^+=G\0_&.DZ->-86$-_HVB>)])L[JSLK6U40I;
MV[1<?\-?^";'@KP/<>'M0UWX\_M$>,M0\*VVIV?AF,>.+3PEIGA6'6+S5[O4
MG\&R>&M'M?%G@^YU$:YJ-KJ5QX>\86!O;:=HY$7?,9>OZGCZ=2G3IY7@W"E0
MQ&'I8B5? 24*=:IAY4Y5(2P:E5JX:G3G3A*4/WUJ$ZCC;$1J_(?Z[^'F89=F
M6/S3Q;XW6*S;/N'.(LWX=H9%XB82KC<PR7+^(Z&9X3+\=A.-YX/*,HXIS#,L
MOS''T<-C%/)54SW Y;#%>UX<Q64U_"_PR^ _P+^'O@CX/ZQ\%OAA\=?VF;CP
M[/K^K^"O"WP^\#ZGK&H^(_$VI:CK>M>(?$6LZEHEOIWP[^&$'B+4-0T_2?$_
MC"72K"+1["WT3PY9ZWKD%AX>NOC/XA?\$?/C=\4/&%]/>?M=S_#/X9>,+#2_
M$'COX;_#7PGJ&E^&&\>74<__  DVE^'_  CHNN^#_"Y\'Z=OBTSP7JFOV^K>
M(K/0$@T[5[>^N+26_P!2_;+X<?"GP!\)M*O=)\!Z NDIJVH2:OK^JWVIZQXD
M\5>*M9E18I-;\8^-/%&H:SXO\8ZX\$<5L=:\4:YJ^J?9(+>T^U_9K>&*/T.N
MJID&"QE&E1QU"'LZ*A&E0PM2IAXPC&/(XUL1AUAL1BY5(V59U7&E+WE"BE*4
MY_(Y9](OCO@K/,VSC@+/,7_:.<UL9B,US_BW+LMXDQ&+Q>*Q+QE.MDG#7$-3
MBCA[@S"95BISJY%0RJCB\WPC5&KCLZK5*&'P>$_'3X3?\$-_V'?AY]ENO%^D
M^/?C-JD.R623QWXON=,T?[2N#NM]$\"0>$T:U##(LM7O-9C8$I</.AVC]+_A
MC\ O@A\%K5;3X2_"/X<_#F,1>3)-X/\ !^A:%?W2$;6:_P!3L+&'4=1E=0!)
M/?W5S/( !)(V!7KE?F!^W%_P5)^"7[((O/ FB ?%SX_W$:6^E_##PU="2WT'
M4+U0NGR^/M9MDN5T19&DCEA\/6<5[XJU%9+15TW3["_BUF&GAN'^'</+%?5L
MORZE3T]LJ-/VTI6?+"G.4:N)JU9VM&G3G*<F]DKM<U'B;Z1_TEN)</PFN)_$
M;Q-SC,I2J?V+4SS,I9+A<-&<?;X_,<%0Q&3\+9/E&#YE4Q689E@L/@<+"";J
MU*WLJ-?]/ZXWQO\ $;X??#/2&U_XC^.O!W@#0EW[M:\:^)M%\+:4#$%:0?VA
MKE[8VF4#J6'FY4,N1\PS_/?IW@W_ (+H_M?65IJVO>/_  _^R=X#\0P+?6NF
MVMS;?#?7K33[L%PT%IX6L/%?QATJ_$3".'3?%/B#0[N)HT>86CR&YD[WP1_P
M05\%ZYJR^+/VGOVE_BO\9?$UQLEU Z(L/A\7#*Q?['?^)/%MUX^\0ZM:AWE+
M3PMH-R_FDQBV<,S\:SS-<9;^R^',9*$DG'%9O6HY70:=FIJBW7QDHM--+V4)
M-/HS[:7@%X/\%SDO%SZ37!&'QV&E*.+X5\&LDSGQ:S^G6IRE&MA)YU2CD/!.
M&Q$*D)T93>;8ZA"I"3YJL$SZC^-7_!:/]AGX2PWEMH/CG6OC/XBMUD1-%^%F
M@75_8F<+B S>+O$#:!X3DLY).)KG1]7UJX@B5Y%L9G\J&;\^O%?B_P#X*,_\
M%=8)/"/@7P*?V4OV0]4FMEUK7?$\^I1S^-=.C:*8FZU:33](U[XAVLP#W%IH
M'A'1M)\$?:DCT_Q/X@N;BVMM03]F?@;_ ,$]OV.?V=KB#4_AC\#/"5IXA@C"
M)XK\3"_\<^)TDWQR/<6FK^,;S6Y](FDDB1V&B#3(5P4CBCC)0_9U*64YUFD>
M3.LSI4,'.ZJY;DM.I0C6@_\ EUB,QKREBITY+2I"C3HJ:O%RY6T:87QC\#/"
M;$1QW@3X59OQ!QG@W&>4^*'CGF.6Y]B,DQD=8YKPWX:9#0H<)8#,\/-1K9=C
ML\S#/*V JJG7IT?K%*$U\W_LJ_LM?"_]D'X0Z/\ "'X66,RZ?:S2:KXB\1:B
M(7U_QGXIO(;>'4O$NOW$$<4;WES':VUI:VT*):Z9I=G8Z;:(L%JA;Z0HHKZ2
MA0HX:C2P^'IPHT*,(TZ5*G%1A3A%6C&*71=6VVVY2DY2E*3_ )>S_/LZXISO
M->).(\TQN=9]GF/Q.9YOFV8UY8C&YAC\74=2OB<16E;FG.7+&,81ITJ-*E0P
M]"C0P^'P]"B5_(W_ ,%JOBW\2OB-^TOH/PL^)/@+Q]X"_9N^#M[8_P!G>,])
M\"_VW?\ C"Y\3:;I=YXD\8:'J>J7?AS0M3B2,1^'M%T)?%=G903Z7>7FIW2:
MC<R:?IO]<E-=$D5D=5='5D='4,KHP(964@AE8$AE((()!&*\K/LHGG> >!CC
M)X.,JM.I5<:,:T*\*3YU0K0<Z4G2E44)R5.I"4G!1;Y=OU[Z/'C+@? CQ$I>
M(&*X)PG&V+PN49GEN54Z^=8K(L9D&,S2DL)6S_)L;1R_-<+'-Z.7U,9@L+/,
M,LQN&P\,;6KTZ+KZR_CT_9Q3_@A5I"65Y\3]=_:!UG51$LMRGQE\/^)K/1([
MM8_-'V?2/@&-;NHX@ZI";2^U[7;>2;>)IIK*1Z_7;X8?\%#O^"-GP5MTM_A+
MXO\ AU\.]L/D27?A/]G+XN:/JEVFT(3J.L6GPC35M3E= $DN-1O;J>10%DD8
M  ?HEXV_9)_9;^(\YN_'?[.OP4\4WYE>8ZGJ_P ,_!]SJQDE;?,3JQT@:D1.
M_P \Z?:MD[A6F5V52. _X=\?L._]&I_ O_PWGA__ .0Z\3!Y%G.66C@8\)PY
M?AK_ -CXZEB'YRE#%5I)]W&LKW?30_>>./I!>!_BI*I7\0,7],;&1Q+<JV01
M\:. LWX;HR<G+EPV$QO"62X>I15TH0Q>2SE%4X-WFO:'S=>_\%I_^"=]I<R0
M0?&37=3B0(5O++X4_%&.VEW(K,(TU'PEI]X#&Q,;^;:1@NC&,O&5D;@]8_X+
MK?L'Z87%EJ7Q9\0A;EH%.C_#J2 21*'Q>)_;^LZ&1;/L4*L@2[!E3?:J!*8_
MLW_AWQ^P[_T:G\"__#>>'_\ Y#KN](_9!_9.T#<=#_9A_9ZTAG\@R2:=\%_A
MQ9RRM:[OL[S30>&XY9I(2\C1R2N\BM([!MSL3W^PXOEOF/#])=X9;F%1^B53
M%I:>;NS\Y6??0LPL8RI^&OTD,WFHI.GCO$_PXRNE)K>4JF6<'5JR<[N\:4%&
M#BN56D[?D[X@_P"#@S]EF"%T\(_!_P"/OB#41*8HH=:TWX>^&=.F_>I''(M_
M:^/O$MW&DH9F7SM*C=?W:NBEV\KDI?\ @L7^UA\2M-DE^ O_  3L\?W0AAN[
MJY\4^);GQMXH\*6%G!$\XO-3N-%\">$-+TNSA@3SKJ[U#Q7;6RAP@E78KS_O
M#I?@?X;^!TN=7T7PAX(\'QV<,][>:II?A_0?#Z6L$%M,+F[N;VTM+18(8;-I
MQ//+*J1VS3"1Q$7K^?/]I?\ :7^,'_!4;XP7_P"Q5^Q5?W&C_ '1[B-?CO\
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B,*523J/T.BBBJ.0**** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ex10-1_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !A 'X# 2(  A$! Q$!_\0
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ME[I>F:+;ZWH<&F0>([^ZU*RTC^;;_@MH;<_\%"/B:(%=95\(_"X7A;.'N/\
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M7EQ/=WEW/+<W5U<RR3W-S<SR-+/<7$\K/+-/-*[R2RR,TDDC,[LS,2?Z:?\
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M,/\ T[0/\6/VDW_*4F;_ /9O_#?_ -4^?!1117VY_!1_(M_P6Y^)/C_X2_\
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MMKNUFE@GB<%)(I'1@0Q%>N_\.GO^"A?_ $;/XH_\*;X>?_-A1_PZ>_X*%_\
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M^48K&9;6S'),QC'!5\7@:[PF849X?&TJ>%JRQN"PA1117T1_- 4444 %%%%
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JAZ6/QY1117UI_&P4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710609926808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lantern Pharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001763950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710609975704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 20,802,542<span></span>
</td>
<td class="nump">$ 1,232,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,672,802<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">22,475,344<span></span>
</td>
<td class="nump">1,232,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">17,608<span></span>
</td>
<td class="nump">8,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">22,492,952<span></span>
</td>
<td class="nump">1,432,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">814,557<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">814,557<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">PPP loan payable</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">923,057<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock - Par Value (1,000,000 authorized at September 30, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding at September 30, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock &#8211; Par Value (25,000,000 authorized at September 30, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,217,577 shares issued and outstanding at September 30, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">31,333,164<span></span>
</td>
<td class="nump">7,694,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,763,891)<span></span>
</td>
<td class="num">(6,751,705)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">21,569,895<span></span>
</td>
<td class="nump">943,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 22,492,952<span></span>
</td>
<td class="nump">$ 1,432,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710615339320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, shares par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">12,180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,217,577<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,217,577<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710615325720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,100,719<span></span>
</td>
<td class="nump">$ 441,251<span></span>
</td>
<td class="nump">$ 2,117,290<span></span>
</td>
<td class="nump">$ 977,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development</a></td>
<td class="nump">600,769<span></span>
</td>
<td class="nump">228,401<span></span>
</td>
<td class="nump">894,896<span></span>
</td>
<td class="nump">775,718<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,701,488<span></span>
</td>
<td class="nump">669,652<span></span>
</td>
<td class="nump">3,012,186<span></span>
</td>
<td class="nump">1,753,018<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (1,701,488)<span></span>
</td>
<td class="num">$ (669,652)<span></span>
</td>
<td class="num">$ (3,012,186)<span></span>
</td>
<td class="num">$ (1,753,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common shares, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.82)<span></span>
</td>
<td class="num">$ (0.89)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding, basic and diluted (in Shares)</a></td>
<td class="nump">6,217,577<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="nump">3,661,942<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710611709320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 4,121,395<span></span>
</td>
<td class="num">$ (4,323,520)<span></span>
</td>
<td class="num">$ (201,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">1,292,952<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,384,919<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,385,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued (in Shares)</a></td>
<td class="nump">804,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,531<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(453,973)<span></span>
</td>
<td class="num">(453,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">6,521,845<span></span>
</td>
<td class="num">(4,777,493)<span></span>
</td>
<td class="nump">1,744,760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2019</a></td>
<td class="nump">2,097,105<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">4,121,395<span></span>
</td>
<td class="num">(4,323,520)<span></span>
</td>
<td class="num">(201,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">1,292,952<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">7,631,143<span></span>
</td>
<td class="num">(6,076,538)<span></span>
</td>
<td class="nump">1,555,047<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2019</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">6,521,845<span></span>
</td>
<td class="num">(4,777,493)<span></span>
</td>
<td class="nump">1,744,760<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2019</a></td>
<td class="nump">2,097,105<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,029<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(629,393)<span></span>
</td>
<td class="num">(629,393)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 210<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">6,527,874<span></span>
</td>
<td class="num">(5,406,886)<span></span>
</td>
<td class="nump">1,121,396<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2019</a></td>
<td class="nump">2,097,105<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,070,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,070,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued (in Shares)</a></td>
<td class="nump">341,761<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">32,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(669,652)<span></span>
</td>
<td class="num">(669,652)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">7,631,143<span></span>
</td>
<td class="num">(6,076,538)<span></span>
</td>
<td class="nump">1,555,047<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2019</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">7,694,547<span></span>
</td>
<td class="num">(6,751,705)<span></span>
</td>
<td class="nump">943,284<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">51,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,460<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(477,276)<span></span>
</td>
<td class="num">(477,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">7,765,002<span></span>
</td>
<td class="num">(7,228,981)<span></span>
</td>
<td class="nump">536,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2020</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">2,028,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">7,694,547<span></span>
</td>
<td class="num">(6,751,705)<span></span>
</td>
<td class="nump">943,284<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">31,333,164<span></span>
</td>
<td class="num">(9,763,891)<span></span>
</td>
<td class="nump">21,569,895<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">7,765,002<span></span>
</td>
<td class="num">(7,228,981)<span></span>
</td>
<td class="nump">536,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2020</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">2,028,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">23,419,546<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,419,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment', window );">Preferred stock conversion to common stock and fractional shares adjustments from stock split and conversion</a></td>
<td class="num">$ (244)<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares', window );">Preferred stock conversion to common stock and fractional shares adjustments from stock split and conversion (in Shares)</a></td>
<td class="num">(2,438,866)<span></span>
</td>
<td class="nump">2,438,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,363<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(833,422)<span></span>
</td>
<td class="num">(833,422)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">31,289,650<span></span>
</td>
<td class="num">(8,062,403)<span></span>
</td>
<td class="nump">23,227,869<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,514<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">43,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,701,488)<span></span>
</td>
<td class="num">(1,701,488)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 31,333,164<span></span>
</td>
<td class="num">$ (9,763,891)<span></span>
</td>
<td class="nump">$ 21,569,895<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssueSharesdPreferredStockConversionToCommonStockNetOfFractionalSharesAdjustmentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710613792840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,012,186)<span></span>
</td>
<td class="num">$ (1,753,018)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Stock based compensation</a></td>
<td class="nump">167,337<span></span>
</td>
<td class="nump">54,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,672,014)<span></span>
</td>
<td class="num">(25,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">431,004<span></span>
</td>
<td class="nump">304,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(4,083,564)<span></span>
</td>
<td class="num">(1,419,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(11,145)<span></span>
</td>
<td class="num">(5,717)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(11,145)<span></span>
</td>
<td class="num">(5,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of common and preferred stock</a></td>
<td class="nump">26,250,000<span></span>
</td>
<td class="nump">2,920,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreaseIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(2,745,279)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from stock option exercise</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowings from notes payable</a></td>
<td class="nump">169,049<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Payments on notes payable</a></td>
<td class="num">(169,049)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable', window );">Borrowings on PPP loan payable</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">23,665,221<span></span>
</td>
<td class="nump">2,920,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">CHANGE IN CASH FOR THE PERIOD</a></td>
<td class="nump">19,570,512<span></span>
</td>
<td class="nump">1,495,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, BEGINNING OF PERIOD</a></td>
<td class="nump">1,232,030<span></span>
</td>
<td class="nump">445,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, END OF PERIOD</a></td>
<td class="nump">20,802,542<span></span>
</td>
<td class="nump">1,940,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock', window );">Conversion of SAFE agreements to Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">535,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ApplicationOfDeferredOfferingCosts', window );">Application of deferred offering costs to initial public offering proceeds</a></td>
<td class="num">$ (456,437)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ApplicationOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of application of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ApplicationOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of SAFE agreements to Series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>IncreaseDecreaseInBorrowingsOnLoanPayable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreaseIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreaseIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for stock option classified as equity. Excludes stock option granted for share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710629154472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Principal Activities, and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Principal Activities, and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. Organization, Principal Activities,
and Basis of Presentation</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Lantern Pharma Inc.,
and Subsidiary (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence
(&#x201c;A.I.&#x201d;), machine learning and genomic data to streamline the drug development process and to identify the patients
that will benefit from its targeted oncology therapies. The Company&#x2019;s portfolio of therapies consists of small molecule
drug candidates that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds
that it is developing with the assistance of its A.I. platform and its biomarker driven approach. The Company&#x2019;s A.I. platform,
known as RADR<sup>&#xae;</sup>, uses big data analytics (combining molecular data, drug efficacy data, data from historical studies,
data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning.
The Company&#x2019;s data-driven, genomically-targeted&#xa0;and biomarker-driven&#xa0;approach allows it to pursue a transformational
drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January&#xa0;15, 2020. The Company&#x2019;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017. All intercompany balances and transactions have been eliminated in
consolidation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24pt">&#xa0;</td>
    <td style="width: 24pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-100&#xa0;(irofulven), out-licensed&#xa0;to Allarity Therapeutics (formerly known as Oncology Venture), in a phase II trial for the treatment of prostate cancer;</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24pt">&#xa0;</td>
    <td style="width: 24pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-300&#xa0;(Tavocept) in planning stages for phase II trial for the treatment of non-small&#xa0;cell lung cancer; and</font></td></tr>
</table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24pt">&#xa0;</td>
    <td style="width: 24pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LP-184&#xa0;in preclinical studies for treatment of solid tumors including prostate, liver and pancreatic cancers and glioblastoma.</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
Company&#x2019;s reincorporation in the state of Delaware on January&#xa0;15, 2020, the par value of the Company&#x2019;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying condensed consolidated financial statements. Additional funds have been reclassified
from Common Stock and Series A Preferred Stock to additional paid-in&#xa0;capital to reflect the change in par value associated
with the reincorporation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company&#x2019;s
fiscal year ends on December 31 of each calendar year. The accompanying interim condensed consolidated financial statements are
unaudited and have been prepared on substantially the same basis as the Company&#x2019;s annual consolidated financial statements
for the fiscal year ended December&#xa0;31, 2019. In the opinion of the Company&#x2019;s management, these interim condensed consolidated
financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair
statement of the Company&#x2019;s financial position, results of operations and cash flows for the periods presented. The preparation
of financial statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of
expenses during the reporting periods. Actual results could differ from these estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The December 31, 2019
year-end condensed consolidated balance sheet data in the accompanying interim condensed consolidated financial statements was
derived from audited consolidated financial statements. These condensed consolidated financial statements and notes do not include
all disclosures required by U.S. generally accepted accounting principles and should be read in conjunction with the Company&#x2019;s
audited consolidated financial statements as of and for the year ended December 31, 2019 and the notes thereto included in the
Company&#x2019;s final prospectus, dated June 10, 2020, for the Company&#x2019;s initial public offering, on file with the Securities
and Exchange Commission.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The results of operations
and cash flows for the interim periods included in these condensed consolidated financial statements are not necessarily indicative
of the results to be expected for any future period or the entire fiscal year.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;)
of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). To date, the Company has operated its business as one segment.
The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary,
Lantern Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Effective June 11, 2020,
in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), the Company completed a forward stock split
of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&#x2019;s preferred stock converted into common
stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying condensed
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying condensed consolidated financial statements
and in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the
forward stock split.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710645832872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. Liquidity </b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company incurred
a net loss of $3,012,186 and $1,753,018 during the nine months ended September 30, 2020 and September 30, 2019, respectively. As
of September 30, 2020, the Company had working capital of $21,660,787, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 5). The Company had working capital of $743,526 as of December 31, 2019. The Company
has received funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in
supporting its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional
source of liquidity. As of December 31, 2019, there was substantial doubt about the Company&#x2019;s ability to continue as a going
concern in the absence of additional funding. We believe that our existing cash and cash equivalents as of September 30, 2020,
and our anticipated expenditures and capital commitments for the remainder of calendar year 2020 and for calendar year 2021, will
enable us to fund our operating expenses and capital expenditure requirements for at least 12 months from the date of this quarterly
report.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710627749896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. Summary of Significant Accounting
Policies</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The significant areas of estimation include determining deferred tax asset
valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could
differ from those estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the
potential risk of business failure.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted.
If the Company&#x2019;s operations are impacted by this outbreak for an extended period, the Company&#x2019;s results of operations
or liquidity may be materially adversely affected.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In conjunction with
the Company&#x2019;s IPO, costs incurred related to the IPO were capitalized as deferred equity issuance costs in other non-current
assets until the time of completion of the IPO. Upon completion of the IPO, these costs have been offset against proceeds received.
Offering costs include direct and incremental costs related to the offering such as legal fees and related costs associated with
the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2020, the Company classified deferred offering costs of $456,437 as a reduction to additional paid-in capital
upon completion of the Company&#x2019;s IPO on June 15, 2020. As of December 31, 2019, the Company recorded deferred offering costs
of $191,000 and as of September 30, 2020, there were no deferred offering costs recorded on the Company&#x2019;s condensed consolidated
balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses and Other Current Assets</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Prepaid expenses and
other current assets as of September 30, 2020 totaled approximately $1,673,000 and included approximately $357,000 of upfront payments
for contractor and academic research studies and services, approximately $48,000 of licensing and other fees to AF Chemicals, LLC,
approximately $6,000 associated with receivables and undeposited funds, and approximately $1,262,000 of prepaid annual insurance
fees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loan Pursuant to Paycheck Protection
Program</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company received
$108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;) pursuant to
the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan is evidenced
by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;) by and between the Company and the Lender. This
amount is recorded as a loan payable on the Company&#x2019;s condensed consolidated balance sheet at September 30, 2020.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710645832152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4: Commitments and Contingencies</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>BioNumerik
Pharmaceuticals.</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2018, the
Company entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with BioNumerik Pharmaceuticals, Inc. (&#x201c;BioNumerik&#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300&#xa0;(Tavocept) for human therapeutic treatment indications. The Assignment Agreement replaced a License Agreement
that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments totaling $25,000 in connection
with entry into the Assignment Agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In the event the Company
develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related&#xa0;payment recipients
designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million,
with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million
and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative
revenue in excess of $1 billion. The Company has the right to first recover certain designated portions of patent costs and development
and regulatory costs before the payment of royalties described above.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">If the Company enters
into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients a specified
percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first recovering
specified direct costs incurred by the Company for the development of LP-300&#xa0;that are not otherwise reimbursed from such third
party transaction.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In addition, the Assignment
Agreement provides that the Company will use commercially diligent efforts to develop LP-300&#xa0;and make specified regulatory
filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides that the Company
will provide TriviumVet DAC (&#x201c;TriviumVet&#x201d;) with (i) specified data and information generated by the Company with respect
to LP-300, and (ii) an exclusive license to use specified LP-300-related&#xa0;patent rights, trademark rights and related intellectual
property to support LP-300&#xa0;development in non-human&#xa0;(animal) treatment indications.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company is also
required to pay all patent costs on covered patents related to LP-300. These patent costs are fully recoverable at the time of
any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment of patent costs until such costs
are fully recovered.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In addition to the recovery
of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection with entry into the Assignment
Agreement, which payments are recoverable prior to making any royalty or third party transaction sharing payments. The Company
also has the right to recover previously incurred LP-300&#xa0;development and regulatory costs, with up to a mid-single&#xa0;digit
percentage of net revenue amounts to be applied towards repayment of development and regulatory costs until such costs are fully
recovered.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">There is approximately
$11,000 payable to BioNumerik as of September 30, 2020 and December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font><b><i>AF Chemicals</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&#x201c;AF Chemicals&#x201d;) for the treatment of cancer in humans for the compounds LP-100&#xa0;(Irofulven) and LP-184. In
February 2016, the Company and AF Chemicals entered into an Addendum providing for additions and amendments to the Technology License
Agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Pursuant to the Technology
License Agreement and Addendum (collectively, the &#x201c;AFC License Agreement&#x201d;) the Company is obligated to make annual
licensing fee payments to AF Chemicals in the amount of $30,000 per year relating to LP-184. The Company paid $0 and $30,000 to
AF Chemicals relating to the LP-184 annual fee&#xa0;during the three and nine months ended September 30, 2020, $7,500 and $22,500
of which was expensed during the three and nine months ended September 30, 2020, respectively. The Company paid $0 and $30,000
to AF Chemicals relating to the LP-184&#xa0;annual fee during the three and nine months ended September&#xa0;30, 2019, $7,500 and
$22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively. Such amounts are included
in research and development expenses in the accompanying condensed consolidated statements of operations. In addition, the Company
is obligated to make milestone payments to AF Chemicals at the time of an Investigational New Drug Application (&#x201c;IND&#x201d;)
filing relating to LP-184&#xa0;and also upon reaching additional specified milestones in connection with the development and potential
marketing approval of LP-184&#xa0;in the United States, specified countries in Europe, and other countries.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In the event of a sublicense
of the LP-184&#xa0;rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income and
fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double digit
percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such sublicense.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184&#xa0;and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the Company
to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development
time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three
and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing
milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September
30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements
of operations. The Company paid AF Chemicals $37,500 during the year ended December&#xa0;31, 2019 in connection with extension
of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts
of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension
payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.
The Company is also obligated to make annual licensing fee payments to AF Chemicals relating to LP-100&#xa0;as described below
under &#x201c;Oncology Venture.&#x201d;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Nothing was accrued
or payable to AF Chemicals as of September 30, 2020 and December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Allarity Therapeutics (formerly known
as Oncology Venture)</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In May 2015, the
Company licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License
and Development Agreement. In February 2016, the Company and Allarity Therapeutics A/S (&#x201c;Allarity&#x201d;) entered into
an addendum and an amendment providing for additions and amendments to the Drug License and Development Agreement. In
connection with the Drug License and Development Agreement, as amended (collectively, the &#x201c;Allarity License and
Development Agreement&#x201d;), Allarity agreed to directly pay to AF Chemicals on behalf of the Company amounts owed to AF
Chemicals with respect to LP-100&#xa0;under the AFC License Agreement. Amounts paid by Allarity to AF&#xa0;Chemicals on
behalf of the Company are then deducted from amounts owed by Allarity to the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The amounts owed to
AF Chemicals with respect to LP-100&#xa0;are in many ways similar to the amounts owed with respect to LP-184&#xa0;as described
above under &#x201c;AF Chemicals&#x201d;. In the event any such amounts relating to LP-100&#xa0;are not paid to AF Chemicals by Allarity,
the Company is obligated to pay such unpaid amounts. In addition to the payments to be made by Allarity, the Company is obligated
to make annual licensing fee payments to AF&#xa0;Chemicals in the amount of $30,000 per year relating to LP-100. The Company paid
$0 and $30,000 to AF Chemicals relating to the LP-100 annual fee&#xa0;during the three and nine months ended September 30, 2020,
respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2020, respectively.
The Company paid $0 and $30,000 to AF Chemicals relating to the LP-100&#xa0;annual fee during the three and nine months ended September
30, 2019, respectively, $7,500 and $22,500 of which was expensed during the three and nine months ended September 30, 2019, respectively.
Such amounts are included in research and development expenses in the accompanying condensed consolidated statements of operations.
In addition, the AFC License Agreement contains specified time requirements for the Company to file an IND, enroll patients in
clinical trials, and file a potential NDA with respect to LP-100. During the three and nine months ended September 30, 2020, the
Company paid AF Chemicals $25,000 relating to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately
$4,000 of which was expensed during the three and nine months ended September 30, 2020 and included under research and development
expenses in the accompanying condensed consolidated statements of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">There is nothing accrued
or payable related to the Allarity License and Development Agreement as of September 30, 2020 and December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font><b><i>EU
Grant</i></b></font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In September 2018, Lantern
Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form of state
aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &#x201c;General Block Exemption&#x201d;), Article 25
Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and development
activities for the prostate cancer biomarker analysis of the LP-184&#xa0;drug candidate. Following the Company&#x2019;s research
and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development expenses
not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting and
consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made under
the grant as of September 30, 2020 and December 31, 2019. No revenue has been recognized from this grant through September 30,
2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patheon API Services</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, the Company
entered into an agreement with Patheon API Services, Inc. (&#x201c;Patheon&#x201d;) for the manufacture and supply of cGMP material
to support the Company&#x2019;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing LP-300
API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer previously
validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used to support
non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing milestones
are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700 pharmaceuticals
for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated global network of
facilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company paid approximately
$194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was
expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services
received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying
condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid
expenses on the Company&#x2019;s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Southwest Research Institute</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
part of the Company&#x2019;s research and development activities, the Company has engaged Southwest Research Institute (&#x201c;SwRI&#x201d;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&#x2019;s product candidates.
Approximately $4,000 and $21,000 was expensed with respect to SwRI during the three months ended September 30, 2020 and September
30, 2019, respectively, and approximately $5,000 and $221,000 was expensed with respect to SwRI during the nine months ended September
30, 2020 and September 30, 2019, respectively. All of such expensed amounts are included in research and development expenses in
the accompanying condensed consolidated statements of operations. Approximately $99,000 was payable to SwRI as of September 30,
2020, and approximately $21,000 was payable to SwRI as of September 30, 2019. In September 2020, the Company entered into an agreement
with SwRI for the non-GMP synthesis of LP-184 material and related analytical development to assist with preclinical studies. Approximately
$97,000 relating to the SwRI agreement is included under prepaid expenses on the Company&#x2019;s condensed consolidated balance
sheet for the period ended September 30, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company
expects to pay additional amounts to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>The Research
Institute of Fox Chase Cancer Center</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&#x201c;FCCC&#x201d;)
as part of the Company&#x2019;s research and development activities, with a focus on <font>advancing
the targeted use of LP-184 in molecularly-defined sub-types of pancreatic cancer.</font> Approximately $6,000 was expensed with
respect to the FCCC agreement during the three months ended September 30, 2020, which amount is included in research and development
expenses in the accompanying condensed consolidated statements of operations. As of September 30, 2020, approximately $71,000 was
payable to FCCC. Approximately $65,000 relating to the FCCC agreement is included under other current assets on the Company&#x2019;s
condensed consolidated balance sheet as of September 30, 2020. The Company expects to pay additional amounts to FCCC in future
periods in accordance with the payment schedule specified under the FCCC agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Other Research
and Service Provider Agreements</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Lease</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company leased office
space in Dallas, Texas under month-to-month lease arrangements during the nine months ended September 30, 2020 and the year ended
December 31, 2019. In connection with the Company&#x2019;s employees working remotely due to COVID-19, the Company in August 2020
reduced its monthly lease commitment and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions
and intends to increase its lease of office space following an improvement in the COVID-19 situation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710618790744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5. Shareholders&#x2019; Equity</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock </b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In March 2019, the Company
sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued 213,510
shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future Equity (SAFE)
agreements. See Note 6. In connection with the sale and issuance of the Series A preferred stock in March 2019, the Company issued
warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price of $3.13 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In July 2019, the Company
sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with the issuance
of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series A preferred stock
at an initial exercise price of $3.13 per share.&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of December 31, 2019,
the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred Stock
were issued and outstanding. The holders of Series A Preferred Stock were entitled to receive dividends when, as and if declared
by the Company&#x2019;s Board of Directors, payable in preference and priority to any declaration or payment of dividends on Common
Stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Effective January 15,
2020, as a result of the reincorporation in the state of Delaware, the par value of the Company&#x2019;s preferred stock was changed
from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein as reflective of
this change</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Upon the Company&#x2019;s
IPO, all shares of the Company&#x2019;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of September 30,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On June 15, 2020, the
Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750 and
other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in its IPO
at a price of $15.00 per share. In connection with the IPO, all shares of the Company&#x2019;s Series A Preferred Stock were converted
into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of
the fractional shares adjustments that occurred in connection with the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion of
the preferred stock that took place in connection with the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the three and
nine months ended September 30, 2020, the Company issued zero and 50,460 shares of common stock, respectively, relating to the
exercise of stock options. The shares were issued at a purchase price of $1.03 for total proceeds of $52,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">As of September 30,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,217,577 shares were issued and outstanding. As of
December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and outstanding.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company had warrants
to purchase 332,014 shares of common stock outstanding and exercisable as of September 30, 2020 at a weighted average exercise
price of $6.42 per share. The Company had warrants to purchase 273,900 shares of Series A Preferred Stock outstanding and exercisable
as of September 30, 2019 at a weighted average exercise price of $3.13 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
IPO, the Company granted the underwriters warrants (the &#x201c;Underwriters&#x2019; Warrants&#x201d;) to purchase an aggregate of
70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price. The
Underwriters&#x2019; Warrants have a five-year term and are not exercisable prior to December 7, 2020. All of the Underwriters&#x2019;
Warrants were outstanding at September 30, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In connection with the
Series A Preferred Stock financing transactions discussed above, during the nine months ended September 30, 2019, the Company issued
warrants to purchase an aggregate of 137,514 shares of Series A Preferred Stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company recorded
stock-based compensation of approximately $167,000 and $54,000 related to stock options during the nine months ended September
30, 2020 and 2019, respectively, and approximately $43,000 and $32,000 of stock-based compensation during the three months ended
September 30, 2020 and 2019, respectively. These amounts are included in general and administrative expenses in the accompanying
condensed consolidated statements of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">A summary of stock option
activity under the Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated (the &#x201c;Plan&#x201d;) during the
nine months ended September 30, 2020 is presented below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/>
Average<br/> Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">607,491</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">306,743</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.00</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(50,460</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.03</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.03</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding September 30, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">820,608</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6.25</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Options were exercisable
for 515,695 shares of Common Stock at September 30, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2019, options to purchase 1,342 shares of Common Stock were granted, no options were exercised, and no options
expired or were canceled.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710618801416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Safe Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDisclosureAbstract', window );"><strong>Safe Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDisclosureTextBlock', window );">SAFE Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6. SAFE Agreements</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In December 2018, the
Company entered into SAFE agreements (the &#x201c;SAFE Financing&#x201d;) with five investors pursuant to which the Company received
funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent
financing of preferred stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&#x2019; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The SAFE agreements
were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in full satisfaction of
these agreements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710618825896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loan Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes and Loan Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 7. Notes and Loan Payable</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed was
approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of September 30, 2020, there is no remaining loan balance on
the Company&#x2019;s condensed consolidated balance sheet related to the First Insurance financing arrangement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">On May 1, 2020 (the
&#x201c;Origination Date&#x201d;), the Company received $108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan
Chase Bank (the &#x201c;Lender&#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past
two years. The Company is tracking further development and guidance related to the Paycheck Protection Program terms.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of September 30, 2020.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710622753928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8. Related Party Transactions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company has from
time to time obtained preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. The Company
recorded expenses of approximately $11,000 and $23,000 related to Biological Mimetics, Inc. during the three and nine months ended
September 30, 2019, all of which is included in research and development. No expenses related to Biological Mimetics, Inc. were
recorded during the three and nine months ended September 30, 2020. Approximately $2,000 was owed to Biological Mimetics, Inc.
at December 31, 2019, all of which is included in accounts payable and accrued expenses in the accompanying condensed consolidated
balance sheet. Nothing was owed to Biological Mimetics, Inc. at September 30, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company has previously
engaged Intuition Systems (&#x201c;Intuition&#x201d;) to provide services relating to development of the Company&#x2019;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&#x2019;s former Chief Executive Officer, President and Director. No expenses
were recorded related to Intuition Systems during the three and nine months ended September 30, 2020 or during the three and nine
months ended September 30, 2019. At both September 30, 2020 and December 31, 2019, approximately $9,000 remained unpaid relating
to Intuition and is included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheet.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In January 2018, the
Company entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with BioNumerik Pharmaceuticals, Inc. (&#x201c;BioNumerik&#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&#x2019;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. The Company recorded no expense related to BioNumerik during the three and nine months ended
September 30, 2020 and September 30, 2019. Amounts payable to BioNumerik as of both September 30, 2020 and December 31, 2019 totaled
approximately $11,000.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710618806840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share of Common Shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 9. Loss Per Share of Common Shares</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.75pt">Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included
in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due to being
anti-dilutive&#xa0;include the following:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding at <br/>
September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Warrants to purchase Common Stock</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">332,014</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Warrants to purchase Series A Preferred stock</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">273,900</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">820,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">630,402</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,152,622</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,343,168</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710613631560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. The significant areas of estimation include determining deferred tax asset
valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued. Actual results could
differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the
potential risk of business failure.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be predicted.
If the Company&#x2019;s operations are impacted by this outbreak for an extended period, the Company&#x2019;s results of operations
or liquidity may be materially adversely affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">In conjunction with
the Company&#x2019;s IPO, costs incurred related to the IPO were capitalized as deferred equity issuance costs in other non-current
assets until the time of completion of the IPO. Upon completion of the IPO, these costs have been offset against proceeds received.
Offering costs include direct and incremental costs related to the offering such as legal fees and related costs associated with
the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">During the nine months
ended September 30, 2020, the Company classified deferred offering costs of $456,437 as a reduction to additional paid-in capital
upon completion of the Company&#x2019;s IPO on June 15, 2020. As of December 31, 2019, the Company recorded deferred offering costs
of $191,000 and as of September 30, 2020, there were no deferred offering costs recorded on the Company&#x2019;s condensed consolidated
balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses and Other Current Assets</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Prepaid expenses and
other current assets as of September 30, 2020 totaled approximately $1,673,000 and included approximately $357,000 of upfront payments
for contractor and academic research studies and services, approximately $48,000 of licensing and other fees to AF Chemicals, LLC,
approximately $6,000 associated with receivables and undeposited funds, and approximately $1,262,000 of prepaid annual insurance
fees.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock', window );">Loan Pursuant to Paycheck Protection Program</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loan Pursuant to Paycheck Protection
Program</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The Company received
$108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;) pursuant to
the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan is evidenced
by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;) by and between the Company and the Lender. This
amount is recorded as a loan payable on the Company&#x2019;s condensed consolidated balance sheet at September 30, 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire policy of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710615186728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/>
Average<br/> Exercise Price Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">607,491</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.03</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">306,743</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15.00</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercised</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(50,460</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.03</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,166</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.03</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding September 30, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">820,608</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6.25</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710618836488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of diluted loss per share due to being anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding at <br/>
September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Warrants to purchase Common Stock</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">332,014</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Warrants to purchase Series A Preferred stock</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">273,900</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">820,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">630,402</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,152,622</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,343,168</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610287528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Principal Activities, and Basis of Presentation (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems', window );"><strong>Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems', window );"><strong>Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems', window );"><strong>Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, shares par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710615352040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,701,488)<span></span>
</td>
<td class="num">$ (669,652)<span></span>
</td>
<td class="num">$ (3,012,186)<span></span>
</td>
<td class="num">$ (1,753,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WorkingCapital', window );">Working capital</a></td>
<td class="nump">21,660,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,660,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 743,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetProceed', window );">Net proceed</a></td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710616555208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expense and other assets</a></td>
<td class="nump">1,673,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontContractorFees', window );">Contract fees</a></td>
<td class="nump">357,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PatentLicenseFees', window );">Licensing and other fees</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UndepositedFunds', window );">Undeposited funds</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceCommissionsAndFees', window );">Prepaid annual insurance fees</a></td>
<td class="nump">1,262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Aggregate loan proceeds</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 456,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PatentLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PatentLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UndepositedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents uneposited funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UndepositedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UpfrontContractorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents upfron contractor fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UpfrontContractorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income from agency and brokerage operations (includes sales of annuities and supplemental contracts); service charges, commissions, and fees from the sale of insurance and related services; and management fees from separate accounts, deferred annuities, and universal life products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610687096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncludedUnderResearchExpensed', window );">Included under research expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ProductCandidates', window );">Product candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ApproximatelyPayable', window );">Approximately payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ResearchandDevelopmentExpensesNotExceedingGbp', window );">Research and development expenses not exceeding GBP (in Pounds) | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 24,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetRevenuePercentage', window );">Net revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ltrn_LP184Member', window );">LP-184 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember', window );">AF Chemicals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Commitments and contingencies, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.<span></span>
</td>
<td class="text">the ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and nine months ended September 30, 2020, the Company paid AF Chemicals $0 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $37,500 of which were expensed during the three and nine months ended September 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, $37,500 of which was paid during the three and nine months ended September 30, 2019. Amounts of $9,375 and $28,125 were expensed during the three and nine months ended September 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_MilestoneExtensionPaid', window );">milestone extension paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember', window );">AF Chemicals [Member] | LP-184 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member', window );">LP-100 [Member] | AF Chemicals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember', window );">EU Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ResearchAndDevelopmentExpensesPercentage', window );">Research and development expenses percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember', window );">Patheon API Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ManufacturingAgreementDescription', window );">Manufacturing agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company paid approximately $194,000 to Patheon during the three months ended September 30, 2020 pursuant to the Patheon agreement. Approximately $78,000 was expensed with respect to the Patheon agreement during the three months ended September 30, 2020, which represents the services received by the Company through September 30, 2020. This amount is included in research and development expenses in the accompanying condensed consolidated statements of operations. Approximately $116,000 relating to the Patheon agreement is included under prepaid expenses on the Company&#x2019;s condensed consolidated balance sheet for the period ended September 30, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember', window );">Southwest Research Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember', window );">Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term, description</a></td>
<td class="text">the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember', window );">AF Chemicals [Member] | LP-184 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember', window );">BioNumerik Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Commitments and contingencies, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.<span></span>
</td>
<td class="text">In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent', window );">Amounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ProductOrServicesAxis=ltrn_LP100Member', window );">LP-100 [Member] | AF Chemicals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_Annualfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_Annualfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ApproximatelyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Approximately payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ApproximatelyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncludedUnderResearchExpensed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Included under research expensed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncludedUnderResearchExpensed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ManufacturingAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ManufacturingAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_MilestoneExtensionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_MilestoneExtensionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ResearchAndDevelopmentExpensesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ResearchAndDevelopmentExpensesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ResearchandDevelopmentExpensesNotExceedingGbp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses not exceeding GBP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ResearchandDevelopmentExpensesNotExceedingGbp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ltrn_LP184Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ltrn_LP184Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ProductOrServicesAxis=ltrn_LP100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ProductOrServicesAxis=ltrn_LP100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610929000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockTotalProceedsValue', window );">Total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stockholders' equity stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with the IPO, all shares of the Company&#x2019;s Series A Preferred Stock were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of the fractional shares adjustments that occurred in connection with the IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,180,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,217,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchasePercentage', window );">Warrants to purchase percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock options (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 167,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Common stock, shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockTotalProceedsValue', window );">Total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,419,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting discounts and commissions (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OtherOfferingExpenses', window );">Other offering expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued relating to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="nump">341,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds (in Dollars)</a></td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="nump">41,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">332,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 6.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted into shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockTotalProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockTotalProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WarrantsToPurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WarrantsToPurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610230616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of stock option activity - 2018 Equity Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of stock option activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding | shares</a></td>
<td class="nump">607,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">306,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Exercised | shares</a></td>
<td class="num">(50,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Exercised | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Shares, Cancelled or expired | shares</a></td>
<td class="num">(43,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Cancelled or expired | $ / shares</a></td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding | shares</a></td>
<td class="nump">820,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareholdersEquityDetailsScheduleofstockoptionactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ltrn_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ltrn_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610260168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Safe Agreements (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDetailsLineItems', window );"><strong>Safe Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_AgreementDescription', window );">Agreement, description</a></td>
<td class="text">the Company entered into SAFE agreements (the &#x201c;SAFE Financing&#x201d;) with five investors pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent financing of preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Triggering equity financing, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDetailsLineItems', window );"><strong>Safe Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series A Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">213,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of net assets at close of period. For schedules of investments that are categorized, each category has a percent of net assets for the aggregated value of the Investments in the category.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710629160856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loan Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Annual amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Description of maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Aggregate loan amount</a></td>
<td class="nump">$ 108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Description of notes payable and loan payable</a></td>
<td class="text">the PPP Loan bears interest at a fixed rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was later updated so that payments of principal and interest were extended past the current fiscal year and maturity was extended past two years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610252360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember', window );">Biological Mimetics, Inc., [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions expenses</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts owed to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember', window );">Intuition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Remaining unpaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember', window );">BioNumerik [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent', window );">Amounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139710610575768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">1,152,622<span></span>
</td>
<td class="nump">3,343,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">332,014<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">820,608<span></span>
</td>
<td class="nump">630,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock {Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock {Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">273,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\-T&H'X%U&\%>DD61 53)7^A%C1[!!$3YIBV&M(#Y53D."+G'34Q!.%/I#,
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M9'T(J"=:5'8?70H-N[(=%G!P(M(8P/V5$/IY8K;F]B@V_0M02P,$%     @
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MJ"YQJ^[T9K+X-D/S!2IW5K=WZ/YFAF!7-;^]LH)N"RD>AGTOQ.00M,4R -/
M/P*Z$5WB%ET#]0NZG'V;+Q9&NVZO78#;THF)3SR_-9?:AD$0XMXQN(W(DO $
MN+/%U3M PW:1O8%'PJ#%;-L2#P-OZ!W9?)!&MDG/^3VP$-E9.:O?G<-O(S1B
M2MQB.A7P:22+PRKX&%A-KF>(;B1C]79VQ23$0I-3O@[<L4Y:_A6CELV<'^[+
MW-MT&]4E;M6=Y'G"HW*##/G&KRF)-5P8>HMO"I,WSX!DFJ!\]P >C4%>Z;8U
M_T'[B"& [4!KK^I&^8$^V=T[$4N9W!0'A0H5.[+R4*E^6A]&3HHCN(/GE_A\
M6AXI-L.4)YS?J=SP3*&$K6%([ZLY$I3EH6%YHT5>G+L]"*U%6EQN&8V9- ;P
M?BU ,ZL;$Z ^NAW_#U!+ P04    "  '@%U1KPL\R$L*  #E&P  &    'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;+U96W/;-A9^YZ_ J#N=9$;1S4Z<-(YG
MY%QVW6T;3Y1T'W;V 2)!"34)L !HQ?WU^YT#DJ)D*;5W=_;%%DG@7+_SG0/R
M?&/=C5\K%<37LC#^S6 =0O7#>.S3M2JE']E*&3S)K2MEP*5;C7WEE,QX4UF,
M9Y/)BW$IM1E<G/.]:W=Q;NM0:*.NG?!U64IW=ZD*NWDSF [:&Y_T:AWHQOCB
MO)(KM5#A2W7M<#7NI&2Z5,9K:X13^9O!?/K#Y2FMYP6_:K7QO=^"/%E:>T,7
M5]F;P80,4H5* TF0^'>KWJJB($$PX_=&YJ!321O[OUOI']AW^+*47KVUQ3]T
M%M9O!B\'(E.YK(OPR6[^IAI_GI.\U!:>_XI-7/MB-A!I[8,MF\VPH-0F_I=?
MFSCT-KR<'-DP:S;,V.ZHB*U\)X.\.'=V(QRMAC3ZP:[R;ABG#25E$1R>:NP+
M%Q_=2AK]AZ00#<6UTR;5E2S$G**E@U9^**3)Q*7TV@N;8XGRR@3><#X.,($$
MC=-&W654-SNB[I7XV9JP]N*]R52VNW\,TSO[9ZW]E[-O"ERH:B1.)D,QF\PF
MWY!WTL7CA.6=')$W3U-;FZ#-2ES;0J<(@/CG?.F# W[^]0T%IYV"4U9P^O\*
M^+?5_6*#$M.1>(#:Y*A:\9,T03DCKM<2E2"N3#J*RQ?UTNM,HYS%D[!6XOOO
M7LYFD]=O;5E)<\=7T]=/!41*D<(VG4*G#RAWL=2V8G&IJ@/?3^.NH<@MD*\R
M <V%NE5.KB@?T@6=(R-8J6%.4>B5,JE*GC1*YZ.K4:MQB!I)UX@%!$AG>#O,
MQ09;ZE1D*!41+"P!D944,T'69ZY>H:1O0545B">(RME4><][L5QGN*GS.UY<
M(32X]$E8RX"J+0JQ5$;E.HC<V5+HX$60;J4">X)"M2O>Z62%<(_$9PCI!6IZ
M]MJ+RKJ0 W>64M"M163 @CYP8GPIH:JTX+6Z4 G;G,) #:>PE*VQM-6+M;R%
M8TZK;"B6->R2NJ#?<*7QDB)IX9Z0%7R]A:5(0JD<15G_@4L2#T!ZL4' Z;\!
MT5*B4"59XSL\1H(;B13JC0YKCI'T9+9$ELARB@@E252%#-1/.*YT%UA 2[A1
M#OI THTYR.#A*.T(&28WQFX,V?9I_NX3(#@].WU]"++)!FL ?.L09DEI@0_0
M2986<N.;F!,^ QO\67W%#J#P%X2F7&+I&1'-]"26* 59R1QJT)YVY&JS*^B=
M@GSI5 )9/TI34[U,GT?2.@*$KD+1?QU7(6#H8*A-6Q5LWLYV00'!0RDV:UL4
M=P*!P:7OJG28[,7E)UWJ0)AH3/YBZ%+\'6G,",2PMX8<.'TV$O,BEIYK*A7]
ML*#D-@7BI/$RC:8R])8*J50%5)C&YH20#'QG[-%(+#1A@_Y4D9E@0](ZLY:,
M*AL:%P"D %S"'*H PHV,['5'B);9+6PA^!%S29>NV:I>.9.3:5%GM$;E"%4@
M.%!QF69&(. F&&YZ5(7E1,G='923+/R^Z!;>C, 6F90:[1NE"-(QNRAK<-RI
MR$!)KYIA7G\A):FE%("!X!PI"25^K.KHSHY9/R3??_?JQ=DKU,CUL^ED(IYH
M9_.Z0-V!-S&X/4/?P]BEF/.0<^DHQ)^9C9BKO7C"0'-(15=\'UN*^Q46U4X]
M94Q) 9+W2EQ=Q<@UOA(M*1G:T*'88ZVD9+5[W;?PA"S\+&\M8>0IR80CABF=
M&XEGD0_18JQY%MDS)3(K:K-J%5)*=L+R\I0UW8="%-T7RW@6H2ZM\SV$M3X-
M10%*<YQTP#JEK6A!47$$T@J$ORPD#7MR!*K:AV2_*CJ&Z%,.+3S&.>( YPR;
M#N;$K2SJ#B;[*G!=6I,L@DUOV-"%<A2".4T'N7(.$(D/B5G3M30KW.'N]Y?)
M:#(5H"[AUV0$D$2W)OV;D;KBMM;\K4U4_40@B5.!>@%-[\ ;%--$OR59F39L
M1$%'X+((W2W1D$D@(,.3 X>',@?BG&>9IM 17JB;]4B+\DYE1(65L$,Q%N(!
ML6 NZB174F?/B&70R0/QAVU=8.NWWF\]AV(+8V%XTM7T7K8/-HTDUYZ0>@>6
M$8H<@L'O5!I;U\F4TJS05&%+@<=81"NCJ)TH,L?K\C'1)#I*:B.!?28G!&@;
M3901O(L#W2Z1,V)EJ>AD14.B/XA#E'O-\^&?&)&T9;\7""SOA8%;^"NN,UI+
M(PO5SY$:**4!R<3V@>=>_4ETDH/1:5-.Y".SWW"NB_>?-),=1=T::MA$4VC,
M!4&P=HXGU^V&IW$4Q-0"M: (#*=4U^2WI/'.)9W28PYM[:NLU['KHC/A%,L#
M4'_<0!)3Z=<BQ]'==YR*!=IF-*+P"4%E$4$QR;PU@9R#88C=EGH'=10&M]P>
MN)J9IT!585"'&=SJ4^+];;DW \HB<'^$HCGZ$ A:M,> O\[GU^TQ -SQ>ZUA
M9R^-5(&EO%%"(>PE2R%'471U647'>:J5>=X6*3S#L$"P+LE65HOU*L2MA99+
M7? A*K9VH*^POJ9Y+R>'R3O2?&Q/U)(UQ,VT\)C*BZ/H(2L3];4B,9BC:H;2
M=AT'/&9R1*? FB$788",%.0&(N BG4?D=Q&+&;]74PD5W#-ELF/V-_.BB.^;
M^!1VB,7_$_Y!!TI0%OJV[4 M%3V@$7QF[QX;<V,).YFE'^V0EU"!;_-/A<\
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MPLOL7W-7H*,O9R">X'=C^U\>SI(#+NK>R+E_C+IG$F=TL]9IS,^^>1ONJPT
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MV#8;RVEF8GK)MUU(2F,7"*)MW[X.(->=:61P!>R(*> ?. ?'N._S* 5X]-9
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MSL8[8#_7&#W=PB?H_R58_0M02P,$%     @ !X!=46.@:"H7!@  #0X  !D
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M?K'A2I%'47%] =E2(^KB>7='EFP7#M:HW]"[][KX4-*K8VC V/MYU6K13<!
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MHLSQ>93834@*<#9N=!(W[ ]:PPZ:L(/.L'<L-LT0-^>0>QO!X(2@-VP%&#8
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;.U;6V\;N17^*X377:2
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M!;E2'@>+NG/J#&QK-$!95$#U$#<,F6@94,'%%A\XJ<Q/D30'@H@*\9 5/A3
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M<VAE970R,RYX;6R]6MMRVS80_16,>DMG7(FXD)1<VS.Q9,?6U!-/W;0/G3[
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M=6\.HIW5VU_,]MQ5D[#_5Q'^ 5!+ P04    "  '@%U1EXJ[',     3 @
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MWO\Q6/_8\>IJ8[R*SOE8&9\I?6N7;:?G!ZVFR2HZ73(UGBZD=.@@AB .'Y1
M4!(^: U!Z_!!&PC:A ]*(2@-'[2%H&WXH!T$[<('[2%H'SZ(8I0Q%I#T@K4
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M[,&?=;^,9I]02P$"% ,4    "  '@%U1!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  > 75'Y Q3)
M[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    (  > 75&97)PC$ 8  )PG   3              "  <P!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ !X!=45U%#;+Y P  W@X
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M965T-2YX;6Q02P$"% ,4    "  '@%U1 '-YX=P%  #&%0  &
M    @(&U(0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M!X!=4:\+/,A+"@  Y1L  !@              ("!QR<  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    (  > 75'<X@*Y.P0  !L)   8
M          " @4@R  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    "  '@%U1XND?%>0(   M%0  &               @(&Y-@  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ !X!=4?R;&JIJ$P  .4,
M !D              ("!TS\  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    "  '@%U18=Z94B8)  !2&P  &0              @(%T4P
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (  > 75$O%%9-
MMP,  !X(   9              " @=%<  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ !X!=46.@:"H7!@  #0X  !D
M ("!OV   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  '
M@%U1FF\R?DL%  #B#0  &0              @($-9P  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  > 75%DC,G-W ,  +D(   9
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M970Q.2YX;6Q02P$"% ,4    "  '@%U1'F -A]P"  "!"   &0
M    @(%\@@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M  > 75$CV"^A$0,  (()   9              " @8^%  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ !X!=453_'A5!"@  *C8  !D
M             ("!UX@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    "  '@%U1UB<#@L,'  #X)@  &0              @(%/DP  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (  > 75%=@PAM& ,
M ) *   9              " @4F;  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ !X!=40XQN-9& P  2 D  !D              ("!
MF)X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  '@%U1
M^1%;:6 #   /"0  &0              @($5H@  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    (  > 75'34X&<^@(  #H*   9
M      " @:RE  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ !X!=40?%=C$Q P  + T  !D              ("!W:@  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  '@%U1J1EV_%T"  !B#
M#0              @ %%K   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  >
M75&7BKL<P    !,"   +              "  <VN  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  > 75$%BA8X$0,  ',3   /              "  ;:O  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  '@%U1+P""5$P!  !K$0  &@
M            @ 'TL@  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  '@%U1(N!HUWL!   Z$@  $P              @ %XM   6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     )  D +,)   DM@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>232</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization, Principal Activities, and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation</Role>
      <ShortName>Organization, Principal Activities, and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Safe Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SafeAgreements</Role>
      <ShortName>Safe Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Notes and Loan Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://laternpharma.com/role/NotesandLoanPayable</Role>
      <ShortName>Notes and Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Loss Per Share of Common Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LossPerShareofCommonShares</Role>
      <ShortName>Loss Per Share of Common Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://laternpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Loss Per Share of Common Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LossPerShareofCommonSharesTables</Role>
      <ShortName>Loss Per Share of Common Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://laternpharma.com/role/LossPerShareofCommonShares</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Organization, Principal Activities, and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails</Role>
      <ShortName>Organization, Principal Activities, and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/Liquidity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Shareholders' Equity (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Safe Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SafeAgreementsDetails</Role>
      <ShortName>Safe Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/SafeAgreements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Notes and Loan Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://laternpharma.com/role/NotesandLoanPayableDetails</Role>
      <ShortName>Notes and Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/NotesandLoanPayable</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ltrn-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable</Role>
      <ShortName>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/LossPerShareofCommonSharesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ltrn-20200930.xml</File>
    <File>ltrn-20200930.xsd</File>
    <File>ltrn-20200930_cal.xml</File>
    <File>ltrn-20200930_def.xml</File>
    <File>ltrn-20200930_lab.xml</File>
    <File>ltrn-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>59
<FILENAME>0001213900-20-033954-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-20-033954-xbrl.zip
M4$L#!!0    (  > 75%$[7NGLF$  /AE P 1    ;'1R;BTR,#(P,#DS,"YX
M;6SM?6MSVTB2X'?]"IS/LV''4C(!OMW=NJ EVZMNV]):=O?,7EQT0"0D80P"
M'#PD:W[]9695 54%@ 1(D*+<_##3LD169>4[L[(R?_X_WV>><>>$D1OXOSPS
MC]K/#,>?!%/7O_GEV=?+P_'ER=G9L_]S;!@'/_^OPT/CO>,[H1T[4^/JP3@)
M9O/+B6M\"6T_N@["F?$BGKTT#HW;.)Z_?O7J_O[^: *?B29NZ$1!$DZ<"']A
M'!["@F+)D]#!!5\;7VX3XWP2&];(:%NONYW79L]X>_K%L-I6FWWEX.?O5Z%G
M ,Q^],LS:1?\]5$0WKRRVNW.*]>/8MN?.,_8)U]_]Q9\^.\?7/^;^*07AW[Z
M60_ "OWYK1W.; 3[%0+2'G7:Z;JPD%L#CJF3?9H^&3F3HYO@[A7\ ;YAC@[;
MYF''%!]/HL,;VYZG7[FVHRM:G/^!X,E])7Z8.U'A=^@O!5]RHZ!KF8-%!V&?
M$%_P ]]/9L6?G\;A*]SH%7SH$#[EA.Y$?(_S0OK%(MY(]UB^@;HX?F"JX9<?
MH/^*_3&E,E!\P6GQSU=V)+&/_OG[#GW:'(U&K^BOXJ-1&.=1#[\LP/KWJ&A)
M ,!\]?>/'RXGM\[,/DPY".7EP#!^QLU>1_3'S\ZU09N_1G3\\BQR9W,/@:;?
MW8;.]2_/D)\/!=L>?8^FSUX=TSJ3P(^=[['A3G]Y-FG_^2X,9N:OMH\?_1)T
MVI?.'']\QL04_^]GQX_=^.%8_!M^XT[Q=]>N$QH$D:,<2/#VR=EOSX[;<*Q!
MOS/JM7]^E7U-6OU5MCS_S1R(&TSE_0 587P*0GDLL-DV?WZ5_=8PI \[_E3Z
MZ.BPT\8]V._$GMD6A)-7'"D"UPJ.S#_'T?FU-00%M7N886P2L\.:[4-K^/,K
M\;M5#FO187>4#93#<LJN<]@..ZQYZDQ0!^_J8<$ZF!;HC_4.V^6BGGA/2M0'
MVQ3UGH0C<Y3B:-=80\81N@X5<80?71]'?<ED/"$<5309S>!HH"B6X9\78)*=
M,'2FEW$P^?;1F5TYX3,)A,WB"['AW,R<5''0KYAC]-KY/O?<B1LSH(RI"Y]C
M(0'W-5]?QH &_/;;?R4 )+K^@0__C,;?W>C9L?A8T1E_?E6XBP+:JQ2VU93C
ML GE.-0(!H><!;Y&K1^&5+G3E=)IIX@TTH@TGD[=&,YO>Q>V.SWS3^RY&]N>
M+%X_#,D6GG6!F.T4 <VV1L'/3FR[OC-]:X>^Z]]$$NE^&,H5G_%I2)QIJ@3;
MGLUZG.-:NF]C?K1#_+',@O\P7+I5Z[V&;]8A(J\5SG=*B5QH]7\<&F_)[#\N
M=;NEU*W@+OPXM'X4?^%Q*=\KI?S>S?B1)#R7@!!TWC'OY'&Q)%(0>P=FL^F'
ME%IK.9Y#C5I[3Z3A<*@9,HTT,NU=BBVF(!HAH=762+CW#79;YBQ3)=B.&?G&
MC\M3$.-Y**Y7?DW\O07?= JB6]TYZZ]]/61U2HF\-_R;"%"V2]UN*77W_L*V
M4Q#;I7ROE/)[-^-'DO!^&9UWS#MY7"SQ%,3>@=E\"J*_=BV<-=2HM?=$F@^'
M&B#32"/3WJ78;@IB?1)VVAH)][[!;LM<QU0)MF-&OO'C6F55L'L+OLD4Q%:K
M>#N=4B+O#?\F I3M4K=;2MV]O[#M%,1V*5_ZA&'O9OQ0$MZ7'VKM3?,F@^L&
M'IH--&KM;6SSCGX#9!IJ9-H;R^T&UPV0<*21<&_U=EOFNFV58#L=7#=P7/5%
MQ=YN;\YN-_%FVM*HM;?;C>N0)LBD/>3?V^WMVNTF2-C52+BWVSLN<SV]=0RK
MT+/:>Y.VJ2QQS=8WZ[\BZ/9+B;RWA$WGD+9/W4$I=?<&=)M9XNU3?EA*^;W=
M_9$D?%1&YQT+LQ\52SWE3<C>@=E43)Y1:QW'LV=JU-I[(LW&!PV1R=+(M'<I
MMA>3-T3"CD;"O6^PXS+750FV8T:^\>/*SRU82TNJT-M;\,VF("J^(L"/KO^*
MH-<O)?+>\&\B0-DN=0>EU-W["]M.06R7\L-2RN_=C!])PD=E=-XQ[^11L=17
MWH3L'9A-IB#6?R'1-S5J[3V1YL.A!LAD:63:NQ3;34$T0,*.1L*];[#C,M=5
M";9C1K[QX_;*IFKL+?@F4Q!;G0K2[Y<2>6_X-Q&@;)>Z@U+J[OV%;:<@MDOY
M82GE]V[&CR3ARIN0O6G>9'"]_@N)05NCUM[&-N_H-T F4R/3WEAN-[AN@(3:
ML,>]U=MUF6/9$+/'Z_G^_.CZ[BR9R3*VNX2*POCU9]N_<1A!\)\*_%NR4.:A
MV5N3#%V=#/;WITT&&?ZG0X:>IK[.+LZ?FK5)KB)WZMKAPZ7M.>?7Y 6H^BH]
MU--QX'AK"CZA8Z>'AM%<[C6/FWM%D3+D&S?X1*/*OUW0*/F)D\3N1/*)=I=#
MIX[[^H-S8WMO"3C&DSA3_/7B0^W@<XD&QKGFGDMDH22L"3[&TU#]0J>\ [,;
M.Q_<.P=<5V#\&_?*<\91Y,31FX>/]C^#\,2S(SVHE$^Z<V\E&B"RGB782^_.
M1B[#=FGF[L.%.>PRL/\<OSL!]./QHB?B&* W=A$&TV02GX>73GCG3AR)>M+A
M*K@#=53"9\<#P9E>@*@]? EM/[(G&-^"/I#_(H&2P^T/F#@<FJ5Z?\]F/S2;
M;=7R#*V]-ML*FST^7VU7?77VZNLOPE?;U5?EW67W?/7#FL6MMS@=Y@;Z[MGL
MK\%F-2;E-L!FN1XWV95F(6OM+F/MS91"V/+$K"1BSXYWF:*-JHJG2,/R$JT<
M"R-5V^T?PP94ET\)D&95A(3-*IL_Q?@HUQUGSUP_,G-M57.-%J:HQ>&?H/=*
M]-.Y*ZI)VQ_)J=FJSAHM3$GOV>K'8:OM:BNK--;>F\(?S!1N/<(>E<\:VS/7
M#\A<6\T2CKK5-=<^??.4M$;YT]H]89^T"UN><'W[]3V@)7Y:U73+J:H<JUP/
M/V'W<5"JA"_L^-8!;%R<"9_^B1CWZN0M.^*V!DQN5RV7U\)>!DE\>^]$\6<G
M<NQP<GOF1W"8)'9^,"V][* _8H"H5\?NB;U18C==,0MA ._#EMQP%2U^_!-"
M&%@J?KA,KO[I3.(OP3G\TXY=_^:#8T?.#V2-LP?2%4Z\M<'?P^KZ>[AVLWNS
MS3.(U".8,0+_\4\P7ZX3C4N>QS\)\J>O0.D%0^&+J@6GW()OAE3L5"?X^M,-
MS+;2B7U/YHV169T5N7Y_:[/=T4-@\>.>AEL*HVI$QH,&1%4T<-^3>5NBFE%N
M/5'M:?,+]Y3;@I)M8(ZAV4Z[N_& UNR)9I-[&FY'R?;KM%K&M@'K*=F!:-_
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M7(%/M5MX:]09-><25N;*Q1NOY^FDK>,7L]NV7<+:8&W<)13]VA=)R%9=PGH
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M^VK+N XF"3XJ"GS#<VCN+MXQVB& [2+?&"Y Y\%I,-@T#E[(^X^/SHZ4S5N
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MX-O!?81L <PU3\((?"$0O-#V(Z25S:Z[.>_*@@>""4Q,PH)LQ>2.L B:=)(
MM8)0?('CP9[>(7NA[,3X<42]*B*:A!P] ?T++',/; Q&)@A!)]ALZOD4Q .%
MRK/O(ZX@4+_&)%M@2^$;H$4_@1CC);TQ:!E X0Y#$RH$Q[Z&C0"5RKJNKRYT
MZL#Z=N@P$P +@AU.0/UG=#9[N++57J3(4@,9L,L*X%L#%P5K+W8EB)4U#.0.
M^*-MW-\&P($&B#/\,TI-$),F#6$?W!E($J@U?I*O/O[3^ W8?HK:&$Z0P%H
MV>#(&'O,HH3< !E7ML?XA["$+,J>OG#M>>6 ,G(\V,(7<!L'$]GEV3E^NG11
MW>+_S9FW@DA!O DLW]JDK(.8XQ;T,\H-X CE!M6QS;R:!Y1?)F"H"]&;L4.4
M;T"5)+:(^8F74'$0J$:P8<BZ:+5\AW#)[(%Q@"4-F6/ ]6/Z&TG=R3J!VPU4
MZ:FV1ZYQ([XMH+(,,F0H.#YX_4P+(!8D6PE RA]&_A%FV\; --- TS*3AK]1
M0'M=R@XQ98<F8$?G]A21Q1FCS?Y#?XGF]B3_E]78Z-Z=QK?XT?;?,N9@4DW@
MA,JZX'J19R8X+0[FZK<.\/_HBU/EBWP;E0<S94'HB*>T2KTE/';8W.D/K^V9
MZSV\7G9^^FP$7@Q#5PXXJS>Y9N#A)U//? FL2\.&S<#\X>(0")FA]84;!M>)
M!_87G-X@B0_!/< 2"<E8@^R"MK-#E.,OY$N2\PWN#:G9$.0]=9C.A9?Z.S \
M>"0O29O:X)=@?NCLC DG%R?T*1T[%M()1I\9CPD*15B*4O9CF/(3^S<*Q0X+
MRUY4GJ*H=!11^6+?!6@,7R)/@Y[VR;.GR#0BEJ["Y7[@'Y)CF2V,/&AXB7\C
M.!_-SY[[]]S_V(9BV,W0BBR?=[L8C\O\30ZM$2>S((PD?TXH]Q:$JT!Y%HS:
ME+_'R),Q/G/:;CPWN/)LB(!G]E$U,5@L!8_D/Y_E75?4!@>%@8X<3.''2Z.I
M18%4BV>60N..[@VX7UFX(:M>-PY8RIPR=)3)-L9&FLPVV!\QA,0DP0W\AA(*
MS]M';=. @,R@TGWT[O%7;?F7+"!C7Q.GR2##T(%"(N,@=&*,]B%0<,"3@*TA
MW);B27O"(RSD(L#GE+P3(PN=$"B1'&;XHNPPA&AI0;QQ34FF+!!#1D;_FSQR
MY!\Z%D=)!8Q0.).NCI6EP .20F>E]_@Q?AXZ2H:,#!$ 18#EV0C'0<HC&C?L
M7&A8&J\3+MT(-<0#1%*&@W@'G)XZ$Y9,Z)C(E0YF=R9X]S2%#^$G&;LHQ*;P
MVIW5(;K!\@T'B6^#VJ'X"\B8T7V.9< ARQ*K$2L)FSV#SU'2W8[*)0?L?D*9
MYV7 $#*X#Z A!;XB4)*Q3<>D3,OHR#ACO(])4%0&B^08B O^!PN?X4.1LPQO
M!X6P"C[%R-U.NW10"I-RQDB0P,=4"KHP(3@P*$1)&%)N//O"2Y9DGCJ(9=!]
M3A1ARA_18&/>. 2<I-LN/%@&YCR(7):!@/@\\5C^6LX' 8TG=G1K7%.Z4*!\
M3G?$F$.BVQ-GRGB,\0#3LIB8NBXF'DL\8(2#<0])ILVJ69@YH[R4!S)VX_@
M"64])N@=9JJ+)Y#HQHI@'D.T!-;34"X?WH_'%^K-!^K$?R4N]GG*J(O*9&9_
M<PRL:YS1BI2VC*)DQAJ:L62G?7TM] T<- A)".CY ($ GW=B]E5/*ONF?$=Z
MG\;Q@I=I<%C<O.QK;*,I-U*DY.I(*TLH%@(*(#BL6C\RIO2P4OHHD8"1]PBO
MSA)B1\8;0",/#X.7ESS_36*1XFTGM:FD()D2(.V!ZN+0\:=E6.5)1["XCA.S
MC'^1V5Q%DZ+1-PY CMT[8?:%3JU@>[\0RNOR@H]U=,8TP!]$4LXX0)64\2:J
M*A(../V#\?7H\JA( HM%%?>(;HD_KI"5["D7\W\FON:EE5BW@\HX0!."\@9;
M"H54H/PS<@M98#B@-#M>&3(DI"JEQ'M$ #SRL><@_$E$=TGPK5\3WP$.%MZA
M *1P#3 U=.O!KH@ =G;YWT);>>U"&)GBYA(5/U, [&[W[7?NVJ 'Y4;1KKHL
MQ>9#W% 7F! A.,*4:.2HR^(AD3<UBQ"?P4)3NH^[<YC.C24P@?[ IJ@%R2$F
M&XJ7&PEFUCA,!H<4\\NAXF;L' 7&/KGWK-P[PR#AGW-]@/>U>$&):8N;!)")
M'Z4OT5_'F5A?XI->.YQB)#/%>U!FT=5[_<L3U;(BF0O7^#HG&Z9]^ZMFEXV,
M1FD]2O%Z;P+XC[K<N_'E&V4]T)(!R6E+%DH*C1AW.OQ..XE<G\H(T)4&9>_<
M(#\=$3BEGG@=QA2J5A@.88-EL,0-^X(;M9(+M48NRW;[JNPM.5THQ$SCFD+C
M(E8*KK#J*F&5D\XNSK5J%9E0B&./W3VARKA'1HPH:HU M&+.PRYY2A3OLC^B
MZVB02D3*FT>#+BD<DT7S$<4D(N9M49BPR'F?IP$S6WU"%72,EB#'?.<#]D='
MPQ[/9A3=_>&&<'S&4N3O!+YV#N H)ZML7))&,)1;V$6^2:JOF*I"70ZNQ+UO
MH*5V?1% X2D(,1!$RE@7YGV2EA(*_-%UIHPL#=7D%"3D+&!ZC?5_I>L2%<5K
MYDM2,Z@=U)4"*#VAD0.+B'M_ZTX8I700[\GUXKR ZLSFMB[%!07,.LL6BWM6
MT]IT%6'^]8U<W'EAA^<A?9]WPW1"ZC.A%$C"+XN[6K"64V:/%R7^^1$D?I;,
M\OT0K&?'F&63GZ94@2)?\"^UJ7@LT"N 4/#JISFD=W7([>_%D'<)\O9*:-\(
MSM>!O!+6E28)64;L-$BNXO%5D,3O ZH QO2\_U3J;*TC\#W !DPQ=;.[!;-R
MQ1*X8 EI2J:'(4:(#0\[ X%F?-YIM4VK90[[9$:>FZU!#W\UE!,C/I;I ;WC
MVXC'F)<8"K,@DT> /*FM_MH<45YM[O 4/-C62'BZ^25T7W4*2CW\1K:&)[T1
M8,ML]?OMUF X:&'\/6.Q3H'"QV/.^4LZ\#YH+$ :ZH*AIQ :RP&_4^X&%GEN
M=5I=@ -XW7@1.8Y!%.^]5 O R@ ;=#NMGM7GP7DN"E<7 1#0&0_A4RP)DK#&
M11Q *CQ%0TR!&%UBL8WH'#P]YT4!716GP0W+A=Z SQOG%F2!'7Z0:H.H2 SS
MI<E<)+W(;>/;^(BT(^,/(+O]P':"6-$+0N;(SX%[7,K44=+6H5"6)8,"J3K7
MF #78<6Q/4FS>A%5\F87' 1$D(2L5,D3HD6<4H3&%LM?4 Y)2K,;4]0JAHUJ
M94%ZG<-,4&)<1;<DP#DWJ(G(74-=E/H[5Y'#:ZAL]<*'RE7_P&C"<QTL8*:*
MYB0$+/&$-D7\:>@O>XV,/XK8GSE)N P>"FL3T3&B5"7L3@DJMB(C$B+:Y;ET
MD54(G9GM4A4F)EGE6Y!,2O&SN3\!>JE*G CB^.R5('$6GI> "D1/!R/-GLK@
M2'"*/%H&&Z#'<VS@.],2FD3D3Z44+SB$_TIL\.6Q\(=RU<B<RWRTZK9%?OKS
M!Q-AWLIJT1,4K>&4_IC/!'4$VH@_CU&7E1Z=?W)B_JYWC;TZ7:N=O1W*EE1>
M!54_F3;M6!]-U>V /BLYE^9278)EHDR)'V=)BPOPEB<@]4_%MG>.C,MD-L-+
M)930[$AR(H9.+D[VJ Y P3&^1B1);Y5[G'%VC[/;#HM\?:;<G4GW>H6W9WC/
M96S\8HNIYP576ZO>:]6[P&+N4PAFQT\X#%5NLYC_$4E,S>J'T7XS[+#:$):N
MFSJ@A&?L?<E41-JQ_9V=BF0 BPS8E^@M!:53!="N/T]B7KR<+41GQ7O:M(3$
MH19DAU?8Q]3 (I0I.Q#\A%X,I@BP^VG)11Q[MZ+<Q@6/?1M7()2?W>@;.]97
M-$?8K3!^;-U1.7C@Z>+($/E&&YED"JN$X@D,.6+_) $**!?KT^7%;.[$/,]T
M$]R!&2:)#)V;Q.-L QC!UV/ ,L[DUL?B7O;NCBY\CHQS]5F&V,0XP.=Q$A^'
M@%]:+)'1*Q6(I?+5RNYF\!_*MBT!6H 99W+$T-.DU2/Y^0!_JF <9*]Y" )@
MYS2=CJ_80"/L7#(9*0M_E>HC7"#S)$XS="Q?FF;H)T$(J+IS0W %7YR<_WYV
M>FB.7F)BE-60<&0RMS(KJG!">D,EO3\H=,=3=)'G.770?Q0O>GC (KU]R!$!
ME%VV>S2G.U>^'3B 5_#O;TA4C[SH.+1A)7PIXD9!*)0WZ),X="?\S1I3FQ-D
MU@=D,\ \+@@:/DSHZC=]PQ$YX9T[<?AW, $*FDP\[8K!G& "-Z3JW9;8J/CU
MQQ3@>X /<?\]8V%R@,FZ\0@:I8MG81TE_))BDS1^,LC'9PX@/85#]/',.DNB
MHDC=NC>WWD.V*??G?;Q)O")[#+$G7;- Q+R D-H#*L93[!:=G'I!#G[/R%@0
M\PC,-+7*5RZ]5@4F":7C8IAZA=$J1J+LOGZ*R7 ,ZYEUAU/LACD03^ -\0;>
MH$?PNVL.S@KJ& Y**79V<=Z"ST?L[H\EGE(A#,0MBW&/03SG4'K%2P^^.&:8
M6T#&GY2(6(ZK9*QSIY5!?@ZXFX7>N<=*XKG8\LLJZ3J$;G>^SMFU3OYOHLB-
M[9;=%@;7U^CSV#<@(9&<4^+)&Y2.E);IR9D;!0[I).:7/!,6$%/D'E%=G(*5
M]$(N2E \(PB8;S#=X*2ZBGV<?5DJ[F0OUPQ&$SSCKC'0:7$JD:<:BO.)VL5C
M5E*;,DF@HAQ3<-U>O]7M#$0V<)HPCBTLJ4W5(X&1%'-%&8=3J;1\H;@X7Y6>
M ZU+.%UP"G3MGYLCDW*0+%8IRQ;Q/)A#E1^E"Z8[<IM=YT*?,*/4@>V,2RV;
MT]/,G.ZN$OU<Y@!@UC'B%3P\CB.J"^4I"M[2&"]+>O/Z64H4VP]AX'DM"D!Q
M,EX0IM]H27Y+G$P?I#^PK44Q,9PZN8;O,G$EKRK!FAGAQ)"_3"ZZZU^'-KA.
MR82\-,Y;$ <G64G:/ GG0<0NE*6^"Z5,2$]4F6.MM%[@G2VH7BQ;1T#$LJWZ
M^WF9)W1CQ)R2$-^(A"PBUS#/%"FF^.F&FCFS2 C6K :UR812#5( X2C>*7_H
M2.ZA38&VD8!Y(CM']_DEO,#"9YNYXV2 0+)M#PM?6!T7]XH3X <%ZOM;Q\\X
M9K.\7R".O 6V\5;."Y^3K3[A=GI,9GIWY5,<04EM@SJF0PAG0Z1T2G0RL 88
M%&0B]5K);/4'G52CIX5^VJ<ZO0%]!I9.YM<AOKP"J4X+*)B(2N)-UF%B3QUL
M&Z-(N(ANLBA%VZH[%#LQ3A7BSDY+'@=6Q+TS3FX=ZK0!2WSX<-(";TM=J,].
MI?DBS#'"*X2(Q^40VV&A/;_H$FTQ="Q9?4O ->?DX \BP/&"8 _-$"'"V9G<
M#C95-"ZP?8C-THT7]L/DUIE\,R["(.;E10?P\TUHSW:7^[^H/@J[DS0.GIOM
M8:O7IG(I^^8F!(<TQOX8MI]YP;F.2Q<7%P:B12UPI/S<KQ<? RRH ;["UZQO
M;/];_OL?T"4,U6_/)0P+3[<(TQS14B.2$RF#,78AU/R,5W;7C /?@CA1UR5>
M=OQ@O#@9?WY[^1+SC2QA*DZ#IL#![HS A%/RBR"P9*BPLP9G_.WA ]/FHI5;
M.8Z,M-V;>MXK5A1YY<3W&('HQ9+X;X8FWF7B@"6'$<C4X2,GF-&*=_U<P054
M7P& 9<IKO:77<Y6NAO+%15^QL7EVD[&S5T<_ZIW+_M9E?^NRYJU+I@148<Y=
M']-%/7HV>#*\+SFARA'\:7<%?W^OL[_7V2'*[N]U]O<Z?_5[';E"N=2B%,SY
M8Z86HI(0*$N^Z<,3*%KZ(6Z2]E=)^ZND_5727_LJ29XIND@5Y\:>UFPF/^AI
MLV,!_\6CSWG'^X4[Y5,6M0%:7( +Q%,F*)5#(0,A;IK&_E2Z!>&I>8;0W35I
M/]+%WOYF;W^SM[&;O4PK5)!W;2*'.K$V@B_271V_JF,W=8_N!/^5KAGW]XQ/
MX9Z1OX1907J*1OS)BX@UV)<_!;Y@A)5?"N&L<VWZ8I4-CQ4]\96QQTG*"^^<
M9D:W 0MFKY@*=U$>-%W8F-GZP%3O,A@6XZ4[S#;.+:N=/N.F=]3CL8&#]Z5C
M:\OK<QDY(V9MCY#3FB* "2*@L,>"_>1'<S1#D-_%?@G$#6QV <OO7Y] [J32
MQ?W^YGY_<__7N+GG2JFN?!]K1BV;6XLK-:.J^%S4TDV.UPO!%]N+VM'W2?8H
M&_3GB;B8QEJ'IS=4KOO:D,Y##*R<Z)'58@'8^(.+/[QQ@T\)]D3]QA[L*J/=
MN%?GII#OI&H_2]MQ8_IOR-)_Z80<:KH@FEZA/HKP[I24UKA<?15]2E5@Y%E+
MV-,PUV+#GY2F8=FGM=YA$/!+ZC]KWI1JQ EOMQFZ-[<L )\&,X<&AK$0A@?(
M/-L:L^M"\!,A&K'#;VHV.XW9F:JE%E[41,!C70M@]05S%S#JN4V BI0-Y8-(
MI/[SHILBZ%AF7PH1#EZV9T^H01IW+*4_&F(<GQVIY"NS%A(9P(Y_M(D1^FHG
MD1G@(A_(482(AWYN]2C641N>&>DE)-Z1/3 HXI)#[=PE &]AC;4X2K,/7IK"
M9Z^Q2T]Y5&#$Z2_XRO,>U)RZ*W6 Q;%P]H.X4<DH<<C9+6,BX36 _7;G?/ B
M0(&(E*>7%?*+C5DHO*C$$91A\&![>%G%ON %]]36!.?#N3?8G@4O%I(9U5G<
ML08WO" )&( ZY9MPN)GK>52=P0@L7Q:Y?*AQVKJN8'.4 UQ9VDAL(MA4WH:U
M#;)ZTK[ROWCYP?.>#)C^&]YZR+@2'V ML8N@$[@F.6+U2,YW:JKQW)(6+#B$
MP70!.XGKT]=X#Z1T9[W1#^O43LJ).J&X812+2@)#W*U+E*;:+[S(IKQMG*4H
M]73@ =-;HBZ%?^K*N4X[[/!S8LT9'1US+;#3)'2O4+M< 0B[)Y=J6T]2<6F!
M$5HI*3W[(/?F)'HQV5PND(72:!0(H6U@?848Q' @<1,U3WX06K.%; -&)_ =
M7M3!F4W4_J5QU=6# EW:P48Z"JQ $PP57J&^(0<9-/PNMRA]K0P:9.4PZJ Y
MW82E>6@L[J#$VKT;T9B'V1487X<WV*:;8(;^@QS^=X^3]"Z5DO(D?LHT*,Z$
M=:<.KRF5$4C51PFK6>-&P'L W-.@WC@= RA-FM5QB\Q E:P9Z22AQ7$':&,C
M$3M*']-S_SE9EV[LV:X+G K6Z:OTG,R6>Y[XB/$E=._<9/8[*,#3\8GJJV5_
M*W#[7K@OY3.PB;-HP-*1J+PA>IQG5Z6DB17S"8G&-5ZX[DM6(C3QD@@5,K]*
M00P@D;)]V=>*["QI5.8K2EZ@\!YE7Y!-9'98_2I)?XAU1JSW%V]ZEB.W-F@1
M:T/((Y3\1=O'V/!EB5^X:V+T156EQ$?<#JI*%2O(%(-%)0QWY*%RM[N$8R-'
MLW38*3SQO >A^RA_P3E6U-.@_7M0_!?248)?B)681]-K_XW&@D@?%5J9M3"G
M% Y!Q>J8,<V=FDX%,E;60WJ07XX>Y(!]G"8!556A<$:E6D;MD/EVWXH#(UP7
M_*4(#'*A P44!?V1RR,%61^W>)B7+F>'CL(*\]!%PT9/!-A]T$-J<,GB%7L(
MV,.4RNKYNEH[Q0/B[=(#SX%YW"")/*D;YB+I+U+9"E_:X#-,#_%"RW.D)=!-
M-_+.QHKLN]2(Y%@Z8V@FY;O*U%^HX A5DG(WAWEK5J\D$I^ )2D(+KT09=4B
M>L?-;;Z#E>?(J9DH^7JS-.VDC*';(4*I.:C>PAR4\25+P.23'W&0V7X@M;#^
M2_,]PKJ3A5"OBHG)/WS0/!P%W^I-1M'03#8>$!4>V?JLE2:6\ 5T\9<;;'N6
M#K8EL-D\0^JM;AR\<ZY"@:^^JH_I89@$73Z'-P4:3),9]^3HC0/>P'/]S]]1
M >13D>6A]0OPKNCDG1-_^=Y-.\!!GG,(;0(S+R:!YXE^P@R]*O%/\KRG<H$6
M7P97 +=P;,C9Y[4 QD%6M'#M.')N3:6BZ!;++G*HJ3+K(8P#"ZF_JI:")&:1
MS1>5(#QG:DQ\F>[+#I2-Y&7H(HF6$O "C)(ERNIDV6QQ7+I*'^>6\7Q %X<L
MKV/1S_SU&[/LE+T4Y4EK[*,VAEZ&#@HH*F!##MX$6FI#*<W-2_M82VA!.\4Q
MTRA6\NVR+ZE^FWL,] 1#%/7P5UNE!6=I@5&-V0W2.TCE74;!U A!JH-""4KS
M*>5"HT4$H/S._#NT!#="_:/R.<7JO[%T2ZL.*_ETJHHV#\@+Y$V-Z<E9I#KM
M$,=%LCF#:55W%HFFYXB*'&(].4-9@/3M&!*(O="AY='/N6.=P@O&W^)2RDB_
ME@0%O9D.V=,WXVV"@:S\D"W]\\ZI>25/CT3&MWZ>9*%X:;R.D#3"7Z"I,6I5
M&.J%_9)NS=6<N:$ZXKCB38B][W$(ZLSAXLQ*O4KS?$6OM=0!C 7<05YY=EZ>
M!;GB0 +=%#!S(4,AI+6@9)Q"W_O5GM/SSF5 [AP'44JLR*2+B&])]B_')786
M:UYG3<EM@\)IFIUNL*"ND'TRF?3Y<^S(]E@==)&:8?)I@TX);HJ4:/')L"0
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M2A9W$Z6)6#Y)BV/AX(U/36WX&P=@([8\V-8@N;G5-C .RCN!;[(C3*J0+VS
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M4)\HLX*.@&PA^Q.RH"->L.-&V?=[/0.<@;3)+19\$FO?!Z$'9BM+XK+VO"S
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M6O)%\/.V+X6=IY:=X2EESHHL$HN=2JR=DLC2,4J.D.;T8"\S"=&%1"M8D"C
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MTDFUT=.;XMP_,G"6;C9M=X=[HY_YV94F<D1+=,U/I[$IL\_I7-E\X'P':OK
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MTV(>X\>X<D38K! E>]K/(67G%3<CKTLUP,ZW/]U<;\Q\HG[[#1P?N_VIQ)3
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M"U1^X:J?V 1_$MS))W_B?AG]"YP,',W5O ([^/G5]ZO0(]']_U!+ P04
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M*?W=GG>]=<Y!KB\L*2S+/+'BR,7'\2$G(RB"/!&\(U4!W4+3ZK>FD!RVUT^
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MUBT\C34DT3&/TASCT4+3AP4KQWF&A%MNF-UBZDQ5B:<B,VXM>>I5;?0B/AK
M)9YYLO'J%LHT_V4*=(SHC&^(LVZ]EF_&U*/4\979I$S3I!F?*; I9PRJ"SL-
M$8SQ;FCIG+ 07IT[YC0ND6,61FIPT52^L35'3Z^:X-)!LV 'G^ R&Z#VO-QY
M>PIGZO_;O(>S$:0E2.FF,1GX.$4DN)9U4QK\*4C:N.*^9E_=3;6AK_[74 E5
MR01HF@-%4Y=,5&7AJ:(5ZV*[3(IIT1F\[>SZ0@8CI5$CCD<WR(.]BE!0%*%;
MV!=!9K/>>%4>+8SX3,E)[JM[S*71)(G(>!"MWZC72X-\%8W^C%>_\6J_3)"7
M:+20^Y;8"Q'<ZG>C]; T^+70#&=$B,^G=Y#Q*+?4Q4%7L#1:Y4(T3*^FWULH
MSVW.0BCE7*Q^W""XUZP8_1]02P,$%     @ !X!=40=Y\MY5!P  9$   !4
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MR:74HV06K8DEGG-W$>MX'C[YGB91U,#B;#KBX:JF,Q-'?^.OX*=O;6RIQ+:
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M?2<2JUO?^!MI6SOIS8XP>O-\8Q3([3*/5 L?8;1@[:NHG/)RY0B2?SXQJ_Z
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M7-X?213/MYHS</H @Q#>V<D-B+7XJ',+I<C(>28X+:[$4-(-\_1WH&991D,
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M^/>(;D4<;M)86T"UP_=HE> !)-&0E)_I?7O(*-TY$6*/_3]02P,$%     @
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M$+G84\F*](_V-W;VS 8PUFW2F.B:3,<;CPQ>/E]M JAFM.^];.3SC:^!C83
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M7HIVHAM#PV1+FM8P"3X<#;N":;MG8;0!;NXD$H?J"-QA4%0'\S:'4XQP*^J
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M!ID:";)+\S!B'K!V M*!CQBL<S]Q@RC)8G@+G]*S8*3LJ,%QM-'08V :>'U
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M++[SB#2K_'-XE^*WI3$I7T3+FZR1V^#Z>_0#O;?D,1_/!=7D(Y W'"CG@QR
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MC 758(!'6PJ?\)"O\UM,H#V-5U#QR:BS1'^ML++('+I 2.,+0E&A'S(08/(
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MJX&8,.KBY-@C!?F8<QO]!OT#7ZE@DOX?4$L#!!0    (  > 75$#?.7_VR,
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MP7P,_)!DOXF!/SHY35.$?Y.BF\ H/:<1(2 DYQ%F:3.3DZ@FM.4Z+_X1+L[
MP6[&$?VQ(/O]I&OZB>-UG @\<I?0WZK-'*.5FCA#U @9PM3MOCD\89EW.ILY
MH'_WKA*TN=S&K%+U)2#^I*H460Z,&A?[A_G]!\=G#G84GCL8;^B:]='Q(V!"
MJF*$L\R!'3G7JGA>L((HZA*TDJ1I9+IVH'?QM 8! 93;:;@$N#!%$W(6(;M=
M;7HN9B$(4R&?MA:RXEIC7*)5LAN \*K%]$Q!3"AT_)R8U(P1T5URN)GY3A+<
M4*^Q9BO*-3!DA37T>B7":KNK0TN;5U64Y1BLV=I/DFE<H\ U9WM<6KM5H8\"
MY$.DRUNJ>TIS+G+ ,6HKP13\HXI@KJ!S#_TXL];!_J*&VA %6 =>BT6OO;4E
M^3N2YD:VT9/KXH@RL>/:B$$*$[<I\F:]+UBJ.* V=YC[D^K&B*V'-7+2K())
MEP]6W$@4]2N;0^"9#7%$R%K>,/)5NL8^J_&SFA(P['3[XE8UK*1;03VW$0_E
M3I-&>S5#!E)S->3L)N14)5D+8"K9%U9,\)95 10.WLR>!W"I#=% Z\!+I?J#
MC9!GEM&+&3260J\B8S4/T*S,I6SJ/DH:DSFJGA8%9L6V1\.NZ<F(;!\>J_D;
MSXM=!'46#O0FP;FSAG2I-1*4<DC9WF/(B8\+F*Z\@)K1W;"B@P!X%PX.Z+I,
M:. <K:*X0&$,YM"%1M9" :H#<J8B&+8(877XUOT)=1/B],!(=84W6QG^:"<E
MD-L1T3BZ&X$VTASFEJ09RE34+UN+FA5)'9>KI-+?=U4\5;Y>]ZV6BK]AH%!-
M<4S.BZ.LK,3=_!Z"2WFH+E046'W;CO;B3VXPC*)PB3#\LK,^<V+?HV@YOZI'
MVOLXVB[-J>)O0DC4G8Q3:D-,]M2!9_-<LXJO:12RS@"LA4)7DLV3_%K$6X!1
MU^ZE95JHR\59A.Q 7;40HMHR\^VS@5TLRG7DAKG)J0505X9>CVC-K<,\4D.-
MJ;G0M<A-: BB]]@RO C7TOMJ9%NU!*MD)/8%;"4E46Z=HZILI7%,YAUXI%JL
M:],U:^!%19K>9" F^><3LQRZ-,@P;Q8U@%DMX$E:L?FCP!MY*QA QA2[8Y^R
M:4*<321M[CT:]3HOTT;L;-\KN*'XT;FSBV5C\ !\%%]YF 0SC%Q C%3^-)$<
MC' ;L;.="MJ;32>NU_(VHHW'U5D-JR2Q:Q F_+.N,R:D521@.X*4D%4)&7TW
MZ]0$E1V!9WD$UIG%98X@Z5!C0G1-)&WZS4J]S8NO$2^[AR.? %PL*1^C!^H1
M%N Z6MT#/)W'K.9V)QU(69$3JU4DC=)7A5=CX5=G.\&:]J3*Y;O;?7;7E;PB
MA)6-;CM\V@W,X 1V_<!:,4KU TSHCT:6Y@HJMM=G*<TK5A4519LSY-9"2*BS
MGN HB(OMGZ!9>502M%RV5V4YE0*H1DO=L?IM^X/D#N#> [8.F#^\3.GTY12K
M3H'YIY496'8#I5SNUIST]HGTY&1*5'(5*-G.!7#*LLT)L9Y@/]RGJ#P;P--6
MV:ZCL-V<1#F4!F:;/+PT%JZK912*_(_1BK)I)(]02:@7Y3RB,N1@E2OEZ,5T
MFJ.SW(8BYT1:[*C^[+<?]G9H@G<=%,*I-< 0T=C,P6&KNJ]."@DXU0-]%QBW
M/$ ACJJ2EZJSCC4I*4D91YBUBXX'CTO+XK]-XY[KY.()8!<2,ZE">2;Z$74U
MVZ@<LC8+<SGL)HIK6Q/JN.C+9EA%&6K1U1;'R:A#CM&DO+2P=3]'0?KTW1W*
M;0VO :N<PDE7;,=/BQ>]/R(2)J]VY16%TZS;".$>NPDS0.NK 593FH0C3\=D
MLG=MI'1'/_U>Q-\-&F0 =6WEQBJJ!*M7S<1:BK,<!=XG!V,G*+>FK%,5Q?'[
M[DU48;-3B5R[)&H3M2J!7D<5[:#35Y>L?\>15E0 CZ5$0$!BS-]B0S5$JJST
M6CE:XYSJQRM+???1'(:FBL9RHP]"AGDT4K&\[DGCM=]/.LS(]5Q,U>AD"1[E
MC-Q%X+646CGK9$AH_;W0(Y>4RTM-.2^7EYJMBSO;MYI5<T';:IEL)*.77FKI
MM4ANTKT.&X]ZT0=(P3S;?"#L4M.V6GKW)*')V2EPT9?%J4;^I9)F:9RMW@3Z
MDU6GJ]M!<^&Z'0'N$A;D#MT %P4N]$&!PSO4 ]LWPJ?M$FD-NF1&?OI*DQ1?
MML' A>ECMFL?Q%()O-$*X3!]#=>$C@G1M9G&-&FLI7=S! 1@N6=N[K!GC!Z#
M&Q0%WB5PP@@#"@<&=%,^!LF_DR"M3UZQSOC&MEM*S%A^:K CC6HA+-MEDOO\
M;>>>%OT9OH8O2MVN)NE9SF3 MGG(O\_GK/!(8S>J4*)I_9:MI)W4"[X,J,)R
M\SH1=P 6;"]OP!/LOX74S;M2BIQ8C7=UZX<8]K97#W&W:#=C\E6L'C)@VWQ8
MA\/G)'@ Q'HZK8Z+KR.=5HNS-H<AHQAE[S:+L+ND_T[GV1NT^>=GA0[M)8>T
MW"I T1R8L&6QTQI'F+5^NU;?SR5!4"M4P+;Y]BR'S[2+GN4EH8Z+KV-)J,79
MZF6^N'44\,@EG38K0F%/&S#75JI*2GX!V+L'[#>&:CY4..ECDEW K$K5(THR
ML',Q>V^KE')\CHA@P5_]" ,6: ,T"@L +S1H:^I)BVK?"4R5;U51ZN6"W\)6
M\R#:[=6_X^D:A2#+69@6;8'6@,VV&4=]5[6-) :MY #[6BTA*70!<*T\I;O/
MUQG"&#VR#@+3X HY0:7P19=<[F@]W*FKKKY\Q*PVZ1>?I=T]V%>Q7LN K>L5
M0J4V1Y1)]H@W_8<EDQX<GQV:)U<!RHIM0BVDZ/>CU%MP2RZ'K,V\?36G(ZK
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ME@KB4#$"'VBCN390B:?=VU.1#YG;T)1+I.NA-(#.>QJ4I9S\EA(IP>'O-^P
M4C"Q0C^?LRGZO[(]%0>TD?K09G],/B5\-*2GE:0CO$T1EX_E_6BEXA40K[@<
M*[WS8X.]AP%<12N]$!8'M71H4XMA:=IV=MXQ(\Z3 ?P+@_82_^*T]6WCANU0
M-<40I?O>:MNRXJG)S,%3'!^^>/%[[%G@;B+:%*1LRSEK#?0*K2<$$5??)#T
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M9!M;)-#?4*]Y/=NA9.62V7OH Q*B %RPFTGLUMO,@6(-PSA?'51HP9N^G4.
M29"\2,&NF>+L3"I5$#&9U(]@Y;1443(-6.1V09VN)!DGH\ ;T_#'1VLVL\R(
M)<- X<&&M0J)8Y1*\567:]1[)XCF-%B)6+>1T0*#N&\@=R_&<WZ-HPQL41*
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H;BTR,#(P,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  $T+ 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
